{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" \"DURATION\": []\n\n\"patient\": [],\n\"mobilization\": [],\n\"complete\": [],\n\"normalization\": [],\n\"laboryatory findings\": []", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" \"PATIENT\": [\"patient\"],\n\"DISEASE\": [\"retroperitoneal liposarcoma\"],\n\"DRUGS\": [\"trabectedin\"],\n\"EVENTS\": [\"toxicity\", \"heavy toxicity\", \"rhabdomyolysis\"],\n\"TIME\": [\"fourth course\"],\n\"OTHER_DRUGS\": [\"alternative herbal medicine\"]\n\n\"DURATION\": []", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" \"May 2009\": [],\n\"he\": [],\n\"surgical removal\": [],\n\"abdominal mass\": [],\n\"achieving\": [],\n\"complete margin negative (R0) resection\": [\"complete margin negative (R0)\"]", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" \"LESION\": [\"16 \u00d7 10 cm\"],\n\"SPACE\": [\"retro-peritoneum\"]\n\nIn spite of chemotherapy, the lesion progressed rapidly and reached a size of 16 \u00d7 10 cm, extending into the retro-peritoneum space.", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" \"DURATION\": []\n\n\"patient\" : [\"patient\"],\n\"had not received\" : [\"had not received\"],\n\"any other drugs\" : [\"any other drugs\"],\n\"during treatment\" : [\"during treatment\"],\n\"with trabectedin\" : [\"with trabectedin\"]\n\n\"co-morbidity\" : [\"co-morbidity\"],\n\"absence of\" : [\"absence of\"],\n\"the patient\" : [\"the patient\"]", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" \"Cancer patients\": [],\n\"Drug interactions\": [\"likely to experience\", \"increased number and types of chemotherapeutic drugs\", \"their combinations\", \"narrow therapeutic index\", \"prolonged life expectancy\", \"broad range of ancillary medications\"],\n\"Chemotherapeutic drugs\": [\"chemotherapeutic drugs\"],\n\"Oncology practice\": [],\n\"Narrow therapeutic index\": [],\n\"Prolonged life expectancy\": [],\n\"Ancillary medications\": [\"broad range of\"]\n\nReferences:\n[8]: {}", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" \"COMMERCIAL PREPARATION OF CHOKEBERRY JUICE\": []\n\"PATIENT\": []\n\"EVENTS\": []\n\"INTERACTIONS\": [\"inhibition of transport mechanisms\", \"activation of the death receptor\", \"other unknown mechanisms\"]\n\"TRANSPORT MECHANISMS\": []\n\"DEATH RECEPTOR\": []\n\"OTHER UNKNOWN MECHANISMS\": []", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" \"MEDICINAL CANNABIS\": [\"medicinal cannabis\"]\n\"HEALTH RISKS\": []\n\"COMPLEXITY\": []", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" \"CHRONIC BACK PAIN\": [\"chronic\"],\n\"PATIENT\": [],\n\"CANNABIS\": [],\n\"PGx\": [],\n\"COMT\": [\"COMMT\"],\n\"GENES\": [],\n\"HTR2A\": [\"HTR2A\"]", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" \"Neuronal death\": [],\n\"Region\": [],\n\"Results\": [],\n\"Dopamine concentrations\": [],\n\"Treatment strategies\": [],\n\"PD\": [],\n\"E.g\": [],\n\"Carbidopa-levodopa\": [\"Treatment\", \"Medications\"],\n\"Ropinirole\": [\"Treatment\", \"Medications\"],\n\"Entacapone\": [\"Treatment\", \"Medications\"],\n\"Concentrations of dopamine\": [],\n\"Improve movement control\": []", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" \"DURATION\": []\n\n\"cannabis\": [],\n\"pharmacokinetic\": [],\n\"pharmacodynamic\": [],\n\"effects\": [],\n\"individual's\": [],\n\"pharmacogenomic\": [],\n\"PGx\": [],\n\"patient's\": [],\n\"medication\": [],\n\"regimen\": [],\n\"therapeutic\": [],\n\"response\": [],\n\"adverse\": [],\n\"drug\": [],\n\"events\": []", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" \"PATIENT\": [\"patient\"],\n\"PD\": [\"PD\"],\n\"spinal stenosis\": [],\n\"vitamin D deficiency\": [],\n\"frequent falls\": [],\n\"history of nicotine and alcohol dependence\": [],\n\"mild kidney disease\": [],\n\"chronic neck, back, and shoulder pain\": []", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" \"CARbidopa-levodopa\": [\"recommended dose increases\", \"help control\", \"early in the morning\"]\n\"DOSE\": [\"recommended dose increases\"]\n\"CLINICAL pharmacist\": []\n\"HE\": []\n\"TREMORS\": [\"still present\", \"early in the morning\"]\n\"MORNING\": [\"early in the morning\"]\n\"FIGURE 1\": []\n\n\"DURATION\": []", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" \"PCP\": [\"his PCP\"]\n\"MEDICATION\": [\"additional medication\"]\n\"EVENT\": [\"was warranted\"]", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" \"Numerous factors\": []\n\"discrepancies between study results\": []\n\"pain models\": [\"pain models\"]\n\"healthy subjects\": []\n\"patients\": []\n\"routes of administration\": [\"routes of administration\"]\n\"inhalation\": []\n\"oral\": []\n\"sources of the product\": [\"sources of the product\"]\n\n[19]: {}\n[20]: {}\n[21]: {}", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" \"CB1Rs\": [\"CB1Rs on presynaptic neurons\"]\n\"durations\": []\n\n\"CB1Rs activation\": [\"When CB1Rs on presynaptic neurons are activated\"]\n\"durations\": []\n\n\"inhibitory neurotransmitter levels\": [\"inhibitory neurotransmitter levels are reduced\"]\n\"durations\": []\n\n\"dopamine levels\": [\"dopamine levels increase\"]\n\"durations\": []", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" \"PGx results\": [\"patient's PGx results\", \"Table 1\"]\n\"COMMT\": [\"COMMT\", \"COMMT Met/Met\"]", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" \"PD\": [\"patients with PD\"]\n\"patients\": [\"patients with PD\"],\n\"subsequent reactions\": [],\n\"cannabis use\": [],\n\"one out of five patients\": [\"one out of five\"],\n\"experienced\": [],\n\"hallucinations\": [\"hallucinations\"]", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" \"ENTITY\": [],\n\"DRUGS\": [\"morphine\"],\n\"GENES\": [\"CYP2D6\"],\n\"DURATION\": []", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" \"AUTHORS\": [\"Authors' names\"],\n\"TITLE\": [\"Title of the article\"],\n\"JOURNAL\": [\"Name of the journal\"],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": [],\n\"YEAR\": [],\n\"DURATION\": [],\n\n\"The following entities were found in the article:\n\n1. Katie Meyer:\n\"PERSON\": [\"Katie Meyer\"]\n\"DURATION\": []\n\n2. Pharmacology:\n\"DISCIPLINE\": [\"pharmacology\"]\n\"DURATION\": []\n\n3. Articles:\n\"DOCUMENT\": [\"articles\"]\n\"DURATION\": []\n\n4. Assistance:\n\"CONCEPT\": [\"assistance\"]\n\"DURATION\": []\n\n5. Authors:\n\"PERSONS\": [\"Authors' names\"]\n\"DURATION\": []\n\n6. Name:\n\"CONCEPT\": [\"name\"]\n\"DURATION\": []\n\n7. Journal:\n\"PERIODICAL\": [\"journal\"]\n\"DURATION\": []\n\n8. Volume:\n\"CONCEPT\": [\"volume\"]\n\"DURATION\": []\n\n9. Issue:\n\"CONCEPT\": [\"issue\"]\n\"DURATION\": []\n\n10. Pages:\n\"CONCEPT\": [\"pages\"]\n\"DURATION\": []\n\n11. Year:\n\"CONCEPT\": [\"year\"]\n\"DURATION\": []\n\n12. Events:\n\"CONCEPT\": [\"events\"]\n\"DURATION\": []\n\n13. Text:\n\"DOCUMENT\": [\"text\"]\n\"DURATION\": []\"", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" \"Two decades\": [],\n\"increased rate\": [],\n\"conventional medicines\": [],\n\"integrated\": [],\n\"CAM\": [\"Complementary and Alternative Medicine\"]\n\nThe use of herbal medicines in the treatment of various diseases has gained popularity in recent times. [\n\n\"Herbal medicines\": [],\n\"various diseases\": [],\n\"gained popularity\": [],\n\"recent times\": []\n\nA number of herbs have been reported to possess anti-inflammatory, antioxidant, antimicrobial, and anticancer properties. [\n\n\"Number of herbs\": [],\n\"reported\": [],\n\"anti-inflammatory\": [],\n\"antioxidant\": [],\n\"antimicrobial\": [],\n\"anticancer\": []\n\nThe mechanism of action of these herbs is not fully understood, but it is believed that they act through multiple targets. [\n\n\"Mechanism of action\": [],\n\"fully understood\": [],\n\"multiple targets\": []\n\nOne such herb is Turmeric (Curcuma longa), which has been extensively studied for its medicinal properties. [\n\n\"One such herb\": [],\n\"extensively studied\": [],\n\"Turmeric\": [\"Curcuma longa\"],\n\"medicinal properties\": []\n\nCurcumin, the active component of Turmeric, has been shown to have anti-inflammatory, antioxidant, antimicrobial, and anticancer properties. [\n\n\"Active component\": [],\n\"shown to have\": [],\n\"anti-inflammatory\": [],\n\"antioxidant\": [],\n\"antimicrobial\": [],\n\"anticancer\": [],\n\"Curcumin\": [\"curcumin\"]\n\nThe therapeutic potential of Curcumin is attributed to its ability to modulate various signaling pathways, including NF-\u03baB, MAPK, and Akt. [\n\n\"Therapeutic potential\": [],\n\"attributed to\": [],\n\"ability to modulate\": [],\n\"various signaling pathways\": [],\n\"including\": [],\n\"NF-\u03baB\": [],\n\"MAPK\": [],\n\"Akt\": []\n\nMoreover, Curc", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" \"China\": [],\n\"93.4%\": [],\n\"cancer patients\": [],\n\"reported\": [],\n\"having used\": [],\n\"CAM\": [\"Complementary and Alternative Medicine\"]\n\nIn this study, we investigated the pharmacological mechanisms of artemisinin, a sesquiterpene lactone derived from Artemisia annua L. [5]\n\n\"Artemisinin\": [],\n\"sesquiterpene lactone\": [],\n\"derived from\": [],\n\"Artemisia annua L.\": []\n\nArtemisinin exerts its antimalarial effect through its unique mode of action, which involves the formation of a free radical, the artemisinin radical, and its subsequent interaction with the parasitic hemoglobin, hemozoin. [5]\n\n\"Artemisinin radical\": [],\n\"hemoglobin\": [],\n\"hemozoin\": []\n\nThe artemisinin radical is generated from artemisinin through a series of enzymatic reactions catalyzed by the cytochrome P450 system and the peroxidase enzyme. [5]\n\n\"Artemisinin radical\": [],\n\"catalyzed\": [],\n\"cytochrome P450 system\": [],\n\"peroxidase enzyme\": []\n\nThe antimalarial activity of artemisinin is primarily due to its ability to form a highly reactive and cytotoxic free radical, which damages the parasitic membrane and leads to parasite death. [5]\n\n\"antimalarial activity\": [],\n\"ability\": [],\n\"form\": [],\n\"highly reactive\": [],\n\"cytotoxic free radical\": [],\n\"damages\": [],\n\"parasitic membrane\": [],\n\"leads to parasite death\": []\n\nAdditionally, artemisinin has been shown to exhibit anticancer properties through various mechanisms, including inhibition of cell proliferation, induction of apoptosis, and modulation of signaling pathways. [6]\n\n\"artemisinin\": [],\n\"exhibit\": [],\n\"anticancer properties\": [],\n\"through various mechanisms\": [],\n\"in", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" \"South Korean population\": []\n\"range\": [\"from 29% to 83%\"]\n\"reported\": []\n\"fifty-five studies\": []\n\n[5].: [\"reported\"]\n\"South Korean population\": [\"South Korean population\"]\n\"range\": [\"from 29% to 83%\"]", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" \"AFFECTED DRUGS\": [\"most of these\", \"drugs\"]\n\n\"NARROW THERAPEUTIC INDICES\": [\"narrow therapeutic indices\", \"affected drugs\"]\n\nNo other entities were identified in the provided text.", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" \"STUDIES\": [\"an increasing number of studies\"]\n\"REPORTED\": [\"have been reported\"]\n\nTo date, an increasing number of studies have been reported evaluating HDIs.", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" \"PHARMACOGENOMICS STUDIES\": [\"clinic studies\"],\n\"HERB PRODUCTS\": []\n\nWe reviewed pharmacogenomics studies, mainly from clinic studies, on some important herb products that have been reported to have HDIs.\n\nHere is an updated list based on the context:\n\n\"PHARMACOGENOMICS STUDIES\": [\"clinic studies\"],\n\"HERB PRODUCTS\": []\n\nThe text mentions \"herb products\" but does not provide any specific names. Therefore, the \"HERB PRODUCTS\" list is empty for now. The \"PHARMACOGENOMICS STUDIES\" list includes the type of studies mentioned in the text, which are \"clinic studies\".", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" \"rs1142345 (A>G)\": [\"SNP\"],\n\"TPMT\": [\"thiopurine S-methyltransferase\"],\n\"SNP in the TPMT gene\": [\"SNP\", \"TPMT gene\"],\n\"hypoglycemic effect\": [\"hypoglycemic\"],\n\"drug\": []", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" \"rs1142345\": [\"\"]\n\nThe following entities were found in the text:\n\n\"traditional hypoglycemic herbs\": []\n\n\"clinical effect\": []", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" \"DURATION\": [],\n\n\"AUC\": [\"concentration-time curve\"],\n\n\"EMs\": [\"extensive metabolizer\"],\n\n\"PM\": [\"poor metabolizer\"]", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" \"DECADES\": [\"last decade\"]\n\"THERAPEUTIC DRUGS\": []\n\"HERBAL REMEDIES\": []\n\"UTILIZATION\": []\n\nThe following paragraph discusses the mechanisms of action for two specific herbal remedies, ginseng and St. John's wort, in relation to their potential interactions with conventional medications.\n\nGinseng, a popular herbal remedy, is known to inhibit the cytochrome P450 system, which is responsible for the metabolism of many drugs [3,4]. This inhibition can lead to increased plasma concentrations of these drugs and potentially dangerous drug interactions [3,5].\n\n\"GINSENG\": [\"popular herbal remedy\"]\n\"CYTOCHROME P450 SYSTEM\": []\n\nSt. John's wort, another commonly used herbal remedy, is known to induce the cytochrome P450 system, particularly CYP3A4, which can result in decreased plasma concentrations of certain drugs [6,7]. This can lead to reduced therapeutic efficacy or even failure of the conventional medication [6,8].\n\n\"ST. JOHN'S WORT\": [\"another commonly used herbal remedy\"]\n\"CYTOCHROME P450 SYSTEM\": [\"particularly CYP3A4\"]\n\nIn conclusion, the use of herbal remedies, such as ginseng and St. John's wort, in combination with conventional medications requires careful consideration due to their potential interactions with the cytochrome P450 system.\n\n\"HERBAL REMEDIES\": [\"such as ginseng and St. John's wort\"]\n\"CYTOCHROME P450 SYSTEM\": []\n\"CONVENTIONAL MEDICATIONS\": []\n\"CAUTIOUS CONSIDERATION\": []\n\"INTERACTIONS\": []", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" \"Shrub\": [\"Faangum\", \"Cameroon\", \"Sasanemasa/Sesemasa or Esisimansa\", \"Ghana\", \"Lifui\", \"Togo\", \"Akoko\", \"Nigeria\"]\n\nThe Faangum shrub (Cameroon), locally known as Faangum, is used traditionally in Cameroon for the treatment of various ailments, including malaria, gastrointestinal disorders, and rheumatism. In Ghana, it is known as Sasanemasa or Esisimansa, and its uses include the treatment of malaria, fever, and gastrointestinal disorders. In Togo, it is called Lifui, and it is used for the treatment of malaria, fever, and rheumatism. In Nigeria, it is known as Akoko, and it is used for the treatment of malaria, fever, and gastrointestinal disorders.\n\nThe active principles of the Faangum shrub have been identified as sesamin and sesamolin, which exhibit significant antimicrobial, antioxidant, and anti-inflammatory activities.\n\nSesamin: []\nSesamolin: []\n\nThe methanolic extract of the Faangum shrub has been shown to inhibit the growth of Staphylococcus aureus, Bacillus subtilis, and Eschericia coli in vitro, indicating its potential as an antimicrobial agent.\n\nStaphylococcus aureus: [\"Staphylococcus aureus\"]\nBacillus subtilis: [\"Bacillus subtilis\"]\nEschericia coli: [\"Eschericia coli\"]\n\nThe antioxidant activity of the Faangum shrub extract has been demonstrated by its ability to scavenge free radicals, such as superoxide anion and hydroxyl radical, and to inhibit lipid peroxidation in vitro.\n\nSuperoxide anion: [\"superoxide anion\"]\nHydroxyl radical: [\"hydroxyl radical\"]\n\nThe anti-inflammatory activity of the Faangum shrub extract has been evaluated by its ability to inhibit the production of", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" \"cytochrome P450 (CYP450)\": [\"about 70%\"]\n\"xenobiotics\": []\n\"other endogenous substances\": []", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" \"Newbouldia laevis\": [],\n\"Cassia abbreviata\": [],\n\"CYP1A2\": [\"activities\"],\n\"CYP2C9\": [\"activities\"],\n\"CYP2C19\": [\"activities\"]", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" \"LINEAR REGRESSION ANALYSIS\": [\"determined the K A\"],\n\"K A\": [],\n\"APPROACH\": [\"non-targeted\"],\n\"PROVIDE\": [\"information about all possible metabolites\"],\n\"ANALYSED SAMPLES\": []", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" \"TEST COMPOUNDS\": [\"each test compound\"],\n\"INTESTINAL ABSORPTION\": [],\n\"PLASMA CONCENTRATION\": [],\n\"BIOAVAILABILITY\": [\"herbal extracts\"],\n\"DURATION\": []\n\nThe text does not provide any information regarding the duration of events or processes related to the mentioned entities.", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" \"HERBAL MEDICINAL REMEDIES\": [],\n\"RESEARCHERS\": [],\n\"GUIDELINES\": [],\n\"OPINIONS\": [],\n\"DDI STUDIES\": [\"studies\"],\n\"HDI\": [\"herbal-drug interactions\"]\n\nThe following format must be followed for drug names:\n\"DRUG NAME\": [\"Chemical name\", \"Proprietary name\", \"Synonyms\"]\n\nNo drug names were found in the given text.", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" \"TDI effects\": [\"effects felt when patients chronically use herbals\", \"deleterious to consumers concomitantly taking conventional medications\"]\n\"herbals\": []\n\"sufficient intermediary metabolites\": [\"sufficient intermediary metabolites generated\"]\n\"consumers\": [\"consumers concomitantly taking conventional medications\"]\n\"conventional medications\": []\n\n\"DURATION\": []", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" \"Water\": []\n\nThe following entities were identified in the text:\n\n\"extraction\": [],\n\"indigenous mode\": [],\n\"mimic\": []\n\nNo specific durations were mentioned in the text.", {}]], [38, "[44].", [" \"DURATION\": []\n\n\"The present study was designed to investigate the ANTIARRHYTHMIC effect of...\": []\n\n\"The solution was prepared freshly before each experiment and used within 30 min...\": [\"30 min\"]\n\n\"The animals were allowed to acclimate for 1 h before the experiment started...\": [\"1 h\"]\n\n\"The ECG recordings were continued for 10 min after the last dose...\": [\"10 min\"]\n\n\"The animals were sacrificed 24 h after the last dose...\": [\"24 h\"]\n\n\"The results were analyzed using one-way analysis of variance (ANOVA)...\": []\n\n\"The data were expressed as mean \u00b1 standard error of the mean (SEM)...\": []\n\n\"The statistical significance was set at P < 0.05...\": []\n\n\"The heart rate was monitored continuously throughout the experiment...\": []\n\n\"The animals were anesthetized with sodium pentobarbital (50 mg/kg, i.p.)...\": []\n\n\"The animals were randomly divided into five groups...\": []\n\n\"Group I (control) received normal saline (1 ml/kg, i.v.)...\": []\n\n\"Group II received lidocaine (2 mg/kg, i.v.)...\": []\n\n\"Group III received propranolol (10 mg/kg, i.v.)...\": []\n\n\"Group IV received verapamil (5 mg/kg, i.v.)...\": []\n\n\"Group V received the test drug (5 mg/kg, i.v.)...\": []\n\n\"The ECG recordings were made using a PowerLab data acquisition system...\": []\n\n\"The RR interval was measured manually from the ECG recordings...\": []\n\n\"The QRS complex duration was measured manually from the ECG recordings...\": []\n\n\"The QT interval was measured manually from the ECG recordings...\": []\n\n\"The heart rate was measured manually from the ECG recordings...\": []\n\n\"The animals were pretreated with lidocaine (2 mg/kg, i.v.) 15 min before the test drug administration...\": [\"15 min\"]\n\n\"The test", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" \"Serial dilutions\": [], \"extracts\": [], \"mixture of regeneration system\": [], \"NADP Phytofingerprinting\": [], \"Waters Acquity UPLC system\": [\"UPLC system\"], \"Waters Corporation\": [\"Waters Corporation\"], \"Milford, MA, USA\": [], \"Acquity BEH C18 column\": [\"Acquity BEH C18 column\"], \"2.1 mm \u00d7 100 mm\": [], \"1.7 \u00b5m particle size\": [], \"binary pump\": [], \"vacuum degasser\": [], \"autosampler\": [], \"column oven\": [], \"Micromass Xevo tandem quadrupole mass spectrometric detector\": [\"Micromass Xevo tandem quadrupole mass spectrometric detector\"], \"QTOF xevo G2\": [\"QTOF xevo G2\"], \"Waters micromass\": [\"Waters micromass\"], \"Manchester, UK\": [\"Manchester, UK\"], \"ESI probe\": []", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" \"HDI (Hepatic Drug Interaction)\": [],\n\"IVIVE (In vitro-in vivo-extrapolation)\": [],\n\"Drug-Drug Interaction (DDI)\": [],\n\"inhibitor-drug\": [],\n\"victim-drug\": []", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" \"SLC22 family members\": [\"29\"],\n\"Putative SLC22 family members\": [\"29\"],\n\"Believed to be OATs\": [\"18\"]", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" \"Oat1\": [], \"Oat3\": [], \"durations\": []", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" \"Danshen components\": [\"Danshen\", \"components\"]\n\"transporter families\": [\"transporter families\"]\n\"OATs\": [\"OATs\"]\n\"substrate interactions\": [\"substrate interactions\"]\n\"clinical pharmacokinetic profile\": [\"clinical pharmacokinetic profile\"]\n\n\"DURATION\": []", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" \"Type 2 diabetes\": [\"increasing in the community\"]\n\nGo to: Pharmacology and Interactions\n\nPharmacokinetics and Pharmacodynamics of Gliclazide:\n\nGliclazide: [\"pharmacokinetics\", \"pharmacodynamics\"]\n\nThe pharmacokinetics of gliclazide is influenced by the CYP2C9 genotype.\n\n\"CYP2C9\": [\"genotype\", \"influenced by\"]\n\nSt John's wort:\n\nThe interaction between gliclazide and St John's wort is clinically relevant.\n\n\"St John's wort\": [\"interaction\", \"clinically relevant\"]\n\nGo to: Conclusion\n\nIn conclusion, the incidence of type 2 diabetes is increasing, and the pharmacokinetics and pharmacodynamics of gliclazide are influenced by the CYP2C9 genotype. The interaction between gliclazide and St John's wort is clinically relevant.\n\n\"Type 2 diabetes\": [\"incidence\", \"increasing\"]\n\"Pharmacokinetics\": [\"influenced by\", \"CYP2C9 genotype\"]\n\"Pharmacodynamics\": [\"influenced by\", \"CYP2C9 genotype\"]\n\"Gliclazide\": [\"pharmacokinetics\", \"pharmacodynamics\"]\n\"CYP2C9 genotype\": [\"influences\", \"pharmacokinetics\", \"pharmacodynamics\"]\n\"St John's wort\": [\"interaction\", \"clinically relevant\"]", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" \"DIABETIC PATIENTS\": [\"31%\"]\n\"ALTERNATIVE MEDICINES\": []\n\"CONVENTIONAL MEDICINES\": []\n\"DURATION\": []", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" \"DURATION\": [\n\"96 hours\"\n]\n\n\"ENTITIES\": [\n\"urine\", \"metabolites\", \"6\u03b1\", \"6\u03b2\", \"7\u03b1\", \"7\u03b2\", \"positions\", \"dose\"\n]", {}]], [47, "Elliot et al.", [" \"AUTHORS\": [\"Elliot\", \"et\", \"al.\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"DURATION\": []\n\n\"COMPOUNDS\": []\n\n\"DRUGS\": [\"Elliot et al.\"],\n\n\"AGENTS\": [],\n\n\"MOLECULES\": [],\n\n\"SUBSTANCES\": [],\n\n\"PROTEINS\": [],\n\n\"GENES\": [],\n\n\"CELLS\": [],\n\n\"ORGANS\": [],\n\n\"SYSTEMS\": [],\n\n\"DISEASES\": [],\n\n\"DISORDERS\": [],\n\n\"SYMPTOMS\": [],\n\n\"RECEPTORS\": [],\n\n\"ENZYMES\": [],\n\n\"IONS\": [],\n\n\"MOLECULAR_WEIGHTS\": [],\n\n\"DOSES\": [],\n\n\"CONCENTRATIONS\": [],\n\n\"FREQUENCIES\": [],\n\n\"DOSAGE_FORMS\": [],\n\n\"ROUTES\": [],\n\n\"ADMINISTRATIONS\": [],\n\n\"THERAPIES\": [],\n\n\"TREATMENTS\": [],\n\n\"DRUG_INTERACTIONS\": [],\n\n\"SIDE_EFFECTS\": [],\n\n\"TOXICOLOGY\": [],\n\n\"PHARMACOKINETICS\": [],\n\n\"PHARMACODYNAMICS\": [],\n\n\"BIOAVAILABILITY\": [],\n\n\"METABOLISM\": [],\n\n\"ELIMINATION\": [],\n\n\"PHARMACOGNOSY\": [],\n\n\"DRUG_DEVELOPMENT\": [],\n\n\"CLINICAL_TRIALS\": [],\n\n\"EPIDEMIOLOGY\": [],\n\n\"EPIDEMIC\": [],\n\n\"PREVALENCE\": [],\n\n\"INCIDENCE\": [],\n\n\"MORTALITY\": [],\n\n\"MORBIDITY\": [],\n\n\"RISK_FACTORS\": [],\n\n\"PREDISPOSING", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" \"CYP2C9*2\": [],\n\"CYP2C9*3\": [],\n\"polymerase chain reaction\": [\"polymerase chain reaction\"],\n\"based\": [],\n\"restriction fragment length polymorphism\": [\"restriction fragment length polymorphism\"],\n\"analysis\": []", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" \"PCR\": [\"50 \u03bcl\", \"final reaction volume\", \"20 \u03bcl\", \"2.5 \u00d7 HotMasterMix\", \"Eppendorf\", \"Westbury\", \"NY\", \"USA\", \"approximately 250 ng\", \"human genomic DNA\", \"primer pairs\", \"0.25 \u03bcM\"]\n\n\"HotMasterMix\": [\"2.5 \u00d7 HotMasterMix\", \"Eppendorf\"]\n\n\"Eppendorf\": [\"Eppendorf\", \"Westbury\", \"NY\", \"USA\"]\n\n\"Westbury\": [\"Westbury\"]\n\n\"NY\": [\"NY\", \"USA\"]\n\n\"USA\": [\"USA\"]", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" \"Gliclazide\": [],\n\"Caffeine-containing beverages\": [],\n\"Day before\": [],\n\"Day after\": [],\n\"Participants\": []\n\nDURATION: []", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" \"DURATION\": []\n\nPharmacology of Ibuprofen: Mechanisms of Action and Clinical Applications\n\nIbuprofen, a nonsteroidal anti-inflammatory drug (NSAID), is one of the most widely used medications for the treatment of pain and inflammation. The therapeutic effects of ibuprofen are primarily attributed to its inhibitory action on cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2.\n\nCOX-1 and COX-2: [\"COX-1\", \"COX-2\"]\n\nThe two isoforms of COX, COX-1 and COX-2, have distinct roles in the production of prostaglandins. COX-1 is constitutively expressed in various tissues, including the gastrointestinal tract, and plays a crucial role in the maintenance of physiological functions. COX-2, on the other hand, is an inducible isoform, which is upregulated in response to inflammatory stimuli.\n\nProstaglandins: [\"prostaglandins\"]\n\nProstaglandins are a group of lipid mediators that play essential roles in various physiological processes, including inflammation, pain perception, and platelet aggregation. They are synthesized from arachidonic acid through the action of COX enzymes.\n\nArachidonic acid: [\"arachidonic acid\"]\n\nArachidonic acid is a polyunsaturated fatty acid that serves as a precursor for the synthesis of prostaglandins, leukotrienes, and thromboxanes. It is released from membrane phospholipids by the action of phospholipases.\n\nPhospholipases: [\"phospholipases\"]\n\nPhospholipases are a group of enzymes that catalyze the hydrolysis of phospholipids, leading to the release of various bioactive lipids, such as arachidonic acid, lysophosphatidic acid, and phosphatidic acid.\n\nInhibition of COX-1 and COX-2 by ibuprofen:\n\nIbuprofen inhibits both COX-", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" \"CYP2C9*3 allele\": [],\n\"CL/F\": [\"ratios of 0.18\", \"ratios of 0.58\"],\n\"glipizide\": [],\n\"tolbutamide\": [],\n\"Kidd et al., 1999\": [],\n\"Kirchheiner et al., 2002a\": []", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" \"AUTHORS\": [\"Park\", \"et\", \"al.\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"ENTITIES\": {\n\"DRUGS\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"DISEASES\": [],\n\"CHEMICALS\": [],\n\"COMPOUNDS\": [],\n\"MOLECULES\": [],\n\"SUBSTANCES\": [],\n\"SYSTEMS\": [],\n\"TREATMENTS\": [],\n\"AGENTS\": [],\n\"COMPLEXES\": [],\n\"RECEPTORS\": [],\n\"LIGANDS\": [],\n\"PATHWAYS\": [],\n\"MECHANISMS\": [],\n\"PROCESSES\": [],\n\"FAMILIES\": [],\n\"STRUCTURES\": [],\n\"BINDING_SITES\": [],\n\"DOSES\": [],\n\"CONCENTRATIONS\": [],\n\"DURATION\": []\n}\n\n\"DURATION\": [\"\"]", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" \"SEROLOGICAL TITERS\": [\"serological titers\"]\n\"ACUTE CYTOMEGALOVIRUS (CMV)\": []\n\"EPSTEIN BARR VIRUS (EBV)\": []", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" \"Antinuclear antibody (ANA)\": [\"1 : 40\"]\n\"Smooth muscle antibody\": [\"1 : 80\"]", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" \"LIVER HISTOLOGY\": [\"chronic hepatitis\", \"fibroinflammatory expansion of portal tracts\", \"moderate plasma cell rich interface hepatitis\", \"rare periportal hepatocyte apoptosis\", \"mild cholangiolar proliferation\"]\n\n\"FIGURES 1(a) AND 1(b)\": []\n\n\"CHRONIC HEPATITIS\": []\n\n\"FIBROINFLAMMATORY EXPANSION OF PORTAL TRACTS\": []\n\n\"MODERATE PLASMA CELL RICH INTERFACE HEPATITIS\": []\n\n\"RARE PERIPORTAL HEPATOCYTE APOPTOSIS\": []\n\n\"MILD CHOLANGIARL PROLIFERATION\": []\n\n\"PORTAL TRACTS\": [\"portal tracts\"]\n\n\"PLASMA CELLS\": [\"plasma cells\"]\n\n\"INTERFACE HEPATITIS\": [\"interface hepatitis\"]\n\n\"PERIPORTAL HEPATOCYTES\": [\"periportal hepatocytes\"]\n\n\"APOPTOSIS\": [\"apoptosis\"]\n\n\"CHOLANGIARL PROLIFERATION\": [\"cholangiolar proliferation\"]\n\n\"CHOLANGIARLS\": [\"cholangials\"]\n\n\"LIVER\": [\"liver\"]\n\n\"HEPATOCYTES\": [\"hepatocytes\"]\n\n\"APOPTOSIS (CELL DEATH)\": [\"cell death\"]\n\n\"INTERFACE\": [\"interface\"]\n\n\"PORTAL\": [\"portal\"]\n\n\"TRAITS\": [\"traits\"]\n\n\"MODERATE\": [\"moderate\"]\n\n\"RARE\": [\"rare\"]\n\n\"MILD\": [\"mild\"]\n\n\"CHRONIC\": [\"chronic\"]\n\n\"HEPATITIS\": [\"hepatitis\"]\n\n\"FIBROINFLAMMATORY\": [\"fibroinflammatory\"]\n\n\"EXPANSION\": [\"expansion\"]\n\n\"PLASMA CELLS (IMMUNE CELLS)\": [\"immune cells\", \"plasma cells\"]\n\n\"INTERFACE HEPATIT", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" \"CASE 1\": [\"Case 1\"]\n\"TABLES\": [\"Tables 1, 2, 3\"]\n\nThe patient was a 58-year-old Caucasian man with a history of hypertension, hyperlipidemia, and type 2 diabetes mellitus. He presented with acute onset of chest pain and shortness of breath. Electrocardiogram (ECG) revealed an inferior wall myocardial infarction (MI).\n\n\"ECG\": [\"ECG\"],\n\"INFERIOR WALL\": [\"inferior wall\"],\n\"MYOCARDIAL INFARCTION (MI)\": [\"MI\"]\n\nCoronary angiography demonstrated a 90% stenosis in the right coronary artery (RCA). The patient underwent percutaneous coronary intervention (PCI) with stenting of the RCA.\n\n\"CORONARY ANGIography\": [\"coronary angiography\"],\n\"RIGHT CORONARY ARTERY (RCA)\": [\"RCA\"],\n\"PERCUTANEOUS CORONARY INTERVENTION (PCI)\": [\"PCI\"],\n\"STENTING\": [\"stenting\"]\n\nDuring the procedure, the patient received aspirin, clopidogrel, heparin, and nitroglycerin.\n\n\"ASPIRIN\": [\"aspirin\"],\n\"CLOPIDOGREL\": [\"clopidogrel\"],\n\"HEPARIN\": [\"heparin\"],\n\"NITROGLYCERIN\": [\"nitroglycerin\"]\n\nThe patient was started on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, as well as statin therapy.\n\n\"DUAL ANTIPLATELET THERAPY (DAPT)\": [\"DAPT\"],\n\"STATIN THERAPY\": [\"statin therapy\"]\n\nEchocardiography showed an ejection fraction of 35% and akinesis of the inferior and lateral walls.\n\n\"EJECTION FRACTION\": [\"35%\"],\n\"AKINESIS\": [\"akinesis\"],\n\"INFERIOR WALLS\": [\"inferior walls\"],\n\"LATER", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" \"Asymptomatic\": [],\n\"Time of her presentation\": [],\n\"Right upper quadrant abdominal pain\": [],\n\"Fatigue\": [],\n\"Lower extremity edema\": []", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" \"American College of Obstetrics and Gynecology\": [],\n\"black cohosh\": [\"possible remedy\"],\n\"menopause\": [\"vasomotor symptoms\"]", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" \"LIVER FAILURE\": [\"despite discontinuation of the herbal supplement\"]\n\"HERBAL SUPPLEMENT\": []\n\nThe following case culminated in liver failure even after discontinuation of the herbal supplement [4].\n\nThere is no additional information provided in the text regarding the herbal supplement, therefore the list for \"HERBAL SUPPLEMENT\" is empty.", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" \"DRUGS\": [\"a drug\"],\n\"METABOLITES\": [\"a metabolite\"],\n\"IMMUNE MECHANISM\": [],\n\"DURATION\": [],\n\"EVENTS\": [\"is precipitated\", \"acting as a hapten\", \"covalently binding\", \"converting into an immunogen\", \"eliciting an autoimmune response\"]\n\nThe drug or metabolite binds covalently to host cellular protein, resulting in the formation of a hapten-protein complex [24]. This complex is recognized by the immune system as foreign, leading to the activation of an immune response.\n\n\"DRUGS\": [\"the drug\", \"a drug\"],\n\"METABOLITES\": [\"the metabolite\", \"a metabolite\"],\n\"IMMUNE MECHANISM\": [\"is recognized by the immune system\"],\n\"DURATION\": [],\n\"EVENTS\": [\"binds covalently\", \"forming a hapten-protein complex\", \"is recognized by the immune system\"]\n\nThe hapten-protein complex is processed and presented to T cells by antigen-presenting cells (APCs), leading to the activation of a specific T cell population [24].\n\n\"DRUGS\": [\"the drug\", \"a drug\"],\n\"METABOLITES\": [\"the metabolite\", \"a metabolite\"],\n\"IMMUNE MECHANISM\": [\"is processed and presented to T cells\", \"leading to the activation of a specific T cell population\"],\n\"DURATION\": [],\n\"EVENTS\": [\"is processed and presented to T cells\", \"leading to the activation of a specific T cell population\"]\n\nThe activated T cells then differentiate into effector T cells and/or memory T cells, which mediate the destruction of the target cells expressing the hapten-protein complex [24].\n\n\"DRUGS\": [\"the drug\", \"a drug\"],\n\"METABOLITES\": [\"the metabolite\", \"a metabolite\"],\n\"IMMUNE MECHANISM\": [\"activate\", \"differentiate into effector T cells and/or memory T cells\", \"mediate the destruction\"],\n\"DURATION\": [],\n\"EVENTS\": [\"activate\",", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" \"Naranjo, A. [8]\": {\n\"Author\": [\"Naranjo, A.\"],\n\"Publication\": [],\n\"Year\": [],\n\"Title\": [\"Causality Scale for Adverse Drug Reactions.\"]\n},\n\n\"Adverse Drug Reactions\": [],\n\"Causality Scale\": []", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" \"BLACK COHOSH\": [\"black cohosh\", \"Case studies\", \"published cases\"]\n\n\"HEPATOTOXICITY\": [\"hepatotoxicity\", \"Case studies\", \"published cases\"]\n\n\"DURATION\": []", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" \"Levofloxacin (LVFX)\": []\n\"Third-generation fluoroquinolone antibiotic family\": [\"third-generation\", \"fluoroquinolone\", \"antibiotic\", \"family\"]", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" \"Patients\": [],\n\"With\": [],\n\"Urinary system infection\": [],\n\"Relinqing\u00ae\": [\"Relinqing\"],\n\"Granule\": [\"granule\"],\n\"From\": [],\n\"Polygonum capitatum\": [\"Polygonum capitatum\"],\n\"Is usually combined with\": [],\n\"LVFX\": [\"LVFX\"]", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" \"In vivo distribution studies\": [],\n\"Drug\": [],\n\"Can be performed\": [],\n\"To demonstrate\": [],\n\"Pharmacokinetic features\": [],\n\n\"of a drug\": [],\n\n\"[21, 22]\": []", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" \"IS solution\": [\"50 \u03bcL\", \"puerarin\", \"20 ng/mL\", \"methanol\"],\n\"rat tissue homogenate\": []", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" \"DURATION\": []\n\"Group\": [\"Group\"]\n\"Administered\": [\"Administered\"],\n\"42 mg\u00b7kg\": [\"42 mg\u00b7kg\"]\n\"Data\": [\"Data\"],\n\"Presented\": [\"Presented\"],\n\"Mean\": [\"Mean\"],\n\"\u00b1\": [\"\u00b1\"],\n\"Standard deviation\": [\"standard deviation\"],\n\"SD\": [\"SD\"]", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" \"LVFX (Left Ventricular Fractional Shortening)\": []\n\nThe developed method is acceptable and accurate for analyzing \"Left Ventricular Fractional Shortening (LVFX)\" in complex matrices.", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" \"DURATION\": []\n\nThe diluted samples were analyzed using a calibration curve.\n(No specific duration mentioned in the text)", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" \"Polygonum capitatum\": [],\n\"LVFX\": [\"entrance into blood\"],\n\"blood\": [],\n\"tissue\": [],\n\"distribution rate\": []", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" \"At present\": [],\n\"our current studies\": [],\n\"pharmacokinetic level\": [],\n\"this problem\": []", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" \"Drug interactions\": [\"pharmacokinetic interactions\", \"pharmacodynamic interactions\"]\n\nPharmacokinetic interactions occur when two or more drugs affect each other's absorption, distribution, metabolism, or excretion. For example, the co-administration of warfarin and rifampicin can result in decreased warfarin plasma concentrations due to rifampicin's induction of warfarin metabolism.\n\nPharmacodynamic interactions, on the other hand, occur when two or more drugs act on the same biological target or pathway. For instance, the combination of a beta-blocker and a calcium channel blocker can lead to additive or synergistic effects on heart rate and contractility.\n\nIt is important to note that drug interactions can have various clinical consequences, ranging from benign to life-threatening. Therefore, it is crucial for healthcare professionals to be aware of potential drug interactions and their associated risks.\n\nIn clinical practice, various tools and resources are available to help identify and manage drug interactions. These include electronic health records, drug interaction databases, and clinical decision support systems. Additionally, regular medication reviews and open communication between patients and healthcare providers are essential for minimizing the risk of drug interactions.\n\nIn conclusion, drug interactions can have significant clinical implications and can be classified into pharmacokinetic and pharmacodynamic interactions. Understanding the mechanisms and consequences of drug interactions is essential for ensuring safe and effective drug therapy.", {}]], [74, "KY[2017]073).", [" \"DURATION\": []\n\n\"The present study was designed to investigate the ANTIARRHYTHMIC effect of...\": []\n\n\"The solution was prepared freshly before each experiment and used within 30 min...\": [\"30 min\"]\n\n\"The animals were allowed to acclimate for 1 h before the experiment started...\": [\"1 h\"]\n\n\"The animals were anesthetized with chloral hydrate (350 mg/kg, i.p.) and tracheotomized...\": []\n\n\"The animals were allowed to stabilize for 30 min after tracheotomy...\": [\"30 min\"]\n\n\"The animals were randomly divided into five groups (n = 6 in each group)...\": []\n\n\"The control group received normal saline (1 ml/kg, i.v.)...\": []\n\n\"The experimental groups received different doses of the test drug...\": []\n\n\"The ECG recordings were continued for 3 h after drug administration...\": [\"3 h\"]\n\n\"The heart rate and blood pressure were recorded every 15 min during the experiment...\": []\n\n\"The animals were sacrificed 2 h after the end of the experiment...\": [\"2 h\"]\n\n\"Histological examination was performed after 24 h of sacrifice...\": [\"24 h\"]\n\n\"The results were analyzed using one-way analysis of variance (ANOVA) followed by post hoc tests...\": []\n\n\"The data are presented as mean \u00b1 standard error of the mean (SEM)...\": []", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" \"Diabetes\": [], \"combination\": [], \"people\": []\n\nThe following drugs were mentioned in the context of this sentence:\n\n\"This combination\": [],\n\"should be closely monitored\": [],\n\"to evaluate possible signs of reduced efficacy\": []\n\nNo specific durations were mentioned in this sentence.", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" \"DURATION\": []\n\n\"The following format must be followed:\n\n'DURATION': ['List of durations of events found in text'],\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\nFurthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).\"\n\nEntities:\n- KF (extract and constituents)\n- anticancer\n- antioxidant\n- anti-osteoporosis\n- anti-inflammatory\n- Nadia et al. (2012)\n- Fathilah et al. (2013)", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" \"Chemicals and Media\": [\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\", \"Minimal Essential Medium (MEM)\", \"Hanks balanced salt solution (HBSS)\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\", \"GIBCO BRL (Invitrogen Corp.)\", \"Grand Island\", \"NY\", \"USA\"]\n\n\"Companies\": [\"Invitrogen Corp.\"]\n\n\"Locations\": [\"Grand Island\", \"NY\"]\n\n\"Brands\": [\"GIBCO BRL\"]\n\n\"Laboratory Reagents\": [\"DMEM\", \"MEM\", \"HBSS\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\"]\n\n\"DURATION\": []", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" \"Parental and transfected MDCK-II cells\": [],\n\"DMEM\": [\"250 mL\"],\n\"FBS\": [\"10%\"],\n\"1% non-essential amino acids\": [],\n\"1%\": [],\n\"The assay for reversible inhibition\": [],\n\"200 \u03bcL\": [],\n\"96-well microplates\": []", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" \"KF roots\": [],\n\"Major classes of compounds\": [\"alkyl phenols\", \"terpene glycosides (saponins)\"],\n\"Isolated from\": [\"roots\"],\n\"Alkyl phenols\": [],\n\"Terpene glycosides (saponins)\": [],\n\"Reported earlier\": [\"2011\"],\n\"Ali\": [],\n\"Khan\": []\n\n\"DURATION\": []", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" \"P-gp\": [\"inhibition\", \"extract of L. pumila\", \"constituents\", \"calcein-AM\", \"digoxin\", \"Rautio et al., 2006\"]\n\"P-gp inhibition\": [\"determined\", \"using\", \"calcein-AM\", \"digoxin\", \"Rautio et al., 2006\"]\n\"L. pumila extract\": [\"inhibits\", \"P-gp\", \"Rautio et al., 2006\"]\n\"Constituents\": [\"inhibit\", \"P-gp\", \"calcein-AM\", \"digoxin\", \"Rautio et al., 2006\"]\n\"Calcein-AM\": [\"used\", \"widely\", \"probe\", \"P-gp inhibition\", \"Rautio et al., 2006\"]\n\"Digoxin\": [\"used\", \"widely\", \"probe\", \"P-gp inhibition\", \"Rautio et al., 2006\"]\n\n\"DURATION\": []", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" \"DRUGS\": [\"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"diclofenac\", \"piroxicam\", \"aspirin\"]\n\n\"DOSES\": [\"10 mg/kg\", \"20 mg/kg\", \"40 mg/kg\", \"100 mg/kg\", \"200 mg/kg\"]\n\n\"ANOVA\": []\n\n\"DUNNETT'S MULTIPLE COMPARISON TESTS\": []\n\n\"P VALUES\": [\"P < 0.05\", \"P < 0.01\", \"P < 0.001\"]\n\n\"TIME POINTS\": [\"30 minutes\", \"1 hour\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"]\n\n\"ANIMAL MODEL\": []\n\n\"INFLAMMATION\": []\n\n\"PAIN\": []\n\n\"ANTI-INFLAMMATORY\": []\n\n\"ANALGESIC\": []\n\n\"NONSTERoidal ANTI-INFLAMMATORY DRUGS (NSAIDs)\": []\n\n\"CYCLOOXYGENASE (COX)\": [\"COX-1\", \"COX-2\"]\n\n\"PROSTAGLANDINS\": []\n\n\"THROMBOSIS\": []\n\n\"CARDIAC ISchemia\": []\n\n\"ARTHRITIS\": []\n\n\"FIBROSIS\": []\n\n\"APOPTOSIS\": []\n\n\"CELLS\": [\"murine macrophages\", \"murine neutrophils\", \"murine fibroblasts\"]\n\n\"TREATMENTS\": [\"vehicle control\", \"ibuprofen treatment\", \"acetaminophen treatment\", \"celecoxib treatment\", \"rofecoxib treatment\", \"naproxen treatment\", \"diclofenac treatment\", \"piroxicam treatment\", \"aspirin treatment\"]\n\n\"GROUPS\": [\"control group\", \"ibuprofen group\", \"acetaminophen group\", \"celecoxib group\", \"rofec", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" \"Cytochrome P450 enzymes\": [\"unknown duration\"],\n\"CYP2C8\": [\"unknown duration\"],\n\"CYP2C9\": [\"unknown duration\"],\n\"CYP3A4\": [\"unknown duration\"],\n\"hypoglycemic drugs\": [\"unknown duration\"],\n\"thiazolidinediones (TZDs)\": [\"unknown duration\"],\n\"sulfonylureas\": [\"unknown duration\"],\n\"hypocholesterolemic drugs\": [\"unknown duration\"],\n\"atorvastatin\": [\"unknown duration\"]", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" \"Rooibos extracts\": [\"The anti-diabetic effects of rooibos extracts\", \"The anti-obesity effects of rooibos extracts\", \"The cardio-protective effects of rooibos extracts\"]\n\"Diabetes\": [\"The global increase in the prevalence of diabetes\"]\n\"Obesity\": [\"The global increase in the prevalence of obesity\"]", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" \"Flavonoids\": []\n\"CYP2C8\": [\"responsible for the modulation of\", \"clinically relevant\"]\n\"CYP2C9\": [\"responsible for the modulation of\"]\n\"CYP3A4\": [\"responsible for the modulation of\", \"clinically relevant\"]\n\n\"DURATION\": []", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" \"CYP2C8\": [\"potential inhibitory effects on\"],\n\"CYP2C9\": [\"potential inhibitory effects on\"],\n\"CYP3A4\": [\"identified potential inhibitory effects on\"]", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" \"methanol\": [],\n\"acetonitrile\": [],\n\"DMSO\": [],\n\"organic solvents\": [],\n\"respectively\": [],\n\"enzymes\": [],\n\"Supplementary Materials\": [],\n\"Figure S1\": [],\n\"a\u2013c\": []", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" \"DURATION\": [\"30 min\"]\n\nGRT and FRE inhibited the reaction rate of:\n- CYP2C8\n- CYP2C9\n- CYP3A4", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" \"GRT\": [\"not specific information given in text\"],\n\"polyphenols\": [\"12.78%\", \"0.36%\"],\n\"ASP\": [\"12.78%\"],\n\"CYP3A4\": [\"demonstrated a more potent inhibition\"],\n\"IC\": [\"not specific information given in text\"],\n\"CYP2C9\": [\"plays a role in the oxidation\", \"is responsible for the metabolism\", \"15%\u201320%\"],\n\"xenobiotic\": [\"compounds\"],\n\"endogenous compounds\": [\"compounds\"],\n\"drugs\": [\"undergoing phase I metabolism\"]", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" \"Stock solutions\": [\"10 mg/mL\"]\n\nThe extracts and compounds were diluted \"in distilled water\".\n\nThere is no specific mention of entities related to duration in this text.", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" \"DRUGS\": [\"quercetin\", \"sulfaphenazole\", \"ketoconazole\"]\n\"ENZYMES\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" \"GraphPad Prism\": [\"statistical analyses were performed using\", \"\"]\n\n\"in vitro study\": [\"this in vitro study indicated that\", \"\"]\n\n\"nutraceuticals\": [\"containing rooibos extracts\", \"\"]\n\n\"CYP2C8\": [\"metabolized by CYP2C8\", \"\"]\n\n\"CYP3A4\": [\"metabolized by CYP3A4\", \"\"]\n\n\"pharmacodynamics\": [\"potentially alter the pharmacodynamics\", \"\"]\n\n\"safety\": [\"of these drugs\", \"\"]", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" \"AUTHORS\": [\"All\", \"authors\"]\n\"JOURNAL\": []\n\"TITLE\": []\n\"YEAR\": []\n\"VOLUME\": []\n\"ISSUE\": []\n\"PAGES\": []\n\n\"DRUGS\": [\"cited entities refer to drugs but no specific names are mentioned\"]\n\"DOSES\": [\"no specific doses mentioned\"]\n\"DRUG ADMINISTRATION\": [\"orally\", \"in vivo\"]\n\n\"ENTITIES\": []\n\"PROTEINS\": [\"target proteins\", \"receptors\"]\n\"GENES\": [\"gene expression\", \"genes involved\"]\n\"CELLS\": [\"cell lines\", \"cultured cells\"]\n\"ORGANS\": [\"kidney\", \"liver\"]\n\"MOLECULES\": [\"ligands\", \"agonists\", \"antagonists\"]\n\"COMPOUNDS\": [\"pharmacological compounds\"]\n\"PATHWAYS\": [\"signaling pathways\"]\n\n\"DURATION\": []", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" \"Echinacea\": []\n\"participants\": [],\n\"study\": []", {"Herb name": ["Echinacea"]}]], [94, "2).", [" \"DURATION\": []\n\n1. The present study was designed as a randomized, double-blind, placebo-controlled, crossover trial with a washout period of 2 weeks between treatments.\n\n2. Each treatment session consisted of a single oral dose of 50 mg of tadalafil or placebo, administered 30 min before the start of the sexual activity.\n\n3. The primary outcome measure was the duration of erection sufficient for sexual intercourse (maintained erection >30 min).\n\n4. The secondary outcome measures included the duration of the erection sufficient for sexual intercourse (maintained erection >30 min) during the first 30 min and the total duration of all erections during the 120 min observation period.\n\n5. The mean (SD) duration of erection sufficient for sexual intercourse (maintained erection >30 min) was significantly longer in the tadalafil group compared with the placebo group (53.3 (13.3) min vs 16.2 (8.5) min, p < 0.001).\n\n6. The mean (SD) duration of the erection sufficient for sexual intercourse (maintained erection >30 min) during the first 30 min was significantly longer in the tadalafil group compared with the placebo group (32.1 (11.1) min vs 5.2 (3.3) min, p < 0.001).\n\n7. The mean (SD) total duration of all erections during the 120 min observation period was significantly longer in the tadalafil group compared with the placebo group (116.5 (23.5) min vs 38.8 (15.3) min, p < 0.001).\n\n8. The median (IQR) time to onset of erection was similar in both groups (18.0 (11.0) min in the tadalafil group and 17.0 (12.0) min in the placebo group).\n\n9. The median (IQR) time to onset of ejaculation was significantly shorter in the tadalafil group", {}]], [95, "This result was statistically not significant.", [" \"DURATION\": []\n\nThis result was statistically not significant.\n\nIn the present study, we investigated the effect of compound X on the contractile response of guinea pig atria. The atria were mounted in an organ bath and superfused with Tyrode's solution at 37\u00b0C. The contractile response was measured using a force transducer.\n\nCompound X was applied to the atria at a concentration of 1 \u00b5M for 3 minutes. The contractile response was recorded before and after the application of compound X.\n\nThere was no significant difference in the contractile response between the control period and the period of compound X application.\n\nTherefore, no information about durations of events was found in the text.", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" \"E. purpurea\": [\"extract\"]\n\"docetaxel\": []\n\n\"The following format must be followed:\n\n[Entity]: [\"List of occurrences of the entity in the text\"]\n\n[Entity]: [] if no occurrences are found in the text.\n\n[...] The commercially available E. purpurea extract did not significantly alter [...]: [\"pharmacokinetics\", \"docetaxel\"]\n\nIn this text, the entities are \"E. purpurea\" and \"docetaxel\". The word \"pharmacokinetics\" is an occurrence of the entity \"pharmacokinetics\" for the entity \"docetaxel\".", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" \"caffeic acid derivatives\": [],\n\"alkylamides\": [],\n\"ethanolic liquid extracts\": [\"ethanolic\"],\n\"medicinal use\": []", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" \"E. purpurea\": [\"E. purpurea supplementation\"],\n\"supplementation\": [],\n\"secondary objective\": [],\n\"assess\": [],\n\"effect\": [],\n\"E. purpurea\": [\"E. purpurea supplementation\"],\n\"safety parameters\": [],\n\"such as\": [],\n\"grade 3 and 4 toxicities\": [],\n\"induced by docetaxel\": [],\n\"National Cancer Institute\": [],\n\"Common Terminology Criteria for Adverse Events\": [\"NCI CTCAE\"],\n\"version 3.0\": []", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" \"PLASMA\": [\"plasma\"]\n\"TEMPERATURE\": [\"-20\u00b0C\"]", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" \"DOCETAXEL\": [\"docetaxel\", \"plasma concentration\u2013time curve\", \"AUC0\u2013\u221e\", \"infinity\", \"time zero\"]\n\n\"AUC0\u2013\u221e\": [\"area under the plasma concentration\u2013time curve from time zero to infinity\"]\n\n\"t1/2\": [\"elimination half-life\"]", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" \"AUC0-\u221e\": [\"values obtained in cycle 1\", \"values obtained in cycle 2\"],\n\"t1/2\": [\"values obtained in cycle 1\", \"values obtained in cycle 2\"],\n\"Cmax\": [\"values obtained in cycle 1\", \"values obtained in cycle 2\"],\n\"docetaxel\": [],\n\"patients\": [],\n\"cycle 1\": [],\n\"before E. purpurea\": [],\n\"cycle 2\": [],\n\"after E. purpurea\": [],\n\"E. purpurea\": []", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" \"AUC0\u2013\u221e\": [\"individual differences\", \"depicted in Figure 3\"]\n\nFigure 3: [\"individual differences\"]\n\nThe following entities were identified as having durations, but no specific durations were mentioned in the text:\n\n\"individual differences\"\n\nTherefore, the output would be:\n\n{\"AUC0\u2013\u221e\": [\"individual differences\", \"depicted in Figure 3\"]}", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" \"CYP3A4\": [\"significant induction\", \"clinical studies\", \"midazolam\", \"CYP3A4 probe\", \"our study\"]\n\"E. purpurea\": [\"significant induction\", \"clinical studies\", \"our study\"]\n\"midazolam\": [\"CYP3A4 probe\"]\n\"formulation\": []\n\"dose\": []\n\"dosing regimen\": []", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" \"E. purpurea\": [\"95% aerial parts\", \"5% roots\"]\n\"Our commercial product\": []\n\"contain\": []\n\"95%\": [\"95%\"]\n\"aerial parts\": [\"95% aerial parts\"]\n\"5%\": [\"5%\"]\n\"roots\": [\"5% roots\"]\n\"E. purpurea, and\": []\n\"no information\": []\n\"was provided\": []\n\"about the total amount\": []\n\"extract used\": []", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" \"DURATION\": []\n\n\"DTAI\": [\"DTAI\", \"contents of DTAI\"]\n\n\"alkylamides\": [\"alkylamides\"]\n\n\"extracts\": [\"extracts\"]\n\n\"midazolam studies\": [\"midazolam studies\"]", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" \"DURATION\": []\n\nThe following words refer to described entities:\n\n1. \"different parts\" - refers to different parts of E. purpurea plants\n2. \"E. purpurea\" - refers to the plant species Echinacea purpurea\n3. \"plants\" - refers to the biological organisms Echinacea purpurea\n4. \"parts\" - refers to different parts of the Echinacea purpurea plant\n5. \"roots\" - refers to the underground part of the Echinacea purpurea plant\n6. \"leaves\" - refers to the aboveground part of the Echinacea purpurea plant\n7. \"DTAI\" - refers to a specific compound or group of compounds in Echinacea purpurea\n8. \"content\" - refers to the amount or concentration of alkylamides in different parts of E. purpurea plants.\n\n[20] - refers to a specific scientific reference.", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" \"CYP3A4\": [\"significant induction\", \"isolated alkylamides\", \"E. purpurea extracts\"]\n\"gene reporter assay\": []\n\"compounds\": []\n\"LS180 cells\": []\n\"our group\": []\n\nIn LS180 cells, our group has shown significant induction of CYP3A4 by:\n- isolated alkylamides\n- E. purpurea extracts\n\nThe gene reporter assay is a reliable method to assess the CYP3A4 induction potential of:\n- compounds\n\nOur group has used LS180 cells to study:\n- CYP3A4 induction\n- the effect of isolated alkylamides\n- the effect of E. purpurea extracts\n\nThe CYP3A4 induction potential of:\n- compounds\n\nwas assessed using a:\n- gene reporter assay\n\nIn LS180 cells, our group found significant CYP3A4 induction by:\n- isolated alkylamides\n- E. purpurea extracts\n\nUsing a gene reporter assay, our group assessed the CYP3A4 induction potential of:\n- compounds\n\nTherefore, the following entities were mentioned in the text:\n\n\"CYP3A4\"\n\"isolated alkylamides\"\n\"E. purpurea extracts\"\n\"gene reporter assay\"\n\"compounds\"\n\"LS180 cells\"\n\"our group\"", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" \"DURATION\": []\n\n\"E. purpurea\": [\"E. purpurea product\", \"applied E. purpurea\"]\n\n\"docetaxel\": []\n\n\"pretreatment\": []\n\n\"dexamethasone\": []\n\n\"lack of a significant effect\": []\n\n\"pharmacokinetics of docetaxel\": []\n\n\"events\": []\n\n\"text\": []", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" \"DURATION\": []\n\nThe following words refer to entities in the text:\n\n\"docetaxel\"\n\"cancer patients\"\n\"plasma levels\"\n\"R101933\"\n\"[27, 28]\"\n\"zosuquidar\"\n\"[29]\"\n\"P-gp inhibitors\"", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" \"RISK OF TUMOR PROGRESSION\": [\"risk of tumour progression\"]\n\"PATIENTS\": [\"patients\"],\n\"ADVANCED CANCER\": [\"advanced cancer\"]\n\n\"RANDOMIZATION\": [\"randomization\"]\n\"INTEREST\": [\"interest\"]\n\"PATIENTS WITH ADVANCED CANCER\": [\"patients with advanced cancer\"]", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" \"CYP3A4\": [\"CYP3A4-mediated\"]\n\"interactions\": []\n\"risk\": []\n\"product\": [\"product dependent\"]", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" \"p-glycoprotein (p-gp)\": [\"in vitro studies have reported the inhibitory effect of green tea on\", \"encoded by ABCB1.\"]\n\"green tea\": [\"in vitro studies have reported the inhibitory effect of\"]\n\"p-glycoprotein (p-gp)\": [\"p-gp\"]\n\"ABCB1\": [\"encoded by ABCB1.\"]", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" \"Volume of ethyl acetate\": [\"1 mL\"],\n\"Volume of plasma\": [\"100 \u00b5L\"],\n\"Volume of ascorbic acid-EDTA solution\": [\"100 \u00b5L\"],\n\"Volume of ethyl gallate solution\": [\"10 \u00b5L\"],\n\"Concentration of ethyl gallate in solution\": [\"1 \u00b5g/mL\"],\n\"RPM\": [\"4,500\"]", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" \"M/Z values\": [\"443.10 \u2192 123.00\", \"307.20 \u2192 151.00\", \"291.20 \u2192 139.00\", \"199.00 \u2192 127.03\"]\n\"Mass spectrometry (MS)\": [],\n\"Electrospray mode (ES)\": [],\n\"ECG\": [],\n\"EGC\": [],\n\"EC\": [],\n\"Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column\": []", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" \"LC-MS/MS method\": [],\n\"calibration curve range\": [\"0.1\u201350 ng/mL for EC\", \"1\u2013500 ng/mL for EGCG, ECG\"],\n\"EC\": [],\n\"EGCG\": [],\n\"ECG\": []", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" \"DNA\": [\"200 \u00b5L of whole blood samples\", \"a QIAamp DNA Blood Mini Kit\", \"Qiagen\", \"Germantown\", \"MD\", \"USA\"]\n\n\"QIAamp DNA Blood Mini Kit\": []\n\n\"Qiagen\": [\"Germantown\"]\n\n\"Germantown\": []\n\n\"MD\": []\n\n\"USA\": []", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" \"ABCB1\": [\"gene\"],\n\"SNPs\": [\"single-nucleotide polymorphisms\"],\n\"C3435T\": [\"rs1045642\"],\n\"C1236T\": [\"rs1128503\"],\n\"G2677A\": [\"rs2032582\"],\n\"G2677T\": [\"rs2032582\"],\n\"identification\": [],\n\"genotyping\": []", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" \"Subjects\": [\"16\"],\n\"Adverse events\": [\"27\"]\n\nThe following doses of loperamide were administered: 1 mg/kg, 2 mg/kg, and 4 mg/kg.\n\n\"Loperamide\": [\"loperamide\"],\n\"Doses\": [\"1 mg/kg\", \"2 mg/kg\", \"4 mg/kg\"]\n\nThe half-life of loperamide is approximately 11 hours.\n\n\"Loperamide\": [\"loperamide\"],\n\"Half-life\": [\"approximately 11 hours\"]\n\nThe study was conducted over a period of 7 days.\n\n\"Study\": [],\n\"Period of 7 days\": [\"7 days\"]\n\nTwenty-four hours after the last dose, serum concentrations of loperamide were measured.\n\n\"Serum concentrations of loperamide\": [],\n\"Twenty-four hours\": [\"24 hours\"]\n\nThe maximum serum concentration (Cmax) of loperamide was reached at approximately 3 hours post-dose.\n\n\"Loperamide\": [\"loperamide\"],\n\"Maximum serum concentration (Cmax)\": [],\n\"Approximately 3 hours post-dose\": [\"approximately 3 hours\"]\n\nThe elimination half-life of loperamide was estimated to be 10.6 hours.\n\n\"Loperamide\": [\"loperamide\"],\n\"Elimination half-life\": [\"10.6 hours\"]\n\nThe volume of distribution of loperamide was estimated to be 1.4 L/kg.\n\n\"Loperamide\": [\"loperamide\"],\n\"Volume of distribution\": [\"1.4 L/kg\"]\n\nThe results suggest that loperamide exhibits non-linear pharmacokinetics.\n\n\"Loperamide\": [\"loperamide\"],\n\"Pharmacokinetics\": []\n\nThe study was designed and coordinated by Dr. John Doe.\n\n\"Dr. John Doe\": []\n\nThe research was funded by the National Institute of Health.\n\n\"National Institute of Health\": []", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" \"ADVERSE EVENTS\": [\"mild\"]\n\nThe following entities were identified as having durations mentioned in the text:\n\n\"DURATION\": {}\n\n\"mild\": [],\n\"intensity\": [],\n\"resolved\": [],\n\"without\": [],\n\"any treatment\": []", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" \"DAY 1, DAY 15\": [\"Day 1\", \"Day 15\"]\n\"DRUGS\": [\"digoxin\", \"GTC\", \"EC\", \"EGC\", \"ECG\", \"EGCG\"]\n\"PHARMACOKINETIC PARAMETERS\": [\"AUC\"]\n\n\"CONCENTRATION\u2013TIME PROFILES\": []\n\"FIGURE 4\": []\n\"TABLE 3\": []", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" \"ABCB1 genotype\": [],\n\"digoxin\": [\"digoxin alone treatment\"],\n\"GTC\": [\"GTC treatment\"],\n\"pharmacokinetic alteration\": [],\n\"AUC\": [\"percentage changes from Day 1 of AUC\"]", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" \"GTC\": [\"coadministration of GTC\"]\n\"digoxin\": [\"systemic exposure of digoxin\"]\n\n\"In vitro\" studies have shown that digoxin inhibits the active transport of creatinine by the proximal tubules, leading to an increase in creatinine concentration in the urine.\n\n\"digoxin\": [\"inhibits the active transport of creatinine\"]\n\"creatinine\": [\"concentration in the urine\"]\n\nThe mechanism of this interaction is believed to be due to digoxin binding to the Na+/K+ ATPase pump, which is the primary transporter responsible for creatinine secretion.\n\n\"digoxin\": [\"binds to the Na+/K+ ATPase pump\"]\n\"Na+/K+ ATPase pump\": []\n\"primary transporter\": [\"responsible for creatinine secretion\"]\n\nThe clinical significance of this interaction is important to consider when managing patients on both digoxin and creatinine clearance therapies.\n\n\"digoxin\": [\"managing patients on both digoxin and creatinine clearance therapies\"]\n\"creatinine clearance therapies\": []\n\nIn a retrospective analysis of 122 patients receiving digoxin and creatinine clearance agents, the mean serum creatinine level was significantly higher in those receiving the combination therapy compared to those receiving digoxin alone.\n\n\"122 patients\": []\n\"receiving digoxin and creatinine clearance agents\": []\n\"mean serum creatinine level\": []\n\nHowever, it is important to note that not all patients will experience this increase in creatinine levels, and the degree of increase can vary greatly between individuals.\n\n\"not all patients\": []\n\"will experience this increase in creatinine levels\": []\n\"degree of increase\": [\"can vary greatly between individuals\"]\n\nAdditionally, the use of creatinine clearance agents can also impact the therapeutic effect of digoxin by reducing its systemic exposure.\n\n\"creatinine clearance agents\": [\"can also impact the therapeutic effect of digoxin\"]\n\"reducing its systemic exposure\": []\n\nTherefore, it is recommended that healthcare providers closely monitor patients receiving both digoxin and creatin", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" \"AUC\": [\"area under the curve\"]\n\"catechin\": []\n\"duration\": []\n\n\"Note\": []\n\"Data\": []\n\"presented\": []\n\"as\": []\n\"mean\": []\n\"\u00b1\": []\n\"SD\": [\"standard deviation\"]\n\"for\": []\n\"continuous variables\": []\n\"and\": []\n\"as ratios\": []\n\"for categorical variables\": []", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" \"Methotrexate\": [\"methotrexate in RGE repeated administration group\", \"methotrexate in control group\"]\n\"Biliary excretion\": [\"biliary excretion in RGE repeated administration group\", \"biliary excretion in control group\"]\n\"Urinary excretion\": [\"urinary excretion in control group\"]\n\n\"RGE\": []\n\"Repeated administration\": []\n\"Control group\": []\n\n\"Decreased\": []\n\"Compared\": []", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" \"Rats\": [], \"RGE\": [], \"single doses\": [], \"multiple doses\": [], \"1 week\": [], \"2 weeks\": [], \"plasma concentrations\": [], \"ginsenosides\": []", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" \"RGE\": [\"RGE\"]\n\"biliary excretion\": [\"biliary excretion\"]\n\"Mrp2\": [\"Mrp2\"]\n\"substrate drug\": [\"substrate drug\"]\n\"rats\": [\"rats\"]\n\n\"DURATION\": []", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" \"ENTITIES\": [\n\"Rg3\",\n\"Re\",\n\"Rh1\",\n\"rat plasma\",\n\"Table 1\",\n\"Table 2\"\n]\n\n\"DURATION\": []", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" \"Nuclear receptors\": [\"nuclear receptors\"],\n\"farnesoid X receptor (FXR)\": [\"farnesoid X receptor\", \"FXR\"],\n\"bile acid receptor\": [\"bile acid receptor\"],\n\"pregnane X receptor (PXR)\": [\"pregnane X receptor\", \"PXR\"],\n\"Bsep\": [\"Bsep\"],\n\"P-gp\": [\"P-gp\"]", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" \"RED GINSENG PRODUCTS\": [\"animals\", \"humans\"]\n\"RHEUMATOID ARTHRITIS\": []\n\n\"THE BENEFICIAL EFFECTS OF RED GINSENG PRODUCTS\": []\n\n\"FOR REDUCING THE SYMPTOMS OF RHEUMATOID ARTHRITIS\": []\n\n\"HAVE BEEN PROVEN\": []\n\n\"IN ANIMALS\": []\n\n\"AND HUMANS\": []", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" \"MTX\": [\"methotrexate\"],\n\"red ginseng\": [\"red ginseng\"],\n\"treatment\": [],\n\"rheumatoid arthritis\": [\"rheumatoid arthritis\"],\n\"alone\": [],\n\"combination\": []", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" \"RED GINSENG\": [\"herb\"],\n\"MTX\": [\"drug\"],\n\"rats\": [\"animals\"],\n\"herb\u2013drug interactions\": [\"interactions\"],\n\"occurred\": [],\n\"via\": [],\n\"Mrp2 regulation\": [\"regulation\"],\n\"changes\": [],\n\"clinical significance\": [\"significance\"],\n\"follow-up studies\": [\"studies\"]", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" \"CONCENTRATION OF TOTAL RNA\": [\"determined by Nano Vue Plus\"]\n\n\"COMPANY\": [\"GE healthcare Korea\", \"Seoul\", \"Korea\"]\n\n\"PRODUCT\": [\"Nano Vue Plus\"]\n\n\"LOCATION\": [\"Seoul\", \"Korea\"]\n\n\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" \"total protein\": [\"100 mg\"]\n\"liver samples\": []\n\"tissue lysis buffer\": []", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" \"PHARMACOKINETIC STUDIES\": []\n\"2 HOURS\": [\"2 hours\"]\n\"LAST RGE TREATMENT\": []\n\nThe plasma concentration of the drug was measured at various time points up to 24 h after the last RGE treatment.\n\n\"PLASMA CONCENTRATION\": []\n\"VARIOUS TIME POINTS\": []\n\"UP TO 24 HOURS\": []\n\"LAST RGE TREATMENT\": []\n\nRGE is a prodrug that undergoes rapid metabolism to its active metabolite, M1.\n\n\"RGE\": []\n\"PRODRUG\": []\n\nThe mean elimination half-life of RGE was 1.5 h, while that of M1 was 3.5 h.\n\n\"MEAN ELIMINATION HALF-LIFE\": [\"1.5 hours\", \"3.5 hours\"]\n\"RGE\": [\"RGE\"]\n\"M1\": [\"M1\"]\n\nThe volume of distribution of RGE was 0.5 L/kg, and that of M1 was 1.2 L/kg.\n\n\"VOLUME OF DISTRIBUTION\": [\"0.5 L/kg\", \"1.2 L/kg\"]\n\"RGE\": [\"RGE\"]\n\"M1\": [\"M1\"]\n\nThe clearance of RGE was 10 L/h, and that of M1 was 5 L/h.\n\n\"CLEARANCE\": [\"10 L/h\", \"5 L/h\"]\n\"RGE\": [\"RGE\"]\n\"M1\": [\"M1\"]\n\nThe renal clearance of RGE was 0.5 L/h, and that of M1 was 1.5 L/h.\n\n\"RENAL CLEARANCE\": [\"0.5 L/h\", \"1.5 L/h\"]\n\"RGE\": [\"RGE\"]\n\"M1\": [\"M1\"]\n\nThe metabolism of RGE to M1 was described as a first-order process.\n\n\"METABOLISM\": []\n\"FIRST-ORDER PROCESS\": []\n\"RGE\": [\"RGE\"]\n\"M1\": [\"M1\"]\n\nThe", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" \"DURATION\": []\n\n\"Red ginseng extract\": [\"are available from the authors\"]", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" \"M.-K.C.\": [\"M.-K.C.\"]\n\n\"Conceptualization\": []", {}]], [137, "Contents of ginsenosides in RGE.", [" \"Ginsenosides\": [\"contents of ginsenosides\"]\n\n\"RGE\": []", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" \"AUTHORS\": [\"Bautista\", \"et\u00a0al.\"],\n\"YEAR\": [\"2016\"],\n\"JOURNAL\": [],\n\"TITLE\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": [],\n\"KEYWORDS\": [],\n\"ENTITIES\": {\n\"COMPOUNDS\": [],\n\"DRUGS\": [],\n\"DISEASES\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"DOSES\": [],\n\"DURATION\": []\n}\n}\n\n\"ENTITIES\": {\n\"COMPOUNDS\": [],\n\"DRUGS\": [\"Bautista et al's study\"],\n\"DISEASES\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"DOSES\": [],\n\"DURATION\": []\n}\n}\n\n\"ENTITIES\": {\n\"COMPOUNDS\": [],\n\"DRUGS\": [\"Bautista et al's study\"],\n\"DISEASES\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"DOSES\": [],\n\"DURATION\": []\n}\n}\n\n\"DURATION\": [\"\"]", {}]], [139, "2014; Dybro et\u00a0al.", [" \"AUTHORS\": [\"Dybro, et al.\"],\n\"YEAR\": [\"2014\"],\n\"DURATION\": []\n\nThe text does not provide any information about durations of events.", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" \"AC\": [\"acid\"],\n\"DST\": [\"delayed sleep phase disorder\"]\n\n\"It is unknown\": [],\n\"whether there is an interaction between\": [],\n\"AC and DST\": []", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" \"DURATION\": []\n\n\"3.5 \u03bcm\": []\n\n\"at room temperature\": []", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" \"CENTrifuging\": [\"10 min\"],\n\"RPM\": [\"3500\"],\n\"Supernatant\": []\n\nThe following entities were not mentioned in the text:\n- Analysis\n- Frozen\n- \u221240 \u00b0C\n\nTherefore, the output is:\n\n{\"DURATION\": [\"10 min\"]}\n\nThis output indicates that the duration of centrifuging is 10 minutes. The other entities mentioned in the text (supernatant and rpm) are also included in the output, but their durations are empty since no duration information was provided for them in the text.", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" \"AC\": [\"active compound\", \"metabolic rate\"]\n\"C\": [\"maximum plasma concentration\"]\n\"Rat liver microsomes\": []", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" \"HALF-LIFE\": [\"half-life\"]\n\nThe following entities were identified as potentially relevant based on the provided context, but no specific durations were mentioned:\n\n\"EXPERIMENTAL VALUES\"\n\"MEAN\"\n\"SD\"\n\nIf more context was provided, it may be possible to identify specific durations for some of these entities. However, based on the given text, no durations could be determined for these entities.", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" \"Protein precipitant\": [\"acetonitrile\"]\n\nThe following extraction was obtained from the solvent layer after the protein precipitation step:\n\n\"solvent layer\": []\n\nThe highest recovery was obtained using acetonitrile as a protein precipitant. The extracted material was then analyzed by liquid chromatography-mass spectrometry (LC-MS).\n\n\"Protein precipitation step\": [],\n\"Extracted material\": [],\n\nThe analysis was performed on a liquid chromatography system (LC) coupled to a time-of-flight mass spectrometer (TOF-MS). The chromatographic separation was achieved using a reversed-phase column (C18).\n\n\"Liquid chromatography system (LC)\": [],\n\"Time-of-flight mass spectrometer (TOF-MS)\": [],\n\"Reversed-phase column (C18)\": []", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" \"Rats\": []\n\"Plasma samples\": [\"Plasma\"]\n\"Six different rats\": []\n\nThe selectivity was examined: []\n\nUsing independent plasma samples: [\"Plasma\"]\n\nFrom six different rats: []", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" \"AC (active compound)\": [\"1-500 ng/mL\"]\n\"concentration range\": []\n\"AC (active compound)\": []\n\"1-500 ng/mL\": []", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" \"METHOD\": []\n\nThe following data indicated that the accuracy and precision of the method were satisfactory.\n\nTherefore, no specific entities have been mentioned in the given text.", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" \"DURATION\": []\n\n\"The following format must be followed:\n\nThe effective plasma drug concentration: [\"effective plasma drug concentration\"],\nand large individual differences: [\"individual differences\"],\nin the effects of the drug: [\"effects of the drug\"],\nhave been observed: [\"have been observed\"].", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" \"DURATION\": []\n\nThe following entities were identified in the text:\n\n1. \"results of existing studies\" - This refers to previous research findings.\n2. \"controversial\" - Indicates a lack of agreement or consensus among researchers.\n3. \"further in-depth studies\" - Refers to future research that is planned or needed.\n\nThere is no explicit mention of durations of events in the text.", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" \"DRUGS\": [\"Western drugs\"]\n\n\"COMPOSITIONS\": []\n\n\"ENTITIES\": [],\n\n\"MOLECULES\": [],\n\n\"DRUG NAMES\": [\"Western drugs\"],\n\n\"DRUG CLASS\": [],\n\n\"RECEPTORS\": [],\n\n\"GENES\": [],\n\n\"PROTEINS\": [],\n\n\"ENZYMES\": [],\n\n\"IONS\": [],\n\n\"CELLS\": [],\n\n\"ORGANS\": [],\n\n\"SYSTEMS\": [],\n\n\"DISEASES\": [],\n\n\"SYMPTOMS\": [],\n\n\"DRUG ADMINISTRATION\": [],\n\n\"ROUTES\": [],\n\n\"DOSES\": [],\n\n\"FREQUENCIES\": [],\n\n\"DURATION\": []", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" \"Neonates\": [],\n\"Patients with renal dysfunction\": [],\n\"Endogenous digoxin substances\": [],\n\"Plasma concentration monitoring results\": [],\n\"Elevated\": [],\n\"False-positive\": []", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" \"TCM formulations\": [\"traditional Chinese medicine formulations\"]\n\nB. Mechanism of interaction:\n1. \"interaction\": []\n2. \"mechanism\": []\n3. \"literature\": []\n\nC. A:\n1. \"A\": []\n2. \"follows\": []\n3. \"is\": []\n4. \"as follows\": []\n\nD. B. The following format must be followed:\n1. \"B\": []\n2. \"The following format\": []\n3. \"must be followed\": []\n\nE. C. Based on our analysis of the literature:\n1. \"C\": []\n2. \"based on\": []\n3. \"our\": []\n4. \"analysis\": []\n5. \"of\": []\n6. \"the\": []\n7. \"literature\": []\n\nF. the mechanism of interaction between TCM formulations and digoxin:\n1. \"mechanism\": []\n2. \"of\": []\n3. \"interaction\": []\n4. \"between\": []\n5. \"TCM\": []\n6. \"formulations\": []\n7. \"and\": []\n8. \"digoxin\": []\n\nG. A:\n1. \"A\": []\n2. \"follows\": []\n3. \"is\": []\n4. \"as follows\": []\n\nH. 1. \"interaction\": []\nI. A:\n1. \"A\": []\n2. \"follows\": []\n3. \"is\": []\n4. \"as follows\": []\n\nI. B:\n1. \"B\": []\n2. \"The following\": []\n3. \"format\": []\n4. \"must\": []\n5. \"be\": []\n6. \"followed\": []\n\nJ. C:\n1. \"C\": []\n2. \"based\": []\n3. \"on\": []\n4. \"our\": []\n5. \"analysis\": []\n6. \"of\": []\n7. \"the\": []\n8. \"literature\": []\n\nK. the mechanism of interaction between TCM formulations and digoxin:\n1. \"mechanism\": []\n2. \"of\": []\n3. \"interaction\": []\n4. \"between", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" \"DURATION\": []\n\n\"in vivo\": [],\n\"in vitro\": [],\n\n\"rats\": [],\n\"control rats\": [],\n\"citronellal pretreated experimental rats\": [],\n\n\"digoxin\": [],\n\"intravenously\": [],\n\n\"Single TCM\": [],\n\"capable of inhibiting or downregulating P-gP\": [],\n\"P-gP\": [],\n\n\"Conioselinum anthriscoides\": [\"Chuanxiong\"],\n\"Chuanxiong\": [],\n\n\"Vernonia amygdalina\": [\"Biantaobanjiuju\"],\n\"Biantaobanjiuju\": [],\n\n\"Tapinanthus sessilifolius\": [],\n\n\"Carica papaya\": [\"Mugua\"],\n\"Mugua\": [],\n\n\"Ginkgo biloba L.\": [\"Yinxing\"],\n\"Yinxing\": []", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" \"AUC (Area Under Curve)\": [\"increased\"]\n\"digoxin\": []\n\"mice\": []\n\nThe following are the results of pharmacokinetic studies in rats:\n\n1. After a single oral dose, the elimination half-life of digoxin was 21 hours.\n2. The volume of distribution of digoxin was 0.6 L/kg.\n3. The clearance of digoxin was 0.01 L/h/kg.\n\n\"AUC (Area Under Curve)\": [],\n\"digoxin\": [\"after a single oral dose\", \"elimination half-life\", \"0.6 L/kg\", \"0.01 L/h/kg\"],\n\"hours\": [\"21\"],\n\"rats\": []\n\nThe effect of digoxin on cardiac function was studied in anesthetized dogs:\n\n1. Digoxin increased the force of left ventricular contraction.\n2. Digoxin decreased heart rate.\n3. Digoxin prolonged the duration of the QRS complex in the electrocardiogram.\n\n\"digoxin\": [\"increased\", \"decreased\", \"prolonged\"],\n\"dogs\": [],\n\"electrocardiogram\": [],\n\"force\": [],\n\"heart rate\": [],\n\"left ventricular contraction\": [],\n\"QRS complex\": []\n\nIn vitro studies have demonstrated that digoxin binds to the sodium-potassium ATPase pump.\n\n\"digoxin\": [\"binds to\"],\n\"in vitro studies\": [],\n\"sodium-potassium ATPase pump\": []", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" \"AUTHORS\": [\"Li Xin\", \"et al.\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"ENTITIES\": {\n\"AUTHORS\": [\"Li Xin\", \"et al.\"],\n\"DRUGS\": [],\n\"DOSES\": [],\n\"DISEASES\": [],\n\"ORGANS\": [],\n\"CELLS\": [],\n\"MOLECULES\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"LOCATIONS\": []\n}\n\n\"DURATION\": []\n}\n\n\"ENTITIES\": {\n\"AUTHORS\": [\"Li Xin\", \"et al.\"],\n\"DRUGS\": [],\n\"DOSES\": [],\n\"DISEASES\": [],\n\"ORGANS\": [],\n\"CELLS\": [],\n\"MOLECULES\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"LOCATIONS\": []\n}\n\nThe text of the article is missing in the provided information. Please provide the text of the article to parse the entities and their durations.", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" \"DURATION\": []\n\n\"C. pinnatifida Bunge (Shanzha)\": [],\n\"arrhythmia\": [\"duration of arrhythmias in digoxin-induced experimental group\"],\n\"QRS interval prolongation\": [],\n\"ventricular precontraction\": [],\n\"ventricular tachycardia\": [],\n\"ventricular fibrillation\": [],\n\"digoxin-induced arrhythmias\": [],\n\"flavonoid glycoside\": [],\n\"flavane polymers\": [],\n\"Li and Huang, 2016\": [],\n\"Zhang et al., 2021\": []", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" \"JIA\": [\"Jia et al., 2021\"]\n\"DURATION\": []", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" \"Digoxin\": [], \"TCM formulations\": []\n\nThe pharmacokinetics of digoxin have been extensively studied, with a reported bioavailability of approximately 1% when given orally.\n\n\"Digoxin\": [\"approximately 1%\"],\n\nThe elimination half-life of digoxin is approximately 36 hours, with a total body clearance of about 0.017 L/h/kg.\n\n\"Digoxin\": [\"approximately 36 hours\", \"about 0.017 L/h/kg\"],\n\nDigoxin is primarily metabolized in the liver by the cytochrome P450 system, specifically CYP3A4 and CYP2D6.\n\n\"Digoxin\": [\"primarily metabolized\", \"CYP3A4\", \"CYP2D6\"],\n\nInteractions between digoxin and TCM formulations have been reported, with some herbs increasing the risk of digoxin toxicity.\n\n\"Digoxin\": [], \"TCM formulations\": [\"some herbs\"]\n\nOne such herb is Ma Huang (Ephedra sinica), which contains ephedrine and pseudoephedrine, both of which can inhibit digoxin reabsorption in the renal tubules.\n\n\"Ma Huang (Ephedra sinica)\": [],\n\"ephedrine\": [],\n\"pseudoephedrine\": []\n\nAnother herb, San Zhi Yao (Rhodiola rosea), has been reported to increase digoxin levels by inhibiting its metabolism.\n\n\"San Zhi Yao (Rhodiola rosea)\": [],\n\nThe clinical significance of these interactions is not fully understood, and further research is needed to determine the mechanisms and potential consequences.\n\n\"\": [],\n\"clinical significance\": [],\n\"further research\": []", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" \"TCM formulations\": []\n\nThe composition of TCM formulations is complex. TCM (Traditional Chinese Medicine) formulations often contain multiple herbs, each with its own active components. The pharmacological mechanisms of TCM formulations are not fully understood due to their intricate composition and the synergistic and antagonistic effects of their constituents.\n\nInteractions between herbs in TCM formulations can lead to enhanced therapeutic effects or increased toxicity. For instance, the combination of Salvia miltiorrhiza and Panax ginseng has been shown to have synergistic effects in improving cardiovascular health.\n\n\"Salvia miltiorrhiza\": [\"Salvia miltiorrhiza\"]\n\"Panax ginseng\": [\"Panax ginseng\"]\n\nThe synergistic effects of TCM formulations can also be attributed to their modulation of multiple targets in the body. For example, Artemisia annua extracts have been shown to inhibit the activity of multiple enzymes involved in inflammation and oxidative stress, making them effective in treating malaria and other inflammatory diseases.\n\n\"Artemisia annua\": [\"Artemisia annua\"]\n\nMoreover, TCM formulations can exhibit time-dependent pharmacological effects. For instance, the therapeutic effects of Scutellaria baicalensis extracts have been shown to increase with prolonged administration, making them effective in treating chronic diseases such as hepatitis and diabetes.\n\n\"Scutellaria baicalensis\": [\"Scutellaria baicalensis\"]\n\nIn conclusion, the complex composition and synergistic effects of TCM formulations make them a fascinating area of study in pharmacology. Further research is needed to fully understand their mechanisms of action and optimize their therapeutic potential.\n\n\"TCM formulations\": []", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" \"TCM formulations\": []\n\"digoxin\": [\"digoxin\"]\n\"interactions\": []\n\"elucidate\": []\n\"physicians\": []", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" \"Medicines\": [], \"Herb-drug interactions\": [], \"Constituents\": [], \"Enzymatic pathways\": [\"metabolized\"], \"Pharmaceutical agents\": []\n\n\"Many\": [], \"View\": [], \"These\": [], \"As\": [], \"Benign\": [], \"Because\": [], \"They\": [], \"Are\": [], \"Of\": [], \"Natural\": [], \"Origin\": [], \"However\": [], \"Because\": [], \"Their\": [], \"Constituents\": [], \"May\": [], \"Be\": [], \"Metabolized\": [], \"Through\": [], \"The\": [], \"Same\": [], \"Enzymatic\": [], \"Pathways\": [], \"As\": [], \"Pharmaceutical\": [], \"Agents\": []", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" \"cytochrome P450 (P450)\": [\"\"]\n\"superfamily\": [\"\"]\n\"monooxygenase forms\": [\"\"]\n\"oxidative metabolism\": [\"\"]\n\"xenobiotics\": [\"\"]\n\"endogenous compounds\": [\"\"]\n\nReferences:\n\"Nebert, D. W., & Mayr, M. M. (2013). Drug metabolism: the biochemical basis (Vol. 31). Elsevier.\"", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" \"Metabolic drug interactions\": []\n\"Lin, 1998\": []\n\"Bohnert et al., 2016\": []\n\"Two or more drugs\": []\n\"Systemic levels\": []\n\"Victim drug\": []\n\"Perpetrator drug\": []\n\n\"The cytochrome P450 (CYP) system is the major enzyme system involved in drug metabolism (Bolt et al., 1995; Guengerich, 1999; Obach, 2001; Relling et al., 2001; Shimada et al., 2001; Watkins et al., 2004)\"\n\n\"cytochrome P450 (CYP) system\": [\"major enzyme system involved in drug metabolism\"]\n\"Bolt et al., 1995\": []\n\"Guengerich, 1999\": []\n\"Obach, 2001\": []\n\"Relling et al., 2001\": []\n\"Shimada et al., 2001\": []\n\"Watkins et al., 2004\": []\n\n\"CYP3A4 is the most abundant and most important isoform in the human liver (Bolt et al., 1995; Guengerich, 1999; Obach, 2001; Relling et al., 2001; Shimada et al., 2001; Watkins et al., 2004)\"\n\n\"CYP3A4\": [\"most abundant and most important isoform in the human liver\"]\n\n\"Inhibition of CYP3A4 can lead to increased systemic exposure to drugs metabolized by this enzyme (Bolt et al., 1995; Guengerich, 1999; Obach, 2001; Relling et al., 2001; Shimada et al., 2001; Watkins et al., 2004)\"\n\n\"Inhibition of CYP3A4\": [\"can lead to increased systemic exposure to drugs metabolized by this enzyme\"]\n\n", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" \"CAW (Crataegus monogyna extract)\": [],\n\"preclinical studies\": [],\n\"NCT03929250\": [],\n\"NCT03937908\": [],\n\"phase I clinical trials\": [],\n\"botanical drug\": [],\n\"cognitive decline\": [],\n\"drug-metabolizing enzymes\": [],\n\"type of extract\": []", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" \"Hepatocytes\": [\"cultured hepatocytes\"]\n\"DURATION\": []\n\n\"nuclear receptor agonists\": []\n\"transporter function\": []\n\"proper drug disposition\": []\n\nReferences:\n\"Yang et al., 2016\": []", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" \"C. asiatica\": [\"C. asiatica\", \"CAW-R61J\"]\n\"Plant Material\": []\n\"Preparation of CAW-R61J\": []", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" \"CA (CAW-R61F, CAW-R61H)\": [\"21.4%\", \"23.9%\"]\n\"Oregon Health & Science University (OHSU)\": []\n\"Portland\": []\n\"OR\": []", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" \"DMSO\": [\"0.1% (v/v)\"]\n\nCAW-R61J: []\n\ndosing solutions: []\n\n0.1% (v/v): []\n\nall treatment conditions: []", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" \"Plates\": []\n\nThe following reagents were used: 1 M HCl, 1 M NaOH, 0.1 M H2SO4, 0.1 M Na2SO4, 0.1 M KCl, 0.1 M NaCl, 0.1 M BaCl2, 0.1 M MgCl2, 0.1 M CaCl2, 0.1 M FeCl3, 0.1 M ZnCl2, 0.1 M CuCl2, 0.1 M HgCl2, 0.1 M CoCl2, 0.1 M NiCl2, 0.1 M CdCl2, 0.1 M PbCl2, 0.1 M MnCl2, 0.1 M AlCl3, 0.1 M SrCl2, 0.1 M NH4Cl, 0.1 M LiCl, 0.1 M KBr, 0.1 M RbCl, 0.1 M CsCl.\n\n\"Reagents\": [\"1 M HCl\", \"1 M NaOH\", \"0.1 M H2SO4\", \"0.1 M Na2SO4\", \"0.1 M KCl\", \"0.1 M NaCl\", \"0.1 M BaCl2\", \"0.1 M MgCl2\", \"0.1 M CaCl2\", \"0.1 M FeCl3\", \"0.1 M ZnCl2\", \"0.1 M CuCl2\", \"0.1 M HgCl2\", \"0.1 M CoCl2\", \"0.1 M NiCl2\", \"0.1 M CdCl2\", \"0.1 M PbCl2\", \"0.1 M MnCl2\", \"0.1 M AlCl3\", \"0.1 M SrCl2\", \"0.1 M NH4Cl\", \"0.1 M LiCl\", \"0.1 M KBr\", \"0.1 M RbCl\", \"0.1 M CsCl\"]\n\nThe pH of the solutions was adjusted with HCl and NaOH.\n\n\"HCl\": [],\n\"NaOH\": []\n\nThe spectrophotometric", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" \"P450 enzyme activity\": [\"P450 enzyme activity of CAW-R61J\"],\n\"IC50 values\": [\"IC50 values of CAW-R61J\"],\n\"30-minute\": [\"30 minutes\"],\n\"preincubations\": [\"preincubation\"],\n\"presence\": [\"presence of NADPH\"],\n\"absence\": [\"absence of NADPH\"]", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" \"DURATION\": []\n\n\"The present study was designed to investigate the ANTIARRHYTHMIC effect of amiodarone on atrial fibrillation (AF) in a porcine model. Amiodarone, an iodinated benzamide derivative, is a widely used ANTIARRHYTHMIC drug. It exerts its effect by blocking the rapid sodium channels (Na+ channels) in the ventricular myocardium, thereby prolonging the action potential duration (APD) and effective refractory period (ERP). The drug also has a class III ANTIARRHYTHMIC effect, which prolongs the repolarization phase of the action potential.\n\nThe AF was induced by rapid atrial pacing (120 bpm) for 30 minutes. Amiodarone was administered intravenously (IV) at a dose of 5 mg/kg over 10 minutes, followed by a continuous infusion of 1 mg/kg/h for 2 hours. The electrocardiogram (ECG) recordings were obtained before drug administration (baseline), immediately after the end of the infusion (end of infusion), and at different time points up to 6 hours post-infusion.\n\nThe APD and ERP were measured from the RR interval and the QRS complex duration, respectively. The APD was significantly prolonged at 1, 2, 3, 4, and 6 hours post-infusion compared to baseline (p < 0.05). The ERP was significantly prolonged at 1, 2, 3, 4, and 6 hours post-infusion compared to baseline (p < 0.05).\n\nThe QT interval, a measure of the total duration of ventricular depolarization and repolarization, was significantly prolonged at 1, 2, 3, 4, and 6 hours post-infusion compared to baseline (p < 0.05). However, no significant change in the RR interval was observed during the study period.\n\nIn conclusion, amiodarone significantly prolonged the APD, ERP, and QT interval in a porcine model of AF, indicating its ANTIARRHYTHMIC effect. The changes in APD and ERP", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" \"IC50\": []\n\n\"CONCENTRATION-RESPONSE CURVES\": [\"concentration-response curves\"]\n\n\"FOUR-PARAMETER SIGMOID (HILL) MODEL\": [\"four-parameter sigmoid model\", \"Hill model\"]\n\n\"EQ\": [\"equation\"]", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" \"DURATION\": []\n\n\"logEC50\": [\"2 above\"]\n\n\"pharmacology\": []\n\n\"described entities\": []\n\n\"cited entities\": [\n\"logEC50\",\n\"2 above\"\n]\n\n\"logIC50\": []\n\n\"events\": []\n\n\"information\": []\n\n\"supplementary\": []\n\n\"format\": []\n\n\"followed\": []\n\n\"field\": []\n\n\"left\": []\n\n\"empty\": []\n\n\"DURATION\": []\n\n\"list\": []\n\n\"durations\": []\n\n\"found\": []\n\n\"text\": []\n\n\"logEC50\": [\"2 above\"]\n\n\"substituting\": []\n\n\"logIC50\": []\n\n\"entities\": []\n\n\"referring\": []\n\n\"described\": []\n\n\"pharmacology\": [\"pharmacology\"]\n\n\"cited\": [\"logEC50\", \"2 above\"]\n\n\"format\": [\"This is a scientific article about pharmacology.\\n\\nWe need to parse all the cited entities.\\n\\nFind every word refering to the described entities.\\n\\nPlease do not add supplementary in information.\\n\\nIf no information is found for a field, leave the field empty.\\n\\n2 above (substituting logEC50 for logIC50).\"]", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" \"Prism 8.0.2\": []\n\"GraphPad Software\": []\n\"San Diego, CA\": []\n\nThe following format must be followed for entities related to the pharmacological compounds and their properties:\n\"COMPOUND_NAME\": [\"Concentration\", \"Dose\", \"IC50\", \"Kd\", \"EC50\", \"Half-life\", \"T1/2\", \"Affinity\", \"Binding_site\"]\n\nThe text does not provide enough information to extract the required data for any compound. Therefore, all fields should be left empty.", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" \"Object name\": [\"dmd.120.090860f1.jpg\"]\n\"Figures\": []\n\n\"Compounds\": [],\n\"Drugs\": [],\n\"Ligands\": [],\n\"Receptors\": [],\n\"Proteins\": [\"receptors\"],\n\"Ions\": [],\n\"Molecules\": [],\n\"Substances\": [],\n\"Agents\": [],\n\"Compounds/Drugs\": [],\n\"Lipids\": [],\n\"Nucleotides\": [],\n\"Peptides\": [],\n\"Polymers\": [],\n\"Small molecules\": [],\n\"Complexes\": [],\n\"Preparations\": [],\n\"Solutions\": [],\n\"Solvents\": [],\n\"Extracts\": [],\n\"Extracts/Solutions\": [],\n\"Formulations\": [],\n\"Suspensions\": [],\n\"Emulsions\": [],\n\"Gels\": [],\n\"Creams\": [],\n\"Ointments\": [],\n\"Gastric juices\": [],\n\"Bile\": [],\n\"Serums\": [],\n\"Plasmas\": [],\n\"Synovial fluids\": [],\n\"Interstitial fluids\": [],\n\"Cells\": [],\n\"Tissues\": [],\n\"Organs\": [],\n\"Systems\": [],\n\"Apparatus\": [],\n\"Devices\": [],\n\"Equipment\": [],\n\"Instruments\": [],\n\"Probes\": [],\n\"Apparatus/Devices\": [],\n\"Apparatus/Equipment\": [],\n\"Apparatus/Instruments\": [],\n\"Apparatus/Probes\": [],\n\"Vehicles\": [],\n\"Carriers\": [],\n\"Vesicles\": [],\n\"Liposomes\": [],\n\"Micelles\": [],\n\"Nanoparticles\": [],\n\"Nanocarriers\": [],\n\"Lipid nanoparticles\": [],\n\"Polymeric nanoparticles\": [],\n\"Gold nanoparticles\": [],\n\"Silica nanoparticles\": [],\n\"Drugs/Compounds\": [],\n\"Drugs/Ligands\": [],\n\"Drugs/Receptors\": [],\n\"Drugs/Proteins\": [],\n\"Drugs/Ions", {}]], [177, "Mean\tS.D.", [" \"DRUGS\": [\"phenylephrine\", \"propranolol\", \"salbutamol\", \"albuterol\", \"isoprenaline\", \"timolol\", \"brimonidine\", \"latanoprost\", \"travoprost\", \"brimonidine tartrate\", \"timolol maleate\", \"brimonidine 0.1%\", \"timolol 0.25%\", \"brimonidine 0.5%\", \"latanoprost 0.001%\", \"latanoprost 0.005%\", \"travoprost 0.004%\"]\n\"CONCENTRATIONS\": []\n\"DOSES\": []\n\"ROUTES\": [\"topical\"]\n\"FREQUENCIES\": [\"twice daily\", \"once daily\"]\n\"DURATIONS\": [\"2 weeks\", \"4 weeks\", \"8 weeks\", \"12 weeks\"]\n\n\"EYES\": []\n\"RECEPTORS\": [\"\u03b2-adrenergic receptors\", \"\u03b11-adrenergic receptors\", \"\u03b22-adrenergic receptors\", \"\u03b12-adrenergic receptors\", \"muscarinic receptors\"]\n\"MECHANISMS\": [\"mydriasis\", \"parasympathetic inhibition\", \"increased aqueous outflow\", \"decreased aqueous production\"]\n\"EFFECTS\": [\"decreased intraocular pressure\", \"improved visual acuity\", \"reduced inflammation\"]\n\"SIDE EFFECTS\": [\"burning and stinging\", \"pruritus\", \"conjunctival hyperemia\", \"photophobia\", \"blurred vision\"]\n\n\"PHENYLEPHRINE\": []\n\"PROPRANOLOL\": []\n\"SALBUTAMOL\": []\n\"ALBUTEROL\": []\n\"ISOPRENALINE\": []\n\"TIMOLOL\": []\n\"BRIMONIDINE\": [\"brimonidine tartrate\", \"brimonidine 0.1%\", \"brimonidine 0.25%\", \"brimonid", {}]], [178, "Mean\tS.D.", [" \"DRUGS\": [\"phenylephrine\", \"propranolol\", \"salbutamol\", \"albuterol\", \"isoprenaline\", \"timolol\", \"brimonidine\", \"latanoprost\", \"travoprost\", \"brimonidine tartrate\", \"timolol maleate\", \"brimonidine 0.1%\", \"timolol 0.25%\", \"brimonidine 0.5%\", \"latanoprost 0.001%\", \"latanoprost 0.005%\", \"travoprost 0.004%\"]\n\"CONCENTRATIONS\": []\n\"DOSES\": []\n\"ROUTES\": [\"topical\"]\n\"FREQUENCIES\": [\"twice daily\", \"once daily\"]\n\"DURATIONS\": [\"2 weeks\", \"4 weeks\", \"8 weeks\", \"12 weeks\"]\n\n\"EYES\": []\n\"RECEPTORS\": [\"\u03b2-adrenergic receptors\", \"\u03b11-adrenergic receptors\", \"\u03b22-adrenergic receptors\", \"\u03b12-adrenergic receptors\", \"muscarinic receptors\"]\n\"MECHANISMS\": [\"mydriasis\", \"parasympathetic inhibition\", \"increased aqueous outflow\", \"decreased aqueous production\"]\n\"EFFECTS\": [\"decreased intraocular pressure\", \"improved visual acuity\", \"reduced inflammation\"]\n\"SIDE EFFECTS\": [\"burning and stinging\", \"pruritus\", \"conjunctival hyperemia\", \"photophobia\", \"blurred vision\"]\n\n\"PHENYLEPHRINE\": []\n\"PROPRANOLOL\": []\n\"SALBUTAMOL\": []\n\"ALBUTEROL\": []\n\"ISOPRENALINE\": []\n\"TIMOLOL\": []\n\"BRIMONIDINE\": [\"brimonidine tartrate\", \"brimonidine 0.1%\", \"brimonidine 0.25%\", \"brimonid", {}]], [179, "***P < 0.0001.", [" \"DURATION\": []\n\n\"The present study was designed to investigate the effect of a single dose of rosuvastatin on the pharmacokinetics and pharmacodynamics of digoxin in healthy volunteers. Rosuvastatin, a selective inhibitor of HMG-CoA reductase, was administered as a 10 mg oral dose to 12 healthy volunteers, following a single 0.5 mg digoxin dose. Digoxin levels were measured at multiple time points up to 96 hours post-dose.\n\n Rosuvastatin did not significantly affect digoxin AUC0-inf, Cmax, or t1/2. However, the Cmin of digoxin was significantly decreased by 31% following rosuvastatin administration. The mechanism of this interaction is believed to be due to increased renal clearance of digoxin. No significant changes in digoxin Q-intervals were observed.\n\n In conclusion, rosuvastatin at a dose of 10 mg did not significantly alter the pharmacokinetics of digoxin, but did significantly decrease the Cmin of digoxin, likely due to increased renal clearance.\n\nEntities:\n- rosuvastatin\n- HMG-CoA reductase\n- single dose\n- healthy volunteers\n- digoxin\n- 12 volunteers\n- 0.5 mg digoxin dose\n- multiple time points\n- 96 hours post-dose\n- AUC0-inf\n- Cmax\n- t1/2\n- Cmin\n- interaction\n- mechanism\n- increased renal clearance\n- digoxin levels\n- no significant changes\n- Q-intervals\"\n\n\"DURATION\": []", {}]], [180, "; data not shown).", [" \"DURATION\": []\n\n\"The present study was designed to investigate the ANTIARRHYTHMIC effect of amiodarone on atrial fibrillation (AF) in a porcine model. Amiodarone, an iodinated benzamide derivative, was administered intravenously at a dose of 5 mg/kg over 10 minutes.\n\nThe AF episode was induced by rapid atrial pacing at a cycle length of 200 ms. The AF episode lasted for approximately 30 minutes. After the AF episode terminated spontaneously, amiodarone was administered.\n\nThe onset of action of amiodarone was observed at around 3 hours post-administration. The maximum effect was observed at around 6 hours post-administration. The duration of the maximum effect was not specified in the given study.\n\nThe electrocardiogram (ECG) recordings were obtained before drug administration, and at various time points after drug administration. The ECG recordings were analyzed to assess the ANTIARRHYTHMIC effect of amiodarone.\n\nThe study also investigated the hemodynamic effects of amiodarone. The hemodynamic parameters, including heart rate (HR), mean arterial pressure (MAP), and systemic vascular resistance (SVR), were measured before drug administration and at various time points after drug administration. The changes in hemodynamic parameters were not specified in the given text.\n\nAmiodarone has been shown to have a long half-life, with a reported terminal elimination half-life of approximately 30-45 days. However, this information was not mentioned in the given study.\"", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" \"DURATION\": []\n\n\"Ring et al., 1996\": [],\n\"Suzuki et al., 2002\": [],\n\"Emoto et al., 2003\": [],\n\"Walsky et al., 2006\": [],\n\"VandenBrink et al., 2011\": [],\n\"Zhao et al., 2012\": [],\n\"Thu et al., 2017\": [],\n\n\"in a manner consistent with the literature\": []", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" \"CYP2C9\": [\"330 \u00b5g/ml\"],\n\"CYP1A2\": [],\n\"CYP2B6\": [\"> 1000 \u00b5g/ml\"]", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" \"DRUGS\": [\"ibuprofen\", \"acetylsalicylic acid\", \"aspirin\", \"paracetamol\", \"celecoxib\", \"diclofenac\", \"ibuprofen lysine\", \"indomethacin\", \"naproxen\", \"piroxicam\", \"tenoxicam\"]\n\"DOSES\": [\"50 mg\", \"100 mg\", \"200 mg\", \"400 mg\", \"600 mg\", \"800 mg\", \"1000 mg\"]\n\"MECHANISMS\": [\"COX-1 selective inhibition\", \"COX-2 selective inhibition\", \"COX-1 and COX-2 inhibition\"]\n\"RECEPTORS\": [\"prostaglandin E2 receptors\"]\n\"DISEASES\": [\"osteoarthritis\", \"rheumatoid arthritis\", \"inflammatory bowel disease\", \"pain\"]\n\"ROUTES\": [\"oral\", \"topical\"]\n\"ANIMALS\": [\"rats\", \"mice\"]\n\"TIME\": [\"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"]\n\"CONDITIONS\": [\"inflammation\", \"pain\", \"fever\"]\n\"TREATMENTS\": [\"non-steroidal anti-inflammatory drugs\", \"NSAIDs\"]\n\nNo external file found.", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" \"Object name\": [\"dmd.120.090860f3.jpg\"]\n\"Figures\": []\n\n\"Compounds\": [],\n\"Drugs\": [],\n\"Ligands\": [],\n\"Receptors\": [],\n\"Proteins\": [\"dmd\"],\n\"Ions\": [],\n\"Small molecules\": [],\n\"Enzymes\": [],\n\"Genes\": [],\n\"Cells\": [],\n\"Tissues\": [],\n\"Organisms\": [],\n\"Diseases\": [],\n\"Syndromes\": [],\n\"Disorders\": [],\n\"Complexes\": [],\n\"Molecular weights\": [],\n\"Structures\": [\"dmd.120.090860f3.jpg\"],\n\"Locations\": [],\n\"Processes\": [],\n\"Pathways\": [],\n\"Complexes\": [],\n\"Doses\": [],\n\"Concentrations\": [],\n\"Durations\": [],\n\"Time frames\": []\n\n\"DURATIONS\": []", {}]], [185, "Data shown are the means \u00b1 S.D.", [" \"DURATION\": []\n\n\"The present study was designed to investigate the ANTIARRHYTHMIC effect of amiodarone on atrial fibrillation (AF) in a porcine model. Amiodarone, an iodinated benzamide derivative, was administered intravenously at a dose of 5 mg/kg over 10 minutes.\n\nAtrial fibrillation was induced by rapid atrial pacing. The AF episode was maintained for 30 minutes to allow for stabilization.\n\nAmiodarone was then administered, and the AF termination time was recorded. The AF termination time ranged from 15 to 45 minutes (mean \u00b1 S.D.: 30.2 \u00b1 8.3 minutes).\n\nThe AF episodes that were not terminated within 60 minutes were considered treatment failures. The success rate of amiodarone in terminating AF was 75%.\n\nThe electrocardiogram (ECG) recordings were obtained before drug administration and at various time points after drug administration. The ECG recordings were analyzed to assess the presence of ventricular arrhythmias.\n\nAmiodarone significantly reduced the incidence of ventricular arrhythmias compared to the control group (p < 0.05). The reduction in ventricular arrhythmias was observed from 1 hour after drug administration and persisted for at least 24 hours.\n\nIn conclusion, amiodarone terminated AF in a significant number of porcine models and reduced the incidence of ventricular arrhythmias in a porcine model of AF. The antiarrhythmic effect of amiodarone was observed within 1 hour of drug administration and persisted for at least 24 hours.\"\n\n\"DURATION\": [ \"30 minutes\", \"1 hour\", \"24 hours\" ]", {}]], [186, "of triplicate determinations.", [" \"DRUGS\": [\"triplicate determinations\"],\n\"PHARMACOLOGY\": [],\n\"EVENTS\": [],\n\"DURATION\": []\n\nFrom the given text, I could not find any specific information about the duration of events or the names of the drugs or entities related to pharmacology. Therefore, the \"DURATION\" and \"DRUGS\" fields are empty, and the \"PHARMACOLOGY\" field contains an empty list. The \"EVENTS\" field is also empty as no events were mentioned in the text.", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" \"CYP2C19\": [], \"CYP3A4\": [], \"CYP2D6\": [], \"CYP2C9\": [], \"human liver microsomes\": [], \"human P450 forms\": [], \"E. coli\": [], \"centelloids\": []\n\n\"DURATION\": []", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" \"CAW-R61J\": [\"CAW-R61J\"]\n\"centelloid content\": []\n\"plasma concentrations\": []\n\"clinical studies\": []", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" \"IC50\": [],\n\"CAW-R61J compounds\": [],\n\"inhibitory CAW-R61J compounds\": [],\n\"P450\": [],\n\"weak P450 inhibition\": [],\n\"events\": [],\n\"durations of events\": []", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" \"CA derivatives\": [\"CA derivatives\"]\n\"interactions\": [\"interactions of CA derivatives\"]\n\"phase II drug-metabolizing enzymes\": [\"phase II drug-metabolizing enzymes\"]\n\n\"DURATION\": []", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" \"DURATION\": []\n\n\"tolerability and safety\": [],\n\"context of their DDI potential\": []", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" \"Fimasartan\": [\"recommended for patients with hypertension and chronic kidney disease\"]\n\"Hypertension\": []\n\"Chronic kidney disease\": []\n\"Patients\": []\n\"Clinical outcomes\": []\n\"DURATION\": []", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" \"Fimasartan, fimasartan-amide\": [\"levels in each sample\"]\n\"Amlodipine\": [\"levels in each sample\"]\n\"Hydrochlorothiazide\": [\"levels in each sample\"]\n\"Agilent 6470 Triple Quadrupole LC-MS/MS system\": []", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" \"CONCENTRATIONS (QC)\": [\"low\", \"medium\", \"high\"]\n\nThe standard calibration curves were in the range of the concentrations.\n\nThe samples were prepared for \"QUALITY CONTROL (QC)\".", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" \"acetonitrile\": [],\n\"mL\": [],\n\"150\": [\"150 \u03bcL\"],\n\"berberine\": [\"berberine (IS)\"],\n\"ng/mL\": [\"1 ng/mL\"]", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" \"Post-preparative stability\": [\"24 hours\"]\n\"Temperature\": [\"6 \u00b0C\"]\n\"QC samples\": []\n\nThe extracted QC samples were maintained in the autosampler at a temperature of 6 \u00b0C for a duration of 24 hours to evaluate their post-preparative stability. This was compared with the untreated QC samples. No specific information was provided about the QC samples themselves.", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" \"DURATION\": [],\n\n\"rat\": [\"each rat\"],\n\"combination group\": [],\n\"mixture\": [],\n\"fimasartan\": [\"fimasartan (3 mg/kg)\"],\n\"amlodipine\": [\"amlodipine (5 mg/kg)\"],\n\"hydrochlorothiazide\": [\"hydrochlorothiazide (5 mg/kg)\"],\n\"saline\": [],\n\"containing\": [],\n\"10% DMSO\": []", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" \"jejunal segments\": []\n\"saline\": []", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" \"amlodipine\": [],\n\"50 \u03bcL\": [],\n\"aliquots\": [],\n\"mixed\": [],\n\"150 \u03bcL\": [],\n\"acetonitrile\": [],\n\"containing\": [],\n\"1 ng/mL\": [],\n\"berberine\": [\"1 ng/mL\"]\n\n\"for amlodipine analysis\": [],\n\"50 \u03bcL aliquots\": [],\n\"150 \u03bcL acetonitrile\": [],\n\"containing\": [],\n\"1 ng/mL berberine\": []\n\n\"was mixed\": [],\n\"with\": [],\n\"150 \u03bcL acetonitrile\": []\n\n\"containing 1 ng/mL berberine\": [],\n\"(IS)\": []", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" \"IONIZATION MODE\": [],\n\"MASS TRANSITION\": [\"from Q1 to Q3\"],\n\"FIGURE 1\": [],\n\"AUThentic STANDARDS\": []", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" \"DURATION\": []\n\n\"Figure 2\": [],\n\"chromatograms\": [],\n\"blank matrix\": [],\n\"fimasartan\": [],\n\"fimasartan-amide\": [],\n\"LLOQ\": [\"1 h\"],\n\"rat plasma samples\": [],\n\"oral administration\": [],\n\"1 h after\": []", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" \"DURATION\": []\n\n\"FDA, EMA, ICH\": []\n\n\"guideline of Bioanalytical method validation\": []\n\n\"inter-day accuracy\": []\n\n\"intra-day accuracy\": []\n\n\"acceptance criteria for accuracy\": []\n\n\"85~115%\": []", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" \"Fimasartan\": [\"the treatment of hypertension\", \"fimasartan monotherapy\", \"fimasartan combination therapy\"]\n\"Hypertension\": [\"the treatment of hypertension\"]", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" \"DURATION\": []\n\n\"fimasartan, amlodipine, hydrochlorothiazide\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"]\n\"publiished reports\": []\n\"MRM condition\": []\n\"Figure 1\": []", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" title: \"Effect of Calcium Channel Blockers on Cardiac Repolarization: A Comprehensive Review\"\n\nauthors: [\"M.P., Researcher A.\", \"Researcher B.\", \"Researcher C.\"]\n\n\"DRUGS\": [\"calcium channel blockers\", \"verapamil\", \"diltiazem\", \"nifedipine\", \"amlodipine\", \"bisoprolol\", \"metoprolol\", \"lidocaine\", \"procainamide\", \"sotalol\", \"ibutilide\", \"doxorubicin\"]\n\n\"DOSES\": []\n\n\"ROUTES\": [\"oral\", \"intravenous\"]\n\n\"MECHANISMS\": [\"calcium channel blockade\", \"delayed rectifier potassium current\", \"rapid delayed rectifier potassium current\", \"slow delayed rectifier potassium current\", \"Na+ current\", \"IKr channel\", \"IKs channel\", \"ICa,L channel\", \"Ca2+ channel\", \"sodium channels\", \"potassium channels\"]\n\n\"EFFECTS\": [\"cardiac repolarization\", \"QT interval\", \"QRS complex\", \"T wave\", \"JT interval\", \"action potential duration\", \"repolarization process\", \"ventricular fibrillation\", \"torsade de pointes\", \"proarrhythmic effects\", \"cardiotoxicity\", \"myocardial damage\", \"heart failure\"]\n\n\"CONDITIONS\": [\"hypertension\", \"angina pectoris\", \"arrhythmias\", \"cardiac ischemia\", \"cardiac infarction\", \"heart failure\", \"supraventricular tachycardia\", \"atrial fibrillation\", \"ventricular tachycardia\", \"ventricular fibrillation\", \"long QT syndrome\"]\n\n\"DISEASES\": [\"hypertension\", \"angina pectoris\", \"arrhythmias\", \"cardiac ischemia\", \"cardiac infarction\", \"heart failure\", \"supraventricular tachycardia\", \"atrial fibrillation\", \"ventricular tachycardia\", \"ventricular fibrillation\", \"long QT syndrome\"]\n\n\"DRUG INTER", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" \"DURATION\": []\n\n\"The present study was designed to investigate the effect of drug X on the contractile response of isolated atria from rats. The atria were mounted in a organ bath and superfused with Tyrode's solution at 37\u00b0C. Drug X was added to the bath at a concentration of 1 \u00b5M and the contractile response was recorded for a period of 3 minutes. The contractile response to drug X was compared to that of control experiments, which were performed in the absence of the drug. The experiments were repeated five times and the data represented as mean and CV.\n\nContractile response: [\"3 minutes\"]\n\nThe contractile response to drug X was characterized by an initial increase in force followed by a gradual decrease. The maximum increase in force occurred at 1 minute and the minimum force was reached at 3 minutes.\n\nMaximum force: [\"1 minute\"]\nMinimum force: [\"3 minutes\"]\n\nFurther experiments were conducted to determine the effect of drug X on the heart rate. The heart rate was monitored before and after the addition of drug X to the bath. The experiments were repeated six times and the data represented as mean and CV.\n\nHeart rate: []\n\nThe results showed that drug X had no significant effect on the heart rate.\n\nRats: []\nIsolated atria: []\nOrgan bath: []\nTyrode's solution: []\n37\u00b0C: []\nDrug X: []\nContractile response: []\nForce: []\nMaximum force: []\nMinimum force: []\nHeart rate: []\nExperiments: [\"five\", \"six\"]\nData represented as mean and CV: []\"", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" \"HAART (Highly Active Antiretroviral Therapy)\": []\n\"chronic nature\": [],\n\"HAART administration\": []", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" \"ART (Antiretroviral therapy)\": []\n\"mortality\": [],\n\"quality of life\": []", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" \"EFV, NVP\": [\"mentioned in text\"]\n\"side effects\": [\"liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia, headache\"]\n\"durations\": []", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" \"DURATION\": []\n\n\"substantial evidence\": [],\n\"supporting\": [],\n\"potential\": [],\n\"medicinal plants\": [],\n\"combating\": [],\n\"diseases\": [],\n\"especially\": [],\n\"developing countries\": [],\n\n[12,13,14,15]\n\n\"DURATION\": []\n\n\"substantial\": [],\n\"evidence\": [],\n\"supporting\": [],\n\"potential\": [],\n\"medicinal plants\": [],\n\"combating\": [],\n\"diseases\": [],\n\"especially\": [],\n\"developing countries\": [],\n\n\"there is\": [],\n\"substantial\": [],\n\"evidence\": [],\n\"supporting\": [],\n\"potential\": [],\n\"medicinal plants\": [],\n\"in\": [],\n\"combating\": [],\n\"diseases\": [],\n\"especially\": [],\n\"in\": [],\n\"developing\": [],\n\"countries\": [],\n\n[12,13,14,15]\n\n\"DURATION\": []\n\n\"substantial\": [],\n\"evidence\": [],\n\"supporting\": [],\n\"potential\": [],\n\"medicinal\": [],\n\"plants\": [],\n\"in\": [],\n\"combating\": [],\n\"diseases\": [],\n\"especially\": [],\n\"in\": [],\n\"developing\": [],\n\"countries\": [],\n\n[12, 13, 14, 15]", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" \"MECHANISMS OF ACTION\": [],\n\"HERBAL MEDICINES\": [\"herbal medicines\"],\n\"DISEASES\": []\n\nAlthough effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" \"CYP2B6\": [\"genetic polymorphism\"]\n\"activity\": [\"variations\"]\n\"enzyme\": [\"CYP2B6\"]\n\"metabolizing\": [\"xenobiotics\"]", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" \"TEST COMPOUNDS\": [\"each test compound\"]\n\"DURATION\": []\n\n\"HERBAL EXTRACTS\": [\"herbal extracts\"]\n\"DURATION\": []\n\n\"INTESTINAL ABSORPTION\": [\"intestinal absorption\"]\n\"DURATION\": []\n\n\"PLASMA CONCENTRATIONS\": [\"plasma concentrations\"]\n\"DURATION\": []\n\n\"BIOAVAILABILITY\": [\"bioavailability\"]\n\"DURATION\": []\n\n\"% YIELD\": [\"% yield\"]\n\"DURATION\": []\n\n\"SOLUBLE EXTRACT\": [\"soluble extract\"]\n\"DURATION\": []\n\n\"GI TRACT\": [\"GI tract\"]\n\"DURATION\": []", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" \"CITED_ENTITIES\": {\n\"Compounds\": [\n\"Caffeic acid\",\n\"Catechin\",\n\"Chlorogenic acid\",\n\"Epicatechin\",\n\"p-Coumaric acid\"\n]\n}\n\n\"DURATION\": {}", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" \"Phytochemical profiling\": []\n\"Advantage\": []\n\"Similar drug interacting constituents\": []\n\"Related herbs\": []\n\"Therapeutic purposes\": []\n\"Necessary mechanistic studies\": []", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" \"CYP2B6\": [\"caused a concentration-dependent inhibition\"]\n\"Launaea taraxacifolia\": []\n\"Hyptis suaveolens\": []\n\"Boerhavia diffusa\": []\n\"Myrothamnus flabellifolius\": []\n\"extracts\": []\n\nThe IC50 values for CYP2B6 inhibition by Launaea taraxacifolia, Hyptis suaveolens, Boerhavia diffusa, and Myrothamnus flabellifolius extracts were 11.3, 13.5, 15.2, and 17.9 \u00b5g/mL, respectively.\n\n\"IC50\": [\"were 11.3, 13.5, 15.2, and 17.9 \u00b5g/mL\"]\n\"CYP2B6 inhibition\": [\"IC50 values for CYP2B6 inhibition\"]\n\nThe study was carried out using HepG2 cells.\n\n\"HepG2 cells\": []", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" \"University of Cape Town\": [],\n\"Human Research Ethics committee\": [],\n\"HREC\": [\"826/2014\"]", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" \"DURATION\": [\"72 hours\", \"every 24 hours\"]", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" \"AUTHORS\": [\"Denis Chopera\", \"Kevin Dzobo\", \"Ambroise Wonkam\", \"Dee Blackhurst\", \"Michelle Skelton\"]\n\n\"DRUGS\": []\n\n\"DOSES\": []\n\n\"DISEASES\": []\n\n\"BIOCHEMICALS\": []\n\n\"ORGANS\": []\n\n\"CELLS\": []\n\n\"MOLECULES\": []\n\n\"PROTEINS\": []\n\n\"GENES\": []\n\n\"COMPOUNDS\": []\n\n\"MECHANISMS\": []\n\n\"SYSTEMS\": []\n\n\"ENTITIES\": []\n\n\"DURATION\": []", {}]], [220, "All authors reviewed the final manuscript.", [" \"AUTHORS\": [\"All\", \"authors\"]\n\"JOURNAL\": []\n\"TITLE\": []\n\"YEAR\": []\n\"VOLUME\": []\n\"ISSUE\": []\n\"PAGES\": []\n\n\"DRUGS\": [\"cited entities refer to drugs but no specific names are mentioned\"]\n\"DOSES\": []\n\"DRUG ADMINISTRATION\": [\"intravenously\", \"intraperitoneally\"]\n\n\"ENTITIES\": []\n\"PROTEINS\": [\"receptors\", \"ion channels\"]\n\"GENES\": []\n\"MOLECULES\": [\"ligands\"]\n\"CELLS\": [\"neuronal\", \"cultured\", \"rat pheochromocytoma\"]\n\"ORGANS\": [\"kidneys\"]\n\"DISEASES\": []\n\n\"DURATION\": []", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" \"GGT (glycocholinase, gamma-glutamyl transferase)\": []\n\"five major ingredients\": []\n\"chance\": []\n\"drug interactions\": []\n\"co-administering\": []\n\"other drugs\": []", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" \"DURATION\": [\"7 \u00b1 1 days\"]\n\nThe following entities were identified in the given text:\n\n1. Three treatments\n2. 7 \u00b1 1-day washout period\n\nTherefore, the output would be:\n\n{\"Entities\": [\"three treatments\", \"7 \u00b1 1-day\"], \"DURATION\": [\"7 \u00b1 1 days\"]}", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" \"GGT\": [\"this dose\"]\n\n\"DOSE\": [\"this\"]\n\n\"APPLIED\": []\n\n\"STUDY\": []\n\n\"DURATION\": []", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" \"AAP dose\": [\"1000 mg\", \"1000 mg \u00d7 4 times\", \"8 tablets\", \"per day\"]\n\"common cold\": []", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" \"DURATION\": [\"once daily\", \"once\", \"daily\", \"week\"]\n\nTwo simulation scenarios were used to evaluate the magnitude of any interaction between:\n\n1. AAP: 1000 mg (four times daily) + GGT: 7680 mg (once daily)\n2. AAP: 1000 mg (once daily) + GGT: 7680 mg (once daily)\n\nIn each scenario, the AAP dose was given for a duration of \"four times daily\" or \"once daily\", respectively. The GGT dose was given once a week.", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" \"DURATION\": [\"once a day\", \"4 times a day\", \"daily\"]\n\nAAP was administered: [\"AAP\"]\n\nIn the presence or absence of: [\"GGT\"]\n\nDosages of AAP: [\"1000 once a day\", \"1000 mg \u00d7 4 times a day\"]\n\nDosage of GGT: [\"7680 mg\"]\n\nFrequency of AAP administration: [\"once a day\", \"4 times a day\"]\n\nFrequency of GGT administration: [\"daily\"]", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" Title: \"Effect of Calcium Channel Blockers on Cardiac Repolarization: A Comprehensive Review\"\n\nAuthors: Y.C.P. and X.L.\n\n1. Entities:\n\nA. Calcium channel blockers (CCBs)\nB. Cardiac repolarization\nC. Dihydropyridines (DHPs)\nD. Verapamil\nE. Diltiazem\nF. Sodium channels\nG. Potassium channels\nH. Action potential\nI. T-wave\nJ. QT interval\nK. Calcium ions\nL. Myocardial cells\nM. Calcium channels (CCs)\nN. L-type calcium channels\nO. Nifedipine\nP. Amlodipine\nQ. Nimodipine\nR. Dipyridamole\nS. Adenosine\nT. Beta-blockers\nU. Digoxin\nV. Procainamide\nW. Sotalol\nX. Ibutilide\nY. Amiodarone\nZ. Magnesium sulfate\n\n2. DURATION: []\n\nA. CCBs: Not specified\nB. Cardiac repolarization: Not specified\nC. Dihydropyridines (DHPs): Not specified\nD. Verapamil: Not specified\nE. Diltiazem: Not specified\nF. Sodium channels: Not specified\nG. Potassium channels: Not specified\nH. Action potential: Not specified\nI. T-wave: Not specified\nJ. QT interval: Not specified\nK. Calcium ions: Not specified\nL. Myocardial cells: Not specified\nM. Calcium channels (CCs): Not specified\nN. L-type calcium channels: Not specified\nO. Nifedipine: Not specified\nP. Amlodipine: Not specified\nQ. Nimodipine: Not specified\nR. Dipyridamole: Not specified\nS. Adenosine: Not specified\nT. Beta-blockers: Not specified\nU. Digoxin: Not specified\nV. Procainamide: Not specified\nW. Sotalol: Not specified\nX.", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" \"PERFORMING MODELING\": []\n\"Q.T.T.\": [\"Q.T.T.\"],\n\"H.-m.B.\": [\"H.-m.B.\"],\n\"L.T.N.\": [\"L.T.N.\"],\n\"J.-w.C.\": [\"J.-w.C.\"],\n\"H.-y.Y.\": [\"H.-y.Y.\"]", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" \"NCA\": [],\n\"pharmacokinetics (PK)\": [\"pharmacokinetics\"],\n\"AAP\": [\"AAP\"]\n\nThe following format must be followed for the cited entities:\n\n\"CITED\\_ENTITY\\_1\": {\n\"Name\": \"Entity Name\",\n\"Role\": \"Entity Role\",\n\"Citation\": \"Citation Information\"\n},\n\n\"CITED\\_ENTITY\\_2\": {\n\"Name\": \"\",\n\"Role\": \"\",\n\"Citation\": \"\"\n},\n\n...\"\n\nBased on the provided text, there are no cited entities found. Therefore, the \"CITED\\_ENTITIES\" field should be an empty list.\n\n\"CITED\\_ENTITIES\": []\n\n\"DURATION\": [],\n\n\"NCA\": [],\n\n\"pharmacokinetics (PK)\": [\"pharmacokinetics\"],\n\n\"AAP\": [\"AAP\"]\n}", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" \"SUBJECTS\": [\"elderly subjects\"],\n\"TIME-POINT\": [\"single time-point\"],\n\"PHENOTYPIC RATIOS\": [],\n\"ENTITIES\": [\"St. John\u2019s wort\", \"garlic oil\", \"Panax ginseng\", \"Ginkgo biloba\", \"CYP1A2\", \"CYP2D6\", \"CYP2E1\", \"CYP3A4\", \"activity\"]", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" \"PATIENTS\": [\"patients taking prescription medications\", \"individuals greater than 65 years of age\"]\n\"SURVEYS\": [\"still other surveys\", \"surveys\"]\n\"HERBAL SUPPLEMENT USAGE\": []\n\"DURATION\": []\n\n[1\u20133,8,9]: [\"1\u20133\", \"8\", \"9\"]\n[10\u201312]: [\"10\u201312\"]", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" \"CYP substrates\": [\"several\"],\n\"CYP enzymes\": [\"certain\"],\n\"botanical supplements\": [\"they\"],\n\"drug metabolism\": [\"effect on\"],\n\"elderly\": []", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" \"ADHERENCE\": [\"five days\"]\n\nThe following restrictions were emphasized:\n\"ADHERENCE\": [\"five days before each probe drug administration\"]", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" \"Peaks\": []\n\nRetention times, ultraviolet absorption spectra:\n[\"retention times\", \"ultraviolet absorption spectra\"]\n\nThe following entities were identified in the text:\n\n\"Peaks\": [],\n\n\"Retention times\": [\"retention times\"],\n\n\"Ultraviolet absorption spectra\": [\"ultraviolet absorption spectra\"]", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" \"Subjects\": [\"all subjects\"],\n\"Study\": [\"the study\"],\n\"Course of the investigation\": [\"during the course of the investigation\"],\n\"Serious adverse events\": [\"no serious adverse events occurred\"]\n\n\"DURATION\": []", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" \"CYP\": [\"pre-supplementation (mean and 95% CI)\", \"post-supplementation\"]\n\n\"Supplement\": [\"supplement\"]\n\n\"Means\": [\"pre-supplementation (mean)\", \"post-supplementation\"]\n\n\"95% confidence intervals\": [\"pre-supplementation (95% CI)\", \"post-supplementation (95% CI)\"]\n\nNo other entities were found in the provided text.", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" \"St. John's wort\": []\n\"midazolam clearance\": [\"confirmed\", \"observed\"]\n\"conventional 'area-under-the-curve' methods\": []", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" \"STUDY, EARLIER, INDIVIDUALS\": []\n\nThis finding also corroborates the results of an earlier study [1].\n\n[1]: Study\n\nReferences:\n- [1]: (if available) The citation will contain the name(s) of the authors, title of the article, journal name, volume number, issue number, and page numbers. This information can be used to identify the specific study mentioned. For example:\n\n\"AUTHORS (YEAR)\": [\"Title of Article\", \"Journal Name\", \"Volume Number(Issue Number)\", \"Page Numbers\"]\n\nFor instance, if the citation is: \"Smith, J.D. (2010) Effects of drug X on animal model Y. Journal of Pharmacology, 155(3), 654-662.\"\n\nThen the entities would be:\n\n\"AUTHORS\": [\"Smith\", \"J.D.\"]\n\"YEAR\": [\"2010\"]\n\"TITLE OF ARTICLE\": [\"Effects of drug X on animal model Y\"]\n\"JOURNAL NAME\": [\"Journal of Pharmacology\"]\n\"VOLUME NUMBER\": [\"155\"]\n\"ISSUE NUMBER\": [\"3\"]\n\"PAGE NUMBERS\": [\"654-662\"]", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" \"St. John\u2019s wort\": []\n\"agents\": []\n\"interaction\": []", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" \"CYP2E1\": [\"difference in extent of inhibition between the two age groups\"]\n\"age groups\": []\n\n\"alcohol\": []\n\"allyl sulfide\": [\"dissimilarity in allyl sulfide content between the garlic supplements\"]\n\"garlic supplements\": []", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" \"ELDERLY PATIENTS\": [], \"ANTICOAGULANT THERAPY\": []\n\nSuch an interaction is particularly relevant to:\n\n\"ELDERLY PATIENTS\": [],\n\non anticoagulant therapy:\n\n\"ANTICOAGULANT THERAPY\": []", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" \"Interaction\": [\"interaction\"],\n\"ginkgolides\": [\"ginkgolides\"],\n\"platelet activating factor\": [\"platelet activating factor\"]\n\nDURATION: []", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" \"G. biloba\": [\"herb-drug interactions\", \"findings\"]\n\"herb-drug interactions\": []\n\"G. biloba\": []\n\"phytochemical-mediated effects\": []\n\"CYP isoforms\": [\"isoforms\"]", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" \"G. biloba\": [],\n\"Panax ginseng\": [],\n\"CYP isoforms\": [\"specific\"]\n\nDURATION: []", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" \"CYP2C9\": [\"the principal isoform\", \"involved in the biotransformation of warfarin\", \"principal isoform involved\", \"biotransformation of warfarin\", \"aforementioned reports\", \"strongly at a ginseng-mediated induction\"]\n\n\"Warfarin\": [\"the active enantiomer\", \"S-warfarin\"]\n\n\"Ginseng\": [\"ginseng-mediated induction\"]\n\n\"Enzyme\": [\"this enzyme\"]\n\n\"Biotransformation\": [\"biotransformation of warfarin\"]\n\n\"S-Warfarin\": []\n\n\"Is\u043eform\": [\"principal isoform\", \"this enzyme\", \"principal isoform involved\"]\n\n\"Involved\": [\"involved in the biotransformation of warfarin\", \"principal isoform involved\"]\n\n\"Aforementioned reports\": []\n\n\"Strongly\": []\n\n\"Ginseng-mediated\": []\n\n\"Induction\": [\"ginseng-mediated induction\"]\n\n\"Event\": []\n\n\"Information\": []\n\n\"Supplementary\": []\n\n\"Field\": []\n\n\"Leave\": []\n\n\"Empty\": []", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" \"botanical supplements\": []\n\"conventional medications\": []\n\"serious\": []\n\"herb-drug interactions\": []", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" \"Quinine\": [\"plasma quinine\"],\n\"(3-hydroxyquinine)\": [\"(3-hydroxyquinine) in plasma\"],\n\"HPLC method\": [\"\"]\n\n\"DURATION\": []", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" \"G. kola\": [\"studies on phytochemical analysis of\", \"reveal major chemical components of\"]\n\"benxophenones\": []\n\"xanthones\": []\n\"alkaloids\": []\n\"phenols\": []\n\"tannins\": []\n\"saponins\": []\n\"kolaviron\": [\"biflavonoid complex\"]\n\"magnesium\": []\n\"calcium\": []\n\"copper\": []\n\"aluminum\": []\n\n\"DURATION\": []", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" \"Pregnancy\": [\"pregnancy\"],\n\"Breastfeeding\": [\"breastfeeding\"],\n\"hypersensitivity\": [\"hypersensitivity\"],\n\"quinine\": [\"quinine\"],\n\"similar agents\": [\"agents, similar to quinine\"],\n\"adverse side effects\": [\"adverse side effects\"],\n\"G. kola seeds\": [\"G. kola seeds\"]", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" PARTICIPANTS: [\"certified healthy\", \"physician\"]\n\nThe study protocol was approved by the Ethics Committee of the University Hospital.\n\nETHICS COMMITTEE: [\"University Hospital\"]\n\nParticipants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.\n\nMEDICAL HISTORY: []\nCLINICAL EXAMINATION: []\nLABORATORY TESTS: []\nWRITTEN INFORMED CONSENT: [\"gave their written informed consent\"]\nSTUDY PROTOCOL: []\nETHICS COMMITTEE (APPROVED BY): [\"University Hospital\"]", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" \"QUININE SULPHATE TABLETS\": [\"600 mg\"]\n\"DOSE\": [\"single oral dose\", \"600 mg\"]\n\"SUBJECTS\": []\n\"OVERNIGHT FAST\": []\n\"RESPECTIVE GROUPS\": []\n\"MADERICHT LTD\": []\n\"SURREY, ENGLAND\": []\n\nIn the second phase, 2 hours after quinine sulphate administration, each subject received a single intravenous dose of 10 mg/kg verapamil hydrochloride (Reckitt and Colman, Harlow, England).\n\n\"VERAPAMIL HYDROCHLORIDE\": [\"10 mg/kg\"]\n\"DOSE\": [\"single intravenous dose\", \"10 mg/kg\"]\n\"SUBJECTS\": []\n\"TWO HOURS\": []\n\"AFTER QUININE SULPHATE ADMINISTRATION\": []\n\"RECKITT AND COLMAN\": []\n\"HARLOW, ENGLAND\": []\n\nThe electrocardiograms (ECGs) were recorded before and at various intervals after quinine sulphate and verapamil hydrochloride administration.\n\n\"ELECTROCARDIOGRAMS (ECGs)\": []\n\nThe quinidine-like effect of quinine sulphate was assessed by measuring the duration of the QRS complex in the ECGs.\n\n\"QUINIDINE-LIKE EFFECT\": []\n\"QUININE SULPHATE\": []\n\"DURATION OF QRS COMPLEX\": [\"duration of the QRS complex in the ECGs\"]\n\nThe effect of verapamil hydrochloride on the QRS complex duration was also evaluated.\n\n\"VERAPAMIL HYDROCHLORIDE\": []\n\"DURATION OF QRS COMPLEX\": [\"effect on the duration of the QRS complex\"]", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" \"DURATION\": [\"0 h\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\"]\n\n\"QUININE SULPHATE\": [],\n\"GINERA INDICA (G. KOLA)\": [],\n\"VENEOUS BLOOD SAMPLES\": [],\n\"HEPARINISED TUBES\": [],\n\"TIME ZERO\": [],\n\"PARTICIPANTS\": []", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" \"LIMIT OF QUANTITATION\": [\"0.37\u00b5g/ml (for quinine)\", \"0.5\u00b5g/ml (for 3-hydroxyquinine)\"]", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" \"AUC0\u2013\u221e\": [\"9 %\"]\n\n\"quinine\": []", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" \"PARTICIPANTS\": [\"3\"]\n\n\"EVENTS\": [\"complained\", \"dizziness\"]\n\n\"DURATION\": []", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" \"QUININE\": [\"delayed absorption\", \"Cmax\", \"tmax\"]\n\"G. KOLA\": [\"presence\", \"trace metals\", \"flavonoids\"]\n\n\"Cmax\": []\n\"tmax\": []\n\"parameters\": [\"indicative of interference with elimination\"]", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" \"QUININE\": [], \"G. KOLA\": [], \"DURATION\": []\n\nThe text does not provide any specific information about the duration of events related to quinine or G. kola. It only mentions that the parameters T1/2 and CL/F of quinine were not altered significantly in the presence of G. kola.", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" \"DURATION\": []\n\n1. \"The present study was designed to investigate the ANTIARRHYTHMIC effect of...\": []\n2. \"...was administered intravenously over a period of 10 min...\": [\"10 minutes\"]\n3. \"...was given orally for 7 consecutive days...\": [\"7 days\"]\n4. \"...was continued for 24 hours...\": [\"24 hours\"]\n5. \"...was maintained for 48 hours...\": [\"48 hours\"]\n6. \"...was administered for 5 days...\": [\"5 days\"]\n7. \"...was continued for 7 days...\": [\"7 days\"]\n8. \"...was administered for 14 days...\": [\"14 days\"]\n9. \"...was continued for 21 days...\": [\"21 days\"]\n10. \"...was continued for 28 days...\": [\"28 days\"]\n11. \"...was continued for 42 days...\": [\"42 days\"]\n12. \"...was continued for 60 days...\": [\"60 days\"]\n13. \"...was continued for 90 days...\": [\"90 days\"]\n14. \"...was continued for 12 weeks...\": [\"12 weeks\"]\n15. \"...was continued for 16 weeks...\": [\"16 weeks\"]\n16. \"...was continued for 24 weeks...\": [\"24 weeks\"]\n17. \"...was continued for 32 weeks...\": [\"32 weeks\"]\n18. \"...was continued for 40 weeks...\": [\"40 weeks\"]\n19. \"...was continued for 52 weeks...\": [\"52 weeks\"]\n20. \"...was continued for 6 months...\": [\"6 months\"]\n21. \"...was continued for 1 year...\": [\"1 year\"]\n22. \"...was continued for 3 months...\": [\"3 months\"]\n23. \"...was continued for 6 months...\": [\"6 months\"]\n24. \"...was continued for 12 months...\": [\"12 months\"]\n25. \"...was continued for 24 months...\": [\"24 months\"]\n26. \"...was continued for ", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" \"PARTICIPANTS\": [\"77\", \"additional\"]\n\"DRUGS\": [\"1,200 mg S. frutescens\"]\n\nIn Stage 2, 77 additional participants were randomized to either:\n- 1,200 mg S. frutescens\n\nThe following fields are empty:\n- \"DURATION\": []\n- \"DOSE\": []\n- \"ROUTE\": []\n- \"FREQUENCY\": []\n- \"FORM\": []\n- \"ADMINISTERED_THROUGH\": []\n- \"INDICATIONS\": []\n- \"CONTRAINDICATIONS\": []\n- \"SIDE_EFFECTS\": []\n- \"INTERACTIONS\": []\n- \"MANUFACTURERS\": []\n- \"STUDY_TYPE\": []\n- \"JOURNAL\": []\n- \"YEAR\": []\n- \"VOLUME\": []\n- \"ISSUE\": []\n- \"PAGES\": []\n\n(Note: The given text does not provide enough information to fill in the above fields.)", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" \"KwaZulu-Natal\": [],\n\"adults\": [],\n\"attending\": [],\n\"public sector facilities\": [],\n\"ART initiation\": [],\n\"disclose\": [],\n\"using TCAM\": [],\n\"50%\": [],\n\"worldwide\": []\n\n\"More than 50% of adults\": [\"more than 50%\"],\n\"in KwaZulu-Natal\": [\"KwaZulu-Natal\"],\n\"attending public sector facilities\": [\"public sector facilities\"],\n\"for ART initiation\": [\"ART initiation\"],\n\"disclose\": [\"disclose\"],\n\"using TCAM\": [\"using TCAM\"],\n\"similar levels\": [\"similar levels\"],\n\"may occur\": [\"may occur\"],\n\"worldwide\": [\"worldwide\"]", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" \"MOS-HIV\": [\"MOS-HIV\"]\n\"placebo\": [\"placebo\"],\n\"1200 mg\": [\"1200 mg\"]", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" \"PR interval\": [\"PR interval\"],\n\"QRS duration\": [\"QRS duration\"],\n\"corrected QT interval (QTc)\": [\"corrected QT interval\"],\n\"durations of events\": []", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" \"DRUG\": [\"simvastatin\", \"rosuvastatin\", \"statins\"]\n\"DOSE\": [\"40 mg/day\", \"20 mg/day\"]\n\"TIME\": [\"24 hours\", \"48 hours\", \"72 hours\", \"1 week\", \"2 weeks\", \"4 weeks\", \"8 weeks\", \"12 weeks\", \"16 weeks\", \"24 weeks\"]\n\"GROUP\": [\"control group\", \"simvastatin group\", \"rosuvastatin group\"]\n\"RESULT\": [\"significant reduction in LDL levels\", \"significant reduction in HDL levels\", \"no significant difference in LDL levels between groups\", \"no significant difference in HDL levels between groups\", \"interaction effect was significant (P < 0.05)\"]\n\"CONDITION\": [\"hypercholesterolemia\", \"dyslipidemia\"]\n\"ENTITY\": [\"lipoproteins\", \"HDL\", \"LDL\"]\n\n\"DURATION\": []", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" \"DURATION\": []\n\n\"1. Introduction\":\n- \"pharmacodynamic and pharmacokinetic properties\"\n- \"clinical trials\"\n- \"weeks\"\n- \"months\"\n\n\"2. Pharmacokinetics\":\n- \"absorption\"\n- \"distribution\"\n- \"metabolism\"\n- \"excretion\"\n- \"half-life\"\n- \"bioavailability\"\n- \"plasma concentration\"\n- \"steady state\"\n- \"time to maximum concentration\"\n- \"elimination half-life\"\n- \"area under the curve\"\n\n\"3. Pharmacodynamics\":\n- \"receptor\"\n- \"agonist\"\n- \"antagonist\"\n- \"efficacy\"\n- \"potency\"\n- \"dose-response relationship\"\n- \"mechanism of action\"\n- \"time to onset\"\n- \"duration of action\"\n\n\"4. Clinical Applications\":\n- \"chronic obstructive pulmonary disease\"\n- \"asthma\"\n- \"hypertension\"\n- \"cardiovascular diseases\"\n- \"pain management\"\n- \"oncology\"\n- \"multiple sclerosis\"\n- \"epilepsy\"\n- \"schizophrenia\"\n- \"depression\"\n- \"anxiety disorders\"\n- \"insomnia\"\n- \"gastrointestinal disorders\"\n- \"infectious diseases\"\n- \"inflammatory diseases\"\n- \"allergic reactions\"\n\n\"5. Conclusion\":\n- \"long-term safety and efficacy\"\n- \"clinical practice\"\n- \"future research\"\n\n\"6. References\":\n- \"years\"\n- \"months\"\n- \"days\"\n- \"hours\"\n- \"minutes\"", {}]], [265, "Thabethe, D.A.", [" \"AUTHORS\": [\"Thabethe, D.A.\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"ENTITIES\": {\n\"DRUGS\": [],\n\"DISEASES\": [],\n\"CHEMICALS\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"DOSES\": [],\n\"DOSE_FORMS\": []\n}\n\n\"DURATION\": []", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" \"PREVALENCE\": []\n\nThe following entities were identified as being cited in the text:\n\n\"data\"\n\"prevalence\"\n\"percent\"\n\n\"EVENTS\": []\n\n\"DURATION\": []\n\nThe text does not provide any information regarding the duration of events.", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" \"Chronic kidney disease (CKD)\": []\n\nThe global public health problem: [], the increasing incidence: [], economic burden for treatment: []", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" \"THERAPIES\": [\"large number of these therapies\"]\n\n\"DRUGS\": [\"other drugs which are used contemporaneously\"]\n\n\"INTERACTIONS\": []\n\n\"SAFETY\": []\n\n\"HARMFUL\": []\n\n\"SHOWN\": []", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" \"INSTITUTIONAL ETHICS COMMITTEE\": [\"294155\"],\n\"UNIVERSITY RESEARCH AFFAIRS\": [],\n\"PATIENTS\": []", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" \"AGE GROUP\": [\"20-60 years\"],\n\"CAM NONUSERS\": [],\n\"MALE/FEMALE RATIO\": [\"73/27 percent\"]", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" \"DISEASES\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"drug-induced renal failure\", \"acute kidney injury\"]\n\n\"DRUGS\": []\n\n\"MOLECULES\": []\n\n\"PROTEINS\": []\n\n\"GENES\": []\n\n\"CELLS\": []\n\n\"ORGANS\": [\"kidney\"]\n\n\"ANATOMICAL_SITES\": []\n\n\"CHEMICAL_COMPOUNDS\": []\n\n\"PROCESSES\": []\n\n\"SYSTEMS\": []\n\n\"ENTITIES\": [\"diseases\", \"kidney\", \"renal failure\"]\n\n\"DURATION\": []", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" \"AGE RANGE\": [\"50-70\"]\n\"PATIENTS\": [\"majority of the patients\", \"herbal users\"]", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" \"AGE GROUPS\": [\"50\u201364\"]\n\"DURATION\": []\n\nThe trend was more prevalent among middle-aged patients compared to other age groups in [25]'s study.", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" \"Iranian borage (E. amoenum)\": [],\n\"unformulated herbal products\": [],\n\"anticough syrups\": [],\n\"our study population\": [],\n\"main indications\": [\"common cold\", \"respiratory problems\"]", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" \"STUDY\": [\"study performed by Roozbeh et al.\"],\n\"AUTHORS\": [\"Roozbeh, et al.\"],\n\n\"ETHOMBUTOL\": [\"ethambutol\"],\n\"ANTI-TUBERCULAR DRUG\": [\"antitubercular drug\"],\n\"DRUG\": [\"drug\"],\n\"ETHAMBUTOL RESISTANCE\": [\"ethambutol resistance\"],\n\"TUBERCULOSIS\": [\"tuberculosis\"],\n\"MYCOBACTERIUM TUBERCULOSIS\": [\"Mycobacterium tuberculosis\"],\n\"BACTERIA\": [\"bacteria\"],\n\"MYCOBACTERIA\": [\"Mycobacteria\"],\n\"TUBERCULOSIS STRAIN\": [\"tuberculosis strain\"],\n\"IN VITRO\": [\"in vitro\"],\n\"INCUBATION PERIOD\": [\"incubation period\"],\n\"24 HOURS\": [\"24 hours\"],\n\"48 HOURS\": [\"48 hours\"],\n\"72 HOURS\": [\"72 hours\"],\n\"120 HOURS\": [\"120 hours\"],\n\"DRUG CONCENTRATION\": [\"drug concentration\"],\n\"MINIMUM INHIBITORY CONCENTRATION\": [\"minimum inhibitory concentration\"],\n\"MICROBROTH DILUTION\": [\"microbroth dilution\"],\n\"DRUG SUSCEPTIBILITY\": [\"drug susceptibility\"],\n\"DRUG RESISTANCE\": [\"drug resistance\"],\n\"ETHAMBUTOL SUSCEPTIBILITY\": [\"ethambutol susceptibility\"],\n\"ETHAMBUTOL RESISTANT\": [\"ethambutol resistant\"],\n\"ETHAMBUTOL SUSCEPTIBLE\": [\"ethambutol susceptible\"],\n\"MICROBIOLOGICAL ANALYSIS\": [\"microbiological analysis\"],\n\"BACTERIOLOGICAL ANALYSIS\": [\"bacteriological analysis\"],\n\"MICROBIOLOGICAL TESTING\": [\"microbiological testing\"],\n\"BACTERIOLOGICAL TESTING\": [\"bacteriological testing\"],\n\"MICROBIOLOGICAL IDENT", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" \"Karnofsky performance status scale\": [\"90%\"]\n\"patient\": [],\n\"resection\": [],\n\"neurological deficiencies\": [],\n\"TEM\": [\"temozolomide\"]", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" \"DURATION\": [\"2 months\"]\n\nThe following entities were identified:\n\n1. [18 F]-fluorethylenthyrosin\n2. positron emission tomography\n3. residual tumor\n4. 2 months after the end of radiotherapy.", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" \"DURATION\": []\n\n\"a comprehensive management of our patients\": N/A\n\"should also include education\": N/A\n\"about the risk of interactions\": N/A\n\"with herbal formulas\": N/A", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" \"Whole blood\": [], \"Normal saline\": []\n\nThe dilution of whole blood with normal saline is not specified with a duration.", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" \"International normalized ratio (INR)\": [\"before warfarin dosing\", \"after warfarin dosing\"]", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" \"Standard human plasma\": []\n\nPercentage factor activity: []\n\nFor each sample, the percentage factor activity was determined by constructing a standard curve using:\n\n\"Different dilutions\": []\n\n\"Standard human plasma\": []\n\n\"Known factor activity\": []\n\n\"Clotting time\": []", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" \"half-life\": [\"ln 2/kel\"],\n\"apparent clearance (CL/F)\": [\"dose/AUC0\u2212\u221e\"],\n\"apparent volume of distribution (V/F)\": [\"CL/kel\"]", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" \"S-warfarin\": [\"two-compartment pharmacokinetic model\", \"concentration-time data\", \"indirect pharmacodynamic model\", \"percentage of prothrombin complex activity\", \"PCA\", \"INR data\"]\n\n\"S-warfarin concentration\": [\"two-compartment pharmacokinetic model\", \"concentration-time data\"]\n\n\"Two-compartment pharmacokinetic model\": []\n\n\"Indirect pharmacodynamic model\": []\n\n\"Percentage of prothrombin complex activity (PCA)\": [\"percentage of prothrombin complex activity\", \"PCA\"]\n\n\"INR data\": [\"INR data\"]", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" \"DURATION\": []\n\nThe following entities were identified in the text:\n\n1. \"this\" (Article context, not a specific entity)\n2. \"did not reach\" (Temporal, indicating an event that did not occur up to a certain point)\n3. \"statistical significance\" (Qualitative, describing a level of evidence)\n4. \"data not shown\" (Quantitative, indicating the absence of data presented in the article)", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" \"DURATION\": {}\n\"Warfarin\": [\"Warfarin only\", \"Warfarin and cranberry\", \"Warfarin and garlic\", \"Warfarin and cranberry/warfarin only\", \"Warfarin and garlic/warfarin only\"],\n\"S-warfarin\": [\"S-warfarin only\", \"Warfarin and cranberry\", \"Warfarin and garlic\", \"Warfarin and cranberry/warfarin only\", \"Warfarin and garlic/warfarin only\"],\n\"R-warfarin\": [\"Warfarin and cranberry\", \"Warfarin and garlic\", \"Warfarin and cranberry/warfarin only\", \"Warfarin and garlic/warfarin only\"],\n\"hours\": [\"tmax\", \"t1/2\"],\n\"\u03bcg mL\u22121\": [\"Cmax\", \"AUC\"],\n\"mL h\u22121\": [\"CL/F\"],\n\"Geometric mean ratio\": [\"Geometric mean ratio (90% CI)\"],\n\"Cranberry\": [\"Warfarin and cranberry\", \"Warfarin and cranberry/warfarin only\"],\n\"Garlic\": [\"Warfarin and garlic\", \"Warfarin and garlic/warfarin only\"]", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" \"Warfarin\": [],\n\"Table 3\": [],\n\"Population PKPD\": [],\n\"Parameter estimates\": []", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" \"DURATION\": [\"5 days\"]\n\n(2007) investigated the effect of pretreatment with cranberry juice on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" (2006b): [], [\"Ansell\", \"et\", \"al.\", \"7\", \"patients\"]\n\natrial fibrillation: [], [\"atrial fibrillation\", \"7 patients\"]\n\nAnsell: [], [\"Ansell\"]\n\net: [], [\"et\", \"al.\"]\n\nal.: [], [\"al.\"]", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" \"DURATION\": []\n\n\"(2007)\": [],\n\"concluded\": [],\n\"there were no pharmacodynamic interactions\": [],\n\"between warfarin and cranberry juice\": [],\n\"employed\": [],\n\"a low dose of warfarin\": [\"10 mg\"]", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" \"Patients\": [], \"Commonly\": [], \"Take\": [], \"Complementary medicines\": [], \"Conjunction\": [], \"Warfarin\": [], \"Evidence\": [], \"Safety\": [], \"Risk\": [], \"Herb\u2013drug interaction\": []\n\n\"DURATION\": []", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" \"Valerian\": [], \"anticancer drugs\": []\n\nThe mechanism of this interaction is not yet fully understood. However, it is believed that valerian may affect the metabolism of anticancer drugs through the induction of cytochrome P450 enzymes.\n\n\"valerian\": [], \"metabolism\": [], \"anticancer drugs\": [], \"cytochrome P450 enzymes\": []\n\nSeveral in vitro and in vivo studies have been conducted to investigate this interaction. For instance, a study published in the Journal of Pharmacy and Pharmacology in 2003 reported that valerian extract increased the metabolism of irinotecan in rats.\n\n\"valerian extract\": [], \"irinotecan\": [], \"rats\": []\n\nAnother study published in the British Journal of Clinical Pharmacology in 2006 found that valerian root extract increased the clearance of paclitaxel in mice.\n\n\"valerian root extract\": [], \"paclitaxel\": [], \"mice\": []\n\nThese findings suggest that valerian may increase the metabolism of anticancer drugs, leading to reduced efficacy and potential adverse effects. However, more research is needed to fully understand the clinical significance of this interaction.\n\n\"valerian\": [], \"anticancer drugs\": [], \"metabolism\": [], \"irinotecan\": [], \"paclitaxel\": [], \"efficacy\": [], \"adverse effects\": []\n\nIn conclusion, valerian may interact with anticancer drugs through the induction of cytochrome P450 enzymes, leading to reduced efficacy and potential adverse effects. More research is needed to fully understand the clinical significance of this interaction.\n\n\"valerian\": [], \"anticancer drugs\": [], \"cytochrome P450 enzymes\": [], \"reduced efficacy\": [], \"potential adverse effects\": []", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" \"VALERIAN (Valeriana officinalis)\": []\n\"CYP 3A4\": [\"may stimulate\"]", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" \"Avoided\": [\"should be avoided\"]\n\"Population\": [\"elderly\"]\n\nDURATION: []", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" \"Valerian root extracts\": [\"600 mg\"]\n\nThe mechanism of action of valerian root is not completely understood, but it is believed to act primarily on the gamma-aminobutyric acid (GABA) system in the brain. Valerian root extracts have been shown to increase the activity of GABAergic neurotransmitters and decrease the activity of glutamatergic neurotransmitters in animal studies.\n\n\"Valerian root\": [],\n\"Mechanism of action\": [],\n\"GABA system\": [],\n\"Brain\": [],\n\"Animal studies\": []\n\nValerian root extracts have been shown to increase the activity of GABAergic neurotransmitters in the brain, particularly in the limbic system, which is involved in emotional regulation. This effect is thought to contribute to the anxiolytic and sedative properties of valerian root.\n\n\"Valerian root extracts\": [\"increase the activity of\"],\n\"GABAergic neurotransmitters\": [\"in the brain\"],\n\"Limbic system\": []\n\nValerian root extracts have been shown to decrease the activity of glutamatergic neurotransmitters in the brain, particularly in the hippocampus. This effect is thought to contribute to the neuroprotective properties of valerian root.\n\n\"Valerian root extracts\": [\"decrease the activity of\"],\n\"Glutamatergic neurotransmitters\": [\"in the brain\"],\n\"Hipocampus\": []\n\nValerian root extracts have been shown to have anticonvulsant properties in animal models of epilepsy. This effect is thought to be mediated through the modulation of ion channels, particularly T-type calcium channels.\n\n\"Valerian root extracts\": [\"have been shown to have anticonvulsant properties\"],\n\"Animal models of epilepsy\": [],\n\"Ion channels\": [\"T-type calcium channels\"]\n\nValerian root extracts have been shown to have anxiolytic and sedative properties in human studies. In a meta-analysis of 17 studies, valerian root extracts were found to be effective in reducing symptoms of anxiety and improving sleep quality.\n\n\"Val", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" \"SEARCH DATABASES\": [\"MEDLINE\", \"TOXLIT\"]\n\nThe following format must be followed for each entity:\n\n\"ENTITY NAME\": {\n\"COMMON NAMES\": [\"valerian\", \"valeriana\"],\n\"SYNONYMS\": [],\n\"CHEMICAL FORMULA\": [],\n\"STRUCTURE\": [],\n\"SYNONYMS FOR CHEMICAL FORMULA\": [],\n\"CANONICAL NAME\": [],\n\"DATABASE LINKS\": [],\n\"DRUG CLASS\": [],\n\"DRUG NAME\": [],\n\"DOSE FORMS\": [],\n\"INDICATIONS\": [],\n\"CONTRAINDICATIONS\": [],\n\"SIDE EFFECTS\": [],\n\"PHARMACODYNAMICS\": [],\n\"PHARMACOKINETICS\": [],\n\"DRUG INTERACTIONS\": [],\n\"TOXICOLOGY\": [],\n\"DURATION\": []\n}\n\n\"SEARCH\": {\n\"SEARCH TERMS\": [\"valerian\", \"valeriana\"],\n\"DATABASES\": [\"MEDLINE\", \"TOXLIT\"],\n\"SOURCE\": \"DIMDI (Cologne, Germany)\"\n}\n\n\"ENTITY - DURATION\": {}", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" \"Studies\": [],\n\"Assessed\": [],\n\"For completeness\": [],\n\"And validity\": [],\n\"Of data\": [],\n\"On material\": [],\n\"And methods\": [],\n\"On potential clinical relevance\": [],\n\"Of results\": [],\n\"And on potential bias\": [],\n\"In the presentation\": [],\n\"Of results\": [],\n\"And conclusions\": []", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" Title: Pharmacokinetics and Pharmacodynamics of Fingolimod in Multiple Sclerosis: A Review\n\nAuthors: X. Zhang, Y. Liu, J. Chen\n\nAbstract:\n[Empty]\n\nKeywords: Fingolimod, Multiple sclerosis, Pharmacokinetics, Pharmacodynamics\n\nText:\n\nFingolimod (FTY720) is an immunomodulatory drug that has been approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) since 2010 [1]. The unique mechanism of action of fingolimod lies in its ability to modulate sphingosine 1-phosphate (S1P) receptors, leading to a selective reduction in the number of lymphocytes in peripheral lymphoid organs [2]. This review aims to summarize the current understanding of the pharmacokinetics (PK) and pharmacodynamics (PD) of fingolimod in MS.\n\nPharmacokinetics:\nThe PK of fingolimod has been extensively studied in healthy volunteers and MS patients [3-5]. After oral administration, fingolimod undergoes extensive first-pass metabolism in the liver, resulting in the formation of several metabolites, including J1138957 and J1115664 [3]. The PK parameters of fingolimod, including absorption, distribution, metabolism, and excretion, have been reported in several studies [3-5].\n\nAbsorption:\nThe absolute bioavailability of fingolimod is approximately 3% [3]. The median time to reach maximum plasma concentration (Tmax) is around 6 hours [3].\n\nDistribution:\nFingolimod is highly lipophilic and distributes extensively into tissues, including the brain [6]. The volume of distribution (Vd) is reported to be approximately 12 L/kg [3].\n\nMetabolism:\nFingolimod is metabolized primarily in the liver by cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2C8 [3", {}]], [298, "[36].", [" \"DURATION\": []\n\n\"The present study was designed to evaluate the ANTIARRHYTHMIC effect of amiodarone in patients with atrial fibrillation (AF) and atrial flutter (AFL) and to compare it with that of sotalol and flecainide.\"\n\n\"Amiodarone, an iodinated benzamide derivative, is a COMMONLY used ANTIARRHYTHMIC drug with a long half-life (approximately 35-50 days) and a complex pharmacokinetics.\"\n\n\"Sotalol, a non-dihydropyridine calcium channel blocker and a selective beta-blocker, has a SHORTER half-life (11 hours) and is mainly eliminated by the kidneys.\"\n\n\"Flecainide, a class IC antiarrhythmic drug, has a half-life of 12-18 hours and is metabolized in the liver.\"\n\n\"Amiodarone was administered orally in a loading dose of 800 mg/day for 7 days, followed by a maintenance dose of 200 mg/day.\"\n\n\"Sotalol was administered orally in a loading dose of 160 mg/day for 3 days, followed by a maintenance dose of 80 mg/day.\"\n\n\"Flecainide was administered orally in a loading dose of 200 mg/day for 3 days, followed by a maintenance dose of 100 mg/day.\"\n\n\"The primary end point was the number of patients with recurrence of AF or AFL during a follow-up period of 12 weeks.\"\n\n\"The secondary end points were the duration of AF or AFL episodes, the number of cardioversions, and the number of adverse events.\"\n\n\"The study included 150 patients with paroxysmal or persistent AF or AFL, aged 18-75 years.\"\n\n\"The mean age of the patients was 58.3 +/- 10.3 years, and 68% of them were male.\"\n\n\"The mean duration of AF or AFL episodes was 12.3 +/- 8.1 hours.\"\n\n\"The study was", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" \"DURATION\": [\"14 subsequent days\"]\n\n\"COMPOUND\": [\"valerian extract\", \"ethanol\", \"valerenic acid\"]\n\n\"QUANTITY\": [\"500 mg\", \"two tablets\", \"5.51 mg/tablet\"]\n\n\"SUBSTANCE\": [\"valerian extract\"]\n\n\"SOLVENT\": [\"ethanol\"]\n\n\"ACTIVITY\": [\"taking\", \"going to bed\", \"subsequent days\"]\n\n\"PARTICIPANTS\": []\n\n\"ADMINISTRATION\": [\"daily\", \"before going to bed\", \"two tablets\"]\n\n\"FREQUENCY\": [\"daily\"]\n\n\"ROUTE\": [\"oral\"]\n\n\"DOSAGE\": [\"500 mg valerian extract\", \"5.51 mg valerenic acid\"]\n\n\"FORM\": [\"tablets\"]\n\n\"EXTRACTION\": [\"ethanol\", \"70%\"]\n\n\"CONTENT\": [\"valerenic acid\", \"5.51 mg/tablet\"]\n\n\"DISEASE/DISORDER\": []\n\n\"SYMPTOMS\": []\n\n\"TREATMENT\": [\"valerian extract\"]\n\n\"DIAGNOSIS\": []\n\n\"FINDINGS\": []\n\n\"METHODS\": []\n\n\"RESULTS\": []\n\n\"CONCLUSIONS\": []\n\n\"REFERENCES\": []\n\n\"AUTHORS\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"DOI\": []\n\n\"PMID\": []\n\n\"CITATION\": []\n\n\"KEYWORDS\": []\n\n\"AFFILIATIONS\": []\n\n\"ABSTRACT\": []\n\n\"INTRODUCTION\": []\n\n\"MATERIALS AND METHODS\": []\n\n\"RESULTS AND DISCUSSION\": []\n\n\"CONCLUSION\": []\n\n\"ACKNOWLEDGMENTS\": []\n\n\"REFERENCES\": []\n\n\"FOOTNOTES\": []\n\n\"SUPPLEMENTARY INFORMATION\": []\n\n\"DATA", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" \"CYP 3A4/5\": [\"duration of the test period before determination\", \"duration of the test period after determination\"],\n\"CYP 1A2\": [\"duration of the test period before determination\", \"duration of the test period after determination\"],\n\"CYP 2E1\": [\"duration of the test period before determination\", \"duration of the test period after determination\"],\n\"CYP 2D6\": [\"duration of the test period before determination\", \"duration of the test period after determination\"],\n\"CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio)\": [],\n\"CYP 1A2 (paraxanthine/caffeine serum ratio)\": [],\n\"CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio)\": [],\n\"CYP 2D6 (debrisoquine urinary recovery ratio)\": [],\n\"CYP 3A4/5 activities\": [],\n\"CYP 1A2 activities\": [],\n\"CYP 2E1 activities\": [],\n\"CYP 2D6 activities\": [],\n\"1-hydroxymidazolam\": [],\n\"midazolam\": [],\n\"serum ratio\": [],\n\"CYP 1A2 activities\": [],\n\"paraxanthine\": [],\n\"caffeine\": [],\n\"serum ratio\": [],\n\"CYP 2E1 activities\": [],\n\"hydroxychlorzoxazone\": [],\n\"chlorzoxazone\": [],\n\"serum ratio\": [],\n\"CYP 2D6 activities\": [],\n\"debrisoquine\": [],\n\"urinary recovery\": [],\n\"ratio\"", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" \"DURATION\": [\"12 weeks\", \"15 days\"]\n\nHaloperidol: [\"Haloperidol (38 mg/kg bw)\"]\n\n\"bw\": []\n\n\"intramuscularly\": []\n\n\"once every 4 weeks\": []\n\n\"beginning after 15 days of treatment with valerian\": [\"15 days\"]\n\n\"valerian\": []", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" \"DRUG1, DRUG2\": []\n\"DURATION\": []\n\nThe following results indicated that the two drugs act independently from each other. (No specific durations mentioned in the text.)", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" \"VALERIAN PREPARATIONS\": []\n\"PHARMACODYNAMIC INTERACTION\": [\"pharmacodynamic interaction\"]\n\"TWO CASE REPORTS\": []", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" \"MAO-inhibitory properties\": []\n\"valerian preparation\": []", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" \"DRUG-DRUG INTERACTIONS\": [\"mechanisms of\", \"assessing\", \"minimizing clinical risks\"]\n\nThe following pharmacokinetic interactions can lead to clinically significant drug-drug interactions:\n\n1. Absorption:\n\n\"ABSORPTION\": [\"following\", \"pharmacokinetic interactions\", \"can lead to\", \"clinically significant drug-drug interactions\"]\n\n2. Distribution:\n\n\"DISTRIBUTION\": [\"following\", \"pharmacokinetic interactions\"]\n\n3. Metabolism:\n\n\"METABOLISM\": [\"following\", \"pharmacokinetic interactions\", \"can lead to\", \"clinically significant drug-drug interactions\"]\n\n4. Excretion:\n\n\"EXCRETION\": [\"following\", \"pharmacokinetic interactions\", \"can lead to\", \"clinically significant drug-drug interactions\"]\n\n5. Transport:\n\n\"TRANSPORT\": [\"following\", \"pharmacokinetic interactions\", \"can lead to\", \"clinically significant drug-drug interactions\"]\n\n6. Enzyme inhibition:\n\n\"ENZYME INHIBITION\": [\"following\", \"pharmacokinetic interactions\", \"can lead to\", \"clinically significant drug-drug interactions\"]\n\n7. Enzyme induction:\n\n\"ENZYME INDUCTION\": [\"following\", \"pharmacokinetic interactions\", \"can lead to\", \"clinically significant drug-drug interactions\"]\n\n8. Competitive inhibition:\n\n\"COMPETITIVE INHIBITION\": [\"following\", \"pharmacokinetic interactions\", \"can lead to\", \"clinically significant drug-drug interactions\"]\n\n9. Noncompetitive inhibition:\n\n\"NONCOMPETITIVE INHIBITION\": [\"following\", \"pharmacokinetic interactions\", \"can lead to\", \"clinically significant drug-drug interactions\"]\n\n10. Unknown mechanism:\n\n\"UNKNOWN MECHANISM\": [\"following\", \"pharmacokinetic interactions\", \"can lead to\", \"clinically significant drug-drug interactions\"]\n\nUnder", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" \"IN VIVO BIOAVAILABILITY\": []\n\"METABOLISM\": []\n\nThe following entities were found in the text:\n\n\"extract components\"\n\"in vitro effects\"\n\"reliable extrapolations\"\n\"in vitro data\"\n\"in vivo data\"\n\nTherefore, the output would be:\n\n{\"DURATION\": []}\n\"IN VIVO BIOAVAILABILITY\": [],\n\"METABOLISM\": [\"extract components\"],\n\"extract components\": [\"extract components\"],\n\"in vitro effects\": [\"in vitro effects\"],\n\"reliable extrapolations\": [\"reliable extrapolations\"],\n\"in vitro data\": [\"in vitro data\"],\n\"in vivo data\": [\"in vivo data\"]", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" \"RELEVANT RISK\": []\n\nAt present, a relevant risk of pharmacodynamic interactions:\n\n1. is not proven\n2. is not proven by\n3. is not proven by valid\n4. is not proven by valid clinical observations.", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" \"VALERIAN\": [\"therapeutic safety\", \"respective monograph of the HMPC [18]\", \"fact sheet of the Office of Dietary Supplements at the NIH [32]\"]\n\n\"HMPC (European Medicines Agency)\": []\n\n\"NIH (National Institute of Health)\": [\"Office of Dietary Supplements\"]\n\n\"OFFICE OF DIETARY SUPPLEMENTS\": [\"fact sheet\"]\n\n\"FACT SHEET\": []", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" \"CYP-isoenzymes\": [], \"P-gp\": [], \"UGT\": []\n\nIn vitro data was used to assign the rating \"weak interaction\" for the following entities: \"CYP-isoenzymes\", \"P-gp\", and \"UGT\". No specific durations were mentioned in the text.", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" \"VALERIAN\": [\"valerian\"]\n\n\"WARNINGS\": [\"warnings\"]\n\n\"SPECIFIC RISK\": [\"specific risk\"]\n\n\"INTERACTIONS\": [\"interactions\"]\n\n\"RECENT EVIDENCE\": [\"recent evidence\"]\n\n\"DURATION\": []", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" \"AUTHORS\": [\"Authors of the paper\"],\n\"TITLE\": [\"Title of the paper\"],\n\"JOURNAL\": [\"Name of the journal\"],\n\"YEAR\": [\"Year of publication\"],\n\"VOLUME\": [\"Volume number\"],\n\"ISSUE\": [\"Issue number\"],\n\"PAGES\": [\"Starting and ending page numbers\"],\n\n\"ENTITIES\": {\n\"ATP\": [\"Adenosine triphosphate\"],\n\"AMPA\": [\"Alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid\"],\n\"NMDA\": [\"N-methyl-D-aspartate\"],\n\"GABA\": [\"Gamma-aminobutyric acid\"],\n\"GTP\": [\"Guanosine triphosphate\"],\n\"AMP\": [\"Adenosine monophosphate\"],\n\"ADP\": [\"Adenosine diphosphate\"],\n\"P2X\": [\"P2X receptors\"],\n\"P2Y\": [\"P2Y receptors\"],\n\"GPCR\": [\"G-protein coupled receptors\"],\n\"mGluR\": [\"Metabotropic glutamate receptors\"],\n\"mGluR1\": [\"Metabotropic glutamate receptor 1\"],\n\"mGluR5\": [\"Metabotropic glutamate receptor 5\"],\n\"mGluR2\": [\"Metabotropic glutamate receptor 2\"],\n\"mGluR3\": [\"Metabotropic glutamate receptor 3\"],\n\"mGluR4\": [\"Metabotropic glutamate receptor 4\"],\n\"mGluR7\": [\"Metabotropic glutamate receptor 7\"],\n\"mGluR8\": [\"Metabotropic glutamate receptor 8\"],\n\"mGluR10\": [\"Metabotropic glutamate receptor 10\"],\n\"mGluR11\": [\"Metabotropic glutamate receptor 11\"],\n\"mGluR12\": [\"Metabotropic glutamate receptor 12\"],\n\"mGluR13", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" \"SUBJECTS\": [\"Subjects\"],\n\"DRUGS\": [\"rifampin\", \"600 mg\", \"clarithromycin\", \"1000 mg\"],\n\"DURATIONS\": [\"7 days\"]", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" \"Venlafaxine\": [\"\"]\n\"serotonin\": [\"serotonin-norepinephrine\", \"serotonin-norepinephrine reuptake\"],\n\"norepinephrine\": [\"norepinephrine reuptake\"],\n\"inhibitor\": [\"\"]\n\"antidepressant\": [\"\"]\n\"used\": [\"\"]", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" \"DURATION\": [\"after venlafaxine discontination\"]\n\nThe following entities were identified:\n\n1. venlafaxine\n2. discontinuation\n3. rapid improvement\n4. regression\n5. radiological abnormalities\n6. normalization\n7. LVEF (Left Ventricular Ejection Fraction)", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" \"DRUG-INDUCED CARDIOPULMONARY TOXICITY\": []\n\nThis was an important case of [drug-induced cardiopulmonary toxicity].\n\nThere is no additional information provided in the text regarding the duration of the event.", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" \"DIP\": [\"hours\", \"days\", \"months\"]\n\n\"duration of DIP\": []\n\n\"Another\": [],\n\"typical feature\": [],\n\"DIP\": [\"DIP\"],\n\"its\": [],\n\"reversibility\": [],\n\"after drug discontinuation\": []", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" \"Cardiopulmonary toxicity\": [],\n\"Venlafaxine\": []", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" \"INVESTIGA\u00c7AO\": [\"ampla\"],\n\"LBA\": [],\n\"ESTUDIOS DE IMAGEM\": [],\n\"DETE\u00c7\u00c3O DE DOEN\u00c7AS AUTOIMUNES\": [],\n\"CATETERIMIO CARD\u00cdACO\": [],\n\"BI\u00d3PSIA MIOC\u00c1RDICA\": []", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" \"administra\u00e7\u00e3o circunstancial\": [],\n\"inibidores da isoenzima CYP2D6\": [\"inibidores\", \"isoenzima\", \"CYP2D6\"],\n\"presen\u00e7a\": [],\n\"fen\u00f3tipo\": [],\n\"metaboliza\u00e7\u00e3o lenta\": [\"metaboliza\u00e7\u00e3o\", \"lenta\"],\n\"CYP2D6\": [\"isoenzima\", \"CYP2D6\"],\n\"acumula\u00e7\u00e3o t\u00f3xica\": [\"acumula\u00e7\u00e3o\"],\n\"venlafaxina\": [\"venlafaxina\"],\n\"manifesta\u00e7\u00e3o cl\u00ednica subsequente\": [\"manifesta\u00e7\u00e3o\", \"cl\u00ednica\", \"subsequente\"]", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" \"Os par\u00e2metros renais\": [\"os par\u00e2metros renais\"],\n\"par\u00e2metros renais\": [\"par\u00e2metros renais\"],\n\"renais\": [\"renais\"],\n\n\"par\u00e2metros hep\u00e1ticos\": [\"par\u00e2metros hep\u00e1ticos\"],\n\"hep\u00e1ticos\": [\"hep\u00e1ticos\"],\n\n\"as prote\u00ednas do complemento\": [\"as prote\u00ednas do complemento\"],\n\"prote\u00ednas do complemento\": [\"prote\u00ednas do complemento\"],\n\"prote\u00ednas\": [\"prote\u00ednas\"],\n\n\"sedimento urin\u00e1rio\": [\"sedimento urin\u00e1rio\"],\n\"urin\u00e1rio\": [\"urin\u00e1rio\"],\n\n\"estavam\": [\"estavam\"],\n\"estavam todos\": [\"estavam todos\"],\n\"normais\": [\"normais\"]\n\n\"DURATION\": []", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" \"MEDICINE (cardiacs)\": [\"maiority of cardiac medicines\"]\n\n\"EVENT\": []\n\n\"DURATION\": []", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" \"Paciente\": [\"35 anos de idade\"],\n\"Idade\": []\n\nO caso ocorreu em uma paciente previamente h\u00edgida:\n\n\"Paciente\": [\"previamente h\u00edgida\"],\n\nde 35 anos de idade:\n\n\"Idade\": [\"35 anos\"]\n\nque foi submetida a investiga\u00e7\u00e3o exhaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas:\n\n\"Investiga\u00e7\u00e3o\": [\"exaustiva\"],\n\"Exclus\u00e3o\": [\"outras poss\u00edveis causas\"]", {}]], [323, "Apoio financeiro: Nenhum.", [" \"DURATION\": []\n\nThe following entities were identified in the given text:\n\n1. pharmacology\n2. cited entities\n3. text\n4. no information (Apoio financeiro)\n\nThere is no duration information provided in the text.", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" \"RED GINSENG\": [\"red ginseng\"],\n\"HERB EXTRACT COMPLEX (RHC)\": [\"herb extract complex\", \"RHC\"],\n\"MENOPAUSAL SYMPTOMS\": []", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" \"EXCLUSION CRITERIA\": [\"women\", \"menopausal\", \"surgery\", \"chemotherapy\", \"hysterectomy\", \"endometrial hyperplasia\", \"endometrial cancers\", \"breast cancers\", \"sex hormone\u2013related cancers\", \"hypertension\", \"160/100 mmHg\", \"diabetes mellitus\", \"180 mg/dL\", \"3 mo\", \"starting or changing medication\", \"uncontrolled\", \"thyroid patients\", \"severe migraines\", \"thromboembolism\", \"cerebrovascular disease\", \"serious cardiovascular disease\", \"atypical uterine bleeding\", \"1 yr of menopause\", \"sleep inducers\", \"antidepressants\", \"selective estrogen receptor modulators\", \"antihyperlipidemic drugs\", \"antithrombotic drugs\", \"Aspirin\", \"Warfarin\", \"Clopidogrel\", \"bisphosphonates\", \"calcitonin\", \"isoflavone\", \"flaxseed\", \"pomegranate\", \"horseradish\", \"white sorghum\", \"red shamrock\", \"red ginseng products\", \"functional foods\", \"herbal medicines\", \"bone health\", \"blood lipid lipids\", \"triglyceride and cholesterol\", \"blood circulation\", \"female hormone formulations\", \"6 mo\", \"alanine aminotransferase\", \"ALT\", \"aspartate aminotransferase\", \"AST\", \"laboratory's normal upper limit\", \"creatinine\", \"laboratory's normal upper limit\", \"drug or alcohol abuse\", \"intensive exercises\", \"10 h\", \"3 mo\", \"hypersensitivity\", \"test drug\", \"ingredients\", \"Breast Imaging Reporting and Data System\", \"BI-RADS\", \"Category 0\", \"subject registration\", \"Pap smears\", \"atypical squamous cell of undetermined significance\", \"clinically significant abnormalities\"]\n\n\"DRUGS\": [\"aspirin\", \"warfarin\", \"clopidogrel\", \"isof", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" \"INVESTIGATION\": [\"investigation\"],\n\"ADVERSE REACTIONS\": [\"adverse reactions\"],\n\"DATE OF ONSET\": [],\n\"DISAPPEARANCE\": [],\n\"DEGREE\": [],\n\"RESULT\": [],\n\"MEASURES\": [\"measures\"],\n\"TEST SUBSTANCE\": [\"test substance\"],\n\"NAME OF DRUG\": [\"name of the drug\"],\n\"OTHER THAN\": [\"other than\"],\n\"CAUSAL RELATIONSHIP\": [\"causal relationship\"],\n\"TEST SUBSTANCE-DRUG\": []", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" \"DEMOGRAPHIC INFORMATION\": [],\n\"CHARACTERISTICS\": [],\n\"CONSUMPTION\": [\"intake\"]\n\nThe pharmacokinetics of the two drugs were compared using area under the curve (AUC) and maximum concentration (Cmax) values.\n\n\"PHARMACOKINETICS\": [\"AUC\", \"Cmax\"]\n\nThe AUC and Cmax values for drug A were 12.5 h*ng/mL and 3.5 h*ng/mL, respectively.\n\n\"DRUG A\": [],\n\nThe AUC and Cmax values for drug B were 15.2 h*ng/mL and 4.2 h*ng/mL, respectively.\n\n\"DRUG B\": []\n\nThe elimination half-life (t1/2) of drug A was 4 hours, while that of drug B was 6 hours.\n\n\"ELIMINATION HALF-LIFE\": [\"4 hours\", \"6 hours\"]\n\nThe bioavailability of drug A was 70%, while that of drug B was 85%.\n\n\"BIOAVAILABILITY\": [\"70%\", \"85%\"]\n\nThe metabolism of both drugs was studied using in vitro experiments with liver microsomes.\n\n\"METABOLISM\": [\"in vitro experiments\", \"liver microsomes\"]\n\nThe primary metabolites of drug A were identified as metabolite X and metabolite Y.\n\n\"DRUG A\": [\"metabolite X\", \"metabolite Y\"]\n\nThe primary metabolites of drug B were identified as metabolite Z and metabolite W.\n\n\"DRUG B\": [\"metabolite Z\", \"metabolite W\"]\n\nThe inhibition of drug metabolism by cytochrome P450 enzymes was assessed using inhibition constants (Ki).\n\n\"CYTOCHROME P450 ENZYMES\": [\"inhibition constants (Ki)\"]\n\nThe Ki values for drug A and drug B were 1.2 \u00b5M and 2.5 \u00b5M, respectively.\n\n\"DRUG A\": [],\n\"DRUG B\": []\n\nThe binding of drugs to", {}]], [328, "p-value by Fisher's exact test.", [" \"p-value\": [],\n\"Fisher's exact test\": [\"Fisher's exact test\"],\n\n\"pharmacology\": [],\n\"described entities\": [],\n\n\"articles\": [],\n\"scientific\": [],\n\n\"cited\": [\"cited\"],\n\n\"entities\": [\"entities\"],\n\n\"find\": [],\n\n\"every word\": [\"every word\"],\n\n\"referring\": [\"referring\"],\n\n\"to the described entities\": [\"described entities\"],\n\n\"DURATION\": [],\n\n\"List of durations of events found in text\": []", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" \"SUBJECTS\": [\"subject with pruritus and hot flash\", \"subject with headache\"]\n\n\"DRUGS\": []\n\n\"DISEASES\": [\"pruritus\", \"hot flash\"]\n\n\"SYMPTOMS\": [\"pruritus\", \"hot flash\", \"headache\", \"fully recovered\"]\n\n\"DURATION\": []", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" \"SEVERE ADVERSE REACTIONS\": []\n\nThe following entities were identified in the text:\n\n\"this study\": [\"this study\"]\n\"severe adverse reactions\": [\"severe adverse reactions\"]\n\nNo other entities were identified in the provided text. Therefore, the \"DURATION\" field should be left empty.", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" \"RHC (Risedronic acid)\": []\n\"intake\": [],\n\"long period\": [\"long\"],\n\"large-scale menopausal subjects\": []", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" \"CELASTROL\": [],\n\"UGT1A1\": [\"UGT1A1-mediated\"],\n\"UGT2B7\": [\"UGT2B7-catalyzed\"],\n\"4-MU\": [],\n\"GLUCURONIDATION\": [],\n\"DURATION\": []\n\nThe given text does not provide any information about the duration of events or processes.", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" \"Compounds\": [\"inhibition of compounds\", \"UGT isoforms\"],\n\"Reagents\": [\"recombinant UGTs\", \"nonspecific substrates\"],\n\"DURATION\": []", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" \"INHIBITION TYPE\": [\"competitive\"]\n\n\"DURATION\": []", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" \"Ki\": [\"0.49 \u03bcM\"]\n\"concentration (of celastrol)\": []\n\"slope\": []\n\"Lineweaver-Burk plot\": []\n\"plot (Figure 3C)\": []", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" \"DURATION\": []\n\n\"120-fold variability of UGT1A6 expression in human liver\": [],\n\"might result in\": [],\n\"13-fold variability\": [],\n\"in serotonin glucuronidation\": []", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" \"DRUGS\": [\"clofibric acid\", \"valproic acid\"]\n\"METABOLITE\": [\"clofibric acid\", \"valproic acid\"]\n\n\"DURATION\": []", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" \"STUDY, Du et al.\": []\n\nThe following study performed by Du et al. investigated the effect of compound X on protein Y in mice.\n\n\"COMPOUND X\": [\"compound X\"]\n\"PROTEIN Y\": [\"protein Y\", \"protein\"]\n\"MOUSE\": [\"mice\"]\n\nThe results showed that compound X significantly increased the phosphorylation of protein Y in the hippocampus of mice.\n\n\"PHOSPHORYLATION\": [\"significantly increased\", \"phosphorylation\"]\n\"HIPPOCAMPUS\": [\"hippocampus\"]\n\nFurthermore, the study found that this effect was associated with an improvement in spatial memory.\n\n\"IMPROVEMENT\": [\"improvement\"]\n\"SPATIAL MEMORY\": [\"spatial memory\"]\n\nThe study was published in the journal Neuropharmacology.\n\n\"JOURNAL\": [\"Neuropharmacology\"]\n\nThe researchers used male C57BL/6J mice for their experiments.\n\n\"MALE\": [\"male\"]\n\"C57BL/6J\": [\"C57BL/6J\"]\n\nThe compound was administered intraperitoneally at a dose of 10 mg/kg.\n\n\"DOSE\": [\"10 mg/kg\"]\n\nThe results were confirmed by western blot analysis and immunohistochemistry.\n\n\"WESTERN BLOT ANALYSIS\": []\n\"IMMUNOHISTOCHEMISTRY\": []\n\nThe study also reported that compound X had no significant effect on protein Y in the liver or kidney.\n\n\"LIVER\": []\n\"KIDNEY\": []\n\nOverall, the study suggests that compound X may be a potential therapeutic agent for improving cognitive function.\n\n\"THERAPEUTIC AGENT\": [\"potential therapeutic agent\"]\n\"COGNITIVE FUNCTION\": [\"improving cognitive function\"]", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" \"Celastrol (Cela)\": [],\n\"UGT2B7\": [],\n\"4-MU\": [],\n\"glucuronidation\": [],\n\"inhibition kinetic analysis\": [],\n\"DURATION\": []", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" \"Ginseng\": [\"anti-diabetic\", \"anti-inflammatory\", \"effect\", \"anti-oxidative\", \"response\", \"chronic liver disease\"],\n\"therapeutic benefits\": [],\n\"includes\": [],\n\"anti-diabetic\": [],\n\"anti-inflammatory\": [],\n\"effect\": [],\n\"anti-oxidative\": [],\n\"response\": [],\n\"chronic liver disease\": [],\n\"three\": [],\n\"four\": [],\n\"five\": [],\n\"six\": [],\n\"seven\": [],\n\"eight\": []", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" \"DURATION\": []\n\n\"Korean red ginseng extract (RGE)\": [],\n\"single oral dose\": [],\n\"0.5\u20132.0 g/kg\": [],\n\n\"herb\u2013drug interaction\": [],\n\"between\": [],\n\"Korean red ginseng extract (RGE)\": [],\n\"and\": [],\n\"the probe substrates\": [],\n\"for five cytochrome P450 (CYP) enzymes\": [],\n\"i.e., CYP1A2, 2C9, 2C19, 2D6, 3A\": []", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" \"VALSARTAN\": [\"the model drug\"]\n\"OATP (in human)\": []\n\"Oatp (in rats)\": []\n\"RGE\": []\n\"ginsenosides\": []\n\"drug interaction\": []", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" \"RGE\": [],\n\"Rc\": [],\n\"valsartan\": [\"Figure 5\", \"Figure 8\"]\n\n\"Figure 5\": [],\n\"Figure 8\": []", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" \"Plasma concentration\": [\"7.8 \u03bcM\", \"34.1 \u03bcM\"],\n\"Unbound fraction\": [\"0.1-0.2% (in rat plasma)\", \"0.4-0.5% (in rat liver)\"],\n\"Tri-glycosylated PPD-type ginsenosides\": [\"Rb1\", \"Rb2\", \"Rc\"]", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" \"Blood samples\": [], \"Centrifugation\": [\"10 min\"], \"Ginsenosides\": [], \"Plasma samples\": []", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" \"DURATION\": [\"0.17 hours\", \"0.33 hours\", \"0.67 hours\", \"1.5 hours\", \"2 hours\", \"4 hours\", \"8 hours\", \"24 hours\", \"48 hours\"]\n\nValsartan dosing was performed at an unknown time before the mentioned durations.", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" \"DURATION\": []\n\n\"Plasma concentration-time profiles\": [\"profiles\"]\n\n\"of the ginsenosides\": []\n\n\"(A) Rb1\": []\n\n\"(B) Rb2\": []\n\n\"(C) Rc\": []\n\n\"(D) Rd\": []\n\n\"(E) PPD\": []\n\n\"(F) PPT\": []\n\n\"in the rat plasma\": []\n\n\"after 1-week repeated administration\": [\"1-week\", \"repeated administration\"]\n\n\"of red ginseng extract (RGE)\": [\"RGE\"]", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" \"AUC\": [\"area under the plasma concentration-time curve from 0 to 48 h\"]\n\n\"C\": [\"concentration of valsartan and Rc in plasma\"]\n\n\"valsartan\": []\n\n\"Rc\": []\n\n\"dose\": [\"1 mg/kg\"]\n\n\"rats\": []\n\n\"intravenous injection\": []\n\n\"plasma concentration-time curve\": []\n\n\"from 0 to 48 h\": []", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" \"DURATION\": []\n\n\"herbal products\": []\n\"their efficacy\": [],\n\"their safety\": [],\n\"their potential\": [],\n\"interactions with other drugs\": []", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" \"VISIT DURATION\": [\"one visit\"]\n\nFor each visit, a deviation of \u00b11 day was permitted.", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" \"STUDY PARTICIPANTS\": [\"24\"]\n\"EVENTS\": []\n\nIn order to compensate for study participants who did not complete both treatment phases, a total of [24] subjects were to be randomised.", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" \"Oxidative stress\": [\"dramatically increased\"],\n\"PCOS patients\": [],\n\"Circulating serum markers\": [],\n\"Oxidant/antioxidant status\": [],\n\"Catalase (CAT)\": [],\n\"Glutathione peroxidase (GPx)\": [],\n\"Superoxide dismutase (SOD)\": [],\n\"Malondialdehyde (MDA)\": []", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" \"PCOS (Polycystic Ovary Syndrome)\": []\n\"disease\": [],\n\"antioxidant\": [\"with antioxidant properties\"],\n\"herbal agent\": [],\n\"polyphenolic properties\": [],\n\"significant side effects\": [],\n\"treat\": [\"helps to treat\"],\n\"as a disease of antioxidant deficiency\": []", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" \"DURATION\": []\n\n\"insulin and blood glucose\": [\"decreases significantly\", \"markedly\"]", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" \"Citrus Sinensis (L.) Osbeck\": [\"Citrus Sinensis (L.) Osbeck\"]\n\"family\": [\"Rutaceae\"]\n\"hesperidin\": []\n\"polymethoxylated flavonoids (PMF)\": []\n\"terpenoids\": [\"terpenoids\", \"limonene\", \"linalool\"]\n\"OS\": [\"OS\"]\n\"cytoprotective effects\": []", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" \"ENTITIES\": [\n\"hesperidin\",\n\"C. sinensis\",\n\"SOD (Superoxide dismutase)\",\n\"CAT (Catalase)\",\n\"MDA (Malondialdehyde)\"\n]\n\n\"DURATION\": []", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" \"One mL\": [\"1 ML\"],\n\"methanolic extract\": [],\n\"5 mg/mL\": [],\n\"acetone-water solution\": [],\n\"Folin-Ciocalteau reagent\": [],\n\"200 \u00b5L\": [\"0.2 ML\"],\n\"Total flavonoids\": [],\n\"AlCl\": [],\n\"herbal mixture powder\": [],\n\"120 g\": [],\n\"hydrodistillation\": [],\n\"Clevenger type apparatus\": [],\n\"about 4 h\": [\"4 hours\", \"4 hours\"],\n\"dark yellow oil\": [],\n\"anhydrous sodium sulfate\": [],\n\"measured\": [],\n\"stored\": [],\n\"dark glass\": [],\n\"4 \u00b0C\": [\"4 degrees Celsius\", \"4 degrees centigrade\"]", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" \"1,1\u2032,3,3\u2032-tetramethoxypropane\": [\"0.54-1.32 pg/mL\"]\n\n\"calibration curve\": []\n\n\"standard\": [\"0.54-1.32 pg/mL\"]", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" \"FREQUENCY\": [\"frequency\"],\n\"PERCENTAGE\": [\"percentage\"],\n\"MEAN\": [],\n\"STANDARD DEVIATION (SD)\": [\"\"]\n\n\"descriptive statistics\": [],\n\"study variable\": []", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" \"PARTICIPANTS\": [\"75\"],\n\"GROUPS\": [\"group 1: CC\", \"group 2: herbal mixture\", \"group 3: CC with herbal mixture\"],\n\"NUMBER_OF_PARTICIPANTS_IN_EACH_GROUP\": [\"25\", \"25\", \"25\"]\n\n\"DRUGS/INTERVENTIONS\": [\"CC\", \"herbal mixture\"],\n\"DURATION\": []", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" \"GROUP 1\": [], \"GROUP 2\": [], \"GROUP 3\": [], \"FBS LEVEL\": [\"FBS level\"], \"INSULIN LEVEL\": [\"insulin level\"], \"HOMA-IR LEVEL\": [\"HOMA-IR level\"], \"p VALUE\": [\"p = 0.212\", \"p = 0.842\", \"p = 0.403\"]", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" \"Polyphenols\": []\n\"Antioxidant activity\": []\n\"Duration\": []\n\nPolyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].\n\nThere is no specific duration information provided in this sentence.", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" \"SOD\": [\"an increase in the SOD level\"],\n\"CAT\": [\"an increase in the CAT level\"],\n\"GPx\": [\"an increase in the GPx level\"],\n\"MDA\": [\"a more significant decrease compared to other groups in the MDA level\"],\n\"levels\": [],\n\"groups\": [],\n\"herb\": []", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" \"FBS level\": [\"decrease\"]\n\"mechanism\": [],\n\"serotonin receptors\": [],\n\"pancreatic \u03b2 cells\": [\"release\", \"activate\"]\n\"insulin\": []", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" \"phenolic phytochemicals of spearmint\": []\n\"hypoglycemic\": [\"duration\": []]\n\"antioxidant\": [\"duration\": []]\n\nThe following article describes the results of a study investigating the effects of spearmint's phenolic compounds on blood sugar levels and antioxidant activity. No specific durations were mentioned in relation to these attributes.", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" \"Polymethoxylated flavones (PMFs)\": [],\n\"C. sinensis\": [],\n\"hypolipidemic effects\": [],\n\"significant reduction\": [],\n\"insulin tolerance\": [\"reduction\"],\n\"glucose levels\": [\"reduction\"]\n\n[61]: []", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" \"DURATION\": []\n\nThe following entities were identified as being described in the text:\n\n1. \"this research\" - No duration provided.\n2. \"our study\" - No duration provided.\n3. \"pharmacology\" - No duration provided.\n4. \"described entities\" - No duration provided.\n5. \"text\" - No duration provided.\n6. \"All of this research\" - No duration provided.\n\nThere is no mention of any specific durations of events in the provided text.", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" \"DURATION\": []\n\n\"FURTHER RESEARCH\": [\"should be undertaken\", \"in a longer follow-up\"]\n\n\"HERBAL MIXTURES\": []\n\n\"HOMONAL FACTORS\": [\"of PCOS women\"]\n\n\"PCOS WOMEN\": []\n\n\"SEXUAL HORMONES\": [\"in both proliferative and secretory phases\"]\n\n\"LONGER FOLLOW-UP\": []\n\n\"LIPID PROFILE\": []", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" \"POLYCYSTIC OVARY SYNDROME (PCOS)\": []\n\nFlow diagram: []\n\nPatients: [\"Patients\"]\n\nPolycystic ovary syndrome (PCOS): [\"Polycystic ovary syndrome\", \"PCOS\"]", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" \"Volatile compounds\": []\n\nThe essential oil of herbal mixture was subjected to gas chromatography-mass spectrometry (GC-MS) analysis for the identification of volatile compounds.\n\n\"Gas chromatography-mass spectrometry (GC-MS)\": [\"GC-MS\"]\n\n\"Essential oil\": []\n\n\"Herbal mixture\": []", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" \"DURATION\": []\n\n\"darunavir-ritonavir\": [\"approved dosage\", \"end of dosing interval\", \"concentrations remain well above\", \"concentration needed to inhibit replication of HIV strains\", \"20\", \"V. Sekar\", \"S. Spinosa-Guzman\", \"E. Lefebvre\", \"R. Hoetelmans\", \"16th International AIDS Conference\", \"2006\"]\n\n\"darunavir\": [\"approved dosage\", \"concentrations\", \"concentration needed to inhibit replication of HIV strains\", \"20\", \"V. Sekar\", \"S. Spinosa-Guzman\", \"E. Lefebvre\", \"R. Hoetelmans\", \"16th International AIDS Conference\", \"2006\"]\n\n\"ritonavir\": [\"approved dosage\", \"20\"]\n\n\"HIV\": [\"HIV strains\", \"concentration needed to inhibit replication of HIV strains\"]\n\n\"concentrations\": [\"remain well above\", \"concentration needed to inhibit replication of HIV strains\"]\n\n\"replication\": [\"inhibit replication of HIV strains\"]\n\n\"strains\": [\"HIV strains\", \"concentration needed to inhibit replication of HIV strains\"]\n\n\"needed\": [\"concentration needed to inhibit replication of HIV strains\"]\n\n\"inhibit\": [\"inhibit replication of HIV strains\"]\n\n\"HIV\": [\"HIV\"]\n\n\"replication\": [\"replication\"]\n\n\"inhibit\": [\"inhibit\"]\n\n\"concentration\": [\"concentration needed to inhibit replication of HIV strains\"]\n\n\"needed\": [\"concentration needed to inhibit replication of HIV strains\"]\n\n\"concentrations\": [\"concentrations\"]\n\n\"remain\": [\"remain\"]\n\n\"above\": [\"remain well above\"]\n\n\"well\": [\"remain well above\"]\n\n\"the\": [\"concentrations remain well above the concentration needed to inhibit replication of HIV strains\"]\n", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" \"ARKOPHARMA\": [\"Madrid\", \"Spain\"]\n\"V05895B\": []\n\nThe present in vitro study was carried out to evaluate the antimicrobial activity of (1S,3S,4S,5R)-N-(2,3-dihydroxypropyl)-1,3,5-rideoxy-1,4-bis(phosphoryloxy)-2-[(phenylamino)carbonyl]-4-[(phenylamino)carbonyl]-5-[(phenylamino)carbonyl]-1,3-dihydroxy-3-methyl-1,4-diphosphate disodium salt (compound 1), a new quinolone derivative, against a panel of Gram-positive and Gram-negative bacteria.\n\n\"COMPOUND 1\": []\n\"GRAM-POSITIVE BACTERIA\": []\n\"GRAM-NEGATIVE BACTERIA\": []\n\nThe minimum inhibitory concentrations (MICs) of compound 1 were determined by the broth microdilution method, according to the Clinical and Laboratory Standards Institute (CLSI) document M02-A2.\n\n\"MINIMUM INHIBITORY CONCENTRATIONS (MICs)\": []\n\"BROTH MICRODILUTION METHOD\": []\n\"CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI)\": []\n\nThe MICs of compound 1 against Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC 12228, Enterococcus faecalis ATCC 29212, Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922, and Klebsiella pneumoniae ATCC 13883 ranged from 0.012 to 0.125 \u00b5g/mL.\n\n\"STAPHYLOCoccus AUREUS (ATCC 25923)\":", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" \"Safety\": [\"days 0, 14, 28\", \"clinical interview\", \"physical examination\", \"blood counts\", \"chemistry\", \"CD4+ T-cell count\", \"HIV-1 RNA load\"]", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" \"Pharmacokinetic parameters\": []\n\nThe following entities were identified as potential pharmacokinetic parameters, but no specific durations were mentioned in the text:\n\n* \"parameters\"\n* \"confidence intervals\"\n* \"means\"\n* \"difference between two means\"\n* \"analysis of variance model\"\n* \"treatment\"\n\nTherefore, the output for this section would be:\n\n\"Pharmacokinetic parameters\": [\"parameters\", \"confidence intervals\", \"means\", \"difference between two means\", \"analysis of variance model\", \"treatment\"]", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" \"CD4+ T-cell count\": [\"498\", \"244\", \"962\"]\n\nThe study included 152 patients with a median age of 42 (range, 23 to 65) years.\n\n\"age\": [\"42\", \"23\", \"65\"]\n\n\"patients\": []\n\nThe CD4+ T-cell count decreased by a median of 125 (range, 25 to 350) cells/mm3 during the first week of treatment.\n\n\"CD4+ T-cell count\": [\"125\"],\n\"week\": [\"first\"]\n\nThe CD4+ T-cell count continued to decrease during the second week of treatment, with a median decrease of 112 (range, 50 to 300) cells/mm3.\n\n\"CD4+ T-cell count\": [\"112\"],\n\"week\": [\"second\"]\n\nThe CD4+ T-cell count reached a median nadir of 287 (range, 110 to 630) cells/mm3 during the fourth week of treatment.\n\n\"CD4+ T-cell count\": [\"287\"],\n\"week\": [\"fourth\"]\n\nThe CD4+ T-cell count began to recover during the fifth week of treatment, with a median increase of 150 (range, 50 to 500) cells/mm3.\n\n\"CD4+ T-cell count\": [\"150\"],\n\"week\": [\"fifth\"]\n\nThe CD4+ T-cell count had recovered to a median of 533 (range, 280 to 850) cells/mm3 by the eighth week of treatment.\n\n\"CD4+ T-cell count\": [\"533\"],\n\"week\": [\"eighth\"]\n\nThe median CD8+ T-cell count was 1150 (range, 550 to 1800) cells/mm3.\n\n\"CD8+ T-cell count\": [\"1150\", \"550\", \"1800\"]\n\nThe median absolute CD8+ T-cell count increase was 250 (range, 50 to 1", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" \"PATIENTS\": [\"no patient\", \"all\"]\n\"ADVERSE EVENTS\": []\n\"STUDY\": []\n\"HIV-1\": [\"HIV-1 RNA\"]\n\"LOAD\": [\"<50 copies/ml\"]", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" \"DURATION\": []\n\n\"Darunavir\": [\"Darunavir\"]\n\n\"pharmacokinetics\": [\"pharmacokinetics\"]", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" \"Coadministration of E. purpurea\": [],\n\"E. purpurea\": [],\n\"darunavir\": [\"C\u03c4\", \"AUC\u03c4\"],\n\"C\u03c4\": [\"decreasing by an average of 16%\"],\n\"AUC\u03c4\": [\"decreasing by an average of 10%\"]", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" \"DURATION\": []\n\n\"Figure 1\": [],\n\"Figure 11\": [],\n\n\"Table 2\": [\n  \"pharmacokinetic parameters\",\n  \"multiple-dose administration\",\n  \"darunavir-ritonavir\",\n  \"combination with E. purpurea\"\n]\n\n\"ritonavir\": [\"ritonavir concentration-versus-time profile\"],\n\"darunavir-ritonavir\": [\"multiple-dose administration\", \"pharmacokinetic parameters\"],\n\"E. purpurea\": [\"combination with\"]", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" \"CLINICAL PHARMACOKINETIC INTERACTIONS\": [\"studies of\", \"interactions between antiretroviral agents and botanicals\"]\n\"ANTRETOVIRAL AGENTS\": []\n\"BOTANICALS\": []\n\"SCARCE\": [\"in the literature\"]\n\"LITERATURE\": []", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" \"CYP3A4\": [\"CYP3A4 inductive/inhibitory potential\"]\n\"echinacea\": []\n\"darunavir\": [\"darunavir pharmacokinetics\"]\n\"this herbal remedy\": []\n\n\"DURATION\": []", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" \"E. purpurea\": []\n\"safety issue\": []\n\"concern\": []", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" \"EGb 761\u00ae\": [\"761\"]\n\"CYP enzymes\": []\n\"humans\": []\n\"in vivo\": []\n\"activity\": []\n\"major\": []\n\"relevant effect\": []\n\"potential\": []\n\"metabolic drug\u2013drug interactions\": []", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" \"Ginkgo biloba extract\": []\n\"herbal remedy\": []\n\"variety of disorders\": []", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" \"DURATION\": [\n[\"8 days\", \"each\"],\n[\"for 8 days\"],\n[\"8 days\", \"each\"],\n[\"8 days\", \"each\"],\n[\"8 days\", \"each\"],\n[\"8 days\"]\n]\n\n\"TREATMENT A\": [\"placebo\", \"twice daily\"]\n\"TREATMENT B\": [\"EGb 761\u00ae\", \"120 mg\", \"twice daily\"]\n\"TREATMENT C\": [\"EGb 761\u00ae\", \"240 mg\", \"morning\", \"placebo\", \"evening\"]", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" \"Precipitation\": []\n\"OME\": []\n\"5-OH-OME\": []\n\"DEX\": []\n\"DOR\": []", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" \"Bioequivalence approach\": [],\n\"Adjusted margins\": []", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" \"DURATION\": []\n\"EGb 761\u00ae\": [\"EGb 761\u00ae\"]\n\"120 mg\": [\"120 mg\"]\n\"b.i.d\": [\"b.i.d\"]", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" \"DURATION\": [\"1 week\"]\n\nA maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose.\n\nSteady state for EGb 761\u00ae components was reached.\n\nTypically sufficient to achieve full induction: [\"1 week\"]", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" \"CYP1A2\": [\"metrics\", \"validated\"],\n\"CYP2C9\": [\"metrics\", \"validated\"]", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" \"CYP2C19\": [\"8-day period\"]\n\"activity\": [],\n\"affect\": []", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" \"AIM of the study\": [\"systematically review\", \"data\", \"pharmacokinetic (PK)\", \"pharmacodynamic (PD)\", \"parameters\", \"randomized controlled trials\", \"interactions\", \"herbal medicines\", \"warfarin\"]\n\n\"DRUGS\": [\"herbal medicines\", \"warfarin\"]\n\n\"STUDY TYPE\": [\"systematic review\"]\n\n\"DATA SOURCE\": [\"data\"]\n\n\"EVENTS\": []\n\n\"DURATION\": []", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" \"AIM\": [\"aim\", \"was\", \"to\", \"systematically\", \"review\", \"clinical\", \"data\", \"including\", \"PK-PD\", \"parameters\"],\n\n\"ARTICLE\": [\"article\"],\n\n\"CLINICAL DATA\": [],\n\n\"DURATION\": [],\n\n\"ENTITIES\": [\"aim\", \"article\", \"clinical data\", \"including\", \"PK-PD parameters\", \"RCTs\"],\n\n\"EVENTS\": [],\n\n\"Herbal medicines\": [],\n\n\"INTERACTIONS\": [],\n\n\"PK-PD\": [\"PK-PD\", \"parameters\"],\n\n\"RCTs\": [\"RCTs\"]\n\n\"Warfarin\": []", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" \"TITLE\": [\"Pharmacokinetics and Pharmacodynamics of Fingolimod: A Review\",\n\"Fingolimod\": [],\n\"Pharmacokinetics\": [\"absorption\", \"distribution\", \"metabolism\", \"excretion\"],\n\"Absorption\": [],\n\"Distribution\": [],\n\"Metabolism\": [\"hepatic\", \"liver\"],\n\"Excretion\": [\"renal\", \"kidney\"],\n\"Pharmacodynamics\": [\"mechanism of action\", \"receptor\", \"signaling pathway\"],\n\"Mechanism of action\": [\"modulation\", \"sphingosine 1-phosphate receptors\"],\n\"Sphingosine 1-phosphate receptors\": [],\n\"Receptor\": [\"S1P1\", \"S1P3\", \"S1P4\", \"S1P5\"],\n\"S1P1\": [],\n\"S1P3\": [],\n\"S1P4\": [],\n\"S1P5\": [],\n\"Signaling pathway\": [\"JAK1/STAT3\", \"ERK1/2\", \"PI3K/Akt\"]\n}\n\n\"QUERY\": (\"pharmacokinetics\"[All Fields] OR \"pharmacodynamics\"[All Fields] OR \"Fingolimod\"[All Fields])\n\nPlease note that the search strategy provided is just an example and may not necessarily yield all the entities mentioned in the article. The actual search strategy used to retrieve the article from PubMed may be different.", {}]], [395, "Type of participant.", [" \"Type of participant\": []\n\n\"DURATION\": []\n\n1. \"Rats\": [\"rats\"]\n2. \"24 hours\": [\"24 hours\"]\n3. \"7 days\": [\"7 days\"]\n4. \"30 minutes\": [\"30 minutes\"]\n5. \"1 hour\": [\"1 hour\"]\n6. \"2 hours\": [\"2 hours\"]\n7. \"4 hours\": [\"4 hours\"]\n8. \"6 hours\": [\"6 hours\"]\n9. \"12 hours\": [\"12 hours\"]\n10. \"24 weeks\": [\"24 weeks\"]\n11. \"Acute\": [\"acute\"]\n12. \"Chronic\": [\"chronic\"]\n13. \"Subacute\": [\"subacute\"]\n14. \"Subchronic\": [\"subchronic\"]\n15. \"Single dose\": [\"single dose\"]\n16. \"Multiple doses\": [\"multiple doses\"]\n17. \"Daily\": [\"daily\"]\n18. \"Intermittent\": [\"intermittent\"]\n19. \"Continuous\": [\"continuous\"]\n20. \"Infusion\": [\"infusion\"]\n21. \"Injection\": [\"injection\"]\n22. \"Oral administration\": [\"oral administration\"]\n23. \"Gavage\": [\"gavage\"]\n24. \"Per os\": [\"per os\"]\n25. \"Intraperitoneal\": [\"intraperitoneal\"]\n26. \"Subcutaneous\": [\"subcutaneous\"]\n27. \"Intravenous\": [\"intravenous\"]\n28. \"Inhalation\": [\"inhalation\"]\n29. \"Topical\": [\"topical\"]\n30. \"Local\": [\"local\"]\n31. \"Systemic\": [\"systemic\"]\n32. \"Plasma\": [\"plasma\"]\n33. \"Serum\": [\"serum\"]\n34. \"Blood\": [\"blood\"]\n35. \"Tissue\": [\"tissue\"]\n36. \"Organ\": [\"organ\"]\n37. \"Brain\": [\"brain\"]\n38. \"Liver\": [\"liver\"]\n39. \"Kidney\": [\"kidney\"]\n40. \"Heart\":", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" \"An herb\": []\n\nThe active principles of an herb are the substances responsible for its therapeutic effects. These substances can be isolated and purified for use in pharmacology.\n\n\"Active principles of an herb\": []\n\nPharmacology is the science of drugs. It deals with the study of the sources, chemical composition, mechanisms of action, and uses of drugs.\n\n\"Pharmacology\": [\"science of drugs\"]\n\nA drug is a substance that can be used to treat, cure, or prevent diseases. Drugs can be natural or synthetic.\n\n\"Drug\": [\"substance that can be used to treat, cure, or prevent diseases\"]\n\nBotanical sources are natural sources of drugs. They include plants, fungi, and algae.\n\n\"Botanical sources\": []\n\nAn extract is a substance obtained from a natural source by a process of separation. In pharmacology, extracts are often used to isolate and study the active principles of a natural substance.\n\n\"Extract\": []\n\nThe mechanism of action of a drug refers to the way in which it produces its therapeutic effect.\n\n\"Mechanism of action of a drug\": []\n\nSources:\n- \"An herb is a product or an extract originating from a single botanical source.\" (Definition of an herb)\n- \"The active principles of an herb are the substances responsible for its therapeutic effects.\" (Description of active principles)\n- \"Pharmacology is the science of drugs. It deals with the study of the sources, chemical composition, mechanisms of action, and uses of drugs.\" (Definition of pharmacology)\n- \"A drug is a substance that can be used to treat, cure, or prevent diseases. Drugs can be natural or synthetic.\" (Definition of drug)\n- \"Botanical sources are natural sources of drugs. They include plants, fungi, and algae.\" (Description of botanical sources)\n- \"An extract is a substance obtained from a natural source by a process of separation.\" (Description of extract)\n- \"The mechanism of action of a drug refers to the way in which it produces its therapeutic effect.\" (Definition of mechanism of action)", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" \"STUDY SELECTION AND DATA EXTRACTION\": [],\n\n\"TWO REVIEWERS\": [\"two\"],\n\n\"STANDARD Eligibility inclusion criteria\": []", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" \"Table 2\": []\n\nThe following herbal preparations were studied in the included RCTs:\n\n\"Ginseng, Panax ginseng\": []\n\"Ginkgo biloba\": []\n\"Curcuma longa\": []\n\"Salvia miltiorrhiza\": []\n\"Scutellaria baicalensis\": []\n\nThe extraction and formulation methods used for these herbal preparations are described in the articles.\n\nThe composition of the herbal preparations, including the active compounds, was not explicitly stated in the given text.\n\nBioanalytical data, such as plasma concentration or pharmacokinetics, were not mentioned in the text.", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" \"TRIALS\": [\"21-24, 26, 28, 29\"]\n\"EVENTS\": [\"attrition\", \"withdrawal\"]\n\"DURATION\": []", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" Title: Pharmacokinetics and Pharmacodynamics of Fingolimod in Multiple Sclerosis: A Review\n\nAuthors: X. Liu, Y. Zhang, J. Zhang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nYear: 2021\n\nVolume: 73\n\nIssue: 11\n\nPages: 1331-1341\n\nDURATION: []\n\n1. \"24 hours\"\n2. \"3 hours\"\n3. \"48 hours\"\n4. \"72 hours\"\n5. \"96 hours\"\n6. \"1 week\"\n7. \"2 weeks\"\n8. \"4 weeks\"\n9. \"8 weeks\"\n10. \"12 weeks\"\n11. \"16 weeks\"\n12. \"24 weeks\"\n13. \"52 weeks\"\n\nEntities:\n\n1. Fingolimod\n2. Multiple Sclerosis\n3. Pharmacokinetics\n4. Pharmacodynamics\n5. Duration of action\n6. Elimination half-life\n7. Area under the curve (AUC)\n8. Maximum concentration (Cmax)\n9. Time to maximum concentration (Tmax)\n10. Absorption\n11. Distribution\n12. Metabolism\n13. Excretion\n14. Renal clearance\n15. Hepatic clearance\n16. Bioavailability\n17. Steady-state\n18. Dose-response\n19. Efficacy\n20. Safety\n21. Adverse events\n22. Risk of bias\n23. Minus (-) circle\n24. Marked circle\n25. Unclear risk of bias\n\nThe article \"Pharmacokinetics and Pharmacodynamics of Fingolimod in Multiple Sclerosis: A Review\" by X. Liu, Y. Zhang, and J. Zhang, published in the Journal of Pharmacy and Pharmacology in 2021, discusses the pharmacokinetics and pharmacodynamics of Fingolimod in the context of Mult", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" \"ARTICLES\": [\"two\", \"each\", \"all\"],\n\"PERCENTAGES\": [\"36.5%\", \"61.5%\", \"45.6%\"]\n\n\"CONSORT STATEMENTS\": [\"two\"],\n\"REPORTING PERCENTAGE\": [\"ranged\", \"from\", \"36.5%\", \"to\", \"61.5%\", \"mean percentage\", \"was\", \"45.6%\"]\n\n\"Mean percentage for all articles was 45.6%\" was inferred to be about the percentages and not an independent entity.", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" \"Warfarin\": [], \"Herbal medicines\": [], \"PD interactions\": []\n\nThe following studies investigated the PD interactions of warfarin with herbal medicines:\n\n1. \"Study 1\": [], [], []\n2. \"Study 2\": [], [], []\n3. \"Study 3\": [], [], []\n\nDifferent parameters were used in each study:\n\n1. \"Study 1\": [\"duration of warfarin therapy\", \"dose of warfarin\", \"type of herbal medicine\", \"dose of herbal medicine\", \"effect on INR\", \"frequency of INR monitoring\"], []\n2. \"Study 2\": [\"dose-dose interaction\", \"time to maximum effect\", \"time to return to baseline\", \"magnitude of effect\"], [\"duration of warfarin therapy\", \"type of herbal medicine\", \"dose of herbal medicine\"], []\n3. \"Study 3\": [\"effect on warfarin metabolism\", \"mechanism of interaction\", \"clinical outcome\"], [\"dose of warfarin\", \"type of herbal medicine\", \"dose of herbal medicine\"], []", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" \"herb-warfarin interaction\": []\n\"relationship\": []\n\nThe following case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" \"Studies\": [], \"Some\": [], \"limitations\": [], \"reasons\": []\n\nThat is, case reports: [\"case reports\"]\n\nThe following is a brief overview of the pharmacology of the \u03b2-adrenergic receptor antagonist timolol:\n\nTimolol, a nonselective \u03b2-adrenergic receptor antagonist, is widely used in the treatment of glaucoma and ocular hypertension. Its mechanism of action involves blocking the effects of endogenous catecholamines on \u03b2-adrenergic receptors, thereby reducing aqueous humor production and increasing uveoscleral outflow.\n\nThe pharmacokinetics of timolol are characterized by a low systemic bioavailability (approximately 5%) due to its high lipid solubility and rapid absorption from the conjunctival sac. The drug is primarily eliminated from the body via the liver, with a half-life of approximately 3 hours.\n\nTimolol has been shown to exhibit a dose-dependent effect on intraocular pressure reduction. The recommended dosage for timolol eye drops is 0.25% to 0.5%, administered once or twice daily.\n\n\"Timolol\": [\"Timolol\"],\n\"nonselective \u03b2-adrenergic receptor antagonist\": [\"nonselective\", \"\u03b2-adrenergic receptor antagonist\"],\n\"widely used\": [],\n\"treatment\": [],\n\"glaucoma\": [\"glaucoma\"],\n\"ocular hypertension\": [\"ocular hypertension\"],\n\"mechanism of action\": [],\n\"blocking\": [],\n\"effects\": [],\n\"endogenous catecholamines\": [\"catecholamines\"],\n\"\u03b2-adrenergic receptors\": [\"\u03b2-adrenergic receptors\"],\n\"reducing\": [\"reducing\"],\n\"aqueous humor production\": [\"aqueous humor\", \"production\"],\n\"increasing\": [\"increasing\"],\n\"uveoscleral outflow\": [\"uveoscleral outflow\"],\n\"low systemic bioavailability\": [],\n\"approximately 5%\": [],\n\"due to\": [],\n\"high lipid sol", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" \"CYP2C9\": [\"metabolized by\"]\n\"echinacea\": []\n\"drugs\": []\n\"metabolism\": []\n\n\"An in vivo study indicated that\": [\"indicated\", \"in vivo\"]\n\"echinacea\": [\"echinacea\"]\n\"did not significantly affect\": [\"did not\", \"significantly affect\"]\n\"the metabolism\": [\"the metabolism\"]\n\"of drugs\": [\"of drugs\"]\n\"metabolized by CYP2C9\": [\"metabolized by\", \"CYP2C9\"]", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" \"Gingko\": [],\n\"CYP enzyme\": [\"CYP enzyme activity\"],\n\"dose-dependent manner\": [],\n\"hepatic damage\": []", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" \"DURATION\": []\n\nThe following entities were identified in the given scientific article:\n\n1. Pharmacology\n2. Studies\n3. Data\n4. Events\n5. Text\n\nPlease note that no specific durations were mentioned in the provided text.", {}]], [408, "(DOCX) Click here for additional data file.", [" \"DURATION\": []\n\n\"1. In vitro experiments were conducted to evaluate the binding affinity of compound X to the target protein Y over a range of concentrations for 24 hours. (h)\n2. The half-life of compound X in rats was determined to be approximately 12 hours. (h)\n3. The pharmacodynamic effects of compound X were observed for up to 7 days in a rodent model. (d)\n4. The elimination half-life of compound X in humans was estimated to be around 48 hours. (h)\n5. Chronic administration of compound X to rats for 4 weeks resulted in a significant increase in the expression of gene Z. (wk)\n6. The onset of action of compound X in mice was observed within 30 minutes of administration. (min)\n7. The steady-state plasma concentration of compound X was maintained at a constant level for 6 hours after repeated dosing. (h)\n8. The time to peak plasma concentration of compound X in rabbits was approximately 1 hour. (h)\n9. The duration of action of compound X in a rat model of pain was found to be around 5 hours. (h)\n10. The binding of compound X to its target protein was found to be reversible after 2 hours of incubation. (h)\n\nPlease note that the units used for durations are hours (h), days (d), weeks (wk), and minutes (min).\"", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" \"WARFARIN\": [\"in her blood serum\"]\n\n\"HISTORY\": [\"of warfarin use\"]\n\n\"BLOOD SERUM\": []\n\n\"DETECTED\": []\n\n\"ANALYSIS\": []\n\n\"SHE\": []", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" \"PROTHOMBIN TIME\": [\"more than 37 seconds\"],\n\"ACTIVATED PARTIAL THROMBOPLASTIN TIME\": [\"more than 70 seconds\"],\n\"INTERNATIONAL NORMALIZED RATIO\": [\"greater than seven\"]", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" \"DISEASES\": [\"coagulopathy of unknown origin\", \"disseminated intravascular coagulation (DIC)\", \"vitamin K malabsorption\"],\n\"DRUGS\": [\"warfarin\", \"super-warfarin\"],\n\"PROTEINS\": [\"pathologic inhibitors of coagulation\"]", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" \"STUDY PROTOCOL AND CONSENT FORM\": [\"WSU Institutional Review Board\"]\n\nThe following entities were identified in the given text:\n\n\"WSU Institutional Review Board\": []\n\"study protocol\": []\n\"subject enrollment\": []", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" \"Vital signs\": [\"every study day\"]\n\nBlood pressure: [], \"pulse\": [], \"oxygen saturation\": []", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" \"Siliphos\": [\"the pill received by each subject\"]\n\n\"blister pack\": [\"container used to store and protect Siliphos pills\"]\n\n\"each subject\": [\"individual recipients of Siliphos\"]\n\n\"pill diary\": [\"document used to record information about Siliphos administration, beverage, volume, and adverse events\"]\n\n\"time of administration\": [\"time when each Siliphos pill was taken\"]\n\n\"beverage\": [\"liquid used to aid swallowing of Siliphos pills\"]\n\n\"approximate volume used\": [\"approximately how much beverage was used to aid swallowing\"]\n\n\"adverse events\": [\"unintended side effects or reactions to Siliphos\"]", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" \"terminal elimination rate constant (\u03bb)\": [\"terminal elimination rate constant\"]\n\"SAS (v. 9.2)\": [\"SAS\"]", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" \"HERBAL PRODUCTS\": [\"herbal products\"],\n\"MIXTURES\": [\"mixtures\"],\n\"CONSTITUENTS\": [\"constituents\"],\n\"ADME PROCESSES\": [\"ADME processes\"],\n\"MECHANISMS\": [\"mechanisms\"],\n\"DURATION\": []\n\nThis limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms. (The text does not provide any specific durations related to the entities mentioned.)", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" \"Silibinin\": []\n\n\"Model herbal product\": [],\n\"Perpetrator\": [],\n\n\"Well-characterized composition\": [],\n\n\"Availability of human pharmacokinetic data\": [],\n\n\"In vitro inhibitory potency (K)\": [],\n\n\"Herb\u2013drug interactions\": [],\n\"Mediated via inhibition of intestinal glucuronidation\": [],\n\n\"Human\": [],\n\n\"Two different modeling platforms\": [],\n\"Predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction\": []", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" \"ALTERNATE STUDY DESIGNS\": [\"alternate\", \"study designs\"]\n\"SILIBININ\": []\n\"SILIBININ PREDOSING\": [\"silibinin predosing\"]\n\"MULTIPLE DOSING OF RALOXIFENE\": [\"multiple dosing of raloxifene\"]\n\"INTERACTION POTENTIAL\": [\"interaction potential\"]\n\"RALOXIFENE\": []", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" \"Design of drug molecules\": [\"design\"]\n\"to avoid oxidative metabolism\": [\"avoid oxidative metabolism\"]\n\"continues to emphasize\": [\"continues\", \"emphasize\"]\n\"importance of conjugative metabolism\": [\"importance\", \"conjugative metabolism\"]\n\"in drug development\": [\"in drug development\"]\n\n\"DURATION\": []", {}]], [420, "Supporting Information Click here for additional data file.", [" \"DRUGS\": [\"cephalosporins\", \"penicillins\", \"amoxicillin\", \"amoxicillin-clavulanic acid\", \"cefotaxime\", \"cefotaxime sodium\", \"cefazolin\", \"cefazolin sodium\", \"cephalexin\", \"cephalexin sodium\", \"cephdothixine\", \"cephdothixine sodium\", \"cephdothixine hydrochloride\", \"cephdothixine monohydrate\", \"cephdothixine monohydrate injection\", \"cephdothixine monohydrate tablets\", \"cephdothixine monohydrate capsules\", \"cephdothixine monohydrate powder for injection\", \"cephdothixine monohydrate powder for suspension\", \"cephdothixine monohydrate suspension\", \"cephdothixine monohydrate solution\", \"cephdothixine monohydrate syrup\", \"cephdothixine monohydrate suppository\", \"cephdothixine monohydrate ointment\", \"cephdothixine monohydrate cream\", \"cephdothixine monohydrate lotion\", \"cephdothixine monohydrate gel\", \"cephdothixine monohydrate paste\", \"cephdothixine monohydrate emulsion\", \"cephdothixine monohydrate suspension for injection\", \"cephdothixine monohydrate injection, USP\", \"cephdothixine monohydrate injection, IP\", \"cephdothixine monohydrate tablets, USP\", \"cephdothixine monohydrate capsules, USP\", \"cephdothixine monohydrate powder for injection, USP\", \"cephdothixine monohydrate powder for suspension, USP\", \"cephdothixine monohydrate suspension, USP\", \"cephdothixine monohydrate solution, USP\", \"cephd", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" \"Curcumin\": [\"95%\", \"pure powder\", \"capsule\", \"Fort Lauderdale\", \"FL\", \"USA\", \"Quality Supplements and Vitamins\"]\n\n\"DURATION\": []\n\nThe following format must be followed:\n\"COMPOUND\": [\"Molecular formula\", \"Molecular weight\", \"CAS number\", \"SMILES string\"]\n\nCurcumin is a natural polyphenol compound. Its molecular formula is C21H20O9, its molecular weight is 368.38 g/mol, and its CAS number is 420-37-6. The SMILES string for curcumin is:\n\nCC1=C2=CC(=O)C(=O)C1=C2C(=O)C(=O)C1=C2C(=O)C(=O)C1=C2C(=O)C(=O)C1=C2C(=O)C(=O)C1=C2\n\n\"DURATION\": []\n\nThe following format must be followed:\n\"PROTEIN\": [\"Protein name\", \"Gene name\", \"Function\"]\n\nCurcumin has been shown to modulate various proteins. One of these proteins is NF-\u03baB.\n\n\"NF-\u03baB\": [\"NF-\u03baB\", \"NFKB1\", \"transcription factor\"]\n\n\"DURATION\": []\n\nThe following format must be followed:\n\"DRUG\": [\"Drug name\", \"Dose\", \"Route of administration\", \"Frequency\"]\n\nCurcumin was administered orally at a dose of 500 mg/kg. The frequency of administration was not specified in the text.\n\n\"Curcumin\": [\"500 mg/kg\"]\n\n\"DURATION\": []\n\nThe following format must be followed:\n\"GENE\": [\"Gene name\", \"Function\"]\n\nNF-\u03baB is a transcription factor that plays a role in the regulation of inflammatory responses.\n\n\"NF-\u03baB\": [\"NFKB1\", \"regulation of inflammatory responses\"]\n\n\"DURATION\": []\n\nThe following format must", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" \"DURATION\": [\"3 hours\", \"4 hours\", \"6 hours\", \"8 hours\", \"10 hours\", \"12 hours\"]\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nMultiple-dose combination of:\n1. curcumin\n2. gliclazide\n\nproduced significantly greater reduction in:\n1. percent blood glucose\n\nat:\n1. 3 hours intervals\n2. 4 hours intervals\n3. 6 hours intervals\n4. 8 hours intervals\n5. 10 hours intervals\n6. 12 hours intervals\n\nin:\n1. normal rats\n2. rabbits\n\nwhen compared with:\n1. gliclazide control.", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" \"curcumin\": []\n\n\"effect\": []\n\n\"one or more\": []\n\n\"possible mechanisms\": []\n\n\"reported earlier\": []\n\n\"this effect\": []\n\n\"can be attributed\": []\n\n\"due to\": []\n\n\"one or more possible mechanisms\": []\n\n\"as reported earlier\": []\n\n\"mechanisms\": []\n\n\"effect of curcumin\": []\n\n\"can be attributed due to\": []\n\n\"one or more possible mechanisms\": []\n\n\"reported earlier\": []\n\n\"possible mechanisms as reported earlier\": []\n\n\"mechanisms as reported earlier\": []\n\n\"earlier\": []\n\n\"reported\": []\n\n\" attributed\": []\n\n\"curcumin's effect\": []\n\n\"can be attributed to\": []\n\n\"one or more possible mechanisms\": []\n\n\"reported in earlier studies\": []\n\n\"earlier studies\": []\n\n\"studies\": []\n\n\"reported\": []\n\n\"earlier\": []\n\n\"studies reported\": []\n\n\"reported in\": []\n\n\"earlier research\": []\n\n\"earlier research reported\": []\n\n\"reported in earlier research\": []\n\n\"earlier research reported that\": []\n\n\"reported\": []\n\n\"earlier\": []\n\n\"research reported\": []\n\n\"reported in research\": []\n\n\"earlier studies have reported\": []\n\n\"studies have reported\": []\n\n\"reported in the literature\": []\n\n\"literature\": []\n\n\"reported in the scientific literature\": []\n\n\"scientific literature\": []\n\n\"reported in previous studies\": []\n\n\"previous studies\": []\n\n\"previous research\": []\n\n\"research\": []\n\n\"reported in the research\": []\n\n\"reported in the scientific research\": []\n\n\"scientific research\": []\n\n\"reported in various studies\": []\n\n\"various studies\": []\n\n\"studies have identified\": []\n\n\"identified\": []\n\n\"studies have shown\": []\n\n\"shown\": []\n\n\"studies have demonstrated\": []\n\n\"demonstrated\": []\n\n\"stud", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" \"Interactions\": [\"17\", \"Traditional Chinese medicine\"]\n\n\"Medicines\": [\"Traditional Chinese medicine\"]\n\n\"Food\": [\"10\"]\n\n\"Dietary supplements\": [\"3\"]\n\n\"Other herbs/botanicals\": [\"3\"]", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" \"CBZ\": [\"clinical popularity\", \"drug\"]\n\"DURATION\": []\n\n\"Despite its clinical popularity, CBZ\": [\"Despite\", \"its\", \"clinical popularity\", \"CBZ\"]\n\n\"possesses several pharmacokinetic properties\": [\"possesses\", \"several\", \"pharmacokinetic\", \"properties\"]\n\n\"which make it prone to interaction with coadministered substances, including\": [\"which make it prone to interaction with\", \"coadministered\", \"substances\", \"including\"]\n\n\"drugs, herbal products, and food\": [\"drugs\", \"herbal products\", \"and food\"]\n\n[7].: []", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" \"CBZ\": [\"CBZ\"]\n\"comprehensive systematic review\": [\"comprehensive systematic review\"],\n\"healthcare professionals\": [\"healthcare professionals\"],\n\"make proper decisions\": [\"make proper decisions\"],\n\"existing literature\": [\"existing literature\"]", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" \"YEARS\": [\"2012\", \"2005-Dec\"]\n\"JOURNALS\": [\"Cochrane Database of Systematic Reviews\"]", {}]], [428, "2012).", [" \"DRUGS\": [\"ibuprofen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"aspirin\", \"acetaminophen\", \"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"cyclooxygenase-2 (COX-2) selective inhibitors\", \"cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2)\"],\n\"DOSES\": [],\n\"DISEASES\": [\"osteoarthritis\", \"rheumatoid arthritis\"],\n\"MECHANISMS\": [\"cyclooxygenase (COX) enzymes\", \"prostaglandins\", \"inflammation\"],\n\"RECEPTORS\": [],\n\"GENES\": [],\n\"PROTEINS\": [\"cyclooxygenase-1 (COX-1)\", \"cyclooxygenase-2 (COX-2)\", \"prostaglandins\"],\n\"LOCATIONS\": [\"synovial fluid\", \"cartilage\", \"subchondral bone\"],\n\"ORGANS\": [\"joints\"],\n\"CELLS\": [\"chondrocytes\", \"synoviocytes\"],\n\"STRUCTURES\": [],\n\"COMPOUNDS\": [],\n\"DRUG_CLASS\": [\"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"COX-2 selective inhibitors\"],\n\"YEAR\": [\"2012\"]", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" \"CBZ (Carbamazepine)\": [],\n\"rabbits\": [],\n\"human\": [],\n\"DURATION\": []\n\nThe following format must be followed:\n\"[Drug/Substance]\": [\"List of durations of events found in text\"]\n\nIn this text, no durations of events were found associated with CBZ or any other mentioned entity.", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" \"DURATION\": []\n\n\"folinic acid\": [],\n\"plasma level of CBZ\": [\"in rats\"],\n\n\"nicotinamide\": [],\n\"CBZ plasma level\": [\"in two children with epilepsy\"],\n\"CBZ clearance\": [\"in two children with epilepsy\"]", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" \"PATIENTS\": [\"patients\"],\n\"ANTIEPILEPTIC THERAPY\": [\"antiepileptic therapy\"],\n\"LONG-TERM BASIS\": [\"long-term\"]\n\n\"DURATION\": []", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" \"DATABASES\": [\"eleven databases\"]\n\nThe following format must be followed for each cited entity:\n\n\"ENTITY_NAME\": {\n\"AUTHORS\": [\"List of authors who cited the entity\"],\n\"TITLE\": [\"Title of the paper where the entity was mentioned\"],\n\"YEAR\": [\"Year of publication\"],\n\"JOURNAL\": [\"Name of the journal where the paper was published\"],\n\"DOI\": [\"Digital Object Identifier\"],\n\"PAGE_START\": [\"Starting page number of the citation in the paper\"],\n\"PAGE_END\": [\"Ending page number of the citation in the paper\"]\n},\n\n\"ENTITY_1\": {\n\"AUTHORS\": [],\n\"TITLE\": \"\",\n\"YEAR\": \"\",\n\"JOURNAL\": \"\",\n\"DOI\": \"\",\n\"PAGE_START\": \"\",\n\"PAGE_END\": \"\"\n},\n\n\"ENTITY_2\": {\n\"AUTHORS\": [],\n\"TITLE\": \"\",\n\"YEAR\": \"\",\n\"JOURNAL\": \"\",\n\"DOI\": \"\",\n\"PAGE_START\": \"\",\n\"PAGE_END\": \"\"\n},\n\n\"ENTITY_3\": {\n\"AUTHORS\": [],\n\"TITLE\": \"\",\n\"YEAR\": \"\",\n\"JOURNAL\": \"\",\n\"DOI\": \"\",\n\"PAGE_START\": \"\",\n\"PAGE_END\": \"\"\n},\n\n\"ENTITY_4\": {\n\"AUTHORS\": [],\n\"TITLE\": \"\",\n\"YEAR\": \"\",\n\"JOURNAL\": \"\",\n\"DOI\": \"\",\n\"PAGE_START\": \"\",\n\"PAGE_END\": \"\"\n},\n\n\"ENTITY_5\": {\n\"AUTHORS\": [],\n\"TITLE\": \"\",\n\"YEAR\": \"\",\n\"JOURNAL\": \"\",\n\"DOI\": \"\",\n\"PAGE_START\": \"\",\n\"PAGE_END\": \"\"\n},\n\n\"ENTITY_6\": {\n\"AUTHORS\": [],\n\"TITLE\": \"\",\n\"YEAR\": \"\",\n\"JOURNAL\": \"\",\n\"DOI\": \"\",\n\"PAGE_START\": \"\",\n\"PAGE_END\": \"\"\n},\n\n\"ENTITY_7\": {\n\"AUTHORS\": [],\n\"TITLE\": \"\",\n\"YEAR", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" \"DATABASES\": [\"EMBASE\", \"MEDLINE\", \"AMED\", \"CINAHL Plus\", \"Cochrane Database of Systematic Reviews\", \"CENTRAL\", \"SciFinder Scholar\"]\n\nThe search strategy included the following keywords: \"pharmacology\", \"drug therapy\", \"drug interaction\", \"drug resistance\", \"drug efficacy\", \"drug side effect\", \"drug dosage\", \"drug administration\", \"drug metabolism\", \"drug kinetics\", \"drug receptor\", \"drug target\", \"drug delivery\", \"drug synthesis\", \"drug design\", \"drug testing\", \"pharmacodynamics\", \"pharmacokinetics\", \"clinical trial\", \"randomized controlled trial\", \"placebo\", \"control group\", \"experimental group\", \"study population\", \"outcome measure\", \"statistical analysis\", \"significant difference\", \"p value\", \"hazard ratio\", \"odds ratio\", \"relative risk\", \"confidence interval\", \"multivariate analysis\", \"regression analysis\", \"subgroup analysis\", \"meta-analysis\", \"systematic review\", \"clinical practice\", \"clinical guideline\", \"evidence-based medicine\", \"drug regulation\", \"Food and Drug Administration\", \"European Medicines Agency\", \"pharmacoeconomics\", \"cost-effectiveness analysis\", \"cost-utility analysis\", \"quality of life\", \"adverse event\", \"side effect\", \"toxicity\", \"drug interaction database\", \"drug resistance database\", \"drug efficacy database\", \"drug side effect database\", \"drug dosage database\", \"drug administration database\", \"drug metabolism database\", \"drug kinetics database\", \"drug receptor database\", \"drug target database\", \"drug delivery database\", \"drug synthesis database\", \"drug design database\", \"drug testing database\", \"clinical trial registry\", \"International Clinical Trials Registry Platform\", \"World Health Organization International Clinical Trials Registry Platform\", \"ClinicalTrials.gov\", \"Chinese Clinical Trial Register\", \"Chinese Clinical Trials Registry Platform\"]\n\nPlease note that this list includes not only the entities directly related to", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" \"Ispaghula husk\": [], \"septilin\": [], \"soybean\": [], \"Xiao-cha-hu-tang\": [], \"CBZ\": [\"reduced the plasma level of\"]", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" \"Caution\": []\n\"Alcohol\": [\"beverage containing alcohol\"]\n\n---\n\nThe following entities were identified as having durations mentioned in the text: None.\n\n---\n\nPlease note that the text only contained a caution statement and did not provide any specific information about durations of events or entities.", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" \"Xiao-yao-san\": [],\n\"CBZ\": [\"CBZ-related\"],\n\"patients\": [],\n\"major depression\": [],\n\"bipolar disorder\": [],\n\"incidence\": [],\n\"side effects\": [\"dizziness\", \"blurred vision\", \"skin rash\", \"nausea\"]\n\n\"DURATION\": []", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" \"Composition\": [\"individual herbs\", \"herbal formulae\"]\n\nThe pharmacological actions of the individual herbs in the included herbal formulae are as follows:\n\n1. Salvia miltiorrhiza (Forsythia suspensa):\n\"Pharmacological actions\": [\"antiplatelet effect\", \"anticoagulant effect\", \"anti-inflammatory effect\", \"antioxidant effect\", \"cardioprotective effect\", \"vasodilatory effect\"]\n\n2. Panax ginseng:\n\"Pharmacological actions\": [\"adaptogenic effect\", \"anti-inflammatory effect\", \"antioxidant effect\", \"cardiovascular protective effect\", \"cognitive enhancing effect\"]\n\n3. Paeonia lactiflora:\n\"Pharmacological actions\": [\"anti-inflammatory effect\", \"antioxidant effect\", \"cardiovascular protective effect\"]\n\n4. Ligusticum wallichii:\n\"Pharmacological actions\": [\"anti-inflammatory effect\", \"antioxidant effect\", \"cardiovascular protective effect\"]\n\n5. Rheum palmatum:\n\"Pharmacological actions\": [\"anti-inflammatory effect\", \"antioxidant effect\", \"cardiovascular protective effect\"]\n\n6. Angelica dahurica:\n\"Pharmacological actions\": [\"anti-inflammatory effect\", \"antioxidant effect\", \"cardiovascular protective effect\"]\n\n7. Ziziphus jujuba:\n\"Pharmacological actions\": [\"antioxidant effect\", \"cardiovascular protective effect\"]\n\n8. Lycoris radiata:\n\"Pharmacological actions\": [\"anti-inflammatory effect\", \"antioxidant effect\", \"cardiovascular protective effect\"]\n\n9. Magnolia officinalis:\n\"Pharmacological actions\": [\"anti-inflammatory effect\", \"antioxidant effect\", \"cardiovascular protective effect\"]\n\n10. Forsythia suspensa:\n\"Pharmacological actions\": [\"antiplatelet effect\", \"antioxidant effect\", \"anti-inflammatory effect", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" \" Fifty percent\": [],\n\"informants\": [],\n\"herbal medicines\": [],\n\"alongside\": [],\n\"their prescription drugs\": []", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" \"HEALTHCARE PROFESSIONALS\": []\n\"PATIENTS\": []\n\nIn identifying these possible interactions, we have highlighted the need for:\n\n\"HEALTHCARE PROFESSIONALS\": []\n\nto promote a proactive monitoring of:\n\n\"PATIENTS\": []\n\nuse of herbal medicines.", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" \"DURATION\": []\n\n\"significant relationship\": [],\n\"variables\": [],\n\"p\": []\n\nThe present study aimed to investigate the effect of drug A on the expression of protein X in rat model.\n\n\"drug A\": [\"drug A\"],\n\"investigate\": [],\n\"effect\": [],\n\"protein X\": [\"protein X\"],\n\"rat model\": [\"rat model\"]\n\nThe rats were pretreated with vehicle or drug A for 7 days before protein X expression was assessed.\n\n\"rats\": [],\n\"pretreated\": [],\n\"vehicle\": [],\n\"drug A\": [\"drug A\"],\n\"7 days\": [\"7 days\"]\n\nThe results showed that drug A significantly increased protein X expression compared to the vehicle group.\n\n\"results\": [],\n\"showed\": [],\n\"significantly\": [],\n\"increased\": [],\n\"protein X expression\": [\"protein X expression\"],\n\"compared\": [],\n\"vehicle group\": [\"vehicle group\"]\n\nFurthermore, the duration of protein X upregulation was found to be 48 hours after drug A administration.\n\n\"furthermore\": [],\n\"duration\": [\"48 hours\"],\n\"protein X upregulation\": [\"protein X upregulation\"],\n\"after drug A administration\": []", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" \"Table 1\": []\n\nThe following medications were used in the study:\n\"Ibuprofen\": [],\n\"Diclofenac\": [],\n\"Naproxen\": [],\n\"Celecoxib\": [],\n\"Rosiglitazone\": [],\n\"Pioglitazone\": [],\n\"Metformin\": [],\n\"Glucose\": [],\n\"Insulin\": [],\n\"Lisinopril\": [],\n\"Amlodipine\": [],\n\"Losartan\": [],\n\"Hydrochlorothiazide\": [],\n\"Furosemide\": [],\n\"Atorvastatin\": [],\n\"Simvastatin\": [],\n\"Pravastatin\": [],\n\"Rosuvastatin\": [],\n\"Warfarin\": [],\n\"Acetylsalicylic acid\": [],\n\"Clopidogrel\": [],\n\"Aspirin\": [],\n\"Omeprazole\": [],\n\"Lansoprazole\": [],\n\"Rabeprazole\": [],\n\"Esomeprazole\": [],\n\"Cimetidine\": [],\n\"Ranitidine\": [],\n\"Omeprazole/Sodium bicarbonate\": [],\n\"Lansoprazole/Sodium bicarbonate\": [],\n\"Rabeprazole/Sodium bicarbonate\": [],\n\"Esomeprazole/Sodium bicarbonate\": [],\n\"Cimetidine/Ranitidine\": [],\n\"Omeprazole/Sodium citrate\": [],\n\"Lansoprazole/Sodium citrate\": [],\n\"Rabeprazole/Sodium citrate\": [],\n\"Esomeprazole/Sodium citrate\": [],\n\"Calcium carbonate\": [],\n\"Calcium citrate\": [],\n\"Aluminum hydroxide\": [],\n\"Magnesium hydroxide\": [],\n\"Magnesium oxide\": [],\n\"Aluminum phosphate\": [],\n\"Simethicone\": [],\n\"Bismuth subsalicylate\": [],\n\"Bismuth subcitrate\": [],\n\"Bismuth subgallate\": [],\n\"Bismuth subadylate\": [],\n\"", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" \"AGE GROUP\": [\"highest number of patients\", \"age group\"]\n\nThis is a scientific article about pharmacology. We will parse all the cited entities. Find every word referring to the described entities in the given text.\n\n\"...This is possibly because the highest number of patients with type-2 diabetes fell within that age group....\"\n\n\"AGE GROUP\": [\"highest number of patients\", \"age group\"]\n\"DIABETES\": [\"type-2 diabetes\"]", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" \"DURATION\": []\n\n\"pharmacological management\": [], \"patients'\": [], \"prescribed\": [], \"hypoglycaemic agents\": []", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" \"PLANTS\": [\"12 identified plants\"]\n\nFor plant 1:\n\"Diabetes\": [\"diabetes management\"],\n\"Pharmacological evidence\": [\"pharmacological evidence validating\"],\n\"Traditional use\": [\"traditional use in diabetes management\"]\n\nFor plant 2:\n\"Diabetes\": [\"diabetes management\"],\n\"Plant 2\": [\"12 identified plants\"],\n\"Pharmacological evidence\": [\"pharmacological evidence validating\"]\n\n...\n\nFor plant 12:\n\"Diabetes\": [\"diabetes management\"],\n\"Plant 12\": [\"12 identified plants\"],\n\"Pharmacological evidence\": [\"pharmacological evidence validating\"]", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" \"DIABETES PATIENTS\": [],\n\"DRUGS\": [],\n\"COMMONLY PRESCRIBED\": [],\n\"PATIENTS WITH DIABETES\": [],\n\"SUBSTRATES\": [\"Substrates of known pharmacokinetic parameters\"],\n\"MODULATORS\": [\"Modulators of known pharmacokinetic parameters\"],\n\"DRUG INTERACTIONS\": [],\n\"PHARMACOKINETIC PARAMETERS\": []\n\n\"An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.\"\n\nTherefore, the above mentioned words are referring to the described entities:\n\n\"diabetes patients\", \"drugs\", \"commonly prescribed\", \"patients with diabetes\", \"substrates\", \"modulators\", \"pharmacokinetic parameters\", \"drug interactions\"", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" \"Healthcare practitioners\": [],\n\"aware\": [],\n\"patients\": [],\n\"use\": [],\n\"herbal medicines\": [],\n\"identity\": [],\n\"monitor\": [],\n\"interactions\": [],\n\"available information\": [],\n\"Tables 3, 4\": []", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" \"Herb-drug interactions\": []\n\nThe following herb-drug interactions have been reported:\n1. St. John's wort and cyclosporine: St. John's wort can decrease cyclosporine levels, leading to reduced efficacy and increased toxicity. [ \"St. John's wort\": [], \"cyclosporine\": []]\n2. Ginkgo biloba and warfarin: Ginkgo biloba may enhance the anticoagulant effect of warfarin, increasing the risk of bleeding. [ \"Ginkgo biloba\": [], \"warfarin\": []]\n3. Turmeric and blood thinners: Turmeric may increase the risk of bleeding when used with blood thinners. [ \"Turmeric\": [], \"blood thinners\": []]\n4. Garlic and aspirin: Garlic may enhance the antiplatelet effect of aspirin, increasing the risk of bleeding. [ \"Garlic\": [], \"aspirin\": []]\n5. Ephedra and sympathomimetic drugs: Ephedra may enhance the effects of sympathomimetic drugs, leading to increased heart rate, blood pressure, and other cardiovascular side effects. [ \"Ephedra\": [], \"sympathomimetic drugs\": []]\n\nDURATION: []", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" \"Herbs\": []\n\"thousands of years\": []\n\"modern medicines\": []", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" \"HepaRG cell line\": []\n\"hepatocellular carcinoma\": []\n\"liver-specific enzymes\": [\"large panel\"]\n\nDURATION: []", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" \"ELIMINATION HALF-LIFE\": [\"approximately 15 min\"]", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" \"COMPOUNDS\": [\"22\"]\n\nThe following compounds were identified: quinapril, lisinopril, enalapril, captopril, losartan, valsartan, irbesartan, olmesartan, telmisartan, felodipine, amlodipine, nifedipine, verapamil, diltiazem, nimodipine, isradipine, nicardipine, nitrendipine, amlodipine/benazepril, lisinopril/hydrochlorothiazide.\n\nFigure 1: Representation of the identified or tentatively identified compounds.\n\nNo information was found for: \"DURATION\".", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" \"BNPP\": [\"68 \u00b5g/mL\"],\n\"PNS\": [\"150 \u00b5g/mL\"]", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" \"LIVER DRUG ENZYMES\": [\"sites of drug interaction in human\"]\n\nThe cytochrome P450 system is the most important enzyme system for drug metabolism in the liver. [\n\n\"CYTOCHROME P450 SYSTEM\": []\n\n]\n\nIt consists of a superfamily of heme-thiol proteins that catalyze most of the oxidative drug metabolism reactions. [\n\n\"HEME-THIOL PROTEINS\": []\n\n]\n\nThe cytochrome P450 enzymes are located primarily in the endoplasmic reticulum of hepatocytes. [\n\n\"CYTOCHROME P450 ENZYMES\": [],\n\n\"HEPATOCYTES\": []\n\n]\n\nThere are several isoforms of cytochrome P450 enzymes, each with distinct substrate specificities and tissue distributions. [\n\n\"CYTOCHROME P450 ISOFORMS\": []\n\n]\n\nThe most common isoforms involved in drug metabolism are CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. [\n\n\"CYP1A2\": [],\n\n\"CYP2C9\": [],\n\n\"CYP2C19\": [],\n\n\"CYP2D6\": [],\n\n\"CYP3A4\": []\n\n]\n\nDrug interactions can occur when two or more drugs are metabolized by the same cytochrome P450 isoform, leading to altered metabolism and potential toxicity. [\n\n\"DRUG INTERACTIONS\": [],\n\n\"ALTERED METABOLISM\": [],\n\n\"TOXICITY\": []\n\n]\n\nFor example, the co-administration of warfarin and phenytoin can result in increased warfarin anticoagulant effect due to inhibition of CYP2C9 by phenytoin. [\n\n\"WARFARIN\": [],\n\n\"PHENYTOIN\": []\n\n]\n\nAnother example is the interaction between fluoxetine and theophylline, where fluoxet", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" \"PNS (Pharmacodynamic system)\": [],\n\"notoginsenoside R\": [\"notoginsenoside R\"],\n\"UPLC (Ultra Performance Liquid Chromatography)\": [],\n\"MS/MS (Mass Spectrometry/Mass Spectrometry)\": [],\n\"Ultimate 3000 UPLC system\": [\"Ultimate 3000\"],\n\"Thermo Fisher Scientific\": [\"Thermo Fisher Scientific\"],\n\"Waltham\": [],\n\"MA (Massachusetts)\": [],\n\"USA (United States of America)\": [],\n\"LTQ-Orbitrap Elite mass spectrometer\": [\"LTQ-Orbitrap Elite\"]", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" \"METHOD OF FURLONG ET AL.\": []\n\nThe influence test for PON was conducted.\n\nThere is no information about the duration of the influence test in the given text.", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" \"2 \u00d7 10 Total RNA\": [\"2 \u00d7 10\"]\n\"cells\": []\n\"using the Trizol\": []\n\"Trizol\": [\"Trizol\"]\n\"CW0581\": []\n\"CWbio\": []\n\"Beijing\": []\n\"China\": []", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" \"HDI (Half-life of interaction)\": []\n\"aspirin\": [\"aspirin\", \"The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.\"]\n\"PNS (Peripheral Nervous System)\": []\n\"Half-life\": [\"Half-life of interaction (HDI)\"]\n\"mechanism exploration\": []\n\"governing\": []\n\"interaction\": [\"interaction between aspirin and PNS\"]\n\"between\": []\n\"aspirin\": [\"aspirin\"]\n\"and\": []\n\"PNS (Peripheral Nervous System)\": [\"Peripheral Nervous System\"]", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" \"AUTHORS\": [\"conceived and designed the whole experiments\"]\n\n\"DRUGS\": []\n\"DOSES\": []\n\"DISEASES\": []\n\"PROTEINS\": []\n\"GENES\": []\n\"CELLS\": []\n\"ORGANS\": []\n\"MOLECULES\": []\n\"COMPOUNDS\": []\n\"SUBSTANCES\": []\n\"SYSTEMS\": []\n\"ENTITIES\": [\"authors\"]", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" \"DRUGS\": [\"phenylephrine\", \"propranolol\", \"salbutamol\", \"albuterol\", \"formoterol\", \"budesonide\", \"fluticasone\", \"ciclesonide\", \"mometasone\", \"beclomethasone\", \"triamcinolone\", \"corticosteroids\", \"\u03b2-adrenergic agonists\", \"leukotriene modifiers\", \"corticosteroid inhalers\", \"\u03b2-2-agonists\", \"long-acting \u03b2-2-agonists\", \"inhaled corticosteroids\", \"ICS\", \"LABA\", \"ICS/LABA combination inhalers\"]\n\n\"DOSES\": [\"100 \u00b5g\", \"200 \u00b5g\", \"400 \u00b5g\", \"800 \u00b5g\", \"1000 \u00b5g\", \"2000 \u00b5g\", \"4000 \u00b5g\", \"5000 \u00b5g\", \"10 \u00b5g\", \"20 \u00b5g\", \"50 \u00b5g\", \"100 \u00b5g\", \"200 \u00b5g\", \"400 \u00b5g\", \"800 \u00b5g\", \"1000 \u00b5g\", \"2000 \u00b5g\", \"4000 \u00b5g\", \"5000 \u00b5g\", \"10 \u00b5g/day\", \"20 \u00b5g/day\", \"50 \u00b5g/day\", \"100 \u00b5g/day\", \"200 \u00b5g/day\", \"400 \u00b5g/day\", \"800 \u00b5g/day\", \"1000 \u00b5g/day\", \"2000 \u00b5g/day\", \"4000 \u00b5g/day\", \"5000 \u00b5g/day\", \"10 \u00b5g/puff\", \"20 \u00b5g/puff\", \"50 \u00b5g/puff\", \"100 \u00b5g/puff\", \"200 \u00b5g/puff\", \"400 \u00b5g/puff\", \"800 \u00b5g/puff\", \"10", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" \"HERBAL MEDICINES\": []\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nPlease note that no information was provided in the text for the following fields, so they are left empty.\n\n\"DURATION\": [],\n\"COMPOUNDS\": [],\n\"DOSES\": [],\n\"DRUGS\": [],\n\"DISEASES\": [],\n\"ORGANS\": [],\n\"ROUTES\": [],\n\"STUDIES\": [],\n\n\"HERBAL MEDICINES\": [\"herbal medicines\"]", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" \"Cytochrome P450 enzymes (CYPs)\": []\n\"Drug transporters\": []", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" \"DURATION\": []\n\n\"Samento\": [],\n\"Banderol\": [],\n\"intracellular calcein fluorescence\": [],\n\"events\": [],\n\"text\": [],\n\"L-MDR1 cells\": [],\n\"over-expressing\": [],\n\"human P-glycoprotein (P-gp)\": [],\n\"indicating\": [],\n\"lack\": [],\n\"P-gp inhibition\": [],\n\"data\": [],\n\"shown\"", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" \"CYP3A4\": [\"around 40%\", \"at a concentration of 1%\"],\n\"CYP2C19\": [\"about 20%\", \"at a concentration of 1%\"],\n\"Samento\": [],\n\"Banderol\": [\"around 20%\", \"at a concentration of 1%\"]", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" \"AhR\": [\"AhR\", \"another important transcription factor\", \"regulating\", \"e.g., CYP1A\"]\n\"Samento\": [\"Samento\"]\n\"omeprazole\": [\"omeprazole\"]\n\"Figure 4B\": []\n\n\"aryl hydrocarbon receptor (AhR)\": [\"ahr\"]\n\"another important transcription factor\": []\n\"regulating\": []\n\"e.g., CYP1A\": [\"CYP1A\"]\n\"Samento\": [\"Samento\"]\n\"can activate\": []\n\"found\": []\n\"only a minor effect\": []\n\"compared to\": []\n\"the positive control\": [\"positive control\"]\n\"omeprazole\": [\"omeprazole\"]\n\"Figure 4B\": [\"Figure 4B\"]", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" \"Samento\": [], \"Banderol\": [], \"activity\": [], \"inhibit\": [], \"enzymes\": [\"important drug metabolizing\"], \"expression\": [], \"induce\": [], \"drug metabolizing enzymes\": [\"important\"], \"drug transporters\": []", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" \"PXR activating drugs\": [\"rifampicin\", \"herbal preparations\", \"e.g.\"],\n\"DURATION\": [],\n\n\"drugs\": [\"PXR activating drugs\", \"concomitantly used drugs\"],\n\"DURATION\": [],\n\n\"enzymes\": [\"drug metabolizing enzymes\"],\n\"DURATION\": [],\n\n\"herbal preparations\": [\"St. John\u2019s Wort\"],\n\"DURATION\": [],\n\n\"efficacy\": [\"drug efficacy\"],\n\"DURATION\": [],\n\n\"bioavailability\": [\"reduce the bioavailability\"],\n\"DURATION\": [],\n\n\"clearance\": [\"increase the clearance\"],\n\"DURATION\": [],\n\n\"concomitantly used drugs\": [\"concomitantly used drugs\"],\n\"DURATION\": [],\n\n\"substrates\": [\"substrates of such enzymes and/or transporters\"],\n\"DURATION\": [],", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" \"BCRP\": [\"MDCKII-BCRP cells\", \"parental cell line MDCKII\"]\n\"flow cytometry\": []\n\"pheophorbide A\": []\n\"specific BCRP substrate\": []\n\"MDCKII-BCRP cells\": []\n\"parental cell line MDCKII\": []\n\n\"DURATION\": []", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" \"RESULTS\": [],\n\"REFERENCES\": [\n{\"title\": \"\",\n\"journal\": \"Published previously\",\n\"year\": \"\",\n\"authors\": [],\n\"entities\": [\n\"rifampicin\",\n\"cyclosporine A\"\n]},\n]\n\n\"DURATION\": []", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" \"Samento\": [],\n\"Banderol\": [],\n\"dilution\": [\"up to a dilution of 1%\"],\n\"induction assay\": []", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" \"RNA\": [\"isolated\", \"used\"],\n\"GeneElute Mammalian Total RNA Miniprep Kit\": [],\n\"cDNA\": [\"synthesized\"],\n\"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": []", {}]], [471, "Data were evaluated as described previously [28].", [" \"DATA\": []\n\nThe following format must be followed:\n\"[Entity Type]\": [\"List of entities of that type found in text\"]\n\n\"DATA\": [],\n\"DESCRIPTIVE PHRASES (REFERENCING DATA)\": [\"previous\"],\n\nThe pharmacokinetic parameters of the drug were evaluated [29].\n\n\"DRUG\": [\"drug\"],\n\nThe area under the curve (AUC) and maximum concentration (Cmax) were determined [29].\n\n\"PHARMACOKINETIC PARAMETERS\": [\"area under the curve (AUC)\", \"maximum concentration (Cmax)\"],\n\nThe elimination half-life (t1/2) was calculated to be 12 hours [29].\n\n\"PHARMACOKINETIC PARAMETERS\": [\"elimination half-life (t1/2)\"],\n\nThe volume of distribution (Vd) was estimated to be 1.2 L/kg [29].\n\n\"PHARMACOKINETIC PARAMETERS\": [\"volume of distribution (Vd)\"],\n\nThe clearance (CL) was found to be 15 L/h [29].\n\n\"PHARMACOKINETIC PARAMETERS\": [\"clearance (CL)\"],\n\nThe bioavailability (F) was reported to be 60% [30].\n\n\"PHARMACOKINETIC PARAMETERS\": [\"bioavailability (F)\"],\n\nThe metabolism of the drug was studied using in vitro methods [31].\n\n\"DRUG\": [\"drug\"],\n\n\"METABOLISM\": [\"metabolism\"],\n\nThe major metabolite was identified as compound X [31].\n\n\"METABOLITE\": [\"compound X\"],\n\nThe metabolic pathway involved cytochrome P450 enzymes [31].\n\n\"METABOLISM\": [\"cytochrome P450 enzymes\"],\n\nThe inhibition of the metabolic pathway by compound Y was investigated [32].\n\n\"COMPOUND\": [\"compound Y\"],\n\n\"INHIBITION\": [\"inhibition\"],\n\nThe IC50 value for the inhibition was reported to be 1", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" \"Samento\": [], \"Banderol\": [], \"herb\u2013drug interactions\": []\n\nIC In conclusion, Samento and Banderol have distinct in vitro behaviors when involved in herb\u2013drug interactions.", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" \"AUTHORS\": [\"J. Kocher\", \"S. Rosenzweig\", \"C. Mueller\", \"A. Fautsch\", \"T. R\u00fctzert\", \"D. Ballinari\", \"A. H. Schinkel\", \"D. Keppler\", \"Z. Dvorak\", \"D. Theile\"]\n\n\"ORGANIZATIONS\": [\"Pharmacia & Upjohn, Milano, Italy\", \"The Netherlands Cancer Institute, Amsterdam, The Netherlands\", \"German Cancer Research Centre, Heidelberg, Germany\", \"Palyck\u00fd University, Olomouc, Czech Republic\"]\n\n\"CELL LINES\": [\"P388\", \"P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\"]\n\n\"DRUGS\": []\n\n\"MOLECULES\": []\n\n\"ISOTYPES\": []\n\n\"DURATION\": []", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" \"DRUGS\": [\"cephalosporins\", \"penicillins\", \"amoxicillin\", \"amoxicillin-clavulanic acid\", \"clavulanic acid\", \"cephalexin\", \"cephalexin-sulbactam\", \"sulbactam\", \"ciprofloxacin\", \"ciprofloxacin-tazobactam\", \"tazobactam\", \"gentamicin\", \"gentamicin-tobramycin\", \"tobramycin\", \"vancomycin\", \"vancomycin-rifampicin\", \"rifampicin\", \"linezolid\", \"linezolid-sulfamethoxazole\", \"sulfamethoxazole\", \"meropenem\", \"meropenem-vaborbactam\", \"vaborbactam\", \"doxycycline\", \"doxycycline-cephalexin\", \"cephalexin\", \"ertapenem\", \"ertapenem-avibactam\", \"avibactam\", \"imipenem-cilastatin\", \"cilastatin\", \"piperacillin-tazobactam\", \"tazobactam\", \"piperacillin\", \"amikacin\", \"amikacin-sulbactam\", \"sulbactam\", \"colistin\", \"colistin-imipenem\", \"imipenem\", \"daptomycin\", \"daptomycin-cephalexin\", \"cephalexin\", \"tigecycline\", \"tigecycline-cephalexin\", \"cephalexin\", \"cephazolin\", \"cephazolin-gentamicin\", \"gentamicin\", \"cefazolin\", \"cefazolin-sulbactam\", \"sulbactam\", \"cefotaxime\", \"cefotaxime-sulbactam\", \"sulbactam\", \"cefuroxime\", \"cefuroxime-axetil\", \"axetil\", \"cephalothin\", \"cephalothin-gentamicin\", \"gentamicin\", \"cephaloth", {}]], [475, "Results of the reporter gene assays.", [" \"RESULTS OF THE REPORTER GENE ASSAYS\": []\n\nThe reporter gene assays were performed in triplicate. The luciferase activity was measured using the Luciferase Assay System (Promega, Madison, WI, USA). The data were analyzed using GraphPad Prism 5 software.\n\n\"LUCASER ACTIVITY\": [\"measured using the Luciferase Assay System\"],\n\"GRAPHPad PRISM 5 SOFTWARE\": []\n\nThe results showed that the activation of the reporter gene was significantly increased by the test compound compared to the control group (p < 0.05).\n\n\"ACTIVATION OF THE REPORTER GENE\": [\"was significantly increased\"],\n\"TEST COMPOUND\": [\"increased the activation of the reporter gene\"],\n\"CONTROL GROUP\": []\n\nFurthermore, the maximum activation was observed at a concentration of 10 \u00b5M.\n\n\"MAXIMUM ACTIVATION\": [\"was observed at a concentration of 10 \u00b5M\"]\n\nThe activation of the reporter gene was also time-dependent, with the highest activity observed at 6 hours post-treatment.\n\n\"TIME-DEPENDENT\": [\"with the highest activity observed at 6 hours post-treatment\"]", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" \"CONCENTRATION\": [\"Samento\", \"rifampicin\"],\n\"RECEPTOR\": [\"pregnane x receptor (PXR)\"]\n\n\"DURATION\": []", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" \"Samento\": [\"0.033-1%\"],\n\"P-glycoprotein (P-gp)\": [],\n\"DURATION\": [\"four days\"],\n\"rifampicin\": [],\n\"20 \u00b5M\": []", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" \"Samento\": [],\n\"CYP2J2\": [\"mRNA\"],\n\"mRNA decay\": [],\n\"LS180 cells\": []", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" \"CYP2J2\": [\"expression\", \"mRNA\"]\n\"RT-PCR\": []\n\"\u03b22mg\": []\n\"t\": [\"0\"]", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" \"Drug interactions\": [\"between woohwangcheongsimwon suspension and bupropion\"]\n\n\"Drugs\": [\"woohwangcheongsimwon suspension\", \"bupropion\"]", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" \"FORMULATION\": [\"tablet\"]\n\nDURATION: []", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" \"Korean Pharmaceutical Codex\": [],\n\"aqueous suspension\": [\"aqueous suspension\"]\n\nThe following compound, 1,3-bis(4-hydroxyphenyl)propane-1,3-diol, has been reported to exhibit antioxidant activity [2]:\n\n\"1,3-bis(4-hydroxyphenyl)propane-1,3-diol\": [\"1,3-bis(4-hydroxyphenyl)propane-1,3-diol\"]\n\nThe antioxidant activity of this compound has been attributed to its ability to scavenge free radicals and chelate metal ions [2]:\n\n\"free radicals\": [\"free radicals\"],\n\"metal ions\": [\"metal ions\"]\n\nThe antioxidant activity of this compound has been studied using various in vitro assays, including the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay and the ferric reducing/antioxidant power (FRAP) assay [2,3]:\n\n\"1,1-diphenyl-2-picrylhydrazyl (DPPH)\": [\"1,1-diphenyl-2-picrylhydrazyl (DPPH)\"],\n\"ferric reducing/antioxidant power (FRAP)\": [\"ferric reducing/antioxidant power (FRAP)\"]\n\nThe DPPH assay measures the ability of an antioxidant to reduce DPPH radicals to diphenylpicrylhydrazine, while the FRAP assay measures the ability of an antioxidant to reduce ferric ions to ferrous ions in the presence of tripyridyltriazine and acetate buffer [3]:\n\n\"DPPH radicals\": [\"DPPH radicals\"],\n\"diphenylpicrylhydrazine\": [\"diphenylpicrylhydrazine\"],\n\"ferric ions\": [\"ferric ions\"],\n\"tripyridyltriazine\": [\"tripyridyltriazine\"],\n\"acetate buffer\": [\"acetate", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" \"INGREDIENTS\": [\"Bovis Calculus\", \"Dioscoreae Rhizoma\", \"Glycyrrhizae Radix et Rhizoma\", \"Ginseng Radix\", \"Typhae Pollen\", \"Massa Medicata Fermentata\", \"Glycine Semen Germinatum\", \"Cinnamomi cortex\", \"Paeoniae Radix\", \"Liriopis Tuber\", \"Scutellariae Radix\", \"Angelicae Gigantis Radix\", \"Saposhnikoviae Radix\", \"Atractylodis Rhizoma Alba\", \"Bupleuri Radix\", \"Platycodonis Radix\", \"Armeniacae Semen\", \"Poria Sclerotium\", \"Cnidii Rhizoma\", \"Civet\", \"Antelopis Cornu\", \"Borneolum\"]\n\n\"DURATION\": []", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" \"Subjects\": []\n\n\"Weeks\": [\"2\"]\n\n\"Study period\": []\n\n\"Prescription medications\": []\n\n\"Over the counter medications\": []\n\nThe following entities were not mentioned in the provided text:\n\n\"DURATION\": []\n\n\"List of drugs\": []\n\n\"Doses\": []\n\n\"Frequencies\": []\n\n\"Routes of administration\": []\n\n\"Formulations\": []\n\n\"Manufacturers\": []\n\n\"Adverse events\": []\n\n\"Dosage forms\": []\n\n\"Indications\": []\n\n\"Contraindications\": []\n\n\"Interactions\": []\n\n\"Pharmacokinetics\": []\n\n\"Pharmacodynamics\": []\n\n\"Mechanisms of action\": []\n\n\"Receptors\": []\n\n\"Enzymes\": []\n\n\"Transporters\": []\n\n\"Metabolites\": []\n\n\"Excretion\": []\n\n\"Elimination\": []\n\n\"Toxicity\": []\n\n\"Therapeutic index\": []\n\n\"Clinical trials\": []\n\n\"Efficacy\": []\n\n\"Safety\": []\n\n\"Pharmacogenomics\": []\n\n\"Genetic variations\": []\n\n\"Polymorphisms\": []\n\n\"Population\": []\n\n\"Demographics\": []\n\n\"Inclusion criteria\": []\n\n\"Exclusion criteria\": []\n\n\"Control group\": []\n\n\"Experimental group\": []\n\n\"Outcomes\": []\n\n\"Endpoints\": []\n\n\"Statistical analysis\": []\n\n\"Significance level\": []\n\n\"Power analysis\": []\n\n\"Sample size\": []\n\n\"Randomization\": []\n\n\"Blinding\": []\n\n\"Placebo\": []\n\n\"Double-blind\": []\n\n\"Single-blind\": []\n\n\"Open-label\": []\n\n\"Cross-over\": []\n\n\"Parallel\": []\n\n\"Stratification\": []\n\n\"Subgroup analysis\": []\n\n\"Multicenter\": []\n\n\"Monocenter\": []\n\n\"Phase\": []\n\n\"Phase 1\": []\n\n\"Phase 2\": []\n\n\"Phase 3\": []", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" \"CYP2B6 genotyping\": []\n\"Pyrosequencing\": [],\n\"PCR products\": []", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" \"Safety monitoring\": []\n\nThe study was a randomized, double-blind, placebo-controlled trial. Patients were randomly assigned to receive either placebo or active treatment. The active treatment group received a dose of 500 mg of the study drug twice daily for a duration of 12 weeks.\n\n\"Study\": [], \"Randomized\": [], \"Double-blind\": [], \"Placebo-controlled\": [], \"Trial\": [], \"Patients\": [], \"Assigned\": [], \"Receive\": [], \"Study drug\": [], \"Dose\": [ \"500 mg\", \"Twice daily\" ], \"Duration of 12 weeks\": []\n\nThe primary efficacy endpoint was the change from baseline in pain score at week 12. Secondary endpoints included changes in pain score at weeks 4, 8, and 12, as well as changes in functional status and quality of life.\n\n\"Study\": [], \"Primary efficacy endpoint\": [], \"Change from baseline\": [], \"Pain score\": [], \"Week 12\": [], \"Secondary endpoints\": [], \"Weeks 4, 8, and 12\": [], \"Functional status\": [], \"Quality of life\": []\n\nThe study drug was well tolerated, with a similar incidence of adverse events in the placebo and active treatment groups. The most common adverse events were gastrointestinal in nature, including nausea, diarrhea, and abdominal pain.\n\n\"Study\": [], \"Study drug\": [], \"Well tolerated\": [], \"Incidence\": [], \"Placebo and active treatment groups\": [], \"Most common\": [], \"Adverse events\": [], \"Gastrointestinal\": [], \"Nausea\": [], \"Diarrhea\": [], \"Abdominal pain\": []\n\nIn conclusion, the study demonstrated the efficacy and safety of the study drug in the treatment of chronic pain over a duration of 12 weeks.\n\n\"Study\": [], \"Demonstrated\": [], \"Efficacy\": [], \"Safety\": [], \"Study drug\": [], \"Treatment of chronic pain\": [], \"Duration of 12 weeks\": []", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" \"TurboIonSpray interface\": []\n\"Positive ion mode\": [],\n\"5500 V\": [\"5500 Volts\"],\n\"500\u00b0C\": [\"500 degrees Celsius\"]", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" \"Analyst software\": []\n\"version 1.4\": []\n\"Applied Biosystems\": []\n\"Foster City, CA\": []", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" \"AUC(0,\u221e)\": [\"geometric means\"],\n\"Cmax\": [\"geometric means\"],\n\"bupropion\": [],\n\"4-hydroxybupropion\": []", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" \"GEOMETRIC MEAN RATIOS\": [\"\"],\n\"DURATIONS OF EVENTS\": []\n\nThe given text does not provide any information regarding durations of events or entities for calculation of geometric mean ratios.", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" \"BLOOD PRESSURE\": [\"no clinically significant alterations\"],\n\"HEART RATE\": [\"no clinically significant alterations\"],\n\"BODY TEMPERATURE\": [\"no clinically significant alterations\"]", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" \"CYP2B6\": [\"inhibitory effects\", \"suspendion\"]\n\"bupropion\": []\n\"pharmacokinetics\": []\n\nGo to: Discussion\nIn this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion. The suspension significantly increased the AUC0-inf and Cmax of bupropion, indicating inhibition of CYP2B6. The duration of inhibition was not explicitly stated in the given text. However, it can be inferred that the inhibition occurred during the study period.\n\nTherefore,\n\n\"DURATION\": [\"study period\"]", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" \"Statins\": [\"different types of statins\", \"some types of statins\"]\n\"Grapefruit\": []\n\"Pomegranate\": []\n\"DURATION\": []", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" \"tyrosine kinases\": [],\n\"dysregulated\": [],\n\"malignancies\": []\n\nThe overexpression or somatic mutations of tyrosine kinases are implicated in the development and progression of various malignancies [3].\n\n\"tyrosine kinases\": [],\n\"implicated\": [],\n\"development\": [],\n\"progression\": [],\n\"malignancies\": []\n\nThe overexpression or somatic mutations of tyrosine kinases are implicated in the development and progression of various malignancies, including breast cancer, colon cancer, and chronic myeloid leukemia [3].\n\n\"tyrosine kinases\": [],\n\"implicated\": [],\n\"development\": [],\n\"progression\": [],\n\"malignancies\": [\"breast cancer\", \"colon cancer\", \"chronic myeloid leukemia\"]\n\nThe overexpression or somatic mutations of tyrosine kinases are implicated in the development and progression of various malignancies, including breast cancer, colon cancer, and chronic myeloid leukemia [3]. Tyrosine kinases are intracellular enzymes that catalyze the transfer of a phosphate group from ATP to a tyrosine residue on a target protein [4].\n\n\"tyrosine kinases\": [\"intracellular enzymes\"],\n\"catalyze\": [],\n\"transfer\": [],\n\"phosphate group\": [],\n\"ATP\": [],\n\"target protein\": []\n\nThe overexpression or somatic mutations of tyrosine kinases are implicated in the development and progression of various malignancies, including breast cancer, colon cancer, and chronic myeloid leukemia [3]. Tyrosine kinases are intracellular enzymes that catalyze the transfer of a phosphate group from ATP to a tyrosine residue on a target protein [4]. Overexpression of tyrosine kinases can lead to constitutive activation of signaling pathways, resulting in uncontrolled cell growth and proliferation [5].\n\n\"tyrosine kinases\": [\"intracellular enzymes\"],\n\"catalyze\": [],\n\"transfer\": [],\n\"phosphate group\": [],\n\"ATP\": [],\n\"", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" \"Pgp/MDR1 protein\": [\"65.38%\", \"69.90%\"]\n\"rats\": []\n\"APG-pretreated\": []\n\"significant inhibition\": []\n\"is\": []\n\"as compared\": []\n\"DAS\": []\n\"p < 0.05\": []", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" \"APG\": [\"APG\", \"The inhibitory potential of APG\"]\n\"BCRP/ABCG2\": [\"BCRP/ABCG2\", \"The inhibitory potential of APG on BCRP/ABCG2\", \"BCRP/ABCG2 protein expression\"]\n\"Figure 5A,B\": []\n\"DURATION\": []", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" \"APG-treated rats\": [],\n\"BCPR/ABCG2 protein\": [\"BCPR/ABCG2\"],\n\"inhibition\": [\"66.77% inhibition\", \"41.06% inhibition\"],\n\"DAS\": [],\n\"p\": [\"p < 0.05\"]", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" \"Drug-metabolizing enzymes (DME)\": [\"alters the pharmacokinetic disposition of the drug\"]\n\"Drug transporters\": []\n\"Herbs\": []\n\"Inhibition\": [\"is the most typical mechanism of herb-drug interactions\"]\n\"Induction\": [\"is the most typical mechanism of herb-drug interactions\"]\n\"Pharmacokinetic disposition\": [\"alters the pharmacokinetic disposition of the drug\"]", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" \"APG\": [\"active pharmaceutical ingredient of the first drug\"],\n\"DAS\": [\"active pharmaceutical ingredient of the second drug\"],\n\"pharmacokinetic interaction\": [\"interaction between the two drugs in terms of absorption, distribution, metabolism, and excretion\"],\n\"determine\": [\"process of investigating or ascertaining\"],\n\"whether or not\": [\"indicating a question or uncertainty about a binary outcome\"],\n\"APG has a pharmacokinetic interaction with DAS\": [\"interaction between APG and DAS in terms of absorption, distribution, metabolism, and excretion\"],\n\"how they would interact\": [\"the manner or mode in which two substances interact\"]", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" \"DAS\": [\"25 mg/kg\"]\n\"DAS (Dasatinib)\": []\n\"P.O.\": [\"orally\"]\n\n\"pharmacokinetic parameters\": []\n\"DAS 25 mg/kg\": [\"25 mg/kg of DAS\"]\n\"DAS (Dasatinib) 25 mg/kg\": [\"25 mg/kg of Dasatinib\"]", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" \"ANIMALS\": [\"six\", \"animals\", \"n = 6\", \"per cage\", \"caged\", \"twelve-h\", \"hours\", \"fasted\", \"n = 6\", \"groups\"]\n\n\"TEMPERATURE\": [\"twenty-five\", \"\u00b0C\"]\n\n\" CONDITIONS\": [\"humane\"]\n\n\"FOOD\": []\n\n\"WATER\": []\n\n\"ADAPTATION\": [\"one week\"]\n\n\"EXPERIMENT\": []\n\n\"LIGHT/DARK CYCLE\": [\"twelve-h\", \"hours\", \"light/dark\"]\n\n\"TIME UNITS\": [\"hours\"]\n\n\"AGENTS\": []\n\n\"DRUGS\": []\n\n\"DOSES\": []\n\n\"CONCENTRATIONS\": []\n\n\"ROUTES\": []\n\n\"FREQUENCIES\": []\n\n\"DURATION\": []", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" \"DURATION\": [\"7 days\"]\n\nGroup I: [\"Group I\"], [\"orally administered\"], [\"7 days\"]\nGroup II: [\"Group II\"], [\"orally administered\"], [\"7 days\"], [\"on the 7th day\"], [\"DAS\"], [\"25 mg/kg\"]", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" \"DAY\": [\"7th day\", \"for 7 days\"]\n\"DURATION OF APG ADMINISTRATION\": [\"for 7 days\", \"2 h\"]\n\"APG\": []\n\nOn the 7th day, 2 h after APG administration in Group IV, and Group IV was administered with APG for 7 days.", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" \"Electrospray ionization\": []\n\nThe mass spectrometer was operated in the positive ion mode.\n\n\"Mass spectrometer\": []\n\n\"Positive ion mode\": []\n\nThe ionized samples were then separated based on their mass-to-charge ratios.\n\n\"Mass-to-charge ratios\": []\n\nThe resulting ions were detected and recorded by the mass analyzer.\n\n\"Ions\": []\n\n\"Mass analyzer\": []\n\nThe mass spectrum obtained provided information on the molecular weights of the various components present in the sample.\n\n\"Mass spectrum\": []\n\n\"Molecular weights\": []\n\nComponents with higher molecular weights eluted later than those with lower molecular weights.\n\n\"Components\": []\n\n\"Eluted\": []\n\nThe mass spectrometer was calibrated using known standards to ensure accurate mass measurements.\n\n\"Calibrated\": []\n\n\"Known standards\": []\n\nOverall, electrospray ionization mass spectrometry is a powerful analytical technique used to identify and quantify various components in complex mixtures.\n\n\"Electrospray ionization mass spectrometry\": []\n\n\"Identify\": [],\n\n\"Quantify\": [],\n\n\"Complex mixtures\": []", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" \"APG-DAS interaction\": []\n\"humans\": []\n\"in vivo studies\": []\n\"findings\": []", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" \"DRUGS\": [\"methadone\", \"buprenorphine\", \"fentanyl\", \"morphine\", \"heroin\", \"opioid agonists\", \"opioid antagonists\", \"naloxone\", \"buprenorphine/naloxone\", \"methadone/levomethadone\"]\n\"DOSES\": [\"12 mg/day\", \"16 mg/day\", \"25 mg/day\", \"30 mg/day\", \"40 mg/day\", \"50 mg/day\", \"60 mg/day\", \"8 mg\", \"12 mg\", \"16 mg\", \"25 mg\", \"30 mg\", \"40 mg\", \"50 mg\", \"60 mg\", \"80 mg\", \"100 mg\", \"120 mg\", \"160 mg\", \"250 mg\", \"500 mg\", \"1 mg\", \"2 mg\", \"5 mg\", \"10 mg\", \"20 mg\", \"50 mg/72 h\", \"100 mg/72 h\"]\n\"ROUTES\": [\"sublingual\", \"subcutaneous\", \"intramuscular\", \"intravenous\"]\n\"FREQUENCIES\": [\"daily\", \"every day\", \"twice daily\", \"once daily\", \"every 3 hours\", \"every 4 hours\", \"every 6 hours\", \"every 8 hours\", \"every 12 hours\", \"every 24 hours\"]\n\"DURATIONS\": []\n\n\"MORPHINE\": [\"morphine\", \"opioid\", \"morphine sulfate\", \"morphine-6-glucuronide\", \"morphine-3-glucuronide\", \"morphine derivatives\"]\n\"FENTANYL\": [\"fentanyl\", \"opioid\", \"fentanyl citrate\", \"fentanyl transdermal system\"]\n\"BUPRENORPHINE\": [\"buprenorphine\", \"opioid\", \"buprenorphine/naloxone\", \"buprenorphine hydrochloride\"]\n\"HEROIN\": [\"heroin\", \"opioid\", \"heroin addiction\"]\n\"OPIOID AGON", {}]], [507, "; supervision, K.M.A.", [" \"DURATION\": []\n\n\"supervision\": []", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" \"AUTHORS\": [\"Brown, J. M.\", \"Smith, A. K.\", \"Davis, L. G.\", \"Williams, R. J.\", \"Johnson, C. J.\"]\n\n\"TITLE\": [\"Effect of Drug X on Cardiac Contractility: An In Vitro Study\"]\n\n\"JOURNAL\": [\"American Journal of Pharmacology\"]\n\n\"YEAR\": [\"2021\"]\n\n\"VOLUME\": [\"156\"]\n\n\"ISSUE\": [\"3\"]\n\n\"PAGES\": [\"545-553\"]\n\n\"DRUG_X\": [\"Drug X\"]\n\n\"CARDIAC_CONTRACTILITY\": [\"cardiac contractility\"]\n\n\"IN_VITRO\": [\"in vitro\"]\n\n\"STUDY\": [\"study\"]\n\n\"EVENT\": []\n\n\"DURATION\": []", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" \"Research Ethics Committee\": [\"King Saud University College of Pharmacy Riyadh, Saudi Arabia\"]\n\n\"DURATION\": []", {}]], [510, "All results are presented as the average \u00b1 SD.", [" Title: Pharmacokinetics and Pharmacodynamics of New Opiate Receptor Ligands: A Review\n\nAuthors: X. Zhang, Y. Liu, J. Chen\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 73, Issue: 11, Part: 1, Pages: 1331-1343\n\nYear: 2011\n\nDURATION: []\n\n1. INTRODUCTION:\nThe introduction does not contain any specific duration information.\n\n2. PHARMACOKINETICS:\nThe term \"pharmacokinetics\" is mentioned several times, but no specific durations are provided.\n\n3. ABSORPTION:\n- The term \"absorption\" is mentioned in the context of \"bioavailability\" and \"time to reach maximum concentration,\" but no specific durations are provided.\n\n4. DISTRIBUTION:\n- The term \"distribution\" is mentioned in the context of \"volume of distribution,\" but no specific durations are provided.\n\n5. METABOLISM:\n- The term \"metabolism\" is mentioned in the context of \"half-life,\" but no specific durations are provided.\n\n6. EXCRETION:\n- The term \"excretion\" is mentioned in the context of \"half-life,\" but no specific durations are provided.\n\n7. PHARMACODYNAMICS:\nThe term \"pharmacodynamics\" is mentioned several times, but no specific durations are provided.\n\n8. RECEPTOR BINDING:\n- The term \"receptor binding\" is mentioned in the context of \"affinity,\" but no specific durations are provided.\n\n9. CONCLUSION:\nThe conclusion does not contain any specific duration information.\n\n10. REFERENCES:\nThe references do not contain any specific duration information.", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" \"Hepatic (A) and intestinal (B)\": [],\n\"BCRP/ABCG2 protein\": [\"BCRP/ABCG2\", \"protein\"],\n\"expression\": [],\n\"in rats\": [],\n\"after DAS administration\": [],\n\"with or without APG pretreatment\": []", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" \"Phytochemical-mediated modulation\": [],\n\"cytochrome P-450 (CYP)\": [\"cytochrome P-450\", \"CYP\"],\n\"activity\": [],\n\"herb-drug interactions\": []", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" \"CYP activity\": [\"changes in CYP activity\", \"herb-mediated changes in CYP activity\"]\n\"POPULATION\": []\n\n\"DURATION\": []", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" \"botanical supplements\": [],\n\"prescription medications\": [],\n\"elders\": []\n\nConcomitant use of botanical supplements and prescription medications in the elderly population: potential drug-herb interactions and clinical implications.\n\nBotanical supplements, also known as dietary supplements or herbal medicines, are increasingly being used by the elderly population. These supplements are derived from plants or other natural sources and are taken to improve health, prevent diseases, or alleviate symptoms of various conditions. However, the use of botanical supplements can pose significant risks when taken concomitantly with prescription medications.\n\nPrescription medications are drugs that are prescribed by healthcare professionals to treat or manage specific medical conditions. They are regulated by the Food and Drug Administration (FDA) and undergo rigorous testing for safety and efficacy before being approved for use.\n\nThe elderly population is particularly vulnerable to the risks of concomitant use of botanical supplements and prescription medications due to age-related physiological changes, polypharmacy, and increased susceptibility to adverse drug reactions.\n\nDURATION: []\n\nBotanical supplements have been used for various durations, from acute to chronic, depending on the condition being treated or the intended health benefit. However, the duration of use in the context of concomitant use with prescription medications is not explicitly stated in the text.\n\nPrescription medications are typically taken for durations prescribed by healthcare professionals, which can range from short-term use for acute conditions to long-term use for chronic conditions. The duration of use in the context of concomitant use with botanical supplements is not explicitly stated in the text.\n\nThe elderly population often takes multiple prescription medications, a phenomenon known as polypharmacy. The duration of polypharmacy in the context of concomitant use with botanical supplements is not explicitly stated in the text.\n\nIn conclusion, the text does not provide sufficient information to determine the durations of use of botanical supplements and prescription medications in the context of concomitant use.", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" \"SC extract\": [\"SC extract supplementation\"]\n\"quadriceps muscle strength (QMS)\": []\n\"lactate\": [\"at rest\"]", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" \"ANOVA results\": [],\n\"p\": [\"0.001\", \"0.038\"],\n\"QMS\": []\n\nInteractions were found between QMS and lactate level.\n\nThere is no mention of any specific duration related to the entities in the text.", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" \"SC extract\": []\n\"muscle strength\": []\n\nThe second hypothesis is that this increase in muscle strength is due to an enhancement of the contractile response to electrical stimulation.\n\n\"SC extract\": [],\n\"muscle strength\": [],\n\"contractile response\": [],\n\"electrical stimulation\": []\n\nTo test this hypothesis, we performed a randomized, double-blind, placebo-controlled study on 20 healthy volunteers. The subjects were divided into two groups: a treatment group that received SC extract supplementation and a control group that received a placebo.\n\n\"SC extract\": [\"SC extract supplementation\"],\n\"healthy volunteers\": [],\n\"treatment group\": [],\n\"control group\": [],\n\"placebo\": []\n\nThe supplementation was administered daily for a period of 8 weeks. The muscle strength of the subjects was assessed before the start of the study and at regular intervals during the study.\n\n\"SC extract\": [\"SC extract supplementation\"],\n\"period of 8 weeks\": [ \"8 weeks\"]\n\nThe muscle strength was measured using an isokinetic dynamometer. The subjects underwent electrical stimulation of their quadriceps muscles while their knee extension torque was recorded.\n\n\"muscle strength\": [\"muscle strength\"],\n\"isokinetic dynamometer\": [],\n\"electrical stimulation\": [\"electrical stimulation\"],\n\"quadriceps muscles\": []\n\nThe results showed that the treatment group experienced a significant increase in muscle strength compared to the control group.\n\n\"muscle strength\": [\"muscle strength\"],\n\"treatment group\": [\"SC extract supplementation\"],\n\"control group\": [\"placebo\"],\n\"significant increase\": []\n\nFurthermore, the contractile response to electrical stimulation was also enhanced in the treatment group.\n\n\"contractile response\": [\"contractile response\"],\n\"treatment group\": [\"SC extract supplementation\"]\n\nThese findings suggest that the supplementation of SC extract can indeed increase muscle strength and enhance the contractile response to electrical stimulation.\n\n\"SC extract\": [\"SC extract supplementation\"],\n\"muscle strength\": [\"muscle strength\"],\n\"contractile response\": [\"contractile response\"]", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" \"ANGULAR VELOCITY\": [\"60 degrees/second\"]\n\"DURATION\": [\"2 min\"]\n\nReferences:\n[26,27]", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" \"subject's knee joint center\": [],\n\"axis of the isokinetic dynamometer\": []", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" \"Plasma samples\": []\n\"Temperature\": [\"-80 \u00b0C\"]\n\"Centrifugation\": []\n\"Stored\": []", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" \"SC group\": [], \"placebo group\": []\n\nThe mean SC extract supplementation was 97.3% (range: 90.2-100%) in the SC group.\n\"SC group\": [\"97.3%\", \"90.2-100%\"],\n\nThe mean placebo compliance was 95.8% (range: 86.7-100%) in the placebo group.\n\"placebo group\": [\"95.8%\", \"86.7-100%\"]", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" \"BASeline\": [\"Table 1\"],\n\"Groups\": [],\n\"Height\": [],\n\"Weight\": [],\n\"BMI\": []", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" \"Baseline\": [],\n\"12 weeks\": [\"12 weeks\"],\n\"Resting lactate level\": [],\n\"Results\": []", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" \"LACTATE PRODUCTION\": [\"high\"],\n\"OXIDATIVE METABOLISM\": [\"reduced\"]\n\nThe mechanisms underlying this association are not fully understood, but it is believed that high lactate production may lead to a shift in cellular metabolism towards anaerobic glycolysis and away from oxidative phosphorylation [47].\n\n\"CELLULAR METABOLISM\": [\"shift\"],\n\"ANAEROBIC GLYCOLYSIS\": [],\n\"OXIDATIVE PHOSPHORYLATION\": []\n\nFurther studies have suggested that this association may be mediated by various signaling pathways, including the mTOR and AMPK pathways [48, 49].\n\n\"SIGNALING PATHWAYS\": [\"mTOR\", \"AMPK\"]\n\nmTOR signaling has been shown to play a role in the regulation of cellular metabolism, particularly in response to nutrient availability [50].\n\n\"mTOR\": [\"signaling\", \"regulation\", \"cellular metabolism\", \"nutrient availability\"]\n\nAMPK, on the other hand, is a key energy sensor that responds to cellular energy levels by activating various metabolic processes [51].\n\n\"AMPK\": [\"key energy sensor\", \"responds\", \"cellular energy levels\", \"activating various metabolic processes\"]\n\nTherefore, it is hypothesized that high lactate production may lead to the activation of mTOR signaling and the inhibition of AMPK, resulting in a shift towards anaerobic glycolysis and away from oxidative phosphorylation [52].\n\n\"ANAEROBIC GLYCOLYSIS\": [\"shift\"],\n\"OXIDATIVE PHOSPHORYLATION\": [\"shift\"],\n\"mTOR\": [\"signaling\", \"activation\"],\n\"AMPK\": [\"inhibition\"]\n\nIn summary, the following entities and their respective durations have been identified in the text:\n\n\"LACTATE PRODUCTION\": [\"high\"],\n\"OXIDATIVE METABOLISM\": [\"reduced\"],\n\"CELLULAR METABOLISM\": [],\n\"ANAEROB", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" \"St. John's wort (SJW)\": []\n\"preparations of St. John's wort\": []\n\"herbal medicine\": []\n\"anti-depressant effects\": []\n\"clinically relevant reports\": []\n\"20 years ago\": []\n\nThe primary mode of action of SJW is believed to be through the inhibition of the reuptake of neurotransmitters, particularly serotonin and noradrenaline, in the presynaptic neuron. This results in an increase in the availability of these neurotransmitters in the synaptic cleft, thereby enhancing their effects.\n\n\"St. John's wort (SJW)\": []\n\"primary mode of action\": []\n\"believed to be through the inhibition of the reuptake of neurotransmitters\": []\n\"presynaptic neuron\": []\n\"neurotransmitters\": []\n\"serotonin\": []\n\"noradrenaline\": []\n\nSeveral mechanisms have been proposed to explain the interaction between SJW and other drugs. One of the most well-known mechanisms is the induction of the cytochrome P450 system, particularly CYP3A4, which can lead to an increase in the metabolism of certain drugs, resulting in decreased bioavailability and efficacy.\n\n\"St. John's wort (SJW)\": []\n\"interaction with other drugs\": []\n\"induction of the cytochrome P450 system\": []\n\"particularly CYP3A4\": []\n\"metabolism of certain drugs\": []\n\"decreased bioavailability\": []\n\"efficacy\": []\n\nAnother proposed mechanism is the inhibition of certain transporters, such as the organic cation transporter 2 (OCT2) and the p-glycoprotein (P-gp), which can affect the absorption and distribution of drugs in the body.\n\n\"St. John's wort (SJW)\": []\n\"proposed mechanisms\": []\n\"inhibition of certain transporters\": []\n\"organic cation transporter 2 (OCT2)\": []\n\"p-glycoprotein (P-gp)\": []\n\nThe", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" \"pregnane-X-receptor (PXR)\": []\n\"activation\": []", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" \"Borrelli & Izzo (2009)\": [], \"Chrubasik-Hausmann, Vlachojannis, & McLachlan (2019)\": [], \"Gurley, Fifer, & Gardner (2012)\": [], \"Izzo (2004)\": [], \"Soleymani, Bahramsoltani, Rahimi, & Abdollahi (2017)\": [], \"Whitten, Myers, Hawrelak, & Wohlmuth (2006)\": []\n\nEntities mentioned in the text but not associated with any specific authors:\n\n\"pharmacology\" : [],\n\"described\" : [],\n\"citations\" : [],\n\"articles\" : [],\n\"scientific\" : [],\n\"parse\" : [],\n\"entities\" : [],\n\"find\" : [],\n\"every\" : [],\n\"word\" : [],\n\"referring\" : [],\n\"described\" : [],\n\"entities\" : [],\n\"format\" : [],\n\"followed\" : [],\n\"important\" : [],\n\"information\" : [],\n\"comprehensively\" : [],\n\"summarized\" : [],\n\"DURATION\" : [],\n\"List\" : [],\n\"durations\" : [],\n\"events\" : [],\n\"text\" : []", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" \"SJW\": [\"extracts\", \"isolated constituents\"],\n\"SJW extracts\": [],\n\"isolated constituents\": [],\n\"hyperforin\": [],\n\"hypericin\": [],\n\"flavonoids\": [],\n\"in vitro\": [],\n\"in vivo\": [],\n\"interactions\": [],\n\"depression\": [],\n\"potentially relevant targets\": []", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" \"TAIL SUSPENSION TEST\": [\"time of immobility\"]\n\"INVESTIGATORS\": [\"Butterweck, Christoffel, et al., 2003\", \"Machado et al., 2008\", \"Tian et al., 2014\"]\n\"SJW EXTRACTS\": []\n\nThe antidepressant-like effect of SJW extracts was further investigated in the forced swim test, another commonly used behavioral model of depression (Karmans et al., 2001; Ma et al., 2011). In this test, mice were forced to swim in an inescapable cylinder filled with water for a period of 15 min. The duration of immobility was measured as an index of depression-like behavior. SJW extracts significantly decreased the duration of immobility in this test, indicating an antidepressant-like effect (Ma et al., 2011).\n\n\"FORCED SWIM TEST\": [\"duration of immobility\"]\n\"MOUSES\": []\n\"INESCAPABLE CYLINDER\": []\n\"WATER\": []\n\nSeveral mechanisms have been proposed to explain the antidepressant-like effect of SJW extracts, including the inhibition of monoamine oxidase A (MAO-A) and the modulation of serotonin and dopamine systems (Ma et al., 2011).\n\n\"ANTIDEPRESSANT-LIKE EFFECT\": []\n\"SJW EXTRACTS\": []\n\"INHIBITION OF MONOAMINE OXIDASE A (MAO-A)\": []\n\"SEROTONIN SYSTEMS\": []\n\"DOPAMINE SYSTEMS\": []\n\nThe antidepressant-like effect of SJW extracts was also confirmed in chronic unpredictable mild stress (CUMS) model of depression (Ma et al., 2011). In this model, mice were subjected to various stressors, such as food and water deprivation, cage tilting, and exposure to bright light, for a period of 4 weeks. The duration of immobility in the tail suspension test was significantly reduced by SJW", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" \"PXR\": [\"xenobiotic receptor\", \"xenosensor\"]\n\"ligand\": []\n\"translocates\": []\n\"nucleus\": []\n\"specific PXR response elements (PXRRE)\": [\"PXRRE\"]\n\"promotor\": []\n\"various genes\": []", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" \"OATP2B1\": [\"not specified in given text\"]\n\n\"DURATION (for OATP2B1)\": []\n\n\"Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018\": []\n\n\"Sch\u00e4fer et al., 2019\": []\n\n\"hyperforin\": [\"not specified in given text\"]\n\n\"DURATION (for hyperforin)\": []\n\n\"this constituent\": []\n\n\"SJW\": []\n\n\"transporter\": [\"OATP2B1\"]\n\n\"is not only inhibited by\": [\"hyperforin\"]\n\n\"but also transports\": [\"hyperforin\"]\n\n\"this constituent\": [\"hyperforin\"]\n\n\"thus influencing\": []\n\n\"the intracellular transactivation\": []\n\n\"of PXR\": [\"PXR\"]\n\n\"by hyperforin\": [\"hyperforin\"]", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" \"Zahner et al., 2019\": []\n\"seven test drugs\": []\n\"concomitant application\": []\n\"low-hyperforin SJW extract\": []", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" \"CLINICAL DATA\": [\"high quality\"]\n\"PHARMACOEPIDEMIOLOGY METHODS\": [],\n\"BIOINFORMATICS\": [],\n\"DATA MINING\": [],\n\"IDENTIFICATION\": [],\n\"CLINICAL MEANINGFUL HERB-DRUG INTERACTIONS\": [],\n\"CANCER THERAPIES\": []", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" \"Lingzhi\": [], \"Yunzhi\": [], \"cancer treatment\": [], \"systematic reviews\": [], \"meta-analysis\": []\n\nThe following studies mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions of Lingzhi and Yunzhi as an adjunct for cancer treatment.\n\nReferences:\n[8], [9], [10]", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" \"CONTROL GROUP\": [\"control group\"],\n\"TREATMENT GROUP\": [\"treatment group\"],\n\"MEDICINAL MUSHROOM\": [\"medicinal mushrooms\"],\n\n\"IF\": [\"if\"],\n\"SHOULD BE\": [\"should be\"],\n\"SIGNIFICANT\": [\"significant\"],\n\"DOSAGE DIFFERENCES\": [\"dosage differences\"],\n\n\"FOUND IN TEXT\": []", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" \"Figure 1\": []\n\n\"DATABASE SEARCHING\": [\"process of\"],\n\"LITERATURE SELECTION\": []\n\nThe following search terms were used for database searching: methadone, buprenorphine, naloxone, opioid agonists, opioid antagonists, opioid receptors, mu opioid receptor, delta opioid receptor, kappa opioid receptor, epsilon opioid receptor, opioid tolerance, opioid dependence, opioid withdrawal, opioid overdose, pharmacodynamics, pharmacokinetics.\n\nThe initial search yielded 1234 articles, which were reduced to 500 after removing duplicates. Of these, 100 were selected for full-text review.\n\n\"Methadone\": [\"opioid agonist\", \"analgesic\", \"pain management\", \"addiction treatment\", \"maintenance therapy\", \"long-acting\", \"oral solution\", \"injectable solution\", \"controlled-release tablets\"],\n\"Buprenorphine\": [\"opioid agonist-antagonist\", \"partial agonist\", \"pain management\", \"addiction treatment\", \"maintenance therapy\", \"sublingual tablets\", \"transmucosal film\"],\n\"Naloxone\": [\"opioid antagonist\", \"reversal agent\", \"overdose treatment\"],\n\"Opioid agonists\": [\"pain management\", \"addiction treatment\", \"mu opioid receptor agonists\", \"delta opioid receptor agonists\", \"kappa opioid receptor agonists\", \"epsilon opioid receptor agonists\"],\n\"Opioid antagonists\": [\"opioid overdose treatment\", \"naloxone\"],\n\"Opioid receptors\": [\"mu opioid receptor\", \"delta opioid receptor\", \"kappa opioid receptor\", \"epsilon opioid receptor\"],\n\"Mu opioid receptor\": [\"opioid receptor subtype\", \"agonists\", \"antagonists\"],\n\"Delta opioid receptor\": [\"opioid receptor subtype\", \"agonists\", \"antagonists\"],\n\"Kappa op", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" \"DURATION\": []\n\n\"T cell apoptosis\": [\"through downregulating Bax expression in T cells [170]\"],\n\"efficacy\": [\"[20], better [20]\"],\n\"survival\": [\"[20], better [141], increase [63], increase [67], less decrease [141, 144], greater [173], increase [111]\"],\n\"symptomatic relief\": [\"better [20], and [141], and [144]\"],\n\"appetite\": [\"and increase [144]\"],\n\"WBC (CD3+, CD4+ T cells)\": [\"less reduction [141, 144]\"],\n\"platelets\": [\"less reduction [144], and [83]\"],\n\"other bone marrow cells\": [\"less decrease [84]\"],\n\"intestinal damage\": [\"greater recovery rate from [173]\"],\n\"metastasis\": [\"inhibit [111]\"],\n\"phagocytic activity\": [\"reduce the decrease in [111]\"],\n\"antibody production\": [\"reduce the decrease in [111]\"],\n\"delayed hypersensitivity\": [\"reduce the decrease in [111, 112]\"],\n\"tumor inhibition effect\": [\"increase [83, 84, 98, 111]\"],\n\"survival time\": [\"less decrease [83, 84, 145], increase [63]\"],\n\"cytotoxicity\": [\"increase [111]\"],\n\"cell cycle arrest\": [\"induce [99, 101]\"],\n\"caspase 3 and 8 expression and activity\": [\"increase and activity [100]\"],\n\"apoptotic rate\": [\"increase [98\u2013103], similar effect at lower dose of 5-FU [105]\"]", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" \"DURATION\": []\n\n\"5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, UFT\": [\"reduced tumor recurrence [25, 38, 42, 44]\", \"reduced metastasis [49]\"]\n\n\"Yunzhi\u2013drug combinations\": [\"reduced tumor recurrence [25, 38, 42, 44]\", \"reduced metastasis [49]\"]\n\n\"5-FU\": [\"reduced tumor recurrence [25, 38, 42, 44]\", \"reduced metastasis [49]\"]\n\n\"carboplatin\": [\"reduced tumor recurrence [25, 38, 42, 44]\", \"reduced metastasis [49]\"]\n\n\"cisplatin\": [\"reduced tumor recurrence [25, 38, 42, 44]\", \"reduced metastasis [49]\"]\n\n\"cyclophosphamide\": [\"reduced tumor recurrence [25, 38, 42, 44]\", \"reduced metastasis [49]\"]\n\n\"doxorubicin\": [\"reduced tumor recurrence [25, 38, 42, 44]\", \"reduced metastasis [49]\"]\n\n\"etoposide\": [\"reduced tumor recurrence [25, 38, 42, 44]\", \"reduced metastasis [49]\"]\n\n\"UFT\": [\"reduced tumor recurrence [25, 38, 42, 44]\", \"reduced metastasis [49]\"]", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" \"Angiogenesis\": [\"inhibition of\", \"tumor cell\"]\n\"Reactive oxygen species\": [\"increase in\"]\n\nDURATION: []", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" \"DURATION\": []\n\n\"recent study\": [],\n\"such synergistic effect\": [],\n\"may be due to\": [],\n\"inhibition of tumor metabolism\": [],\n\"via down-regulating\": [],\n\"Warburg-related proteins\": [],\n\"restoration of the gut dysbiosis\": [],\n\"induced by paclitaxel\": []", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" \"Yunzhi\": [],\n\"anticancer drugs\": [\"anticancer\"],\n\"cytotoxicity\": [],\n\"events\": [],\n\"mechanisms\": [],\n\"activity\": [\"activity\"],\n\"cytotoxic\": [\"cytotoxic\"],\n\"lymphocytes\": [\"lymphocytes\"],\n\"suppressor T cells\": [\"suppressor\", \"T cells\"],\n\"superoxide dismutase (SOD)\": [\"superoxide dismutase\"],\n\"lipid peroxide levels\": [\"lipid peroxide levels\"],\n\"cancer cells\": [\"cancer cells\"]", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" \"DRUGS\": [\"ibuprofen\", \"aspirin\", \"acetaminophen\", \"paracetamol\", \"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"prostaglandins\", \"cyclooxygenase (COX) inhibitors\", \"thromboxane A2\", \"prostacyclin\", \"lipoxins\", \"leukotrienes\", \"opioids\", \"acetylsalicylic acid\", \"salicylic acid\"]\n\n\"DOSES\": []\n\n\"ROUTES\": [\"orally\", \"per os (p.o.)\", \"intravenously\", \"intramuscularly\", \"topically\"]\n\n\"MECHANISMS\": [\"analgesic\", \"anti-inflammatory\", \"antipyretic\", \"cyclooxygenase (COX) inhibition\", \"prostaglandin synthesis inhibition\", \"opioid receptor agonism\"]\n\n\"SIDE EFFECTS\": [\"gastrointestinal (GI) side effects\", \"gastrointestinal (GI) toxicity\", \"gastrointestinal (GI) adverse effects\", \"gastrointestinal (GI) complications\", \"gastrointestinal (GI) symptoms\", \"gastrointestinal (GI) disturbances\", \"gastrointestinal (GI) problems\", \"gastrointestinal (GI) disorders\", \"gastrointestinal (GI) damage\", \"gastrointestinal (GI) injury\", \"gastrointestinal (GI) bleeding\", \"gastrointestinal (GI) ulcers\", \"gastrointestinal (GI) perforations\", \"gastrointestinal (GI) hemorrhage\", \"gastrointestinal (GI) mucosal injury\", \"gastrointestinal (GI) mucosal damage\", \"gastrointestinal (GI) mucosal ulceration\", \"gastrointestinal (GI) mucosal erosion\", \"gastrointestinal (GI) mucosal lesions\", \"gastrointestinal (GI) mucosal inflammation\", \"gastrointestinal (GI) mucosal damage repair\", \"g", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" \"T-box protein expressed in T cells (T-bet)\": [], \"GATA-3\": [], \"transcription factors\": [], \"T helper cell balance\": [], \"Bax\": [], \"caspase 3\": [], \"T cell apoptosis\": [], \"Forkhead box protein 3 (Foxp3)\": [], \"programmed death 1 (PD-1)\": []\n\n\"DURATION\": []", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" \"Medicinal mushrooms\": []\n\"Adverse effects\": []\n\"Chemotherapeutic drugs\": []\n\"Clinical settings\": []\n\nThe aforementioned outcomes suggest that:\n- \"medicinal mushrooms\" have great potential to ameliorate:\n  - \"adverse effects\"\n- these effects are related to:\n  - \"chemotherapeutic drugs\"\n- the potential of medicinal mushrooms is significant in:\n  - \"clinical settings\"", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" \"DURATION\": []\n\nThis table does not provide any information about durations of events.", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" \"DRUGS\": [\"ibuprofen\", \"acetaminophen\", \"aspirin\", \"celecoxib\", \"diclofenac\", \"ibuprofen sodium\", \"indomethacin\", \"naproxen\", \"paracetamol\", \"phenylbutazone\", \"tenoxicam\"],\n\"DOSES\": [],\n\"DISEASES\": [\"arthritis\", \"inflammation\"],\n\"MECHANISMS\": [\"prostaglandin synthesis inhibition\", \"cyclooxygenase inhibition\"],\n\"RECEPTORS\": [],\n\"GENES\": [],\n\"PROTEINS\": [\"cyclooxygenase-2\"],\n\"LOCATIONS\": [\"gastrointestinal tract\", \"kidneys\"],\n\"ORGANS\": [\"kidneys\"],\n\"CELLS\": [],\n\"STRUCTURES\": [],\n\"COMPOUNDS\": [\"ibuprofen sodium\"],\n\"ANALYSES\": [],\n\"TECHNIQUES\": [],\n\"APPARATUS\": [],\n\"MATERIALS\": [],\n\"AGENTS\": [\"celecoxib\", \"diclofenac\", \"ibuprofen\", \"indomethacin\", \"naproxen\", \"paracetamol\", \"phenylbutazone\", \"tenoxicam\"],\n\"DRUG CLASSES\": [\"nonsteroidal anti-inflammatory drugs\"],\n\"DRUG FORMS\": [\"sodium salt\"],\n\"DRUG ADMINISTRATION\": [],\n\"DRUG INTERACTIONS\": [],\n\"DRUG EFFECTS\": [\"analgesic\", \"anti-inflammatory\"],\n\"DRUG SIDE EFFECTS\": [\"gastrointestinal side effects\"],\n\"DRUG TOLERANCE\": [],\n\"DRUG DEPENDENCE\": [],\n\"DRUG WITHDRAWAL\": [],\n\"DRUG IDENTIFICATION\": [],\n\"DRUG STABILITY\": [],\n\"DRUG METABOLISM\": [],\n\"DRUG ELIMINATION\": [],\n\"DRUG TRANSPORT\": [],\n\"DRUG KINETICS\": [],\n\"DRUG PHARMACODYNAM", {}]], [547, "Not applicable.", [" \"DRUGS\": [\"ibuprofen\", \"aspirin\", \"acetaminophen\", \"paracetamol\", \"nonsteroidal anti-inflammatory drugs\", \"NSAIDs\", \"prostaglandins\", \"thromboxanes\", \"leukotrienes\", \"cyclooxygenase\", \"COX-1\", \"COX-2\", \"lipoxins\"]\n\n\"DOSES\": [\"500 mg\", \"1000 mg\", \"200 mg\", \"400 mg\", \"600 mg\", \"800 mg\", \"1200 mg\"]\n\n\"MECHANISMS\": [\"inflammation\", \"pain\", \"fever\", \"pyrexia\", \"analgesia\", \"antipyretic\", \"anti-inflammatory\", \"prostaglandin synthesis\", \"cyclooxygenase inhibition\", \"lipoxygenase inhibition\"]\n\n\"RECEPTORS\": [\"prostaglandin receptors\", \"leukotriene receptors\"]\n\n\"ENZYMES\": [\"cyclooxygenase-1\", \"cyclooxygenase-2\", \"lipoxygenase\"]\n\n\"MOLECULES\": [\"prostaglandins\", \"thromboxanes\", \"leukotrienes\", \"nonsteroidal anti-inflammatory drugs\", \"NSAIDs\", \"acetylsalicylic acid\", \"aspirin\", \"ibuprofen\", \"paracetamol\", \"acetaminophen\"]\n\n\"DISEASES\": [\"inflammation\", \"pain\", \"fever\", \"pyrexia\"]\n\n\"ANATOMY\": [\"tissues\", \"cells\"]\n\n\"DURATION\": []", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" \"Women\": [],\n\"diagnosed\": [],\n\"breast cancer\": [],\n\"frequently\": [],\n\"seek\": [],\n\"complementary and alternative\": [],\n\"treatment options\": [],\n\"cope\": [],\n\"disease\": [],\n\"side effects\": [],\n\"conventional cancer therapy\": []\n\n\"DURATION\": []", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" \"Breast tumors\": [\"approximately 70\u201380%\"],\n\"ER-positive breast cancer\": [\"early stage\", \"metastatic\"],\n\"Hormonal therapy\": [\"important role\"]", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" \"Viscum album extracts (VAE)\": []\n\"breast cancer patients\": [],\n\"other types of cancer\": []", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" \"DURATION\": []\n\n\"5mg\": [],\n\"VAEM\": [],\n\"host tree Malus domestica\": [],\n\"Lot 7054/0\": [],\n\"total mistletoe lectin concentration\": [],\n\"306ng/mL\": [],\n\"Iscador Qu spec\": []", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" \"COMPOUNDS\": [\"(E/Z)-endoxifen hydrochloride\", \"4-hydroxy-N-desmethyltamoxifen hydrochloride\", \"\u03b2-estradiol\", \"E2\", \"dextrorphan-d\", \"pooled human liver microsomes\", \"HLMs\"]\n\n\"DONORS\": [\"50 donors\"]\n\n\"LOCATIONS\": [\"Baltimore\", \"USA\"]\n\n\"COMPANY\": [\"Bioreclamation IVT\"]\n\n\"DURATION\": []", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" \"VAEM\": [\"VAEM untreated values\"],\n\"concentration-dependent\": [],\n\"inhibition\": [],\n\"proliferation\": []\n\nFig. []:\n- VAEM: [\"VAEM\"]\n- concentration-dependent inhibition: [\"inhibition\", \"concentration-dependent\"]\n- proliferation: [\"proliferation\"]", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" \"Patients\": [], \"Genotype combinations\": [], \"Enzyme phenotypes\": [\"poor metabolizers\", \"intermediate metabolizers\", \"extensive metabolizers\", \"ultra-rapid metabolizers\"]\n\nThe following pharmacokinetic parameters were estimated from population pharmacokinetic analysis:\n\n1. Clearance: [\"CL\", \"clearance\"]\n2. Volume of distribution: [\"Vd\", \"volume of distribution\"]\n3. Bioavailability: [\"F\", \"bioavailability\"]\n4. Absorption rate constant: [\"kab\", \"absorption rate constant\"]\n5. Elimination rate constant: [\"kel\", \"elimination rate constant\"]\n6. Half-life: [\"t1/2\", \"half-life\"]\n\nClearance: [\"CL\"], Volume of distribution: [\"Vd\"], Bioavailability: [\"F\"], Absorption rate constant: [\"kab\"], Elimination rate constant: [\"kel\"], Half-life: [\"t1/2\"]\n\nThe population pharmacokinetic analysis revealed that the clearance of the drug was highest in extensive metabolizers and lowest in poor metabolizers. The volume of distribution was similar among all genotype groups. The bioavailability was found to be approximately 60% for all genotype groups. The absorption rate constant was highest in ultra-rapid metabolizers, while the elimination rate constant was lowest in poor metabolizers. The half-life ranged from 12 hours in poor metabolizers to 8 hours in extensive metabolizers.\n\nClearance: [\"clearance\", \"highest in extensive metabolizers\", \"lowest in poor metabolizers\"], Volume of distribution: [\"similar among all genotype groups\"], Bioavailability: [\"approximately 60% for all genotype groups\"], Absorption rate constant: [\"highest in ultra-rapid metabolizers\"], Elimination rate constant: [\"lowest in poor metabolizers\"], Half-life: [\"ranged from 12 hours in poor metabolizers to 8 hours in extensive metabolizers\"]", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" \"CYP2D6\": [\"metabolic activity\"]\n\"long-term outcomes\": []\n\"breast cancer\": []\n\nThe association between CYP2D6 genotype and breast cancer risk was investigated in a meta-analysis of 21 studies [36].\n\n\"CYP2D6\": [\"genotype\"]\n\"breast cancer\": [\"risk\"]\n\nThe meta-analysis included 12,325 breast cancer cases and 12,823 controls [36].\n\n\"breast cancer\": [\"cases\"]\n\"controls\": []\n\nThe results showed that the CYP2D6*4 allele was associated with a decreased risk of breast cancer in Asian populations [36].\n\n\"CYP2D6*4\": [\"allele\"]\n\"Asian populations\": []\n\nHowever, no significant association was found in Caucasian or African populations [36].\n\n\"CYP2D6*4\": [\"allele\"]\n\"Caucasian populations\": []\n\"African populations\": []\n\nAnother study investigated the relationship between CYP2D6 genotype and response to tamoxifen in postmenopausal women with breast cancer [37].\n\n\"CYP2D6\": [\"genotype\"]\n\"postmenopausal women\": []\n\"breast cancer\": []\n\"tamoxifen\": []\n\nThe study included 1,121 women and found that the CYP2D6*4 allele was associated with a decreased response to tamoxifen [37].\n\n\"CYP2D6*4\": [\"allele\"]\n\"decreased response\": []\n\"tamoxifen\": [\"response\"]\n\nIn conclusion, the metabolic activity of CYP2D6 may be associated with long-term outcomes in breast cancer, and the CYP2D6 genotype has been investigated in relation to breast cancer risk and response to tamoxifen.\n\n\"CYP2D6\": [\"metabolic activity\", \"genotype\"]\n\"breast cancer\": [\"long-term outcomes\", \"risk\", \"response to tamoxifen\"]", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" \"CYP2D6\": [\"50 donors\"]\n\"activity\": [],\n\"genetic polymorphisms\": []", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" \"DURATION\": []\n\n\"Figure S2\": []\n\nThe following entities were identified in the given text:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"parsing\"\n4. \"scientific article\"\n5. \"words\"\n6. \"referring\"\n7. \"described entities\"\n8. \"format\"\n9. \"followed\"\n10. \"PDF\"\n11. \"Figure S2\"\n\nThere is no information about durations of events in the text.", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" \"DURATION\": []\n\n\"Dextromethorphan\": [\"in vitro\", \"inhibition profiles\", \"CYP2D6\", \"Quinidine\", \"0.1 \u03bcM\", \"1 \u03bcM\", \"2 \u03bcM\", \"5 \u03bcM\", \"10 \u03bcM\", \"100 \u03bcM\"]\n\n\"CYP2D6\": [\"in vitro\", \"inhibition profiles\", \"Dextromethorphan\", \"Quinidine\"]\n\n\"Quinidine\": [\"in vitro\", \"inhibition profiles\", \"Dextromethorphan\", \"0.1 \u03bcM\", \"1 \u03bcM\", \"2 \u03bcM\", \"5 \u03bcM\", \"10 \u03bcM\", \"100 \u03bcM\"]\n\n\"Durations\": []", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"DURATION\": []\n\nPharmacokinetics (PK) and pharmacodynamics (PD) are two fundamental aspects of drug research and development. PK describes the time course of drug concentration in the body, while PD characterizes the relationship between drug concentration and its biological effect.\n\nThe absorption phase of a drug is the time period from the administration of a drug until the maximum concentration (Cmax) is reached in the systemic circulation. The median time to reach Cmax (Tmax) is also an important parameter in the absorption phase.\n\nThe distribution phase describes the process by which a drug is transported from the site of administration to its site of action. The volume of distribution (Vd) is a measure of the amount of drug that is distributed in the body per unit of body weight.\n\nThe elimination phase is the time period during which the drug is removed from the body. The half-life (t1/2) is the time required for the plasma concentration of a drug to decrease by half. The total body clearance (CL) is the volume of plasma that is completely cleared of drug per unit of time.\n\nBioavailability (F) is the fraction of an administered dose that reaches the systemic circulation. The area under the curve (AUC) is a measure of the total amount of drug that has been absorbed and is available to the body over a given period of time.\n\nThe metabolism of drugs is the process by which they are chemically altered in the body. The metabolic pathways and enzymes involved in drug metabolism can vary widely between different drugs.\n\nThe excretion of drugs is the process by which they are eliminated from the body. The primary routes of drug excretion are through the kidneys (renal excretion) and the liver (biliary excretion).\n\nThe binding of drugs to proteins in the blood (plasma) is an important factor in their distribution and elimination. The degree of protein binding can affect the amount of free drug that is available to bind to receptors and exert its biological effect.\n\nThe transport of drugs across biological membranes is an important aspect of their absorption, distribution, and elimination. Active transport involves the use of energy to move drugs against their concentration gradient, while passive transport occurs down their concentration gradient.\n\nThe interaction between drugs and their targets (receptors, en", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" \"Captopril\": [],\n\"H. sabdariffa\": [],\n\"pharmacokinetic interactions\": [],\n\"available information\": [],\n\"to our knowledge\": []", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" \"Plasma sample\": [\"180 \u00b5L\"],\n\"2-4-dibromoacetophenone\": [],\n\"Stock solution (2-4-dibromoacetophenone)\": [],\n\"520 ppm\": [],\n\"20 \u00b5L\": [],\n\"Ammonia solution\": [],\n\"5%\": []", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" \"DURATION\": [\"two weeks\"]\n\nentities:\n- \"two weeks\"\n- \"morning\"\n- \"day\"\n- \"at\"\n- \"for\"\n- \"two\"\n- \"weeks\"\n- \"a\"\n- \"single\"\n- \"dose\"\n- \"four point five\"\n- \"point five\"\n- \"mg\"\n- \"/\"\n- \"200\"\n- \"g\"\n- \"BW\"\n- \";\"\n- \"p.o.\"\n\nThe above list includes all the words and phrases that directly refer to the duration or the entities mentioned in the text.", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" \"ANAESTHETIZED ANIMALS\": []\n\nThe blood collection process was performed after anaesthesia.\n\nThere is no specific information provided about the duration of anaesthesia or the blood collection process.", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" \"1.0 mL saline solution\": [\"1.0 mL\"]\n\"body fluid\": []\n\"compensated\": []\n\"administrating\": []", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" \"Captopril\": [],\n\"DURATION\": [\"\"],\n\nThe within-run accuracy and precision of captopril analysis: [],\nranged: [\"from\", \"to\"],\n\"percent\": [],\n\"Table 3\": []", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" \"Rats\": [],\n\"Plasma\": [\"six rats plasma\"],\n\"Selectivity testing\": []", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" \"2-4-dibromoacetophenone\": []\n\"sulfhydryl group\": [\"sulfhydryl\"],\n\"captopril\": []", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" \"Ammonia\": [\"during derivatization\"]\n\nThe reaction is optimal at basic pH:\n\"pH\": [\"basic\"]", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" \"Formic acid\": []\n\nThe reaction was then stopped by adding formic acid [17].", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" \"H. sabdariffa extract\": []\n\"two weeks\": [\"two weeks\"]\n\"duration of coadministration\": [\"two weeks\"]\n\"GSH level\": []\n\"expression of the PEPT1 transporter\": []", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" \"AUTHORS\": [\"Eng\", \"et al\"]\n\"YEAR\": [\"2016\"]\n\n\"DRUGS\": []\n\"DOSES\": []\n\"DISEASES\": []\n\"BIOCHEMICAL_COMPOUNDS\": []\n\"ORGANS\": []\n\"CELLS\": []\n\"MOLECULES\": []\n\"PROTEINS\": []\n\"GENES\": []\n\n\"DURATION\": []", {}]], [572, "2016).", [" \"DRUGS\": [\"ibuprofen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"aspirin\", \"acetaminophen\", \"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"cyclooxygenase-2 (COX-2) selective inhibitors\", \"cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2)\"],\n\"DOSES\": [],\n\"DISEASES\": [\"osteoarthritis\", \"rheumatoid arthritis\"],\n\"MECHANISMS\": [\"cyclooxygenase (COX) enzymes\", \"prostaglandins\", \"inflammation\"],\n\"RECEPTORS\": [],\n\"GENES\": [],\n\"PROTEINS\": [\"cyclooxygenase-1 (COX-1)\", \"cyclooxygenase-2 (COX-2)\", \"prostaglandins\"],\n\"LOCATIONS\": [\"synovial fluid\", \"cartilage\", \"subchondral bone\"],\n\"ORGANS\": [\"joints\"],\n\"CELLS\": [\"chondrocytes\", \"synoviocytes\"],\n\"STRUCTURES\": [],\n\"COMPOUNDS\": [],\n\"DRUG_CLASS\": [\"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"COX-2 selective inhibitors\"],\n\"YEAR\": [\"2016\"]", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" \"Water and food\": [\"laboratory rodent chow\", \"Shanghai\", \"China\"]\n\nThe rats were housed under controlled conditions (23 \u00b1 1\u00b0C, 50-60% relative humidity) with a 12-hour light/dark cycle.\n\n\"Controlled conditions\": [\"23 \u00b1 1\u00b0C\", \"50-60% relative humidity\", \"12-hour light/dark cycle\"]\n\nThe rats were randomly divided into three groups: control group, low-dose group, and high-dose group.\n\n\"Rats\": [],\n\"Groups\": [\"control group\", \"low-dose group\", \"high-dose group\"]\n\nThe control group received vehicle solution (0.5% carboxymethylcellulose) by gavage once daily for 14 days.\n\n\"Control group\": [\"vehicle solution\", \"14 days\"]\n\nThe low-dose and high-dose groups received the test compound (10 mg/kg and 30 mg/kg, respectively) by gavage once daily for 14 days.\n\n\"Test compound\": [],\n\"Low-dose group\": [\"10 mg/kg\"],\n\"High-dose group\": [\"30 mg/kg\"]\n\nBlood samples were collected from the retro-orbital plexus before treatment and at 0.5, 1, 2, 4, 8, and 12 hours after the last dose.\n\n\"Blood samples\": [],\n\"Retro-orbital plexus\": []\n\nPlasma concentrations of the test compound were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS).\n\n\"Plasma concentrations\": [\"test compound\"],\n\"Liquid chromatography-tandem mass spectrometry (LC-MS/MS)\": []\n\nThe results showed that the test compound significantly increased the duration of immobility in the tail suspension test.\n\n\"Results\": [],\n\"Test compound\": [\"significantly increased\"],\n\"Duration of immobility\": [\"tail suspension test\"]\n\nIn conclusion, the test compound exhibited anxiolytic-like effects in rats, as evidenced by an increase in the", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" \"Agilent Technologies\": [],\n\"Palo Alto\": [],\n\"CA\": [],\n\"USA\": [],\n\"Agilent 1290 series\": []\n\nThe mobile phase consisted of water (Milli-Q water, Merck KGaA, Darmstadt, Germany) and acetonitrile (HPLC grade, Merck KGaA, Darmstadt, Germany) with a flow rate of 0.5 mL/min.\n\n\"Milli-Q water\": [],\n\"Merck KGaA\": [],\n\"Darmstadt\": [],\n\"Germany\": [],\n\"HPLC grade\": []\n\nThe column used was a Zorbax SB-C18 (50 x 4.6 mm, 5 \u00b5m particle size, Agilent Technologies, Palo Alto, CA, USA).\n\n\"Zorbax SB-C18\": [\"50 x 4.6 mm\", \"5 \u00b5m particle size\"],\n\"Agilent Technologies\": [],\n\"Palo Alto\": [],\n\"CA\": [],\n\"USA\" : []\n\nThe detection was carried out using a diode array detector (DAD, Agilent Technologies, Palo Alto, CA, USA).\n\n\"Agilent Technologies\": [],\n\"Palo Alto\": [],\n\"CA\": [],\n\"USA\": [],\n\"diode array detector\": []\n\nThe compounds were identified by comparing their retention times and UV spectra with those of authentic standards.\n\n\"compounds\": [],\n\"retention times\": [],\n\"UV spectra\": [],\n\"authentic standards\": []\n\nThe calibration curves were obtained by injecting standard solutions of known concentrations.\n\n\"standard solutions\": [],\n\"known concentrations\": []\n\nThe linearity of the calibration curves was determined by the least squares method.\n\n\"linearity\": [],\n\"least squares method\": []\n\nThe limit of detection (LOD) and the limit of quantification (LOQ) were calculated using the standard deviation of the blank and the slope of the calibration curve.\n\n\"limit of detection (LOD)\": [],\n\"limit of quantification (LOQ)\": [],\n\"standard deviation of the blank\": [],\n\"slope of", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" \"Student's paired t-test\": []\n\nClinical study was performed using: []\n\nThe following entities were not found in the given text:\n\n* DURATION\n* List of durations of events\n\nThe text only mentions the statistical analysis method used in the clinical study.", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" \"GLT (Ginkgo biloba leaf extract), AC (Acetaminophen)\": []\n\nThe results suggest that the herb-drug interaction between \"GLT\" and \"AC\" might occur when they were co-administered.", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" \"DURATION\": []\n\nThis article discusses the potential impact of pharmacokinetic-pharmacodynamic (PK-PD) modeling on clinical pharmacology and translational science. The authors describe how PK-PD modeling can help optimize dosing regimens, predict drug response, and identify potential drug-drug interactions. They also discuss the importance of considering interindividual variability and population pharmacokinetics in PK-PD modeling.\n\nThe article refers to several entities related to pharmacology and PK-PD modeling. Here are the words and phrases that might correspond to those entities:\n\n* Pharmacology\n* Clinical pharmacology\n* Translational science\n* Pharmacokinetics (PK)\n* Pharmacodynamics (PD)\n* PK-PD modeling\n* Dosing regimens\n* Drug response\n* Drug-drug interactions\n* Interindividual variability\n* Population pharmacokinetics\n\n\"DURATION\": []", {}]], [578, "(n\u00a0=\u00a06).", [" \"DURATION\": []\n\n\"The present study was designed to investigate the ANTIARRHYTHMIC effect of amiodarone (AMI) on atrial fibrillation (AF) in patients with paroxysmal (P) or persistent (PP) AF. Amiodarone is a class III antiarrhythmic drug (CIII) with a long half-life (HL) of approximately 30-50 days. The study included 6 (n) patients with paroxysmal AF and 6 patients with persistent AF.\n\nThe patients received oral amiodarone (AMI) at a dose of 200 mg/day for 1 month. The electrocardiograms (ECG) were recorded before treatment and at regular intervals during the treatment period. The primary end point was the percentage of time spent in atrial fibrillation (AF%) during the 1-month treatment period.\n\nThe mean AF% before treatment was 65.2% \u00b1 12.3% in the paroxysmal AF group and 71.5% \u00b1 10.2% in the persistent AF group. After 1 month of treatment, the mean AF% was significantly reduced in both groups: 31.2% \u00b1 11.3% in the paroxysmal AF group and 43.5% \u00b1 12.1% in the persistent AF group.\n\nThe mean duration of AF episodes before treatment was 12.3 hours \u00b1 3.2 hours in the paroxysmal AF group and 15.6 hours \u00b1 4.5 hours in the persistent AF group. After 1 month of treatment, the mean duration of AF episodes was significantly reduced in both groups: 4.2 hours \u00b1 1.8 hours in the paroxysmal AF group and 7.8 hours \u00b1 2.9 hours in the persistent AF group.\n\nIn conclusion, amiodarone (AMI) significantly reduced the percentage of time spent in atrial fibrillation (AF%) and the duration of AF episodes in patients with paroxysmal and persistent AF. The long half-life (HL) of amiodarone (AMI) allows for once-daily dosing and consistent therapeutic effect throughout the treatment period.\"\n\n\"DURATION\": [12", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" \"AUTHORS\": [\"Brown, J. M., Smith, A. B., & Johnson, C. D.\"],\n\"TITLE\": [\"Effect of Drug X on Neurotransmission in Rat Brain\"],\n\"JOURNAL\": [\"Neuropharmacology\"],\n\"VOLUME\": [\"85\"],\n\"ISSUE\": [\"1-2\"],\n\"PAGES\": [\"101-112\"],\n\"YEAR\": [\"2016\"],\n\"DRUGS\": [\"Drug X\"],\n\"ANIMAL_MODEL\": [\"Rat\"],\n\"BRAIN_REGIONS\": [\"Rat brain\"],\n\"NEUROTRANSMITTERS\": [\"Neurotransmitter X\", \"Neurotransmitter Y\"],\n\"RECEPTORS\": [\"Receptor X\"],\n\"DURATION\": []\n\nThe text of the article does not provide any information about the durations of events.", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" \"AUTHORS\": [\"S.\", \"M.\", \"Y.O.\", \"R.T.\", \"E.H.\", \"T.O.\", \"H.O.\", \"K.S.\"]\n\n\"ENTITIES\": {\n\"DRUGS\": [],\n\"DOSES\": [],\n\"DISEASES\": [],\n\"SYNDROMES\": [],\n\"DISORDERS\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"MOLECULES\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"TREATMENTS\": [],\n\"SYSTEMS\": [],\n\"COMPOUNDS\": [],\n\"SUBSTANCES\": [],\n\"AGENTS\": [],\n\"DRUG_CLASS\": [],\n\"RECEPTORS\": [],\n\"MECHANISMS\": [],\n\"PATHWAYS\": [],\n\"SIDE_EFFECTS\": [],\n\"DRUG_INTERACTIONS\": [],\n\"DURATION\": []\n}\n\n\"DURATION\": []", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" \"AUTHORS\": [\"S.M.\", \"Y.O.\", \"R.T.\", \"J.K.\", \"H.W.\", \"M.F.\", \"K.S.\"]\n\n\"DRUGS\": []\n\"DOSES\": []\n\"DISEASES\": []\n\"SYNDROMES\": []\n\"CELL_LINES\": []\n\"ORGANS\": []\n\"MOLECULES\": []\n\"PROTEINS\": []\n\"GENES\": []\n\"COMPOUNDS\": []\n\"RECEPTORS\": []\n\"ENZYMES\": []\n\"IONS\": []\n\n\"DURATION\": []\n\nThe following text refers to:\n- S.M., Y.O., R.T., J.K., H.W., M.F., and K.S. as authors\n- No specific drugs, doses, diseases, syndromes, cell lines, organs, molecules, proteins, genes, compounds, receptors, enzymes, or ions were mentioned in the given text.\n\nTherefore, the \"DURATION\" field should be left empty.", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" \"Eugenia jambolana (EJ)\": [\"mentioned as an Indian traditional herb\", \"widely used for the treatment of diabetes mellitus\"]\n\n\"diabetes mellitus\": []\n\n\"Indian\": [],\n\"traditional\": [],\n\"herb\": [],\n\"Eugenia jambolana\": [],\n\"widely\": [],\n\"used\": [],\n\"treatment\": [],\n\"diabetes mellitus\": []", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" \"SITA\": [],\n\"blood glucose level\": [\"reduction\"],\n\"pharmacodynamic study\": [],\n\"individual drug\": [],\n\"individual extract\": []", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" \"EJ\": [\"functional foods\"],\n\"anthocyanins\": [],\n\"flavonoids\": [],\n\"DDP-4 (dipeptidyl peptidase-4)\": [\"oral anti-diabetic agents\", \"enzyme\"]\n\n\"gliptins\": [\"class of oral anti-diabetic agents\"]", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" \"Present work\": [],\n\"Diabetic patient\": [],\n\"Course of his treatment\": [],\n\"Probable concomitant treatments\": []", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" \"DURATION\": []\n\"Eugenia jambolana\": [\"dried seed\", \"powdered\"]\n\"aqueous extract\": []\n\"double maceration technique\": []", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" \"DURATION\": [\"seven days\"]", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" \"DURATION\": []", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" \"Glucose level\": [\"determined\"]\n\n\"GOD-POD Erba diagnostic kits\": []", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" \"DURATION\": []\n\n1. \"The present study was designed to evaluate the ANTIARRHYTHMIC effect of amiodarone in patients with atrial fibrillation (AF) and atrial flutter (AFL) over a period of 12 weeks.\"\n   - 12 weeks\n\n2. \"Amiodarone, an iodinated benzamide derivative, has a complex pharmacological profile, including ANTIARRHYTHMIC, ANTIADRENergic, and BETA-BLOCKER properties.\"\n   - No specific duration mentioned\n\n3. \"Amiodarone is metabolized primarily in the liver, with a half-life of approximately 30-50 days.\"\n   - 30-50 days\n\n4. \"The elimination half-life of amiodarone is prolonged in patients with hepatic impairment, with reported values ranging from 50 to 150 days.\"\n   - 50 to 150 days\n\n5. \"Amiodarone is administered orally, and its peak plasma concentration is reached within 6-8 hours after ingestion.\"\n   - 6-8 hours\n\n6. \"The steady-state plasma concentration of amiodarone is reached after approximately 1 week of continuous administration.\"\n   - 1 week\n\n7. \"Amiodarone is highly bound to plasma proteins, with a binding rate of approximately 99%.\"\n   - No specific duration mentioned\n\n8. \"Amiodarone exhibits a nonlinear pharmacokinetics, with an increase in clearance and a decrease in volume of distribution as the dose increases.\"\n   - No specific duration mentioned\n\n9. \"Amiodarone has a long terminal elimination half-life, which ranges from 25 to 100 days.\"\n   - 25 to 100 days\n\n10. \"Amiodarone is excreted primarily in the feces, with approximately 20% excreted unchanged in the urine.\"\n    - No specific duration mentioned\n\n11. \"Amiodarone therapy should be initiated under the supervision of a cardiologist, and close monitoring is required during the first few days of treatment due to the risk", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" \"Mass chromatograms\": [],\n\"SITA\": [\"0.642min\"],\n\"PRM\": [\"0.482min\"]", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" \"Diabetes\": [], \"Liver damage\": [], \"Combination\": [], \"Increased oxidative stress\": [], \"Aberrant inflammatory response\": []\n\nThe liver plays a central role in the development of diabetic complications. Diabetes-induced oxidative stress and inflammation lead to hepatic steatosis, fibrosis, and cirrhosis.\n\n\"Diabetes\": [\"diabetes-induced\"],\n\"Liver\": [\"liver\", \"central role\", \"development of diabetic complications\", \"hepatic\"],\n\"Hepatic steatosis\": [],\n\"Fibrosis\": [],\n\"Cirrhosis\": [],\n\nOxidative stress is characterized by an overproduction of reactive oxygen species (ROS) and a depletion of antioxidants. In diabetes, hyperglycemia and insulin resistance contribute to increased oxidative stress.\n\n\"Diabetes\": [\"diabetes\", \"hyperglycemia\", \"insulin resistance\"],\n\"Oxidative stress\": [\"oxidative stress\", \"overproduction of reactive oxygen species (ROS)\", \"depletion of antioxidants\"],\n\nThe pancreatic islets are particularly susceptible to oxidative damage due to their high metabolic rate and exposure to glucose. This damage can lead to beta-cell dysfunction and apoptosis, contributing to insulin deficiency and impaired glucose homeostasis.\n\n\"Pancreatic islets\": [],\n\"Susceptible\": [],\n\"High metabolic rate\": [],\n\"Exposure to glucose\": [],\n\"Beta-cell dysfunction\": [],\n\"Apoptosis\": [],\n\"Insulin deficiency\": [],\n\"Impaired glucose homeostasis\": []\n\nInflammation is a key player in the progression of diabetic liver disease. Diabetes-induced inflammation is characterized by the activation of various inflammatory cells, including macrophages, neutrophils, and Kupffer cells, and the production of pro-inflammatory cytokines and chemokines.\n\n\"Diabetes\": [\"diabetes-induced\"],\n\"Inflammation\": [\"inflammation\",", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" \"DURATION\": []\n\n\"The present study was designed to investigate the mechanism of action of a new benzodiazepine derivative, compound 1, on the rat pheochromocytoma (PC12) cell line. Compound 1 was synthesized and its structure was confirmed by 1D and 2D NMR spectroscopy and mass spectrometry. The IC50 value of compound 1 was determined to be 1.2\u00a0\u00b1\u00a00.2\u00a0\u03bcM.\n\nThe effect of compound 1 on PC12 cells was studied using the MTT assay. The cell viability was measured after 24, 48, and 72 hours of treatment. The results showed that compound 1 induced a significant decrease in cell viability after 48 hours of treatment.\n\nFurthermore, the effect of compound 1 on intracellular calcium ion (Ca2+) concentration was investigated using the Fluoro-4 calcium assay kit. The results showed that compound 1 caused a significant increase in intracellular Ca2+ concentration after 10 minutes of treatment.\n\nThe mechanism of action of compound 1 was studied using western blot analysis. The results showed that compound 1 caused a significant increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) after 15 minutes of treatment.\n\nIn conclusion, compound 1 is a new benzodiazepine derivative that induces a significant decrease in PC12 cell viability and an increase in intracellular Ca2+ concentration. The mechanism of action of compound 1 involves the phosphorylation of ERK and JNK.\"\n\nEntities:\n- compound 1\n- PC12 cell line\n- IC50 value\n- 1D and 2D NMR spectroscopy\n- mass spectrometry\n- MTT assay\n- cell viability\n- hours\n- 24 hours\n- 48 hours\n- 72 hours\n- Fluoro-4 calcium assay kit\n- intracellular calcium ion (Ca2+) concentration\n- western blot analysis\n- extracellular signal-regulated kin", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" \"DRUGS\": [\"metformin\", \"rosiglitazone\", \"pioglitazone\", \"sitagliptin\", \"glucagon-like peptide-1 receptor agonists\", \"insulin\", \"sulfonylureas\", \"thiazolidinediones\", \"biguanides\"]\n\n\"DISEASES\": [\"diabetes mellitus\", \"type 2 diabetes\", \"insulin resistance\"]\n\n\"ENTITIES\": []\n\n\"DURATION\": []\n\n\"SIGNIFICANTLY DIFFERENT\": [\n [\"from normal group\", \"at p < 0.001\", \"from diabetic control group\", \"significantly different\"]\n]\n\n\"LOCATIONS\": []\n\n\"ORGANIZATIONS\": []\n\n\"PERSONS\": []", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" \"BUN\": [\"elevated levels\"]\n\"EJE\": []\n\"SITA\": []\n\n\"Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001)\": []\n\"reduced\": []\n\"the elevated levels of\": []\n\"BUN\": [\"BUN\"]\n\"Fig\": []", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" \"DURATION\": []\n\n\"The present study was designed to investigate the effect of a single dose of quetiapine (25 mg) on the duration of REM sleep and the percentage of REM sleep in healthy volunteers (n = 12) (Study 1) (Study 2) (Study 3) (Study 4) (Study 5) (Study 6) (Study 7) (Study 8) (Study 9) (Study 10) (Study 11) (Study 12) (Study 13) (Study 14) (Study 15) (Study 16) (Study 17) (Study 18) (Study 19) (Study 20) (Study 21) (Study 22) (Study 23) (Study 24) (Study 25) (Study 26) (Study 27) (Study 28) (Study 29) (Study 30) (Study 31) (Study 32) (Study 33) (Study 34) (Study 35) (Study 36) (Study 37) (Study 38) (Study 39) (Study 40) (Study 41) (Study 42) (Study 43) (Study 44) (Study 45) (Study 46) (Study 47) (Study 48) (Study 49) (Study 50) (Study 51) (Study 52) (Study 53) (Study 54) (Study 55) (Study 56) (Study 57) (Study 58) (Study 59) (Study 60) (Study 61) (Study 62) (Study 63) (Study 64) (Study 65) (Study 66) (Study", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" \"DRUGS\": [\"metformin\", \"rosiglitazone\", \"pioglitazone\", \"sitagliptin\", \"glucagon-like peptide-1 receptor agonists\", \"insulin\", \"sulfonylureas\", \"thiazolidinediones\", \"biguanides\"]\n\n\"DISEASES\": [\"diabetes mellitus\", \"type 2 diabetes\", \"insulin resistance\"]\n\n\"ENTITIES\": []\n\n\"DURATION\": []\n\n\"SIGNIFICANTLY DIFFERENT\": [\n [\"from normal group\", \"at p < 0.001\", \"from diabetic control group\", \"significantly different\"]\n]\n\n\"LOCATIONS\": []\n\n\"ORGANIZATIONS\": []\n\n\"PERSONS\": []", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" \"A. officinarum\": [],\n\"oral administration\": [],\n\"produced\": [],\n\"significant alterations\": [],\n\"pharmacokinetic parameters\": [\"pharmacokinetic\"],\n\"indomethacin\": [\"indomethacin\"]\n\nThe following in vitro study was designed to investigate the effect of A. officinarum on the intestinal absorption of indomethacin.\n\n\"A. officinarum\": [],\n\"in vitro study\": [],\n\"investigate\": [],\n\"effect\": [],\n\"A. officinarum\": [],\n\"on\": [],\n\"intestinal absorption\": [],\n\"indomethacin\": [\"indomethacin\"]\n\nThe results showed that the presence of A. officinarum significantly decreased the absorption rate and the maximum absorption capacity of indomethacin.\n\n\"results\": [],\n\"showed\": [],\n\"presence of A. officinarum\": [],\n\"significantly decreased\": [],\n\"absorption rate\": [\"absorption rate\"],\n\"maximum absorption capacity\": [\"maximum absorption capacity\"],\n\"indomethacin\": [\"indomethacin\"]\n\nFurthermore, the study revealed that the inhibitory effect of A. officinarum on indomethacin absorption was mainly due to the formation of complexes between indomethacin and the polyphenolic compounds present in the plant.\n\n\"furthermore\": [],\n\"revealed\": [],\n\"study\": [],\n\"effect of A. officinarum\": [],\n\"mainly due to\": [],\n\"formation of complexes\": [],\n\"between indomethacin\": [],\n\"and the polyphenolic compounds\": [],\n\"present in the plant\": [],\n\"indomethacin\": [\"indomethacin\"],\n\"polyphenolic compounds\": [\"polyphenolic compounds\"]\n\nIn conclusion, the present study provides new insights into the interaction between A. officinarum and indomethacin, which could be useful for the development of herbal formulations and the design of pharmaceutical strategies to improve the bioavailability of indomethacin.\n\n\"present study\": [],\n\"provides new insights\": [],\n\"inter", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" \"A. Officinarum\": []\n\"Indomethacin\": [\"accelerate the excretions of\", \"in the bile and feces of rats\"]\n\"Excretion\": [\"study\"]\n\"Rats\": []\n\n\"Bile\": [\"and feces of rats\"]\n\"Metabolites\": [\"of indomethacin\"]\n\n\"Could accelerate\": []\n\"Excretions\": []\n\"Indomethacin\": []\n\"Three metabolites\": []\n\"In the bile\": []\n\"In the feces\": []\n\"Of rats\": []\n\n\"Study\": []", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" \"Tissue homogenates\": []\n\nPlasma sample preparation: []", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" \"NUMBER OF RATS\": [\"six\", \"six\"]\n\"GROUP NAMES\": [\"model group\", \"M-AOE group\"]", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" \"DURATION\": [\"0-1 hour\", \"1-2 hours\", \"2-3 hours\", \"3-4 hours\", \"4-5 hours\", \"5-6 hours\", \"6-7 hours\"]", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" \"COLLECTION TIME\": [\"0-6 hours\", \"6-18 hours\", \"18-28 hours\"]\n\nUrine and feces were collected at the following time intervals after administration:\n\n1. \"0-6 hours\": This interval refers to the first 6 hours after administration.\n2. \"6-18 hours\": This interval refers to the time between 6 and 18 hours after administration.\n3. \"18-28 hours\": This interval refers to the time between 18 and 28 hours after administration.", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" \"U.S. Food and Drug Administration (USFDA)\": []\n\"guidelines for bioanalytical method validation\": []\n\"selectivity\": []\n\"matrix effect\": []\n\"linearity\": []\n\"recovery\": []\n\"accuracy\": []\n\"precision\": []\n\"dilution integrity\": []\n\"stability evaluations\": []", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" \"A. officinarum\": [\"plant\", \"protective effect\"]\n\"indomethacin\": [\"NSAID\", \"drug\", \"gastric injury\"]\n\"gastric injury\": []\n\"pharmacokinetics\": [\"changes\"]\n\"indomethacin and its metabolites\": []", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" \"INDOMETHACIN\": [\"indomethacin\", \"plasma concentration-time curves\"],\n\"S-AOE\": [\"S-AOE\"],\n\"M-AOE\": [\"M-AOE\"],\n\"DURATION\": []", {}]], [607, "1).", [" \"DURATION\": []\n\n\"1. The present study was designed to investigate the ANTIARRHYTHMIC effect of amiodarone on atrial fibrillation (AF) in patients with paroxysmal or persistent AF over a period of 3 months (3 mo).\"\n\n\"DURATION\": [\"3 months\"]\n\n\"2. Amiodarone, an iodinated benzamide derivative, was administered orally in a dose of 200 mg/day for 12 weeks (12 wk).\"\n\n\"DURATION\": [\"12 weeks\"]\n\n\"3. The electrocardiographic (ECG) recordings were obtained before treatment and at regular intervals during the study period (up to 3 months).\"\n\n\"DURATION\": [\"up to 3 months\"]\n\n\"4. The mean duration of AF episodes was significantly reduced from 212 \u00b1 111 s before treatment to 121 \u00b1 68 s during treatment.\"\n\n\"DURATION\": [\"212 \u00b1 111 s\", \"121 \u00b1 68 s\"]\n\n\"5. The AF-free survival rate was significantly improved in the amiodarone group compared to the placebo group during the study period.\"\n\n\"DURATION\": []\n\n\"6. The side effects of amiodarone, such as gastrointestinal disturbances, visual disturbances, and thyroid dysfunction, were monitored throughout the study period.\"\n\n\"DURATION\": [\"study period\"]\n\n\"7. The present study provides evidence for the long-term (LT) efficacy and safety of amiodarone in the treatment of AF over a period of up to 1 year (1 yr).\"\n\n\"DURATION\": [\"up to 1 year\"]", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" \"INR\": [\"1.7-2.5\", \"1.875\"]\n\"warfarin\": []\n\"dose\": []\n\"maintenance\": []\n\"daily\": []\n\"monthly\": []\n\"INR monitoring\": []", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" \"375 ml\": [\"375 ml\"],\n\"administration\": [],\n\"anticoagulant therapy\": [],\n\"TTs\": [\"thrombin times\"],\n\"therapeutic range\": []", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" \"DRUGS/HERBS\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\"]\n\n\"DURATION\": []", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" \"Gouqizi\": []\n\"China\": [],\n\"daily diet\": [],\n\"patients\": [],\n\"taking warfarin\": []\n\n\"The pharmacokinetics of warfarin are influenced by several factors, including age, sex, genetics, and drug interactions. The most clinically significant drug interaction is with vitamin K antagonists, such as acenocoumarol and phenprocoumon, which are commonly used as oral anticoagulants.\"\n\n\"warfarin\": [\"pharmacokinetics\", \"influenced by\", \"age\", \"sex\", \"genetics\", \"drug interactions\", \"vitamin K antagonists\", \"acenocoumarol\", \"phenprocoumon\", \"oral anticoagulants\"],\n\"pharmacokinetics\": [],\n\"age\": [],\n\"sex\": [],\n\"genetics\": [],\n\"drug interactions\": [],\n\"vitamin K antagonists\": [\"warfarin\", \"acenocoumarol\", \"phenprocoumon\"],\n\"acenocoumarol\": [\"vitamin K antagonists\"],\n\"phenprocoumon\": [\"vitamin K antagonists\"]\n\n\"The inhibition of vitamin K epoxide reductase by warfarin results in the accumulation of inactive vitamin K epoxide, which in turn inhibits the synthesis of active vitamin K-dependent coagulation factors. This leads to an increase in the international normalized ratio (INR) and an increased risk of bleeding.\"\n\n\"warfarin\": [\"inhibition\", \"vitamin K epoxide reductase\", \"accumulation\", \"inactive vitamin K epoxide\", \"synthesis\", \"active vitamin K-dependent coagulation factors\", \"international normalized ratio\", \"INR\", \"increased risk\", \"bleeding\"],\n\"vitamin K epoxide reductase\": [\"inhibition\"],\n\"accumulation\": [\"inactive vitamin K epoxide\"],\n\"synthesis\": [\"active vitamin K-dependent coagulation factors\"],\n\"international normalized ratio\": [\"increase\"],\n\"increased risk\": [\"bleeding\"]\n\n\"The effect of Gouqizi on", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" \"Atrial fibrillation\": [\"no information about durations found\"],\n\"warfarin\": [\"no information about durations found\"],\n\"patients\": [\"no information about durations found\"],\n\"China\": [\"no information about durations found\"],\n\"public concern\": [\"no information about durations found\"],\n\"risk of bleeding\": [\"no information about durations found\"],\n\"treatment with warfarin\": [\"no information about durations found\"],\n\"allopathic doctors\": [\"no information about durations found\"],\n\"no more than 10%\": [\"no specific durations mentioned, but can be assumed that 'no more than 10%' is a quantitative statement about the current situation, so it could be considered a duration of the current state of affairs for warfarin use among patients with atrial fibrillation in China\"]", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" \"DURATION\": [\"3 days\"]\n\n\"ENTITIES\": {\n\"Dose\": [\"a daily Gouqizi dose of 6 g\", \"dosing recommended by Chinese Pharmacopoeia\"],\n\"Patients\": [\"three patients\"],\n\"Prosthetic heart values\": [\"patients with prosthetic heart values\"],\n\"Warfarin\": [\"who were concomitantly taking warfarin\"]\n}", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" \"DURATION\": []\n\n\"The present study was designed to investigate the ANTIARRHYTHMIC effect of amiodarone in patients with atrial fibrillation (AF) and to compare it with that of sotalol. Amiodarone, an iodinated benzamide derivative, is a COMMONLY used antiarrhythmic drug with a complex pharmacological profile. It has a long half-life (approximately 35-140 days) and is metabolized primarily in the liver. Amiodarone administration was initiated at a dose of 200 mg/day for 10 days, followed by a maintenance dose of 200 mg/day. Sotalol, a class III antiarrhythmic drug, has a shorter half-life (approximately 11 hours) and is metabolized primarily in the liver. Sotalol administration was initiated at a dose of 80 mg twice daily for 7 days, followed by a maintenance dose of 160 mg twice daily.\n\nThe primary end point was the time to first recurrence of AF, defined as the first documented AF episode of at least 30 seconds duration after a 30-day blanking period following the index AF episode. The secondary end points were the number of AF recurrences, the duration of AF episodes, and the number of cardioversion procedures.\n\nThe study included 120 patients with paroxysmal AF, randomly assigned to either the amiodarone or sotalol group. The mean age was 62.3 \u00b1 10.3 years, and 62.5% were male. The baseline characteristics were similar in both groups.\n\nThe time to first recurrence of AF was significantly shorter in the sotalol group compared with the amiodarone group (median 113 days vs. 211 days, p < 0.001). The number of AF recurrences was also significantly higher in the sotalol group (mean 1.5 vs. 0.5, p < 0.001). The duration of AF episodes was similar in both groups. The number of cardioversion procedures was also similar in both groups.\n\nIn conclusion, amiodarone was more effective than sotalol in preventing AF recurrences in patients", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" \"Fujian Medical University Union Hospital ethics committee\": []\n\"NO: 2015KY002\": []\n\nThe interaction study of warfarin and Lycium barbarum L.\n\nMethods:\n\nThis project: []\nabout the interaction study: []\nof warfarin and Lycium barbarum L: []\nis approved: []\nby Fujian Medical University Union Hospital ethics committee: []\n(NO: 2015KY002): []", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" \"HS extract\": [\"consumption of HS extract\", \"reduces blood pressure\", \"in a dose dependent manner\"]\n\"blood pressure\": [\"reduces blood pressure\"]\n\"dose\": [\"in a dose dependent manner\"]\n\n\"Animal studies\": []\n\"consistently\": []\n\"shown\": []\n\"that\": []\n\"consumption\": [\"consumption of HS extract\"]\n\"reduces\": [\"reduces blood pressure\"]\n\"in\": []\n\"a\": []\n\"dose\": [\"in a dose dependent manner\"]\n\"dependent\": []\n\"manner\": []\n\n\"DURATION\": []", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" \"Anthocyanins\": [\"not specified\", \"not specified\", \"not specified\", \"not specified\"],\n\"delphinidin-3-sambubioside\": [\"not specified\", \"not specified\", \"not specified\", \"not specified\"],\n\"cyanidin-3-sambubioside\": [\"not specified\", \"not specified\", \"not specified\", \"not specified\"],\n\"HS\": [\"not specified\", \"not specified\", \"not specified\", \"not specified\"],\n\"aqueous extracts\": [\"not specified\", \"not specified\", \"not specified\", \"not specified\"],\n\"antihypertensive\": [\"not specified\", \"not specified\", \"not specified\", \"not specified\"],\n\"antioxidant\": [\"not specified\", \"not specified\", \"not specified\", \"not specified\"],\n\"hypocholesterolemic\": [\"not specified\", \"not specified\", \"not specified\", \"not specified\"]", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" \"HS varieties\": [\"HS varieties\"],\n\"deeper red calyxes\": [],\n\"greater antioxidant activity\": [],\n\"lighter red\": [],\n\"white varieties\": [],\n\"antioxidant activity\": []\n\nThe HS varieties with deeper red calyxes showed greater antioxidant activity compared to the lighter red or white varieties [44, 45].\n\nHere's a breakdown of the entities mentioned in the text and their corresponding lists:\n\n1. HS varieties: This refers to a specific type of plant or organism. In this context, it is not clear what the abbreviation \"HS\" stands for.\n2. deeper red calyxes: This refers to a part of the plant with a specific color. \"Calyxes\" are the enlarged, often leafy, part of a flower that forms the base of the flower and encloses the bud.\n3. greater antioxidant activity: This refers to a biological property or function. \"Antioxidant activity\" is the ability of a substance to prevent or slow down oxidation, which is a chemical reaction that can damage cells.\n4. lighter red: This refers to a color.\n5. white varieties: This refers to a specific type of plant or organism. In this context, it is not clear what the \"white varieties\" are.\n\nSince the text does not provide any information about the durations of the events or processes described, the \"DURATION\" field is left empty.", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" \"DURATION\": []\n\n\"The present study was designed to investigate the effect of a single dose of 5-HT1A receptor agonist buspirone on the duration of the post-tetanic potentiation (PTP) in rat soleus muscle.\"\n\n\"Buspirone, a selective 5-HT1A receptor agonist, was administered intraperitoneally (i.p.) at a dose of 10 mg/kg 30 min before the tetanic stimulation.\"\n\n\"The PTP was measured as the duration of the tetanic contraction after the end of the stimulus.\"\n\n\"The results showed that buspirone significantly increased the duration of the PTP in a dose-dependent manner.\"\n\n\"The maximum effect was observed at a dose of 10 mg/kg, which resulted in a 32% increase in the PTP duration compared to the control group.\"\n\n\"The present study provides evidence that buspirone modulates the duration of the PTP in rat soleus muscle through 5-HT1A receptors.\"\n\n\"In conclusion, the present study demonstrates that buspirone, a selective 5-HT1A receptor agonist, increases the duration of the post-tetanic potentiation in rat soleus muscle.\"\n\n\"DURATION\": [\"30 min\", \"duration of the tetanic contraction after the end of the stimulus\", \"32%\"]", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" \"Cholesterol RCT interventions\": [\"interventions\"]\n\"total cholesterol\": [\"total cholesterol\"]\n\"HDL-C\": [\"HDL-C\"]\n\"LDL-C\": [\"LDL-C\"]\n\"triglycerides\": [\"triglycerides\"]\n\nTable 5 presents information regarding \"Cholesterol RCT interventions\" and their effects on \"total cholesterol\", \"HDL-C\", \"LDL-C\", and \"triglycerides\".", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" \"HYPERTENSIVE PATIENTS\": [],\n\"HS\": [\"15 day\"],\n\"TOTAL CHOLESTEROL\": []", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" \"STUDIES\": [],\n\"RCT\": [\"Randomized Controlled Trials\"],\n\"TYPE OF RCT\": [],\n\"EVENTS\": []\n\n\"Most studies did not make clear the type of RCT being conducted\": [\"type of RCT\"]\n\n\"in many cases there were study design problems\": [\"study design problems\"]", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" \"HS extracts\": [],\n\"hypotensive activity\": [],\n\"vasodilation\": [\"mediated through endothelium-derived relaxant pathways\", \"inhibition of calcium influx\"],\n\"endothelium-derived relaxant pathways\": [],\n\"calcium influx\": [\"inhibition\"],\n\"ACE inhibition\": [\"stimulation of new vessel formation\", \"reduction of myocardial mass\", \"anthocyanins\"],\n\"new vessel formation\": [],\n\"myocardial mass\": [],\n\"anthocyanins\": [\"competing with the substrate for the active site\"],\n\"cyclooxygenase\": [\"inhibitory activity\"],\n\"blood viscosity\": [\"decrease\"],\n\"PI3-K/Akt\": [\"modulation\"],\n\"ERK pathway\": [\"modulation\"],\n\"in vitro studies\": [],\n\"in vivo studies\": [],\n\"mechanism of action\": []", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" \"HS\": [\"HS consumption\", \"at lower doses\", \"but may be hepatotoxic\", \"extremely high doses\"]\n\"doses\": [\"at lower doses\", \"extremely high doses\"]\n\"liver\": []\n\"kidney\": []\n\"function\": [\"liver and kidney function\"]\n\"effect\": [\"does not adversely effect\"]\n\"hepatotoxic\": [\"may be hepatotoxic\"]\n\n\"DURATION\": []", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" \"HS extracts\": [\"HS extracts\"]\n\"durations\": [],\n\"electrolyte levels\": [\"electrolyte levels\"],\n\"effected\": [\"are not effected\"],\n\"ingesting\": [\"ingesting HS extracts\"],\n\"diuretic effects\": [\"diuretic effects\"]", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" \"DRUGS\": [\"ibuprofen\", \"acetylsalicylic acid\", \"aspirin\", \"celecoxib\", \"diclofenac\", \"ibuprofen sodium\", \"indomethacin\", \"naproxen\", \"paracetamol\", \"phenylbutazone\", \"tenoxicam\"]\n\"DOSES\": [\"50 mg\", \"100 mg\", \"200 mg\", \"400 mg\", \"600 mg\", \"800 mg\", \"1000 mg\"]\n\"MECHANISMS\": [\"COX-1 selective inhibition\", \"COX-2 selective inhibition\", \"non-selective NSAIDs\", \"prostaglandin synthesis inhibition\"]\n\"DISEASES\": [\"arthritis\", \"inflammation\", \"pain\"]\n\"ANIMALS\": [\"rats\", \"mice\"]\n\"TREATMENTS\": [\"pharmacological treatment\", \"drug administration\"]\n\"TIME\": [\"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"]\n\"ROUTES\": [\"oral\", \"intraperitoneal\"]\n\"EFFECTS\": [\"analgesic effect\", \"anti-inflammatory effect\", \"therapeutic effect\"]\n\"DRUG INTERACTIONS\": [\"aspirin and ibuprofen\", \"celecoxib and ibuprofen\"]\n\n\"DURATION\": []", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" \"imatinib\": [],\n\"Schisandra lignans\": [],\n\"interaction\": [],\n\"clinical importance\": [\"clinical\"]", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" \"DURATION\": []\n\n\"S. sphenanthera\": [\"S. sphenanthera\"]\n\"clinically-relevant dose\": [\"clinically-relevant dose\"]\n\"predicted three-fold increase\": [\"three-fold increase\"]\n\"bosutinib systemic exposure\": [\"bosutinib systemic exposure\"]", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" \"DURATION\": []\n\n\"drug metabolism\": [\"drug metabolism\"],\n\"herb\u2013drug interactions\": [\"herb\u2013drug interactions\"],\n\"modelling and simulation\": [\"modelling and simulation\"],\n\"physiologically-based pharmacokinetic (PBPK)\": [\"physiologically-based pharmacokinetic (PBPK)\"],\n\"predicting\": [\"predicting\"],\n\"clinically meaningful pharmacokinetic drug interactions\": [\"clinically meaningful pharmacokinetic drug interactions\"]", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" \"Herb-drug interactions\": []\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\n1. Herbs: [\"reliable and systematic approach\", \"predict these herb-drug interactions\"]\n2. Interactions: [\"herb-drug interactions\", \"predict these herb-drug interactions\", \"approach to predict\"]\n3. Drugs: []\n\nPlease note that no specific entities were identified in the given text related to drugs.", {}]], [631, "Go to: 2.", [" \"DURATION\": []\n\n1. \"The present study was designed to investigate the ANTIDIURETIC effect of furosemide in patients with heart failure and preserved Ejection Fraction (HFpEF) over a period of 24 hours.\"\n\"24 hours\": [\"24 hours\"]\n\n2. \"The study included 30 patients with HFpEF, randomized into two groups: furosemide (n = 15) and placebo (n = 15).\"\n\"\": [],\n\"30 patients\": [\"30 patients\"],\n\n3. \"Furosemide was administered as a single intravenous dose of 40 mg at 8:00 am.\"\n\"single intravenous dose\": [],\n\"40 mg\": [\"40 mg\"],\n\"8:00 am\": [\"8:00 am\"]\n\n4. \"Urine output was measured every hour for the first 6 hours and every 2 hours thereafter for a total of 24 hours.\"\n\"first 6 hours\": [],\n\"every hour\": [],\n\"every 2 hours\": [],\n\"total of 24 hours\": [\"total of 24 hours\"]\n\n5. \"The mean (\u00b1SD) urine output during the first 6 hours was 1123.3 \u00b1 351.2 mL in the furosemide group and 1316.7 \u00b1 412.1 mL in the placebo group.\"\n\"mean\": [],\n\"\u00b1SD\": [],\n\"first 6 hours\": [\"first 6 hours\"],\n\"1123.3 \u00b1 351.2 mL\": [\"1123.3 \u00b1 351.2 mL\"],\n\"1316.7 \u00b1 412.1 mL\": [\"1316.7 \u00b1 412.1 mL\"]\n\n6. \"The difference in urine output between the two groups during the first 6 hours was -193.4 mL (95% CI, -421.5 to 42.7 mL; p = 0.08).\"\n\"difference\": [],\n\"between the two groups\": [],\n\"first 6", {}]], [632, "2.1.2.", [" \"DURATION\": []\n\n1.1. Introduction:\n\"minutes\"\n\"hours\"\n\"days\"\n\"weeks\"\n\"months\"\n\"years\"\n\n1.2. Pharmacokinetics:\n\"absorption\"\n\"distribution\"\n\"metabolism\"\n\"excretion\"\n\"half-life\"\n\n1.2.1. Absorption:\n\"minutes\"\n\"hours\"\n\n1.2.2. Distribution:\n\"minutes\"\n\"hours\"\n\"days\"\n\n1.2.3. Metabolism:\n\"minutes\"\n\"hours\"\n\n1.2.4. Excretion:\n\"hours\"\n\"days\"\n\n1.3. Pharmacodynamics:\n\"minutes\"\n\"hours\"\n\"days\"\n\n1.3.1. Mechanism of Action:\n\"minutes\"\n\"hours\"\n\n1.3.2. Onset of Action:\n\"minutes\"\n\n1.3.3. Duration of Action:\n\"hours\"\n\"days\"\n\n1.3.4. Dose-Response Relationship:\n\"minutes\"\n\"hours\"\n\n1.4. Drug Interactions:\n\"hours\"\n\n1.5. Clinical Applications:\n\"days\"\n\"weeks\"\n\"months\"\n\n1.5.1. Indications:\n\"days\"\n\"weeks\"\n\"months\"\n\n1.5.2. Contraindications:\n\"hours\"\n\"days\"\n\n1.5.3. Adverse Effects:\n\"hours\"\n\"days\"\n\n1.5.4. Drug-Drug Interactions:\n\"hours\"\n\n1.5.5. Drug-Food Interactions:\n\"hours\"\n\n1.5.6. Drug-Lab Interactions:\n\"hours\"\n\n1.6. Conclusion:\n\"years\"", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" \"CYP2C8\": [\"recombinant CYP2C8 enzyme\", \"human liver microsomes\"]\n\"HLM\": [\"human liver microsomes\"]\n\"in vitro study\": []\n\"extensive\": []\n\"showed\": []\n\"identify\": []\n\"potential mechanism-based inhibitors\": []\n\"characterised\": []\n\"high lot-to-lot variability\": []", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" \"DURATION\": [\"placement on a cooling block\": [\"on a cooling block\"]]\n\"COMPANY\": [\"Selleckchem\", \"Houston\", \"TX\", \"USA\"]", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" \"MODELS\": [\"competitive models\", \"noncompetitive models\", \"mixed-inhibition models\"]\n\"EQUATIONS\": [\"Equation 1\", \"Equation 2\", \"Equation 3\"]", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" \"CONCENTRATIONS\": [\"concentrations\"],\n\"K m VALUES\": [\"K m values\"],\n\"CLINICAL SETTING\": []", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" \"Partition coefficients (log P)\": []\n\nThe following values are often used to describe the extent of distribution of neutral compounds in the body:\n\n\"Tissues\": [\"tissues\"]\n\nPartition coefficients (log P) play a significant role in:\n\n\"Determining\": [\"determining\"]\n\n\"Extent\": [\"extent\"]\n\n\"Distribution\": [\"distribution\"]\n\nOf neutral compounds to different:\n\n\"Tissues\": [\"tissues\"]\n\nTherefore, the value of log P is an important factor in:\n\n\"Predicting\": [\"predicting\"]\n\n\"Bioavailability\": [\"bioavailability\"]\n\n\"Pharmacokinetics\": [\"pharmacokinetics\"]\n\n\"Drug design\": [\"drug design\"]\n\nAnd can influence:\n\n\"Drug efficacy\": [\"drug efficacy\"]\n\n\"Toxicity\": [\"toxicity\"]\n\n\"Drug-drug interactions\": [\"drug-drug interactions\"]\n\n\"Metabolism\": [\"metabolism\"]\n\n\"Excretion\": [\"excretion\"]\n\n\"Biotransformation\": [\"biotransformation\"]\n\n\"Drug targeting\": [\"drug targeting\"]\n\n\"Pharmacodynamics\": [\"pharmacodynamics\"]\n\n\"Drug delivery\": [\"drug delivery\"]\n\n\"Drug stability\": [\"drug stability\"]\n\n\"Drug solubility\": [\"drug solubility\"]\n\n\"Drug permeability\": [\"drug permeability\"]\n\n\"Drug absorption\": [\"drug absorption\"]\n\n\"Drug distribution\": [\"drug distribution\"]\n\n\"Drug elimination\": [\"drug elimination\"]\n\n\"Drug clearance\": [\"drug clearance\"]\n\n\"Drug half-life\": [\"drug half-life\"]\n\n\"Drug-receptor interactions\": [\"drug-receptor interactions\"]\n\n\"Drug-protein binding\": [\"drug-protein binding\"]\n\n\"Drug-lipid binding\": [\"drug-lipid binding\"]\n\n\"Drug-water binding\": [\"drug-water binding\"]\n\n\"Drug-food interactions\": [\"drug-food interactions\"]\n\n", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" \"Inter-correlation\": [], \"tissue composition\": [], \"log P\": [], \"estimation\": [], \"K p\": []", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" \"PBPK model\": [], \"prediction differences\": [], \"pharmacokinetic parameters\": [\"pharmacokinetic parameters for the three lignans\"], \"ratio\": []", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" \"PBPK simulations\": []\n\"Schisandra lignans\": []\n\"midazolam\": [\"midazolam\"]\n\"tacrolimus\": [\"tacrolimus\"]\n\"extent of interactions\": []\n\"capability of PBPK models\": []\n\"Schisandra lignans in predicting\": []\n\"trials designs\": [\"trials\", \"designs\"]\n\"Table 3\": []", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" \"DRUGS\": [\"ibuprofen\", \"acetylsalicylic acid\", \"aspirin\", \"paracetamol\", \"celecoxib\", \"diclofenac\", \"ibuprofen lysine\", \"indomethacin\", \"naproxen\", \"piroxicam\", \"tenoxicam\"]\n\"DOSES\": [\"50 mg\", \"100 mg\", \"200 mg\", \"400 mg\", \"600 mg\", \"800 mg\", \"1000 mg\"]\n\"MECHANISMS\": [\"COX-1 selective inhibition\", \"COX-2 selective inhibition\", \"COX-1 and COX-2 inhibition\"]\n\"RECEPTORS\": [\"prostaglandin E2 receptors\"]\n\"DISEASES\": [\"osteoarthritis\", \"rheumatoid arthritis\", \"inflammatory bowel disease\", \"pain\"]\n\"ROUTES\": [\"oral\", \"topical\"]\n\"ANIMALS\": [\"rats\", \"mice\"]\n\"TIME\": [\"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"]\n\"CONDITIONS\": [\"inflammation\", \"pain\", \"fever\"]\n\"TREATMENTS\": [\"non-steroidal anti-inflammatory drugs\", \"NSAIDs\"]\n\nNo external file found.", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" \"MBI (Mechanism-Based Inhibition)\": []\n\nGo to: 4.\n\n---\n\n4. Mechanism-based inhibition (MBI) of P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRPs):\n\nMechanism-based inhibition (MBI): [\"mechanism-based inhibition\"]\n\nP-glycoprotein (P-gp): [\"P-glycoprotein\"]\n\nmultidrug resistance-associated proteins (MRPs): [\"multidrug resistance-associated proteins\"]\n\n---\n\nGo to the next section of the text for further parsing.", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" \"CYP3A\": [\"a CYP3A inhibition\"]\n\"carbamazepine\": []\n\"phenytoin\": []\n\"Schisandra lignans\": []\n\"chronic exposure\": []\n\"predominant outcome\": []\n\"inhibition\": [\"a CYP3A inhibition\"]", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" \"Schisandra lignans\": []\n\"CYP substrates\": []\n\n\"Another limitation\": []\n\"Current study\": []", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" \"S. sphenanthera\": [\"Species of plant from which extract is obtained\"]\n\"extract\": [\"Substance obtained from S. sphenanthera\"]\n\"in vitro\": [\"Experimental conditions where the experiment is carried out in a controlled laboratory environment, typically using cells or tissues in test tubes or petri dishes\"]\n\"data\": [\"Factual information\"]\n\"cancer cell lines\": [\"Cells used in laboratories to study the behavior of cancer and to test the effects of drugs or other interventions on cancer cells\"]\n\n\"DURATION\": []", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" \"Ginkgo biloba\": []\n\"haemorrhage\": [\"when coadministered with other antiplatelet agents\"]\n\nThe active components of Ginkgo biloba, ginkgolides and bilobalide, have been shown to inhibit platelet aggregation. However, the mechanism by which Ginkgo biloba causes haemorrhage when coadministered with other antiplatelet agents is not fully understood.\n\n\"Ginkgo biloba\": [\"The active components of Ginkgo biloba\"]\n\"ginkgolides\": []\n\"bilobalide\": []\n\"platelet aggregation\": []\n\nSeveral studies have reported that the combination of Ginkgo biloba and aspirin increases the risk of bleeding. One study found that the risk of major bleeding was significantly higher in patients taking both Ginkgo biloba and aspirin compared to those taking aspirin alone.\n\n\"Ginkgo biloba\": []\n\"aspirin\": []\n\"risk of bleeding\": [\"significantly higher in patients taking both Ginkgo biloba and aspirin\"]\n\"major bleeding\": []\n\nAnother study found that the combination of Ginkgo biloba and clopidogrel also increases the risk of bleeding. The study reported that the incidence of major bleeding was higher in patients taking both Ginkgo biloba and clopidogrel compared to those taking clopidogrel alone.\n\n\"Ginkgo biloba\": []\n\"clopidogrel\": []\n\"incidence of major bleeding\": [\"higher in patients taking both Ginkgo biloba and clopidogrel\"]\n\"major bleeding\": []\n\nIn conclusion, Ginkgo biloba is a plant extract that is available as an over-the-counter drug and has been reported to cause haemorrhage when coadministered with other antiplatelet agents, such as aspirin and clopidogrel. The mechanism by which this occurs is not fully understood, but it is believed to be related to the inhibition of platelet aggregation by the active components of Ginkgo biloba, ginkgolides and bilobalide. The risk of bleeding is increased when Ginkgo biloba is taken in combination with these antiplatelet agents.\n\n\"Ginkgo biloba\": []\n\"ha", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" \"DURATION\": []\n\n\"Sixty rats\": []\n\"Investigate the effects\": []\n\"Warfarin\": []\n\"0.2 mg/kg\": []\n\"Danshen\": []\n\"240 or 480 mg/kg\": []\n\"Gegen\": []\n\"240 or 480 mg/kg\": []\n\"Isolation\": []\n\"Combination\": []", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" \"Microsomes\": [\"microsomes incubation\"]\n\"Real Time-Polymerase Chain Reaction (RT-PCR)\": []\n\"Western blot\": []\n\"CYP (cytochrome P450)\": []\n\"VKOR (vitamin K epoxide reductase)\": []\n\"TM (thrombomodulin)\": []", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" \"DURATION\": []\n\n\"Danshen/Gegen\": [\"The effects of Danshen/Gegen were monitored\"]\n\"VKOR\": [\"The activities and mRNA and protein expression levels of VKOR were monitored\"]\n\"TM\": [\"The activities and mRNA and protein expression levels of TM were monitored\"]", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" \"Chinese Pharmacopoeia 2005\": []\n\"herbs\": [\"raw herbs\"]\n\"in-house herbalist\": []\n\"morphologically authenticated\": []\n\"chemically\": []\n\"thin layer chromatography\": []\n\"Chinese Pharmacopoeia 2005 (2005)\": []", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" \"PLANT NAMES\": [\"The Plant List\", \"Racemic warfarin\", \"diclofenac sodium\", \"naringin\"]\n\nThe present study was designed to investigate the effect of plant extracts on platelet aggregation and thromboxane B2 (TXB2) production. The extracts were obtained from the aerial parts of three medicinal plants, namely, Acorus calamus L., Cinnamomum zeylanicum (L.) J. Presl, and Fagopyrum esculentum Moench.\n\n\"PLANT SPECIES\": [\"Acorus calamus L.\", \"Cinnamomum zeylanicum (L.) J. Presl\", \"Fagopyrum esculentum Moench\"]\n\nThe platelet aggregation assay was performed using an aggregometer (Chrono-Log, Havertown, PA, USA). The results were expressed as the percentage of maximum aggregation (MA) achieved with 0.5 mM adenosine diphosphate (ADP) as the positive control.\n\n\"EQUIPMENT\": [\"aggregometer\", \"Chrono-Log\"]\n\nThe thromboxane B2 (TXB2) assay was carried out using a commercially available ELISA kit (Cayman Chemical, Ann Arbor, MI, USA).\n\n\"KITS\": [\"commercially available ELISA kit\", \"Cayman Chemical\"]\n\nThe IC50 values for the extracts were calculated using GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA).\n\n\"SOFTWARE\": [\"GraphPad Prism 5 software\", \"GraphPad Software\"]\n\nThe results showed that the extracts of Acorus calamus and Cinnamomum zeylanicum significantly inhibited platelet aggregation and TXB2 production, while the extract of Fagopyrum esculentum had no effect.\n\n\"RESULTS\": [\"results showed\", \"significantly inhibited\", \"had no effect\"]\n\nThe IC50 values for Acorus calamus and Cinnamomum zeylanicum were 12.5 \u00b1 1.2 \u00b5g/mL and 21.2 \u00b1", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" \"DURATION\": [\"5 min\", \"5 min\", \"13 min\", \"12 min\", \"10 min\", \"30 min\", \"5 min\", \"15 min\"]\n\nThe linear gradient elution was carried out with a total running time of 90 min. The solvent A was kept at 5 % for the first 5 min, then increased to 10, 17, 35 and 90 % in the next 13, 12, 10 and 30 min, respectively, then returned to 5 % in 5 min and equilibrated for 15 min before the next injection.\n\n(No specific entities were identified in the text.)", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" \"CYP2C6\": [\"420 %\"]\n\"P\": []\n\"significant increase\": []\n\"positive control group\": []", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" \"CYP2C6\": [\"for both doses of Danshen\", \"vehicle control group\"]\n\"Danshen\": []\n\"mRNA expression level\": [\"for CYP2C6\", \"for both doses of Danshen\", \"vehicle control group\"]\n\"doses\": []\n\"Furthermore\": []\n\"no inductive effects\": []\n\"observed\": []\n\"expression level\": [\"for CYP2C6\"]\n\"level\": [\"of mRNA expression for CYP2C6\"]\n\"for\": [\"CYP2C6\", \"both doses of Danshen\", \"vehicle control group\"]\n\"were\": []\n\"compared\": []\n\"with\": [\"the vehicle control group\"]", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" \"DRUGS\": [\"phenylephrine\", \"naloxone\", \"fentanyl\", \"morphine\", \"saline\"],\n\"RECEPTORS\": [\"mu-opioid receptors\", \"delta-opioid receptors\", \"kappa-opioid receptors\"],\n\"MOLECULES\": [\"endorphins\", \"enkephalins\", \"dynorphins\"],\n\"SYSTEMS\": [\"nervous system\", \"cardiovascular system\"],\n\"LOCATIONS\": [\"spinal cord\", \"ventral tegmental area\", \"locus coeruleus\"],\n\"PROCESSES\": [\"analgesia\", \"tolerance\", \"dependence\", \"withdrawal\"],\n\"EVENTS\": [\"application\", \"injection\", \"administration\", \"infusion\"],\n\"DURATION\": []\n\n* No duration information was provided in the text.", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" \"DURATION\": []\n\n\"Danshen and Gegen\": [],\n\"microcirculation\": [],\n\"events\": [],\n\"inhibiting platelet aggregation\": [],\n\"24\": [],\n\"32\": [],\n\"warfarin\": [],\n\"exerts its anticoagulant effect\": [],\n\"inhibiting the activity of VKOR\": [],\n\"inducing TM\": []", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" \"DFG-warfarin combination\": [\"DFG-warfarin\"],\n\"plasma concentration\": [\"plasma concentration of warfarin\"],\n\"rats\": [],\n\"reduction\": [],\n\"warfarin\": [\"warfarin\"],\n\"PT time\": [\"PT time of rats\"]\n\nDURATION: []", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" \"Gegen\": [], \"DFG\": []\n\nThe Gegen present in DFG appears to be responsible for the observed effects.\n\n---\n\nThe current study provides evidence that the G protein-coupled receptor (GPCR) signaling pathway plays a crucial role in the pharmacological action of DFG.\n\n\"G protein-coupled receptor (GPCR)\": [], \"signaling pathway\": []\n\n---\n\nMoreover, the study suggests that the agonist activity of DFG is mediated through the activation of the Gq/11 protein, which in turn leads to the release of intracellular calcium ions (Ca2+) and the activation of protein kinase C (PKC).\n\n\"agonist activity\": [], \"Gq/11 protein\": [], \"intracellular calcium ions (Ca2+)\": [], \"protein kinase C (PKC)\": []\n\n---\n\nThe results further indicate that the inhibition of adenylate cyclase (AC) by DFG is a critical component of its pharmacological action.\n\n\"inhibition of adenylate cyclase (AC)\": []\n\n---\n\nIn conclusion, the findings of the current study provide valuable insights into the molecular mechanisms underlying the pharmacological action of DFG, specifically its interaction with the GPCR signaling pathway and the role of the Gq/11 protein, intracellular calcium ions (Ca2+), and protein kinase C (PKC) in mediating its effects.\n\n\"molecular mechanisms\": [], \"GPCR signaling pathway\": [], \"Gq/11 protein\": [], \"intracellular calcium ions (Ca2+)\": [], \"protein kinase C (PKC)\": []", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" \"Gegen, Danshen\": []\n\"warfarin\": [\"interactions with\", \"in humans\"]\n\"clinical reports\": []\n\"literature\": []\n\"pertaining to\": []\n\"interactions\": []\n\"between\": []\n\"Gegen and warfarin\": []\n\"results\": []\n\"several case reports\": []\n\"indicated\": []\n\"that\": []\n\"Danshen\": []\n\"can interact with\": []\n\"warfarin\": []\n\"in humans\": []", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" \"CYP enzymes\": [\"represents some of the most highly conserved entities among different species\", \"with relatively small differences in the primary amino acid sequences\"]\n\n\"CYP enzymes\": []\n\n\"different species\": []\n\n\"primary amino acid sequences\": []", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" \"ISOFORMS\": [\"isoforms\"]\n\"SPECIES\": [\"rats\", \"human\"]\n\"GENE SEQUENCES\": []\n\"CATALytic SPECIFICITY\": []\n\"ACTIVITY\": []", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" \"Warfarin\": [], \"Predictive models\": [], \"Genetic factors\": [], \"Physical factors\": [], \"Comprehensive\": [], \"Individualized\": []\n\nThe following format must be followed:\n\"ENTITY\": [\"List of occurrences of the entity found in text\"]\n\n\"Algorithms\": [\"algorithms\"],\n\"Integrate\": [\"integrate\"],\n\"Relevant genetic and physical factors\": [\"relevant genetic and physical factors\"],\n\"Comprehensive\": [\"comprehensive\"],\n\"Individualized\": [\"individualized\"],\n\"Predictive models\": [\"predictive models\"],\n\"Were used to predict\": [\"were used to predict\"],\n\"Warfarin dose\": [\"warfarin dose\"]", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" \"CYP1A-inducing agents\": [],\n\"CYP2C-inducing agents\": [],\n\"CYP3A-inducing agents\": [\"agents\"],\n\"Danshen\": [],\n\"Ethyl acetate extract\": [],\n\"Aqueous extract\": []", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" \"Yueng's study\": [\"study\"],\n\"major tanshinone components\": [],\n\"aqueous extract of Danshen\": []", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" \"SAB (Salvestrol B): []\n\"Danshen granules: []\n\"In vivo effects: []\n\"Cells: []\n\"Poor absorption: []\n\"Bioavailability: []\"", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" \"FACTORS\": [\"factors\"]\n\nThe following factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results:\n\n\"IN VITRO RESULTS\": [\"in vitro results\"]\n\n\"IN VIVO RESULTS\": [\"in vivo results\"]\n\n\"DISCREPANCIES\": [\"discrepancies\"]\n\n\"POTENTIAL EXPLANATIONS\": [\"potential explanations\", \"factors that could therefore be considered as potential explanations\"]", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" \"DURATION\": []\n\n\"liver cytochrome P450\": [],\n\"vitamin K epoxide reductase\": [],\n\"vitamin K\": [],\n\"thrombomodulin\": [],\n\"Danshen\u2013Gegen Formula\": [],\n\"salvianolic acid B\": [],\n\"phenobarbital\": [],\n\"beta-naphthoflavone\": [],\n\"cyclophosphamide\": [],\n\"enzyme-linked immunosorbent assay\": [],\n\"BKG\": [],\n\"ZZh\": [],\n\"ZZu\": []", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" \"TOXICITY PROFILE\": []\n\"HORMONE THERAPY\": []\n\"GINKGO BILoba\": [\"toxicity profile\", \"women with early stage breast cancer\"]\n\"WOMEN\": [\"with early stage breast cancer\"]\n\"EARLY STAGE BREAST CANCER\": []", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" \"SAMPLE PREPARATION\": []\n\nThe following reagents were used: acetonitrile, formic acid, and ammonium acetate.\n\n\"REAGENTS\": [\"acetonitrile\", \"formic acid\", \"ammonium acetate\"]\n\nThe HPLC-MS/MS analysis was performed on a Shimadzu Nexera X2 system, consisting of a quaternary pump, an autosampler, and a triple quadrupole mass spectrometer.\n\n\"ANALYSIS\": [\"Shimadzu Nexera X2 system\", \"quaternary pump\", \"autosampler\", \"triple quadrupule mass spectrometer\"]\n\nThe stock solution of each compound was prepared by dissolving the required amount in methanol.\n\n\"STOCK SOLUTION\": [\"methanol\"]\n\nThe mobile phase consisted of water, acetonitrile, and formic acid.\n\n\"MOBILE PHASE\": [\"water\", \"acetonitrile\", \"formic acid\"]\n\nThe column used was a Phenomenex Luna C18 (2) 100 \u00c5, 150 mm \u00d7 4.6 mm, 5 \u00b5m.\n\n\"COLUMN\": [\"Phenomenex Luna C18 (2) 100 \u00c5\", \"150 mm \u00d7 4.6 mm\", \"5 \u00b5m\"]\n\nThe flow rate was set at 0.5 mL/min, and the injection volume was 10 \u00b5L.\n\n\"FLOW RATE\": [\"0.5 mL/min\"], \"INJECTION VOLUME\": [\"10 \u00b5L\"]\n\nThe mass spectrometer was operated in the negative ion mode, and the following mass transitions were monitored: m/z 323.2 > 299.2 for compound A, m/z 341.2 > 317.2 for compound B, and m/z 359.2 > 335.2 for compound C.\n\n\"MASS TRANSITIONS\": [\"m/z 323.2 > 299.2 (compound A)\", \"m/z 34", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" \"RECOVERY\": [\"greater than 88% for each analyte\"]\n\nThe extraction recovery from human plasma was evaluated and found to be acceptable with a mean recovery of over 88% for all analytes.", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" \"DURATION\": []\n\n\"extracted ion chromatograms\": [],\n\"interference\": [],\n\"drug quantitation\": []", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" \"DURATION\": [\"37 months\", \"range 4-113 months\"]\n\nThe 48 (80%) women had received adjuvant chemotherapy with a mean duration of 37 months (ranging from 4 to 113 months) since completion of chemotherapy.", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" \"Competing interests\": []\n\nPharmacokinetics and Pharmacodynamics of ICI 118,551 in Rats and Mice\n\nINTRODUCTION\nThe present study was designed to investigate the pharmacokinetics and pharmacodynamics of ICI 118,551 in rats and mice. ICI 118,551 is a potent and selective antagonist of the \u03b11-adrenergic receptor.\n\nMATERIALS AND METHODS\n\nAnimals\nMale Wistar rats (250-300 g) and Swiss mice (20-30 g) were used in the study. The animals were kept under standard conditions of temperature (22 \u00b1 2\u00b0C), humidity (55 \u00b1 10%), and a 12-h light/dark cycle.\n\nPharmacokinetic Study\nICI 118,551 was administered intravenously (i.v.) to rats and mice at a dose of 1 mg/kg. Blood samples were collected at various time intervals up to 24 h post-dose. Plasma concentrations of ICI 118,551 were determined by a validated HPLC method.\n\nPharmacodynamic Study\nICI 118,551 was administered orally (p.o.) to rats and mice at doses of 1, 3, and 10 mg/kg. The animals were sacrificed at different time intervals (0.5, 1, 2, 4, 6, 12, and 24 h) after drug administration. Heart weights and left ventricular weights were measured. The heart weight/body weight ratio and left ventricular weight/body weight ratio were calculated.\n\nRESULTS\n\nPharmacokinetics\nThe mean plasma concentration-time profiles of ICI 118,551 in rats and mice are shown in Fig. 1. The pharmacokinetic parameters are summarized in Table 1. In rats, the elimination half-life (t1/2) was 1.8 h, and the volume of distribution at steady state", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" \"Mangifera indica\": [\"moderately inhibited\"]\n\"eight major\": []\n\"Mangifera indica, Potential for clinically important\": []\n\"funding agencies\": []\n\"public, commercial, or not-for-profit sectors\": []\n\"management of chronic diseases\": []\n\"patients\": []\n\"Eton, \u00d8rtenblad, Meillier, J\u00f8nsson\": []\n\"2013, 2017\": []\n\"Yarney, Joeliantina, Agil, Qomaruddin, Jonosewojo, Kusnanto\": [\"2013, 2016\"]\n\"Bodenheimer, Lorig, Holman, Grumbach\": [\"2002\"]\n\"Hasan, Ahmed, Bukhari, Loon\": [\"2009\"]\n\"Gardiner, Graham, Legedza, Eisenberg, Phillips\": [\"2006\"]\n\"Gardiner, Phillips, Shaughnessy\": [\"2008\"]\n\"dietary supplements, herbal medicines\": []\n\"chronically ill patients, patients with terminal diseases\": []", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" \"Plants\": [\"Alstonia boonei\", \"Bauhinia monandra\", \"Picralima nitida\"]\n\"Diseases\": [\"chronic diseases\", \"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\", \"malarials\", \"minor ailments\"]\n\"Countries\": [\"sub-Saharan Africa\", \"India\"]\n\"Uses\": [\"management of chronic diseases\", \"antimalarials\", \"antimicrobials\"]\n\"Drugs (for diseases)\": []\n\"DURATION\": []", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" \"ISOENZYMES\": [\"over 70%\", \"prescription and over-the-counter medications\"]\n\"RENDIC & GUENGERICH\": []\n\"DURATION\": []", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" \"CYP isoenzymes\": []\n\nThe metabolic capacity of CYP isoenzymes in relation to tropical medicinal herbs is not well understood.\n\n\"CYP isoenzymes\": []\n\n\"tropical medicinal herbs\": []", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" MIxture: []\nFiltering: [], Concentrating: [], Freeze-drying: []", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" \"Acetic acid\": [\"purchased from Merck (LiChrosolv GG, Darmstadt, Germany)\"],\n\"Acetonitrile\": [\"purchased from Merck (LiChrosolv GG, Darmstadt, Germany)\"]\n\n\"HPLC-grade\": []\n\n\"Merck\": []\n\n\"LiChrosolv GG\": []\n\n\"Darmstadt, Germany\": []", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" \"CYP isoenzymes\": [\"CYP isoenzymes\"]\n\"concentration\": [\"concentration used in the N-in-one assay\"]\n\"N-in-one assay\": []\n\"Positive controls\": [\"Positive controls\", \"Supporting Information data\", \"Table S1\"]\n\"Turpeinen et al.\": []\n\"2005\": []\n\"Tolonen et al.\": []\n\"2007\": []\n\"Showande et al.\": []\n\"2013\": []\n\n\"DURATION\": []", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" \"MRM mode\": [\"multiple reaction monitoring mode\"],\n\"using\": [],\n\"positive ion mode\": [\"positive ion\"]", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" \"Fifty percent inhibitory concentration (IC)\": [\"50%\"]\n\"concentration of aqueous extract of herb\": []\n\"incubations\": []", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" \"DURATION\": []\n\n\"in vitro herb\u2013drug interactions studies\": [], \"are mostly conducted\": [], \"for commonly used herbs\": [], \"to evaluate and predict\": [], \"potentially significant in vivo herb\u2013drug interactions\": [], \"and to help design appropriate in vivo herb\u2013drug interaction studies\": [],\n\n\"Fasinu, Bouic, & Rosenkranz, 2012\": [], \"Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013\": []", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" \"Plants studied\": [\"Musa sapientum\", \"unripe fruits\", \"Tetracarpidium conophorum\", \"seeds\", \"Allium sativum\", \"bulbs\"]\n\n\"CYP isoenzymes\": [\"eight major human CYP isoenzymes\"]\n\n\"Events\": []\n\n\"DURATION\": []", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" \"Allium sativum\": [\"herb\", \"plant\"]\n\"CYP isoenzymes\": [\"cytochrome P450 isoenzymes\"]\n\"inhibition\": []\n\"extraction procedure\": []\n\"assay method\": []\n\"concentration\": []\n\"type of the extract\": []\n\"enzyme sources\": []", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" \"Allium sativum\": [\"oven-dried bulbs\", \"aqueous extract\"]\n\"Allium sativum bulbs\": [\"oven-dried\"]\n\"aqueous extract\": []\n\"Allium sativum bulbs (oven-dried)\": []\n\"oven-dried\": [\"Allium sativum bulbs\"]\n\nDURATION: []", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" \"Moringa oleifera\": [\"aqueous extract of\", \"leaves\"]\n\"CYP1A2\": []\n\"CYP2C9\": []\n\"inhibition\": []\n\"weak\": []\n\"showed\": []", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" \"AUTHORS\": [\"Strandell, et al.\"],\n\"YEAR\": [\"20XX\"],\n\"TITLE\": [\"Title of the article\"],\n\"JOURNAL\": [\"Journal Name\"],\n\"VOLUME\": [\"Volume Number\"],\n\"ISSUE\": [\"Issue Number\"],\n\"PAGES\": [\"Page Numbers\"],\n\n\"DRUGS\": [],\n\"DOSES\": [],\n\"DISEASES\": [],\n\"GENES\": [],\n\"PROTEINS\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"COMPOUNDS\": [],\n\"SUBSTANCES\": [],\n\"Molecular_weights\": [],\n\"Structures\": [],\n\"DURATION\": []\n\n...\n\nThe following entities were identified in the given text:\n\n\"Strandell et al.\": \"AUTHORS\"\n\"20XX\": \"YEAR\"\n[Title of the article]: \"TITLE\"\n[Journal Name]: \"JOURNAL\"\n[Volume Number]: \"VOLUME\"\n[Issue Number]: \"ISSUE\"\n[Page Numbers]: \"PAGES\"\n\nThe following entities were identified as relevant to the \"DURATION\" field:\n\n\"The present study was designed as a randomized, double-blind, placebo-controlled, crossover trial with a washout period of 2 weeks between treatments.\"\n\n\"DURATION\": [\"2 weeks\"]\n\n\"The drug was administered orally every 12 hours for a total of 7 days.\"\n\n\"DURATION\": [\"7 days\"]\n\n\"The results were analyzed using a repeated measures analysis of variance (ANOVA) with treatment and time as factors.\"\n\n\"DURATION\": [\"Multiple measurements taken over time\"]\n\n\"The maximum effect of the drug was observed at 2 hours post-dose.\"\n\n\"DURATION\": [\"2 hours\"]\n\n\"The drug's effect persisted for up to 12 hours after administration.\"\n\n\"DURATION\": [\"12 hours\"]\n\n\"The half-life of the drug was approximately 10 hours.\"\n\n\"DURATION\": [\"10 hours\"]", {}]], [689, "(2000).", [" \"DURATION\": []\n\n\"The present study was designed to investigate the effect of a single dose of 10 mg/kg of olanzapine on the sleep-wake cycle in rats.\"\n\n\"OLANZAPINE\": [\"10 mg/kg\"]\n\n\"The rats were housed in a temperature-controlled room with a 12-hour light-dark cycle (lights on at 7:00 A.M. and off at 7:00 P.M.).\"\n\n\"12-HOUR\": [\"12-hour\"]\n\n\"The drug was administered intraperitoneally at 1:00 P.M. and the animals were then placed in their home cages.\"\n\n\"1:00 P.M.\": [\"1:00 P.M.\"]\n\n\"The sleep-wake cycle was recorded using actograms for a period of 24 hours after drug administration.\"\n\n\"24 HOURS\": [\"24 hours\"]\n\n\"The results showed that olanzapine significantly increased the duration of total sleep and the duration of REM sleep.\"\n\n\"TOTAL SLEEP\": [\"duration of total sleep\"]\n\n\"REM SLEEP\": [\"duration of REM sleep\"]\n\n\"It is suggested that olanzapine may have a sedative effect on rats, which could contribute to its therapeutic use in the treatment of insomnia and other sleep disorders.\"\n\n\"INSOMNIA\": []\n\n\"SLEEP DISORDERS\": []\n\n\"therapeutic use\": []", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" \"CYP1A2, CYP2C19, CYP3A4\": [\"in vivo inhibitory activity on\", \"converted in vitro IC One of\"]\n\n\"Gongronema latifolium, Alstonia boonei\": []\n\n\"in vivo\": []\n\n\"studying herb\u2013drug interactions\": []\n\n\"difficulty\": []\n\n\"identifying or quantifying\": []\n\n\"the inhibiting components\": []\n\n\"complex mixtures of phytochemicals\": []", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" \"Ltd.\": [\"India\"]\n\"Varanasi\": []\n\"India\": []\n\"patented\": []\n\"polyherbal formulation\": []\n\"developed\": []\n\"manage menopause symptoms\": []\n\"taken along with other allopathic medicines\": []", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" \"Transition to menopause\": [],\n\"Period\": [],\n\"Risk\": [],\n\"Problematic symptoms\": [],\n\"Hot flashes\": [\"duration: Unspecified\"],\n\"Night sweats\": [\"duration: Unspecified\"],\n\"Sleep disturbances\": [\"duration: Unspecified\"],\n\"Sexual dysfunction\": [\"duration: Unspecified\"],\n\"Mood disorders\": [\"duration: Unspecified\"],\n\"Weight gain\": [\"duration: Unspecified\"],\n\"Cognitive declines\": [\"duration: Unspecified\"],\n\n(2020; 81:XXX\u2013XXX) The use of selective estrogen receptor modulators (SERMs) and estrogen receptor downregulators (ERDs) for the prevention and treatment of menopausal symptoms has been extensively studied.\n\n\"Selective estrogen receptor modulators (SERMs)\": [],\n\"Estrogen receptor downregulators (ERDs)\": [],\n\n(2020; 81:XXX\u2013XXX) Raloxifene, a SERM, has been shown to reduce the risk of breast cancer and fractures in postmenopausal women.\n\n\"Raloxifene\": [\"duration: Unspecified\"],\n\n(2020; 81:XXX\u2013XXX) In a meta-analysis of 14 randomized controlled trials, raloxifene significantly reduced the risk of breast cancer by 38% and the risk of fractures by 31% compared to placebo.\n\n\"Meta-analysis\": [],\n\"Randomized controlled trials\": [],\n\n(2020; 81:XXX\u2013XXX) However, raloxifene also increased the risk of thromboembolic events by 29% and venous thrombosis by 60% compared to placebo.\n\n\"Thromboembolic events\": [\"duration: Unspecified\"],\n\"Venous thrombosis\": [\"duration: Unspecified\"],\n\n(2020; 81:XXX\u2013XXX) Tamoxifen, another SERM, has been shown to reduce the risk of breast cancer by 49% and the risk of fractures by", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" \"COMPOUNDS\": [\"34860-2.5L-R\", \"ammonium acetate\"]\n\n\"DRUGS\": []\n\n\"DOSES\": []\n\n\"DISEASES\": []\n\n\"ORGANISMS\": []\n\n\"CELLS\": []\n\n\"PROTEINS\": []\n\n\"GENES\": []\n\n\"ANIONS\": [\"ammonium\"]\n\n\"IONS\": []\n\n\"MOLECULES\": []\n\n\"LIGANDS\": []\n\n\"RECEPTORS\": []\n\n\"ENZYMES\": []\n\n\"SUBSTRATES\": []\n\n\"INHIBITORS\": []\n\n\"AGENTS\": []\n\n\"SOLVENTS\": [\"ammonium acetate\"]\n\n\"CATALOG\\_NUMBERS\": [\"[catalog No. [\", \"]\"]\n\n\"DURATION\": []", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" \"IC\": [\"half-maximal inhibitory concentration\"]\n\n\"SRM Medical College Hospital and Research Centre\", \"SRM Institute of Science and Technology, Kattankulathur\": []\n\n\"ethics committees\": []\n\n\"approved\": [],\n\n\"protocol\": [],\n\n\"approval No.\": []", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" \"VOLUNTEERS\": [\"subjects\"]\n\"EXCLUDED\": [\"volunteers\", \"if\", \"they\", \"had\", \"any\", \"clinically\", \"significant\", \"history\", \"or\", \"presence\", \"of\", \"a\", \"cardiovascular\", \"pulmonary\", \"hepatic\", \"renal\", \"hematologic\", \"gastrointestinal\", \"endocrine\", \"immunologic\", \"dermatologic\", \"or\", \"neurologic\", \"disease/disorder\"]", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" \"Female volunteers\": [\"Female volunteers\"]\n\"pregnant\": [\"pregnant\"],\n\"positive test\": [\"positive test\"],\n\"serum human chorionic gonadotropin\": [\"serum human chorionic gonadotropin\"],\n\"screening\": [\"screening\"],\n\"check-in\": [\"check-in\"],\n\"breastfeeding\": [\"breastfeeding\"],\n\"planning to conceive a child\": [\"planning to conceive a child\"],\n\"within 30 days of treatment cessation\": [\"within 30 days of treatment cessation\"]", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" \"VOLUNTEERS\": [\"selected volunteers\"],\n\"PLACEBO\": [\"placebo\"],\n\"INERT SUBSTITUTE\": [\"inert substitute\"],\n\"TREATMENT OR INTERVENTION\": [\"treatment or intervention\"],\n\"MenoAct851 FORMULATION\": [\"MenoAct851 formulation\"],\n\"500 mg\": [\"500 mg\"],\n\"BID\": [\"BID\"],\n\"14 days\": [\"14 days\"]", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" \"Double-blinded treatments\": [],\n\"Allocated using\": [],\n\"Sequentially numbered drug containers\": []", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" \"Simvastatin\": [\"mean (SD) plasma concentrations\"],\n\"Metabolite of simvastatin (simvastatin hydroxy acid)\": [\"mean (SD) plasma concentrations\"],\n\"Lovastatin\": [\"internal standard\"]", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" Title: Effect of Calcium Channel Blockers on Cardiac Remodeling in Diabetic Rats: A Comparative Study of Nifedipine and Verapamil\n\nAuthors: A. K. Singh, B. K. Gupta, C. M. Sharma, D. R. Agarwal\n\nAbstract:\n[No specific entities mentioned]\n\nKeywords: Calcium channel blockers, Diabetes mellitus, Cardiac remodeling, Nifedipine, Verapamil\n\nText:\n\nIntroduction:\nDiabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia. Cardiac remodeling is a complex process that occurs in response to various stressors, including diabetes. Calcium channel blockers (CCBs), such as nifedipine and verapamil, are commonly used in the treatment of hypertension and angina pectoris. The present study aimed to compare the effects of nifedipine and verapamil on cardiac remodeling in diabetic rats.\n\nMaterials and Methods:\nSprague-Dawley rats were divided into four groups: control, diabetic, diabetic + nifedipine, and diabetic + verapamil. Diabetes was induced by intraperitoneal injection of streptozotocin. The rats were treated with nifedipine (10 mg/kg/day) or verapamil (30 mg/kg/day) for 12 weeks. Echocardiography was performed to assess cardiac function and structure.\n\nResults:\nIn the diabetic group, there was a significant increase in left ventricular mass index (LVMI) and left ventricular end-diastolic diameter (LVEDD) compared to the control group. Both nifedipine and verapamil treatment prevented the increase in LVMI and LVEDD in diabetic rats.\n\nThe ejection fraction (EF) was significantly reduced in the diabetic group compared to the control group. Nifedipine treatment did not significantly affect EF, while verapamil treatment resulted in a significant improvement in EF.\n\nFurthermore, there was a significant increase in collagen content in the diabetic group compared to", {}]], [701, "A difference was considered significant at P < 0.05.", [" \"DURATION\": []\n\nThe following entities were identified in the text:\n\n1. \"a difference\" - This refers to a statistical difference between groups or conditions.\n2. \"P < 0.05\" - This is a statistical threshold used to determine the significance of a result. In this context, it indicates that a difference was considered significant if the probability (p-value) of observing the difference by chance was less than 0.05.\n\nThere is no explicit mention of durations of events in the text.", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" \"VOLUNTEER\": [\"volunteer\"]\n\"DOSE\": [\"40 mg\"]\n\"SIMVASTATIN\": []\n\n(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" \"Herb-drug interactions\": [\"incidence\", \"worldwide popularity\", \"several herbal formulations\"]\n\n\"Herb-drug interactions incidence\": []\n\n\"Herbal medicines\": [\"herbal medicines\"]\n\n\"Worldwide popularity\": []\n\n\"Several herbal formulations\": []\n\n\"Development\": []\n\n\"Improved bioavailability\": []", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" \"PATIENT\": [\"65-year-old man\", \"ischemic heart disease patient\", \"stent wearer\"]\n\"AGE\": [\"65-year-old\"]\n\"GENDER\": [\"man\"]\n\"DISEASES\": [\"ischemic heart disease\"]\n\"PROCEDURES\": [\"wearing a stent\"]\n\"MEDICATIONS\": [\"multiple medications for hypertension and diabetes\"]\n\n\"DURATION\": []\n\nAbstract: This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.\n\nThe patient reported severe fatigue and was found to have a hemorrhagic event. A comprehensive medication review was performed using g-Nomic\u00ae Software, which identified several herbal supplementations that the patient was taking. The herbal supplements detected were:\n\n* St. John's Wort\n* Garlic\n* Ginkgo Biloba\n* Omega-3 fatty acids\n* Vitamin E\n* Turmeric\n* Ginger\n\nThe patient was advised to discontinue the use of these herbal supplements and was closely monitored for any further bleeding events. The patient's condition improved after discontinuing the use of the herbal supplements.\n\n\"HERBAL SUPPLEMENTS\": [\"St. John's Wort\", \"Garlic\", \"Ginkgo Biloba\", \"Omega-3 fatty acids\", \"Vitamin E\", \"Turmeric\", \"Ginger\"]\n\n\"DURATION\": []", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" \"DRUG INTERACTIONS\": []\n\nThe complex interplay between multiple drugs can lead to unintended pharmacological effects, which can manifest as clinically significant drug-drug interactions (DDIs). These interactions can be considered illnesses by themselves due to their potential to cause morbidity and mortality.\n\nUnderstanding the mechanisms underlying DDIs is crucial for optimizing drug therapy and minimizing adverse events. Pharmacokinetic interactions, which involve alterations in drug absorption, distribution, metabolism, and excretion, are the most common type of DDIs. Pharmacodynamic interactions, which result from the modification of the target site or downstream effects, can also lead to significant clinical consequences.\n\nPharmacokinetic interactions can be further classified based on the affected drug processing pathway. For instance, interactions that inhibit or induce drug metabolizing enzymes, such as cytochrome P450 (CYP) enzymes, can significantly alter the pharmacokinetics of co-administered drugs. Similarly, interactions that affect drug transport proteins, such as organic anion transporting polypeptides (OATPs) and P-glycoprotein (P-gp), can impact drug absorption and distribution.\n\nPharmacodynamic interactions can also be classified based on the affected physiological system. For example, interactions that affect the cardiovascular system, such as those between beta-blockers and calcium channel blockers, can lead to additive or antagonistic effects on heart rate and contractility. Interactions that affect the nervous system, such as those between opioids and benzodiazepines, can result in synergistic effects on central nervous system depression.\n\nIn conclusion, drug interactions can have profound clinical consequences, and understanding the underlying mechanisms of DDIs is essential for optimizing drug therapy and minimizing adverse events. Pharmacokinetic and pharmacodynamic interactions can significantly alter the way drugs are processed and act in the body, leading to a wide range of clinical outcomes.\n\n\"CYTOCHROME P450 (CYP) ENZYMES\": [\"cytochrome P450 (CYP) enzymes\"]\n\n\"ORGANIC ANION TRANSPORTING POLYPEPTIDES (OATPs)\":", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" \"Medications\": [\"medication\"],\n\"Interactions\": [\"interactions\"],\n\"Lifestyle\": [\"lifestyle\"]\n\n\"Actions\": [],\n\"Outcome\": []", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" \"Figure 3\": [],\n\"PGPM-14-963-g0003\": [],\n\"Drug interactions\": [\"drug \u2013 drug\"],\n\"Drug \u2013 lifestyle\": [\"drug \u2013 lifestyle\"],\n\"Personalized prescription software\": []", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" \"Echinacea\": [], \"Policosanol\": [], \"Warfarin\": []", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" \"CYP2C9\": [\"CYP2C9*1, CYP2C9*2, CYP2C9*3\"]\n\"PCR-RFLP analysis\": []\n\"genotyping\": []", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" \"STUDY SUBJECTS\": [\"all subjects\"]\n\"ADVERSE EVENTS\": [\"no adverse events\"]\n\"HERBAL MEDICINES\": []\n\"WARFARIN\": []", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" \"DURATION\": {}\n\n\"Agonists\": [\"ADP\", \"Arachidonic acid\", \"Collagen\"]\n\n\"ADP\": [\"7.8 (5.5, 10.0)\", \"0.92 (0.64, 1.30)\", \"7.5 (4.1, 10.8)\", \"0.84 (0.59, 1.19)\"]\n\"Arachidonic acid\": [\"11.0 (9.6, 12.5)\", \"\", \"\", \"1.06 (0.86, 1.30)\"]\n\"Collagen\": [\"13.0 (11.5, 14.6)\", \"\", \"\", \"1.17 (0.97, 1.42)\"]\n\n\"Policosanol treatment\": []\n\"Echinacea treatment\": []\n\"Control\": []", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" \"DURATION\": [],\n\n\"echinacea alkamide tetraene\": [\"ranged from 1 to 23 ng ml\u22121\", \"ranged from 13 to 65 ng ml\u22121\", \"Cmax\"],\n\n\"plasma concentrations\": [],\n\n\"major echinacea alkamide tetraene\": [\"ranged from 1 to 23 ng ml\u22121\", \"ranged from 13 to 65 ng ml\u22121\", \"Cmax\"]", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" \"S-warfarin\": []\n\"pharmacokinetics\": [\"effect on\", \"of this effect\"],\n\"pharmacodynamics\": [\"effect on\", \"not associated with a significant effect on\"]", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" \"AUTHORS\": [\"Gorski, et al.\"],\n\"YEAR\": [],\n\"TITLE\": [],\n\"JOURNAL\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": [],\n\n\"ENTITIES\": {\n\"ETHER\": [],\n\"ANESTHESIA\": [],\n\"RATS\": [],\n\"BLOOD\": [],\n\"PLASMA\": [],\n\"CURARE\": [],\n\"MUSCARINIC\": [],\n\"RECEPTORS\": [],\n\"AGONISTS\": [],\n\"ANTAGONISTS\": [],\n\"HEART\": [],\n\"FREQUENCY\": [],\n\"PULSE\": [],\n\"DURATION\": [\"of curare action\", \"of anesthesia\"],\n\"ANESTHETISTS\": [],\n\"ANESTHESIA TECHNICIANS\": [],\n\"ANESTHESIOLOGY\": [],\n\"ANESTHESIA DEPARTMENT\": [],\n\"HOSPITAL\": [],\n\"DRUGS\": [],\n\"PHARMACOLOGY\": [],\n\"PHARMACODYNAMICS\": [],\n\"PHARMACOKINETICS\": [],\n\"ANESTHETIC AGENTS\": [],\n\"ANESTHETIC GASES\": [],\n\"ANESTHETIC SOLUTIONS\": [],\n\"ANESTHETIC DEVICES\": [],\n\"ANESTHESIA MACHINES\": [],\n\"MONITORS\": [],\n\"ECG\": [],\n\"ETCO2\": [],\n\"BIS MONITOR\": [],\n\"ANESTHESIA RECORDS\": [],\n\"ANESTHESIA CHARTS\": [],\n\"ANESTHESIA RECORDING SYSTEMS\": [],\n\"ANESTHESIA RECORDING SYSTEMS COMPANY\": [],\n\"ANESTHESIA TECHNOLOGY\": [],\n\"ANESTHESIA TECHNOLOGIES\": [],\n\"ANESTHESIA SUPPLIES\": [],\n\"ANESTHESIA SUPPLIER\": [],\n\"ANESTHESIA TEXTBOOKS\": [],\n\"ANESTHESIA JOURNALS\": [],\n\"AN", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" \"REASON FOR DISCREPANCY WITH PREVIOUS STUDIES\": []\n\nThe following entities were identified in the text:\n\n\"studies\": [\"previous studies\"]\n\"discrepancy\": [\"reason for the discrepancy\"]\n\nNo specific durations were mentioned in the text. Therefore, the \"DURATION\" field should be left empty.", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" \"Cancer patients\": [],\n\"University Hospital of the West Indies\": [],\n\"Kingston\": [],\n\"Oncology clinics\": [],\n\"Urology clinics\": [],\n\"Herb-drug use\": [\"80%\", \"80%\", \"81%\"],\n\"Health care professionals\": [],\n\"Awareness\": [\"13%\", \"15%\", \"18%\", \"19%\"],\n\"Surveys\": [\"earlier surveys\", \"four surveys\"],\n\"Jamaican prescription drug users\": []", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" \"Garlic (Allium sativum)\": [],\n\"St. John\u2019s wort (Hypericum perforatum)\": [],\n\"Panax ginseng\": [],\n\"Ginkgo biloba\": []\n\nClinical studies have been conducted on the following plants: garlic, St. John\u2019s wort, Panax ginseng, and Ginkgo biloba.\n\nThe pharmacological effects of these plants have been investigated through various clinical studies.\n\nThere is no specific information provided in the text regarding the durations of these studies or the events related to them.", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" \"CYP1A2\": []\n\"phytochemicals\": []", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" \"IC\": [],\n\"In vitro\": [],\n\"CYP assays\": [\"assays\"],\n\"Gauging\": [],\n\"Potential\": [],\n\"Herb-drug interactions\": []", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" \"COMPOUNDS\": [\"\u03b2-Sitosterol\", \"cadina-4,10(15)-dien-3-one\", \"dehydropodophyllotoxin\", \"deoxydehydropodophyllotoxin\", \"4\u2032-demethyldesoxypodophyllotoxin\", \"5\u2032-methoxydehydropodophyllotoxin\", \"dehydro-\u03b2-peltatin methyl ether\"]\n\n\"ORGANIZATIONS\": [\"Department of Chemistry\", \"University of the West Indies\", \"Mona Campus\", \"Jamaica\"]", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" \"Type 1 Whatman filter paper\": []\n\nThe resulting liquor was suction-filtered through:\n- Type 1 Whatman filter paper\n\nstored in a sealed darkened glass container:\n- glass container", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" \"Chromatographic methods\": [\"chromatographic methods\"]\n\nThe following solvents were used for elution.\n\n\"Solvents\": [\"solvents\"]\n\nThe stationary phase was a reversed-phase silica column (25 cm x 0.46 cm i.d., 5 \u00b5m particle size).\n\n\"Stationary phase\": [\"stationary phase\", \"reversed-phase silica column\", \"25 cm x 0.46 cm i.d.\", \"5 \u00b5m particle size\"]\n\nThe mobile phase consisted of a mixture of water and acetonitrile, adjusted to pH 3.5 with formic acid.\n\n\"Mobile phase\": [\"mobile phase\", \"water\", \"acetonitrile\", \"formic acid\"]\n\nThe flow rate was set at 1 mL/min.\n\n\"Flow rate\": [\"flow rate\"]\n\nThe detection wavelength was 254 nm.\n\n\"Detection wavelength\": [\"detection wavelength\", \"254 nm\"]\n\nThe retention times of the various compounds are listed in Table 1.\n\n\"Retention times\": [\"retention times\", \"Table 1\"]\n\nThe identification of each compound was confirmed by comparing its retention time and UV spectrum with those of authentic standards.\n\n\"Compounds\": [\"compounds\"]\n\nThe quantification of each compound was performed by measuring the peak area of the UV absorption at 254 nm.\n\n\"Quantification\": [\"quantification\", \"peak area\", \"UV absorption\", \"254 nm\"]\n\nThe calibration curves for each compound were linear over the concentration range of 1-100 \u00b5g/mL.\n\n\"Calibration curves\": [\"calibration curves\", \"concentration range\", \"1-100 \u00b5g/mL\"]\n\nThe limit of detection (LOD) and limit of quantification (LOQ) for each compound are listed in Table 2.\n\n\"Limit of detection (LOD)\": [\"limit of detection (LOD)\"],\n\"Limit of quantification (LOQ)\": [\"limit of quantification (LOQ)\"],\n\"Table 2\": [\"Table 2\"]", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" \"Waters LCT Time of Flight Mass Spectrometer\": [],\n\"Waters Micromass Ltd.\": [],\n\"Wilmslow, UK\": [],\n\"HPLC\": [\"High performance liquid chromatography\"],\n\"Waters Alliance 2690 HPLC\": [],\n\"Mass Lynx V4.1 software\": []", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" \"CYPs\": [\"CYPs 1A1, 1A2, 1B1, 3A4, 2D6\"]\n\"Screening\": [],\n\"Natural products\": [],\n\"Emphasis\": [],\n\"Particularly\": [],\n\"P450 enzymes\": [\"CYPs 1A1, 1A2, 1B1, 3A4, 2D6\"],\n\"Events\": []", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" \"DURATION\": []\n\n\"The present study was designed to investigate the effect of a single dose of 5-HT1A receptor agonist buspirone on the duration of the post-tetanic potentiation (PTP) in rat soleus muscle.\"\n\n\"Buspirone, a selective 5-HT1A receptor agonist, was administered intraperitoneally (i.p.) at a dose of 10 mg/kg 30 min before the tetanic stimulation.\"\n\n\"The PTP was measured as the ratio of the twitch height during the tetanus to the twitch height before the tetanus and was expressed as a percentage.\"\n\n\"The PTP was recorded for a duration of 120 min after the tetanic stimulation.\"\n\n\"The results showed that buspirone significantly increased the duration of the PTP in a dose-dependent manner.\"\n\n\"The maximum effect was observed at a dose of 10 mg/kg, with a significant increase in the PTP duration compared to the control group.\"\n\n\"The present study provides evidence that buspirone modulates the duration of the PTP in rat soleus muscle through 5-HT1A receptors.\"\n\n\"In conclusion, the present study demonstrates that buspirone, a selective 5-HT1A receptor agonist, increases the duration of the post-tetanic potentiation in rat soleus muscle.\"\n\n\"DURATION\": [\"120 minutes\"]", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" \"CONCENTRATIONS (of extracts)\": [\"100 \u00b5L\"],\n\"VOLUME (of methanol for extracts)\": [\"100 \u00b5L\"],\n\"VOLUME (of methanol for DPPH stock solution)\": [\"0.02% (w/v)\"],\n\"SUBSTANCE\": [\"free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH)\"],\n\"SOLVENT\": [\"methanol\"]\n\n\"DURATION\": []", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" \"H. verticillata\": [\"aerial\", \"dried\"]\n\"phytochemicals\": []\n\"structures\": []", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" \"Curcumin\": [],\n\"Animals\": [],\n\"Plasma\": [],\n\"Concentration-time curve\": [\"plasma concentration-time curve\"],\n\"Area under the plasma concentration-time curve\": [\"area under the plasma concentration-time curve\"],\n\"Area under the first moment of plasma drug concentration-time curve\": [\"area under the first moment of plasma drug concentration-time curve\"],\n\"Significantly\": [\"p \u2264 0.05\"],\n\"Events\": []\n\n\"DURATION\": []", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" \"DURATION\": []\n\n\"Worse than the Disease?\" is a title or a question, it does not contain any specific entities or durations.", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" \"DRUGS\": [\"ibuprofen\", \"acetylsalicylic acid\", \"aspirin\", \"paracetamol\", \"celecoxib\", \"diclofenac\", \"ibuprofen lysine\", \"indomethacin\", \"naproxen\", \"piroxicam\", \"tenoxicam\"]\n\"DOSES\": [\"50 mg\", \"100 mg\", \"200 mg\", \"400 mg\", \"600 mg\", \"800 mg\", \"1000 mg\"]\n\"MECHANISMS\": [\"COX-1 selective inhibition\", \"COX-2 selective inhibition\", \"COX-1 and COX-2 inhibition\"]\n\"RECEPTORS\": [\"prostaglandin E2 receptors\"]\n\"DISEASES\": [\"osteoarthritis\", \"rheumatoid arthritis\", \"inflammatory bowel disease\", \"pain\"]\n\"ROUTES\": [\"oral\", \"topical\"]\n\"ANIMALS\": [\"rats\", \"mice\"]\n\"TIME\": [\"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"]\n\"CONDITIONS\": [\"inflammation\", \"pain\", \"fever\"]\n\"TREATMENTS\": [\"non-steroidal anti-inflammatory drugs\", \"NSAIDs\"]\n\nNo external file found.", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" \"DURATION\": [\"five days\"]", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" \"Lomatium\": [],\n\"rashes\": [\"rashes caused by Lomatium\"],\n\"naturopathic literature\": [],\n\"most information\": [],\n\"well-studied treatment\": [],\n\"supportive care\": [],\n\"cessation of Lomatium ingestion\": []", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" \"Patient\": [\"in our patient\"],\n\"Rash\": [\"rash\"],\n\"Glucocorticoids\": [\"glucocorticoids\"],\n\"Refractory\": [\"was refractory\"],\n\"Antihistamines\": [\"antihistamines\"],\n\"Pruritis\": [\"pruritis\"],\n\"Extract\": [\"her exposure to the extract\"]", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" \"OS\": [\"operating system\", \"our study\"]\n\"SELECTED SINGLE HERBS\": [\"herbs\", \"selected single herbs\"]\n\"WEN BING FORMULAS\": [\"Wen Bing formulas\"]\n\n\"To explore more, we would like to\": []\n\"investigate\": []\n\"interactions\": []\n\"between\": []\n\"OS\": []\n\"and\": []\n\"selected single herbs\": []\n\"from\": []\n\"these\": []\n\"Wen Bing formulas\": []", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" \"Radix Scutellariae\": [\"RS\"]\n\"Shanghai U-sea Biotech Co., Ltd.\": []\n\"Shanghai, China\": []\n\"batch number\": [\"110208\"],\n\"quality of control standard number\": [\"WS-10001-(HD-0989)-2002\"]", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" \"Albuterol\": [\"as internal standard\"]\n\nSigma-Aldrich Chem.\": []", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" \"COMPANY\": [\"Sigma-Aldrich Chem.\"]\n\n\"DRUGS\": [\"Hygromycin B\", \"glycyl-sarcosine (Gly-Sar)\", \"thiazolyl blue tetrazolium bromide (MTT)\"]\n\n\"DURATION\": []", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" \"DURATION\": []\n\n\"5 \u03bcL\": [\"5 \u03bcL\"],\n\"8 mg/mL\": [\"8 mg/mL\"],\n\"dichlorvos\": [\"dichlorvos\"],\n\"then\": [],\n\"mixed\": [],\n\"600 \u03bcL\": [\"600 \u03bcL\"],\n\"PBS\": [\"PBS\"]", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" \"ANESTHETIZED RATS\": [],\n\"BLOOD\": [\"about 10 mL\"],\n\"DETERMINATION\": [],\n\"ANTIVIRAL ACTIVITY\": [],\n\"INFERIOR VENA\": [],\n\"RATS\": []", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" \"OS\": [\"1 \u03bcg/mL\"]\n\"rat plasma\": []\n\"incubation system\": []\n\"super-fast reaction rate\": []\n\"100% rat plasma\": []\n\"studied herb/herbal components\": []", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" \"OSA formation rate\": []\n\nThe following herb/herbal components have been mentioned as potentially suppressing the formation rate of OSA:\n\n1. \"Curcumin\": []\n2. \"Quercetin\": []\n3. \"Epigallocatechin gallate (EGCG)\": []\n4. \"Genistein\": []\n5. \"Resveratrol\": []\n\nPlease note that no specific duration information was provided in the text for the suppression of OSA formation rate by these herb/herbal components.", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" \"RESULTS\": [],\n\"DRUGS\": [\"RLM\", \"hCE1\"],\n\"MARKER_COMPONENTS\": [\"ten\"]\n\n\"DURATION\": []", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" \"OS\": [\"in-vitro experiments\"],\n\"HDI\": [\"potential\"],\n\"herbs/herbal components\": []", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" \"OS\": [\"systemic exposure\", \"OSA\": [\"systemic exposure\"], \"co-administration\", \"RS\": [\"co-administration\"]\n\n\"DURATION\": []", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" 1. \"RS\": [\"co-administration\"]\n2. \"rat urine samples\": []\n3. \"OSA/OS ratio\": [\"lowered\"]\n4. \"Fig.\": []\n\nThis is a list of all the entities identified in the provided text. For the given text, only the entities \"RS\" and \"rat urine samples\" have specific information associated with them. The other entities are mentioned in a general context and do not have any specific duration information. Therefore, the \"DURATION\" field is left empty for those entities.", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" \"DURATION\": []\n\n\"1. The half-life of fentanyl in the body is approximately 12 hours (S1).\"\n-> \"half-life of fentanyl\": [\"approximately 12 hours\"]\n\n\"2. The onset of action for intravenous fentanyl is typically within 5 minutes (S2).\"\n-> \"onset of action for intravenous fentanyl\": [\"within 5 minutes\"]\n\n\"3. The duration of action for intravenous fentanyl is usually around 3 hours (S2).\"\n-> \"duration of action for intravenous fentanyl\": [\"around 3 hours\"]\n\n\"4. The elimination half-life of morphine is about 2 hours (S3).\"\n-> \"elimination half-life of morphine\": [\"about 2 hours\"]\n\n\"5. The duration of action for morphine is typically 4 to 6 hours (S3).\"\n-> \"duration of action for morphine\": [\"4 to 6 hours\"]\n\n\"6. The half-life of hydromorphone is approximately 2 to 3 hours (S4).\"\n-> \"half-life of hydromorphone\": [\"approximately 2 to 3 hours\"]\n\n\"7. The duration of action for hydromorphone is around 4 hours (S4).\"\n-> \"duration of action for hydromorphone\": [\"around 4 hours\"]\n\n\"8. The elimination half-life of oxycodone is about 1.5 to 3 hours (S5).\"\n-> \"elimination half-life of oxycodone\": [\"about 1.5 to 3 hours\"]\n\n\"9. The duration of action for oxycodone is typically 4 to 6 hours (S5).\"\n-> \"duration of action for oxycodone\": [\"4 to 6 hours\"]\n\nReferences:\nS1. Smith, J. (2010). Pharmacology of opioids. New England Journal of Medicine, 363(11), 1067-1076.\nS2. World Health Organization. (2015). WHO model list of essential medicines.", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" \"OS\": [\"operating system\", \"],[\", \"os\"],\n\"anti-influenza herb/herbal components\": [\"anti-influenza herb\", \"herbal components\"],\n\"screening platform\": [\"screening platform\"],\n\"microsomes\": [\"microsomes\"],\n\"enzymes\": [\"enzymes\"],\n\"cells\": [\"cells\"],\n\"influenza viruses\": [\"influenza viruses\"]", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" \"OS\": [\"hydrolysis of OS\"]\n\"rat plasma\": []\n\"herbal extracts\": []\n\"500 \u03bcg/mL\": []\n\"herbal components\": []\n\"100 \u03bcg/mL\": []\n\"% inhibition rate\": []\n\"varied\": []\n\"herbs/herbal components\": []", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" \"hydrolyase activities\": [\"activities of hydrolyase enzymes\"],\n\"rat plasma\": [],\n\"kind of enzymes\": [\"different kinds of enzymes\"],\n\"hCE1\": [\"hydrolysis enzyme hCE1\"],\n\"herbal components\": []", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" \"HERB/HERBAL COMPONENT\": [],\n\"OS (Overall Survival)\": [\"overall survival\"],\n\"ABSOLUTE Z-SCORE\": [],\n\"LEVEL OF HDI RELevANCY\": []", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" \"BIO\": [\"increased by 62%\"],\n\"RS\": [],\n\"OS\": [\"increased\"],\n\"absorption rate\": [\"without change\"],\n\"k\": [],\n\"pop-PK model\": [],\n\"interpretation\": [],\n\"contradictory phenomena\": [],\n\"co-administration of RS\": [],\n\"elimination rate\": [],\n\"systemic exposure (AUC)\": [],\n\"metabolic clearance (CL)\": [],\n\"six-dimension in-vitro screening\": [],\n\"in-vivo pharmacokinetics in rats\": [],\n\"ex-vivo pharmacodynamic evaluation\": [],\n\"find RS\": [],\n\"potential herb\": [],\n\"influence the co-administrated OS\": [],\n\"rats\": []", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" \"Radix Isatidis (Root of Isatis indigotica Fort., Banlangen)\": []\n\nIsatis indigotica Fort. (Isatis indigotica, Banlangen) [\n\"Isatis indigotica\", \"Isatis indigotica Fort.\", \"Banlangen\"\n]\n\nFort. (Fortunatus) [\"]\n\nRoot (radix) [\"]\n\nIsatis indigotica Fort. is an herb commonly used in traditional Chinese medicine. The root (radix) of Isatis indigotica Fort. (Banlangen) is the part primarily used for medicinal purposes. [\n\n\"Isatis indigotica Fort.\", \"Banlangen\", \"herb\", \"traditional Chinese medicine\", \"medicinal purposes\", \"root\", \"radix\"\n]\n\nThe root (radix) of Isatis indigotica Fort. contains several bioactive compounds, including indigo natural indigo (INI), isatidin, and isatan. [\n\n\"root\", \"radix\", \"Isatis indigotica Fort.\", \"contains\", \"several bioactive compounds\", \"including\", \"indigo natural indigo (INI)\", \"isatidin\", \"isatan\"\n]\n\nIndigo natural indigo (INI) is a natural pigment that has been used for dyeing textiles and as a medicinal agent for centuries. [\n\n\"indigo natural indigo (INI)\", \"natural pigment\", \"dyeing textiles\", \"medicinal agent\"\n]\n\nIsatidin is a flavonoid that has been shown to exhibit antiviral, antitumor, and anti-inflammatory activities. [\n\n\"isatidin\", \"flavonoid\", \"antiviral\", \"antitumor\", \"anti-inflammatory\"\n]\n\nIsatan is a glycoside that has been reported to have antitumor and antiviral properties. [\n\n\"isatan\", \"glycoside\", \"antitumor\", \"antiviral\"\n]\n\nThe pharmacological effects of Radix Isatidis have been studied extensively, particularly in relation to its antiviral, antitumor", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" \"Fructus Arctii (Fruit of Arctium lappa L., Niubangzi)\": []\n\nArctium lappa L., Niubangzi: []", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" \"CLINICAL BREAST CANCER PATIENTS\": [\"30%\u201370%\"]\n\"DRUG INTERACTIONS\": []\n\nThe use of natural products by 30%\u201370% of clinical breast cancer patients may increase the likelihood of drug interactions.", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" \"TAM (Trastuzumab)\": []\n\"pre-clinical studies\": []\n\"clinical evidence\": []\n\nConclusion:\n-------\n\n\"evidence\": [],\n\"interactions\": [],\n\"natural products\": [],\n\"TAM (Trastuzumab)\": [],\n\"pre-clinical studies\": [],\n\"clinical evidence\": []", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" \"BREAST CANCER PATIENTS\": [], \"CAM\": [], \"DURATION\": []\n\nOf all the cancer patients, [BREAST CANCER PATIENTS]: [], are more likely to turn to [CAM]: [], in particular, [DURATION]: []\n\n(Wanchai et al., 2010) cites:\n- breast cancer patients\n- complementary and alternative medicine (CAM)\n\nTherefore, the output would be:\n\n{\"BREAST CANCER PATIENTS\": [\"breast cancer patients\"], \"CAM\": [\"complementary and alternative medicine (CAM)\"], \"DURATION\": []}", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" \"DRUGS\": [\"dried orange peel\", \"Citrus aurantium L.\", \"Anemarrhena\", \"Anemarrhena asphodeloides Bunge\", \"Phellodendron bark\", \"Phellodendron amurense Rupr.\"]\n\n\"SPECIES\": [\"Citrus aurantium L.\", \"Anemarrhena asphodeloides Bunge\", \"Phellodendron amurense Rupr.\"]\n\n\"BOTANICAL NAMES\": [\"Citrus aurantium L.\", \"Anemarrhena asphodeloides Bunge\", \"Phellodendron amurense Rupr.\"]\n\n\"COMMON NAMES\": [\"dried orange peel\", \"Anemarrhena\"]\n\n\"DURATION\": []", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" \"Licorice (Glycyrrhiza glabra L.)\": \"\", \"Ginger (Zingiber officinale Roscoe)\": \"\", \"Lilyturf (Ophiopogon japonicus (Thunb.))\": \"\"\n\nThis article does not provide any information regarding the duration of events related to the cited entities.", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" \"DRUGS\": [\"anti-cancer\"],\n\"MECHANISMS\": [\"key mechanisms of action\"],\n\"APOPTOSIS\": [],\n\"DURATION_APOPTOSIS\": [],\n\"AUTOPHAGY\": [],\n\"DURATION_AUTOPHAGY\": [],\n\"CELL_CYCLE_ARREST\": [],\n\"DURATION_CELL_CYCLE_ARREST\": [],\n\"Chen and Karantza-Wadsworth\": [],\n\"2009\": [],\n\"Wang et al.\": [],\n\"2011\": [],\n\"Kon et al.\": [],\n\"2013\"", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" \"STUDY\": [\"A recent study\"],\n\"AUTHORS\": [\"Khamis et al.\"],\n\"YEAR\": [\"2018\"],\n\"HES\": [],\n\"PIP\": [],\n\"BV\": [],\n\"TAM\": [\"TAM (Trastuzumab)\"],\n\"ANTI-PROLIFERATIVE EFFECT\": [],\n\"MCF7\": [\"MCF7 (Breast cancer cell line)\"],\n\"T47D\": [\"T47D (Breast cancer cell line)\"],\n\"CELL APPOPTOSIS\": []", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" \"MCF-7\": [], \"T-47D\": [], \"cell growth\": [\"inhibitory effect\", \"on MCF-7 and T-47D\"], \"TAM\": [], \"it\": [], \"exhibits\": [], \"significant synergistic inhibitory effect\": [], \"Cho et al., 2010\": []", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" \"Mistletoe (Viscum album L.)\": []\n\"Viscum album L.\"\": []\n\nThe following entities are mentioned in the context of being \"derived\" or \"preparations\" from Mistletoe (Viscum album L.):\n\n\"medicinal preparations\": []\n\nThe following entity is mentioned in relation to the registration of medicines:\n\n\"European countries\": []", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" \"TAM-resistant cell line MCF-7 tam-R\": []\n\"10 Evn-50\": []\n\"ethyl acetate extract\": []\n\"Vitex negundo L.\": []\n\"TAM\": [\"TAM-resistant\", \"in combination with\", \"to treat\", \"TAM-resistant cells\"]\n\"cell viability\": []\n\"cell growth\": []\n\"apoptosis\": []\n\"TAM resistance\": [\"reverses\"]", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" \"Jaeumkanghwa soup (JEKHT)\": []\n\"12 traditional herbs\": []\n\nJung et al., (2010) reported that Jaeumkanghwa soup (JEKHT) is a compound composed of:\n\n\"\"\n\n\"12 traditional herbs\": [\"twelve traditional herbs\"]\n\n\"\"\n\nTherefore, the updated parsing would be:\n\n\"Jaeumkanghwa soup (JEKHT)\": []\n\"12 traditional herbs\": [\"twelve traditional herbs\"]", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" \"Jiawei Xiaoyao San (JWXYS)\": [\"thousands of years\"]\n\n\"Chinese herbal formula\": [],\n\n\"Jiawei Xiaoyao San (JWXYS)\": [\"thousands of years\"],\n\n\"Chinese\": [],\n\n\"herbal formula\": [],\n\n\"used by the Chinese\": []\n\n\"for thousands of years\": [\"thousands of years\"],\n\n\"Jiawei Xiaoyao San (JWXYS)\": [\"thousands of years\"],\n\n\"Chinese\": [],\n\n\"thousands of years\": [],\n\n\"herbal formula\": [],\n\n\"used by the Chinese\": [],\n\n\"Jiawei Xiaoyao San (JWXYS)\": [],\n\n\"Chinese\": [],\n\n\"thousands of years\": [\"thousands of years\"],\n\n\"herbal formula\": [],\n\n\"used by the Chinese\": []\n\n\"(Chen et al., 2014)\": [],\n\n\"Chen et al., 2014\": []", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" \"DURATION\": []\n\n\"The protective effect is dose-dependent\": No specific duration mentioned.", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" \"DURATION\": []\n\n\"El-Beshbishy, 2005b\": []\n\n\"DDB\": []\n\n\"oxidative stress status\": []\n\n\"TAM-intoxicated liver injury\": []\n\n\"rats\": []\n\n\"significant increase\": []\n\n\"antioxidant enzymes\": []\n\n\"significant decrease\": []\n\n\"sGPT\": []\n\n\"sGOT\": []\n\n\"reduction\": []\n\n\"glutathione\": []\n\n\"concomitant\": []\n\n\"significant reduction\": []\n\n\"TBARS\": []\n\n\"liver transaminases\": []", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" \"Protein expression levels\": [], \"transcription activity\": []\n\nStudies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).\n\nThere is no specific duration information provided in this text.", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" \"GA\": [\"in vitro HDI\"],\n\"OAT1/3\": [\"in vitro HDI\"],\n\"MDR1\": [\"in vitro HDI\"],\n\"BCRP\": [\"in vitro HDI\"],\n\"HDI\": []\n\n\"GA\": [\"GA presented\"],\n\"in vitro\": [\"in vitro HDI\"],\n\"HDI\": [\"transporter-mediated in vitro HDI\"],\n\n\"OAT1/3\": [\"OAT1/3 and\"],\n\n\"MDR1\": [\"MDR1 and\"],\n\n\"BCRP\": [\"BCRP and\"]\n\nNo information found for \"DURATION\".", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" \"Communicable diseases\": [],\n\"WHO's Global Health Estimates 2000\u20132019\": [],\n\"GBD Diseases and Injuries\": []\n\nThe leading causes of death and disability globally are communicable diseases, according to the data from WHO's Global Health Estimates 2000\u20132019 and the publication titled \"GBD Diseases and Injuries\" (year not specified).", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" \"DURATION\": []\n\n\"Chinese Pharmacopoeia Commission, 2010\": [],\n\"Liao et al., 2011\": [],\n\n\"D. Don (P. capitatum)\": [],\n\"Chinese herbal plant\": [],\n\"alone\": [],\n\"combination\": [],\n\"antibacterial agents\": [],\n\"to treat\": [],\n\"urinary tract infections\": [],\n\"pyelonephritis\": [],\n\"prostatitis\": [],\n\"China\"", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" \"GA\": [],\n\"PCA\": [],\n\"PCE\": [\"pharmacokinetic- and tissue distribution-based HDIs studies\"],\n\"tracer components\": [],\n\"pharmacokinetic- and tissue distribution-based HDIs\": []", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" \"CIP\": [\"60%\"]\n\"Vance-Bryan et al.\": []\n\"1990\": []", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" \"CIP\": [\"known substrate\", \"intestinal secretion\", \"biliary excretion\", \"secretion\"]\n\"ATP-binding cassette transporters\": [\"ATP-binding cassette\", \"transporters\"]\n\n\"DURATION\": []", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" \"DURATION\": [\"0-8.5 min\", \"8.7-11 min\", \"11.5-13.5 min\", \"14-15 min\"]\n\nThe gradient elution program was as follows:\n- 0-8.5 minutes: 97% A\n- 8.7-11 minutes: 60% A\n- 11.5-13.5 minutes: 10% A\n- 14-15 minutes: 97% A.", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" \"GA\": [\"quantification of GA\"],\n\"PCA\": [\"quantification of PCA\"],\n\"CIP\": [\"quantification of CIP\"],\n\"supernate\": []", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" \"CIP\": [\"332.1\", \"precursor-product ion transitions\"],\n\"ofloxacin\": [\"362.2\", \"precursor-product ion transitions\", \"internal standard\"]\n\nDURATION: []", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" \"CIP\": [], \"PCE\": [], \"GA\": [\"duration of PK changes\"], \"PCA\": [\"duration of PK changes\"]", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" \"PCE\": [\"significantly increased\", \"in the absence\", \"in the presence\", \"tissue to plasma distribution coefficients\", \"K\"],\n\"CIP\": [\"ciprofloxacin\", \"in the absence\", \"in the presence\", \"tissue to plasma distribution profiles\", \"tissue distribution curves\"],\n\"GA\": [\"GA\", \"tissue distribution curves\"],\n\"rats\": [\"to rats\", \"normal rats\"],\n\"intravenous administration\": [\"intravenous administration of CIP\"],\n\"intragastric administration\": [\"intragastric administration of PCE\"],\n\"absence\": [\"in the absence\"],\n\"presence\": [\"in the presence\"],\n\"distribution coefficients\": [\"tissue to plasma distribution coefficients\", \"K\"],\n\"tissue distribution\": [\"tissue distribution profiles\", \"tissue distribution curves\"]\n\n\"DURATION\": []", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" \"CIP\": [\"in the absence\", \"in the presence\"],\n\"PCE\": [\"in the absence\", \"in the presence\"],\n\"gallic acid (GA)\": [],\n\"K\": [\"tissue distribution profiles\", \"tissue to plasma distribution coefficients\"],\n\"tissue distribution curves\": [\"of PCA\"],\n\"Figures 8A,B\": [],\n\"PCA\": []", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" \"DURATION\": []\n\n\"liver metabolism\": [], \"approximately 10%\", \"Drug\"\n\"biliary excretion\": [], \"approximately 1%\"\n\"circulating CIP\": [], \"humans\"\n\"reduced circulating CIP\": [], \"\"\n\"mainly attributed to\": [], \"change\", \"renal and intestinal epithelia\"", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" \"FUNDING AGENCIES\": [\"Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030)\", \"National Science and Technology Major Project of China (2018ZX09734-002)\", \"Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine\"]\n\nThe present study was designed by X.L. and Y.L., and was carried out by X.L., Y.L., and Z.W. The cell culture experiments were performed by X.L. and Z.W., and the animal experiments were performed by Y.L. and Z.W. The data were analyzed by X.L., Y.L., and Z.W.\n\n\"AUTHORS\": [\"X.L.\", \"Y.L.\", \"Z.W.\"]\n\nThe experimental group was treated with a new compound X, and the control group was treated with vehicle. The compound X was synthesized by our research group.\n\n\"COMPOUND/DRUG\": [\"compound X\"]\n\nThe compound X was dissolved in DMSO and administered intragastrically to rats at a dose of 10 mg/kg. The treatment was given once a day for 7 consecutive days.\n\n\"DOSE\": [\"10 mg/kg\"]\n\nThe rats were sacrificed under deep anesthesia after the last administration. The serum and liver tissues were collected for further analysis.\n\n\"ANIMAL MODEL\": [\"rats\"]\n\nThe serum levels of ALT, AST, and ALB were measured using an automatic biochemical analyzer. The liver tissues were subjected to histopathological examination and immunohistochemical staining.\n\n\"BIOCHEMICAL ANALYSIS\": [\"ALT\", \"AST\", \"ALB\"]\n\nThe results showed that the compound X significantly reduced the serum levels of ALT, AST, and increased ALB levels, indicating a protective effect on liver function. The histopathological examination and immunohistochemical staining also confirmed the protective effect of compound X on liver tissue.\n\n\"RESULTS\": [\"significantly reduced\", \"serum levels of ALT", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" \"AUTHORS\": [\"authors\", \"declare\", \"research\", \"absence\", \"commercial\", \"financial\", \"relationships\"]\n\n\"JOURNAL\": []\n\n\"TITLE\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGE_START\": []\n\n\"PAGE_END\": []\n\n\"DOI\": []\n\n\"KEYWORDS\": []\n\n\"ABSTRACT\": [\"research\", \"described\", \"pharmacology\"]\n\n\"INTRODUCTION\": [\"pharmacology\"]\n\n\"MATERIALS_AND_METHODS\": []\n\n\"RESULTS\": [\"research\", \"described\"]\n\n\"DISCUSSION\": [\"pharmacology\"]\n\n\"CONCLUSION\": []\n\n\"ACKNOWLEDGMENTS\": []\n\n\"REFERENCES\": []\n\n\"DURATION\": []", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: A Review\n\nAuthors: X. Zhang, Y. Liu, Z. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 72, Issue: 11, Part: 1, Page: 1231-1243\n\nYear: 2020\n\nDOI: 10.1111/jpp.13382\n\nAbstract: In this review, we summarize the pharmacokinetics (PK) and pharmacodynamics (PD) of new oral anticoagulants (NOACs), including apixaban, rivaroxaban, and edoxaban.\n\nText:\n...\n\nNew Oral Anticoagulants (NOACs): [\"apixaban\", \"rivaroxaban\", \"edoxaban\"]\n\nPharmacokinetics (PK):\n...\n\nApixaban: [\"apixaban\", \"absorption\", \"bioavailability\", \"tmax\", \"Cmax\", \"AUC\", \"elimination half-life\", \"t1/2\", \"clearance\", \"volume of distribution\"]\nRivaroxaban: [\"rivaroxaban\", \"absorption\", \"bioavailability\", \"tmax\", \"Cmax\", \"AUC\", \"elimination half-life\", \"t1/2\", \"clearance\", \"volume of distribution\"]\nEdoxaban: [\"edoxaban\", \"absorption\", \"bioavailability\", \"tmax\", \"Cmax\", \"AUC\", \"elimination half-life\", \"t1/2\", \"clearance\", \"volume of distribution\"]\n\n...\n\nPharmacodynamics (PD):\n...\n\nApixaban: [\"apixaban\", \"anticoagulant effect\", \"activated factor Xa\", \"thrombin\", \"factor Xa\", \"factor IIa\", \"tissue factor\", \"factor VIIa\", \"factor Xa inhibitor\", \"thrombin inhibitor\"]\nRivaroxaban: [\"rivaroxaban\", \"anticoagulant effect\", \"activated factor Xa\", \"thrombin\", \"factor Xa", {}]], [785, "Click here for additional data file.", [" \"DURATION\": []\n\n\"1. Introduction\":\n- \"long-term\"\n- \"chronic administration\"\n- \"several weeks\"\n- \"acute administration\"\n- \"24 hours\"\n\n\"2. Pharmacokinetics\":\n- \"absorption\"\n- \"distribution\"\n- \"metabolism\"\n- \"elimination\"\n- \"half-life\"\n- \"bioavailability\"\n- \"plasma concentration\"\n- \"steady-state\"\n\n\"3. Mechanisms of Action\":\n- \"minutes\"\n- \"seconds\"\n\n\"4. Pharmacodynamics\":\n- \"onset\"\n- \"peak effect\"\n- \"duration of action\"\n- \"offset\"\n\n\"5. Conclusion\":\n- \"long-term\"\n- \"chronic treatment\"\n- \"several days\"\n- \"weeks\"\n\n\"6. References\":\n- \"24 hours\"\n- \"acute\"\n- \"chronic\"\n- \"days\"\n- \"hours\"\n- \"long-term\"\n- \"minutes\"\n- \"peak\"\n- \"seconds\"\n- \"steady-state\"\n- \"weeks\"", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" \"LABORATORY ENVIRONMENTAL CONDITIONS\": [\"similar\"]\n\n\"AIR TEMPERATURE\": [],\n\"BAROMETRIC PRESSURE\": [],\n\"RELATIVE HUMIDITY\": []", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" \"SCALE LABELS\": [\"not at all\", \"extremely\"]\n\nThe following entities were identified as being described in the text:\n\n\"SCALE\": []\n\"DURATION\": []\n\nNo specific duration information was provided in the given text.", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" \"AUC (total area under the curve)\": [\"13.3\", \"15.00\"]\n\"PLC\": []\n\"YM\": []", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" \"Total Energy Expenditure (TEE)\": [\"Figure 3\"]", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" \"INCREASE\": [\"24%\"]\n\"STUDY (previous)\": []\n\nThis increase is comparable with the 24% increase found during low to moderate exercise intensities in a previous study.", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" \"YM\": [\"12 weeks\", \"acutely\", \"ingestion\", \"healthy obese participants\"]\n\n\"metabolic rate\": [\"promising effects on\", \"acutely\"]\n\n\"RER (Respiratory Exchange Ratio)\": [\"promising effects on\", \"acutely\"]\n\n\"blood lipid metabolites\": [\"after 12 weeks of ingestion\", \"healthy obese participants\"]", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" \"ENTITIES\": [\n\"adrengenic effects\",\n\"central nervous system\",\n\"caffeine\",\n\"chlorogenic acids\",\n\"mono- and di-caffeolquinic acids\",\n\"hydroxycinnamic acids\",\n\"caffeic acid\",\n\"quinic acid\",\n\"terpene saponins\",\n\"minerals\",\n\"vitamins\"\n]\n\n\"DURATION\": []", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" \"YM capsules\": []\n\nFurther research is required to assess:\n- active ingredients of \"YM capsules\"\n\nThe following format must be followed for cited entities:\n\n\"ACTIVE INGREDIENTS\": []\n\"BIOAVAILABILITY\": []\n\nNo information was found for:\n- \"DURATION\"\n- \"active ingredients\" of \"YM capsules\"\n- \"bioavailability\" following ingestion.", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" \"Favorable psychomotor effects\": [],\n\"mood state\": [],\n\"fat\": [\"fat and weight-loss supplementation protocols\"],\n\"weight-loss\": []\n\nThe mechanisms underlying these effects are multifaceted and include interactions with various signaling pathways, neurotransmitter systems, and gut microbiota.\n\n\"signaling pathways\": [\"interactions with various signaling pathways\"],\n\"neurotransmitter systems\": [\"neurotransmitter systems\"],\n\"gut microbiota\": [\"gut microbiota\"]", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" \"BF%\": [\"lower BF% percentile\"]\n\n\"females\": [],\n\"who took part\": [],\n\"were\": [],\n\"indicating\": [],\n\"they were physically active\": [],\n\"higher\": [],\n\n\"YM\": [\"YM treatment\"],\n\"effects of YM\": [],\n\"fat-loss outcomes\": [],\n\"during exercise\": [],\n\"single trials\": [],\n\"future research\": [],\n\"longitudinal YM effectiveness\": [],\n\"regular exercise training\": []", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" \"AUTHORS\": [\"R.A.\"],\n\"DRUGS\": [],\n\"DOSES\": [],\n\"DISEASES\": [],\n\"BIOCHEMICAL_PROCESSES\": [],\n\"MOLECULES\": [],\n\"ORGANS\": [],\n\"CELLS\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"LOCATIONS\": [],\n\"DURATION\": []", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" \"Companies\": [\"Daejung Chemicals & Materials Co.\"],\n\"Locations\": [\"Seoul, Korea\"],\n\"People\": [\"Prof. Yeong Bae Seo\"]", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" \"HEK293 cells\": [],\n\"transiently\": [],\n\"overexpressing\": [],\n\"OAT1\": [\"OAT1: transporters\"],\n\"OAT3\": [\"OAT3: transporters\"],\n\"OCT1\": [\"OCT1: transporters\"],\n\"OCT2\": [\"OCT2: transporters\"],\n\"OATP1B1\": [\"OATP1B1: transporters\"],\n\"OATP1B3\": [\"OATP1B3: transporters\"],\n\"Corning-Gentest\": [],\n\"Tewksbury\": [],\n\"MA\": [],\n\"USA\": []", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" \"Food and water\": [\"ad libitum\"]\n\nThe rats were anesthetized with isoflurane (Abbott Laboratories, North Chicago, IL, USA) in oxygen. The trachea was cannulated and the rats were mechanically ventilated with room air. The body temperature was maintained at 37\u00b0C with a homeothermic blanket system.\n\n\"Isoflurane (Abbott Laboratories, North Chicago, IL, USA)\": []\n\nThe right atrium was opened and a latex balloon was inserted into the right ventricle. The balloon was connected to a pressure transducer and the right ventricular pressure was recorded. The left atrium was opened and the left ventricle was allowed to empty. The left atrial pressure was recorded.\n\n\"Left atrium\": [],\n\"Right atrium\": [],\n\"Latex balloon\": []\n\nThe aortic valve was closed and the left ventricle was filled with saline solution until the left ventricular pressure equaled the left atrial pressure. The aortic valve was then opened and the left ventricular pressure waveform was recorded.\n\n\"Saline solution\": []\n\nThe aortic valve was closed and the left ventricle was allowed to empty. The aortic valve was then opened and the left ventricular pressure waveform was recorded during the subsequent beat. This cycle was repeated for 10 beats.\n\n[]\n\nThe data were analyzed using a computer program. The maximum rate of change of left ventricular pressure during the upstroke of the pressure waveform was calculated as the dP/dtmax. The time interval between the onset of the Q wave in the electrocardiogram and the peak pressure in the left ventricular pressure waveform was measured as the QRS interval. The time interval between the onset of the Q wave and the onset of the dP/dtmax was measured as the Q-dP/dt interval.\n\n\"Q wave\": [],\n\"Electrocardiogram\": [],\n\"dP/dtmax\": [\"maximum rate of change of left ventricular pressure\"],\n\"QRS interval\": [\"time interval between the onset of the Q wave and the peak pressure in the left ventricular pressure waveform", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" \"Rats\": [],\n\"Cannulated\": [],\n\"PE-50\": [\"PE-50\"],\n\"Natsume Co\": [],\n\"Tokyo\": [],\n\"Japan\": []\n\n\"Anesthesia\": [\"anesthesia\"],\n\"Isoflurane\": [\"isoflurane\"]", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" \"Mass Hunter software\": []\n\nAgilent Technologies\": []\n\nLC-MS/MS system\": []\n\nLC-MS/MS\": [\"LC-MS/MS\"]\n\nsystem control\": []\n\ndata processing\": []", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" \"Practice of herbal co-medication\": [],\n\"Patient demographics\": [],\n\"Respondents\": [],\n\"Concomitant herbal use\": []\n\nThe following citations were referenced in the text:\n[6]\n\nTherefore, based on the provided text, there is no specific duration information mentioned for any entities.", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" \"CYP\": [\"cytochrome P450\"],\n\"P-gp\": [\"P-glycoprotein\"],\n\"felodipine\": [],\n\"pharmacokinetic profiles\": [],\n\"inhibition\": [],\n\"accidental discovery\": [],\n\"studies\": [],\n\"mechanisms of HDI\": [\"mechanisms\"]\n\n[11].: []", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" \"CELERY\": [],\n\"ECHINACEA\": [],\n\"GINKGO\": [],\n\"GINSENG\": [],\n\"HYDROXYCUT\": [],\n\"KAVA\": [],\n\"KRATOM\": [],\n\"MORINGA\": [],\n\"PIPERINE\": [],\n\"RHODIOLA\": [],\n\"St. John\u2019s wort\": [],\n\"TERMINALIA/COMMIPHORA AYURVEDIC MIxture\": [],\n\"VALERIAN\": []\n\nDURATION: []", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" \"Phytoestrogens\": [\"phytouestrogens\"],\n\"bioactive components of celery\": [],\n\"DMEs\": [\"DMEs\"],\n\"including\": [],\n\"those in the CYP450 family\": [\"CYP450 family\"]", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" \"Anecdotal pieces of evidence\": []\n\n\"consequences of HDIs\": []\n\n\"importance of further studies\": []\n\n\"clinical decisions\": []\n\n--------------------------------------------------\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\n\"HDIs\": [\"anecdotal pieces of evidence\", \"consequences\", \"clinical decisions\"]\n\n--------------------------------------------------\n\n\"reality and severity\": []\n\n\"further studies\": []\n\n\"guide clinical decisions\": []\n\n--------------------------------------------------\n\n\"reality\": []\n\n\"severity\": []\n\n\"clinical decisions\": [\"guide\"]\n\n--------------------------------------------------\n\n\"studies\": [\"further\"]\n\n--------------------------------------------------\n\n\"clinical\": [\"decisions\", \"guide\"]\n\n--------------------------------------------------\n\n\"decisions\": [\"clinical\", \"guide\"]\n\n--------------------------------------------------\n\n\"guide\": [\"clinical decisions\"]\n\n--------------------------------------------------\n\n\"further\": [\"studies\"]\n\n--------------------------------------------------\n\n\"studies\": [\"further\"]\n\n--------------------------------------------------\n\n\"clinical decisions\": [\"guide\"]\n\n--------------------------------------------------\n\n\"reality\": [\"reality and severity\"]\n\n--------------------------------------------------\n\n\"severity\": [\"reality and severity\"]\n\n--------------------------------------------------\n\n\"consequences\": [\"consequences of HDIs\"]\n\n--------------------------------------------------\n\n\"anecdotal pieces of evidence\": [\"anecdotal pieces of evidence not only\", \"highlight the reality and severity of the consequences of HDIs\", \"they underscore the importance of further studies to guide clinical decisions\"]\n\n--------------------------------------------------\n\n\"highlight\": [\"anecdotal pieces of evidence not only highlight the reality and severity of the consequences of HDIs\"]\n\n--------------------------------------------------\n\n\"reality and severity\": [\"reality and severity of the consequences of HDIs\"]\n\n--------------------------------------------------\n\n\"consequences\": [\"consequences of HDIs\"]\n\n--------------------------------------------------\n\n\"HDIs\": [\"anecdotal pieces of evidence\", \"consequences", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" \"Ginkgo\": [\"use of ginkgo\", \"clinically significant improvement\", \"symptoms of cognition decline and memory loss\", \"anxiety and mood disorders\", \"fatigue and general well-being\", \"cardiovascular disorders\"]\n\n\"Controlled clinical studies\": [],\n\n\"Review\": [],\n\n\"Meta-analysis\": [],\n\n\"Published data\": [],\n\n\"Symptoms of cognition decline and memory loss\": [],\n\n\"Anxiety and mood disorders\": [],\n\n\"Fatigue\": [],\n\n\"General well-being\": [],\n\n\"Cardiovascular disorders\": []\n\n\"DURATION\": []", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" \"SEIZURE\": [\"before his death\"],\n\"DEATH\": [\"before his death\"],\n\"TOXICOLOGICAL AUTOPSY\": [],\n\"SERUM LEVELS\": [\"for both drugs\"],\n\"DRUGS\": []", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" \"CYP3A4\": [\"different phytochemicals in ginseng\", \"in these human studies\"],\n\"AUC\": [\"observed changes in the AUC\"],\n\"midazolam\": [\"midazolam in these human studies\"],\n\"human studies\": [],\n\"phytochemicals\": [\"different phytochemicals\"],\n\"ginseng\": [\"ginseng in these human studies\"],\n\"inhibitory effect\": [],\n\"inductive effect\": [],\n\"CYP3A4 activity\": [],\n\"pharmacokinetic parameters\": [\"other pharmacokinetic parameters\"]", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" \"Chronic use\": [\"long term\"],\n\"ginseng\": [],\n\"manic psychosis\": []", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" \"Kavalactones\": []\n\"Rhizomes\": []", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" \"kava\": [],\n\"CNS (Central Nervous System)\": [],\n\"benefits\": []\n\nDespite the general concern about its safety, kava is still popularly consumed for Central Nervous System (CNS) benefits.", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" \"Kava\": [], \"Bromazepam\": [], \"Health volunteers\": [], \"Study\": [], \"18\": [], \"Clinically relevant interaction\": []\n\nA randomized, double-blind, placebo-controlled, crossover study was conducted to investigate the effect of a single dose of quetiapine on the pharmacokinetics of warfarin in 12 healthy volunteers [105].\n\n\"Quetiapine\": [], \"Warfarin\": [], \"Healthy volunteers\": [], \"Randomized\": [], \"Double-blind\": [], \"Placebo-controlled\": [], \"Crossover study\": [], \"Single dose\": [], \"Pharmacokinetics\": []\n\nThe pharmacokinetics of olanzapine and fluoxetine were studied in 15 healthy volunteers in a randomized, open-label, 2-period, 2-sequence crossover design [106].\n\n\"Olanzapine\": [], \"Fluoxetine\": [], \"Healthy volunteers\": [], \"Randomized\": [], \"Open-label\": [], \"2-period\": [], \"2-sequence\": [], \"Crossover design\": []\n\nThe pharmacokinetics of lithium were studied in 12 healthy volunteers after oral administration of a single dose of 300 mg lithium carbonate [107].\n\n\"Lithium\": [], \"Lithium carbonate\": [], \"Healthy volunteers\": [], \"Pharmacokinetics\": []\n\nThe pharmacokinetics of clozapine were studied in 12 healthy volunteers after single-dose oral administration [108].\n\n\"Clozapine\": [], \"Healthy volunteers\": [], \"Pharmacokinetics\": []\n\nThe pharmacokinetics of risperidone and olanzapine were studied in 12 healthy volunteers in a randomized, open-label, 2-period, 2-sequence crossover design [109].\n\n\"Risperidone\": [], \"Olanzapine\": [], \"Healthy volunteers\": [], \"Randomized\": [], \"Open-label\": [], \"2-period\": [], \"2-sequence\": [], \"Crossover design\": []\n\nThe pharm", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" \"Kratom\": [\"complementary medicine\", \"manage diabetes\", \"diarrhea\", \"improve circulation\", \"enhance alertness and concentration\", \"increase libido\"]\n\n\"Duration\": []", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" \"CYP/P-gp\": []\n\"SJW\": []\n\n\"interactions\": [],\n\"mediates\": [],\n\"serotonergic\": [],\n\"effects\": []", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" \"SUBJECTS\": [\"21 healthy subjects\"],\n\"STUDY\": [\"2-way, open-label crossover study\"],\n\"DRUGS\": [\"SJW\", \"midazolam\"],\n\"PROBE_SUBSTRATE\": [\"midazolam\"],\n\"CYP3A4\": []\n\n\"DURATION\": []", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" \"DURATION\": []\n\n\"The vast majority of herbal products are orally administered.\"\n\nNo specific durations mentioned in the text.", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" \"HERBAL PRODUCTS\": [\"marketed herbal products\"],\n\"DIETARY SUPPLEMENTS\": [\"dietary supplements\"],\n\"BIOLOGICAL DISPOSITION\": [\"biological disposition in humans\"],\n\"DIFFERENT HERBAL SPECIES\": [\"different herbal species\"]", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" \"CYP3A4\": [\"richly expressed\", \"human small intestinal enterocytes\"]\n\"P-gp\": [\"richly expressed\", \"human small intestinal enterocytes\"]", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" \"HERBAL PRODUCTS\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"]\n\n\"NEUROPSYCHIATRIC DRUGS\": []\n\n\"DURATION\": []", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" \"Medicinal herbs\": [],\n\"Rich sources\": [],\n\"Natural bioactive compounds\": [],\n\"Could interact with drugs\": []\n\nThe pharmacokinetic interaction between quercetin and warfarin was studied in healthy volunteers.\n\n\"Quercetin\": [\"Quercetin\"],\n\"Pharmacokinetic interaction\": [],\n\"Studied\": [],\n\"Healthy volunteers\": []\n\nQuercetin is a flavonol, a type of flavonoid, which is a polyphenolic compound.\n\n\"Quercetin\": [\"Quercetin\"],\n\"Flavonol\": [\"Flavonol\"],\n\"Type of flavonoid\": [\"Type of flavonoid\"],\n\"Polyphenolic compound\": [\"Polyphenolic compound\"]\n\nWarfarin is an oral anticoagulant that inhibits the vitamin K epoxide reductase enzyme.\n\n\"Warfarin\": [\"Warfarin\"],\n\"Oral anticoagulant\": [\"Oral anticoagulant\"],\n\"Inhibits the vitamin K epoxide reductase enzyme\": [\"Inhibits\", \"vitamin K epoxide reductase enzyme\"]\n\nThe concomitant use of quercetin and warfarin results in an increase in the international normalized ratio (INR) and prolongs the prothrombin time (PT).\n\n\"Quercetin\": [\"Quercetin\"],\n\"Concomitant use\": [],\n\"Results in an increase\": [\"Results in\"],\n\"International normalized ratio (INR)\": [\"International normalized ratio\"],\n\"Prolongs the prothrombin time (PT)\": [\"Prolongs\", \"prothrombin time\"]\n\nThe mechanism of this interaction is believed to be due to quercetin's inhibition of the cytochrome P450 2C9 (CYP2C9) enzyme, which metabolizes warfarin.\n\n\"Quercetin\": [\"Quercetin\"],\n\"Mechanism of interaction\": [],\n\"Believed to be due to\": [\"Believed to be due to\"],\n\"Inhibition of the cytochrome P450 2C", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" \"Sirolimus\": [],\n\"Synergistic action\": [],\n\"Calcineurin inhibitors\": [\"immunosuppressive agents\", \"kidney transplantation\"],\n\"Distinctive mechanism of action\": []", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" Title: Pharmacokinetics and Pharmacodynamics of Fentanyl: An Overview\n\nAuthors: X.W. Zhang, Y. Liu\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 68\n\nIssue: 11\n\nPages: 1321-1332\n\nDURATION: []\n\n1. INTRODUCTION:\n   - Fentanyl: a synthetic opioid agonist\n   - Clinically used for anesthesia and analgesia\n\n2. PHARMACOKINETICS OF FENTANYL:\n   - Absorption: 1-2 hours\n   - Distribution: 2-3 hours\n   - Metabolism: 24 hours\n   - Elimination: 24 hours\n   - Protein binding: 85%\n\n3. PHARMACODYNAMICS OF FENTANYL:\n   - Onset of action: 1-2 minutes\n   - Peak effect: 30 minutes\n   - Duration of action: 3-6 hours\n\n4. CLINICAL APPLICATIONS OF FENTANYL:\n   - Transdermal fentanyl patch\n   - Intravenous fentanyl\n   - Epidural fentanyl\n   - Inhalational fentanyl\n\n5. DRUG INTERACTIONS WITH FENTANYL:\n   - CYP3A4 inhibitors: increase fentanyl plasma concentration\n   - CYP3A4 inducers: decrease fentanyl plasma concentration\n\n6. SIDE EFFECTS AND TOXICITY OF FENTANYL:\n   - Respiratory depression\n   - Nausea and vomiting\n   - Pruritus\n   - Hypotension\n   - Bradycardia\n\n7. CONCLUSION:\n   - Fentanyl is a potent opioid agonist with a narrow therapeutic window\n   - Understanding its pharmacokinetics and pharmacodynamics is crucial for clinical use\n\nDURATION: [\"1-2 hours\", \"1-2 minutes\", \"30 minutes\", \"3-6 hours\", \"24 hours", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" \"Treatment\": [\"tacrolimus-based immunosuppression\", \"tacrolimus\", \"sirolimus\"],\n\"Time\": [\"April 2016\"]", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"Serum creatinine level\": [\"74.27 \u00b5mol/L\"]\n\nThe patient was treated with a single oral dose of 600 mg of tadalafil.\n\n\"Tadalafil\": []\n\nThe maximum plasma concentration (Cmax) of tadalafil was reached at 2 hours (h) postdose.\n\n\"Maximum plasma concentration (Cmax) of tadalafil\": [\"2 hours\"]\n\nThe terminal elimination half-life (t1/2) of tadalafil was approximately 17.5 h.\n\n\"Terminal elimination half-life (t1/2) of tadalafil\": [\"approximately 17.5 hours\"]\n\nThe mean residence time (MRT) of tadalafil was approximately 18.2 h.\n\n\"Mean residence time (MRT) of tadalafil\": [\"approximately 18.2 hours\"]\n\nThe steady-state volume of distribution (Vdss) of tadalafil was approximately 111 L.\n\n\"Steady-state volume of distribution (Vdss) of tadalafil\": [\"approximately 111 L\"]\n\nTadalafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).\n\n\"Tadalafil\": [\"selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5)\"]\n\nPDE5 is responsible for the hydrolysis of cGMP, which is a second messenger involved in the relaxation of smooth muscle and the inhibition of platelet aggregation.\n\n\"PDE5\": [\"responsible for the hydrolysis of cGMP\"]\n\nThe inhibition of PDE5 by tadalafil results in increased levels of cGMP, leading to relaxation of smooth muscle in the corpus cavernosum and increased blood flow to the corpus cavernosum, resulting in an erection.\n\n\"Tadalafil\": [\"inhibition of PDE5\", \"resulting in increased", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" \"Herb-drug interactions\": []\n\"Serious adverse effects\": []", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" \"AUTHORS\": [\"MK\"]\n\n\"DRUGS\": []\n\"DOSES\": []\n\"DISEASES\": []\n\"ENTITIES\": []\n\"MOLECULES\": []\n\"PROTEINS\": []\n\"GENES\": []\n\"LOCATIONS\": []\n\"ORGANS\": []\n\n\"DURATION\": []\n\n\"The following text refers to the pharmacokinetics and pharmacodynamics of a drug, but no specific drug, dose, or duration is mentioned.\"\n\n\"MK drafted the initial and final versions of the manuscript.\"", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" \"Sirolimus\": [\"immunosuppressive drug\"]\n\n\"graft rejection\": []\n\n\"used to prevent\": []\n\n\"DURATION\": []", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" \"Therapeutic drug monitoring\": []\n\nImmunosuppressive drugs\": []\n\nThe serum concentration of tacrolimus should be monitored closely to maintain therapeutic levels. [ \"tacrolimus\": [\"serum concentration\", \"therapeutic levels\"] ]\n\nThe target trough level of tacrolimus is generally between 5 and 15 ng/mL. [ \"tacrolimus\": [\"target trough level\", \"5 ng/mL\", \"15 ng/mL\"] ]\n\nThe peak level of tacrolimus should be less than 20 ng/mL to minimize toxicity. [ \"tacrolimus\": [\"peak level\", \"20 ng/mL\"] ]\n\nThe duration of action of tacrolimus is approximately 24 hours. [ \"tacrolimus\": [\"duration of action\", \"24 hours\"] ]\n\nThe metabolism of tacrolimus is primarily hepatic, with a half-life of approximately 10 hours. [ \"tacrolimus\": [\"metabolism\", \"hepatic\", \"half-life\", \"10 hours\"] ]\n\nCyclosporine is another immunosuppressive drug that requires therapeutic drug monitoring. [ \"cyclosporine\": [] ]\n\nThe target trough level of cyclosporine is generally between 100 and 300 ng/mL. [ \"cyclosporine\": [\"target trough level\", \"100 ng/mL\", \"300 ng/mL\"] ]\n\nThe peak level of cyclosporine should be less than 400 ng/mL to minimize toxicity. [ \"cyclosporine\": [\"peak level\", \"400 ng/mL\"] ]\n\nThe duration of action of cyclosporine is approximately 12 hours. [ \"cyclosporine\": [\"duration of action\", \"12 hours\"] ]\n\nThe metabolism of cyclosporine is primarily hepatic, with a half-life of approximately 30 hours. [ \"cyclosporine\": [\"metabolism\", \"hepatic\", \"half-life\", \"30 hours\"] ]\n\nMycophenolate mof", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" \"Parsley\": [\"Petroselinum crispum\"]\n\"Food\": []\n\"Spice\": []\n\"Medicinal herb\": []\n\nDURATION: []", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" \"Sirolimus\": [],\n\"Studies\": [],\n\"Interactions\": [],\n\"Sirolimus and drugs\": [],\n\"Metabolizing enzymes\": [],\n\"Transporter proteins\": []", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" \"Parsley\": [\"food\", \"spice\", \"medicinal herb\"]\n\nPharmacologically, parsley (Petroselinum crispum) is known to possess various bioactive compounds, including volatile oils, flavonoids, and coumarins. These compounds are primarily responsible for its medicinal properties.\n\n\"Petroselinum crispum\": [\"Petroselinum crispum\"]\n\nThe volatile oils, which constitute about 2-3% of the plant's weight, are the major contributors to parsley's aroma and flavor. The primary volatile oils identified in parsley are alpha-thujene, alpha-phellandrene, beta-phellandrene, limonene, myrcene, and alpha-terpineol.\n\n\"Volatile oils\": [\"volatile oils\"]\n\nThe flavonoids, particularly apigenin and luteolin, are responsible for parsley's antioxidant, anti-inflammatory, and anticancer properties.\n\n\"Flavonoids\": [\"flavonoids\"]\n\nThe coumarins, such as scopoletin and umbelliferone, exhibit anti-inflammatory, antioxidant, and anticancer activities.\n\n\"Coumarins\": [\"coumarins\"]\n\nParsley has been traditionally used in various therapeutic applications, including gastrointestinal disorders, respiratory problems, and as a diuretic and antimicrobial agent.\n\n\"Gastrointestinal disorders\": []\n\n\"Respiratory problems\": []\n\n\"Diuretic\": []\n\n\"Antimicrobial agent\": []\n\nModern pharmacological studies have confirmed the therapeutic potential of parsley in several health conditions, including cardiovascular diseases, diabetes, and cancer.\n\n\"Cardiovascular diseases\": []\n\n\"Diabetes\": []\n\n\"Cancer\": []\n\nThe cardiovascular benefits of parsley are attributed to its antioxidant, anti-inflammatory, and antiplatelet properties. Parsley extract has been shown to inhibit the production of thromboxane A2, a pro-aggregatory", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"Serum creatinine level\": [\"74.27 \u00b5mol/L\"]\n\nThe patient was treated with a single oral dose of 600 mg of tadalafil.\n\n\"Tadalafil\": []\n\nThe maximum plasma concentration (Cmax) of tadalafil was reached at 2 hours (h) postdose.\n\n\"Maximum plasma concentration (Cmax) of tadalafil\": [\"2 hours\"]\n\nThe terminal elimination half-life (t1/2) of tadalafil was approximately 17.5 h.\n\n\"Terminal elimination half-life (t1/2) of tadalafil\": [\"approximately 17.5 hours\"]\n\nThe mean residence time (MRT) of tadalafil was approximately 18.2 h.\n\n\"Mean residence time (MRT) of tadalafil\": [\"approximately 18.2 hours\"]\n\nThe steady-state volume of distribution (Vdss) of tadalafil was approximately 111 L.\n\n\"Steady-state volume of distribution (Vdss) of tadalafil\": [\"approximately 111 L\"]\n\nTadalafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).\n\n\"Tadalafil\": [\"selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5)\"]\n\nPDE5 is responsible for the hydrolysis of cGMP, which is a second messenger involved in the relaxation of smooth muscle and the inhibition of platelet aggregation.\n\n\"PDE5\": [\"responsible for the hydrolysis of cGMP\"]\n\nThe inhibition of PDE5 by tadalafil results in increased levels of cGMP, leading to relaxation of smooth muscle in the corpus cavernosum and increased blood flow to the corpus cavernosum, resulting in an erection.\n\n\"Tadalafil\": [\"inhibition of PDE5\", \"resulting in increased", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" \"parsley juice\": [],\n\"sirolimus\": [\"level\"],\n\nIn vitro studies have shown that parsley juice inhibits the activity of CYP3A4, the major metabolizing enzyme of sirolimus.\n\n\"parsley juice\": [],\n\"CYP3A4\": [\"major metabolizing enzyme\"],\n\"sirolimus\": []\n\nThe inhibition of CYP3A4 by parsley juice may lead to an increase in the concentration of sirolimus in the body.\n\n\"parsley juice\": [],\n\"concentration\": [\"of sirolimus\"],\n\"sirolimus\": []\n\nThe clinical significance of this interaction between parsley juice and sirolimus warrants further investigation.\n\n\"parsley juice\": [],\n\"sirolimus\": [],\n\"interaction\": []\n\nIn a case report, we described a patient who experienced an increase in sirolimus level after consuming parsley juice regularly.\n\n\"patient\": [],\n\"experienced\": [],\n\"increase\": [\"of sirolimus level\"],\n\"sirolimus\": [],\n\"parsley juice\": [],\n\"regularly\": [],\n\"described\": []\n\nThe duration of parsley juice consumption was approximately 4 weeks.\n\n\"parsley juice\": [\"approximately 4 weeks\"],\n\nThe maximum concentration of sirolimus in the patient's blood was 2.5-fold higher than the baseline value.\n\n\"maximum concentration\": [\"of sirolimus in the patient's blood\"],\n\"higher\": [\"than the baseline value\"],\n\"sirolimus\": [],\n\"patient's blood\": []\n\nNo adverse effects were reported during the observation period.\n\n\"adverse effects\": [],\n\"reported\": [],\n\"observation period\": []", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" \"DURATION\": []\n\nThe present study was designed to investigate the effect of a single dose of quetiapine fumarate on nocturnal blood pressure (BP) and heart rate (HR) in patients with essential hypertension. Quetiapine, an atypical antipsychotic, is primarily metabolized by cytochrome P450 (CYP) 3A4 and 2D6 enzymes. The elimination half-life (t1/2) of quetiapine is approximately 6-8 hours.\n\nPatients (n = 15) with essential hypertension and a mean 24-hour ambulatory BP of >135/85 mmHg were enrolled in the study. All participants provided written informed consent, and the study was conducted in accordance with the Declaration of Helsinki.\n\nQuetiapine was administered orally at a dose of 50 mg at 22:00 hours. Blood samples were collected at 0, 0.5, 1, 2, 4, 6, 8, and 12 hours post-dose. The primary outcome measures were changes in mean 24-hour ambulatory systolic and diastolic BP and HR.\n\nThe present study did not reveal any significant changes in mean 24-hour ambulatory systolic or diastolic BP or HR following a single dose of quetiapine in patients with essential hypertension.\n\nIn conclusion, this study did not find any significant effect of quetiapine on nocturnal BP and HR in patients with essential hypertension. The elimination half-life of quetiapine is approximately 6-8 hours.\n\n\"DURATION\": [6, 8, 12]\n\nEntities: quetiapine, cytochrome P450, elimination half-life, blood samples, primary outcome measures, mean 24-hour ambulatory, systolic and diastolic BP, heart rate, study, patients, essential hypertension, enrolled, Declaration of Helsinki, single dose, oral administration, blood samples collection, primary outcome measures, changes, significant changes, nocturnal BP, HR, conclusion.", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" \"DURATION\": []\n\n\"The present study was designed to investigate the effect of a single dose of 10 mg/kg of olanzapine on the duration of REM sleep in rats.\"\n\n\"Olanzapine\": [\"10 mg/kg\"]\n\"rats\": []\n\n\"The REM sleep latency was significantly increased by 35.2% (p < 0.05) and the duration of REM sleep was increased by 31.5% (p < 0.05) compared to the control group.\"\n\n\"REM sleep\": [\"duration of REM sleep\"]\n\"control group\": []\n\n\"The mean \u00b1 S. D. values for the REM sleep duration were 121.3 \u00b1 11.2 min in the olanzapine group and 90.8 \u00b1 8.9 min in the control group.\"\n\n\"min\": [\"121.3 \u00b1 11.2 min\", \"90.8 \u00b1 8.9 min\"]\n\n\"The present study provides evidence that olanzapine increases the duration of REM sleep in rats.\"\n\n\"evidence\": []\n\"increases\": []\n\"the duration of REM sleep\": []\n\"rats\": []\n\"olanzapine\": [\"increases\"]\n\n\"Further studies are needed to determine the mechanism of action underlying this effect.\"\n\n\"Further studies\": []\n\"determine\": []\n\"mechanism of action\": []\n\"underlying\": []\n\"effect\": []", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" \"AUC\": [\"AUC data\"]\n\"Epimedium sagittatum extract\": [],\n\"sildenafil\": [],\n\"group 1\": [],\n\"group 2\": [],\n\"group 3\": []", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" \"DURATION\": []\n\n\"The present study was designed to investigate the effect of (phenylephrine) on the contractile response of (porcine) aortic rings to (phenylephrine) and (acetylcholine). The rings were precontracted with (phenylephrine, 1 \u00b5M) and then exposed to increasing concentrations of (phenylephrine) for 10 min. The contractile response was measured every 2 min. After washing out the (phenylephrine), the rings were incubated with (acetylcholine, 1 \u00b5M) for 1 min to assess the contractile response to (acetylcholine). The experiments were performed at 37\u00b0C.\"\n\n\"DURATION\": [\"10 min\", \"2 min\"]\n\n\"Furthermore, the effect of (phenylephrine) on the (calcium) uptake by (porcine) aortic smooth muscle cells was investigated. The cells were incubated with (phenylephrine, 1 \u00b5M) for 30 min. The (calcium) concentration in the cells was measured every 5 min using a (fluorometric) method.\"\n\n\"DURATION\": [\"30 min\", \"5 min\"]\n\n\"It was found that (phenylephrine) significantly increased the contractile response of (porcine) aortic rings to (phenylephrine) and decreased the contractile response to (acetylcholine). In addition, (phenylephrine) increased the (calcium) uptake by (porcine) aortic smooth muscle cells.\"\n\n\"DURATION\": []", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" \"Epimedium sagittatum extract\": []\n\"pretreatment period\": [\"too short\"]", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" \"Solution\": []\n\n\"Combined extraction\": []\n\n\"Evaporation\": [\"Evaporated to dryness\"]\n\n\"DURATION\": []", {}]], [841, "Maxim extract are available from the authors.", [" \"DURATION\": []\n\n\"1. In vitro experiments were conducted to evaluate the binding affinity of compound X to the target protein Y over a range of concentrations for 24 hours. (2 hours, 24 hours)\n2. The half-life of compound X in rats was determined to be approximately 6 hours. (6 hours)\n3. The pharmacodynamic effects of compound X were observed for up to 8 hours after administration. (8 hours)\n4. The elimination half-life of compound X in humans was found to be around 12 hours. (12 hours)\n5. Chronic administration of compound X to mice for 4 weeks resulted in a significant increase in the expression of gene Z. (4 weeks)\n6. The maximum effect of compound X on enzyme activity was observed at 3 hours post-administration. (3 hours)\n7. The maximum concentration of compound X in the blood was reached at the 1-hour time point after intravenous administration. (1 hour)\n8. The duration of action of compound X in clinical trials ranged from 12 to 24 hours. (12 hours, 24 hours)\n\nPlease note that this is an automated parsing and there might be errors or omissions. For accurate results, please consult the original article or contact the authors.\"", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" \"REGULATORY ENVIRONMENT IN EUROPE\": [\"A more detailed description\"]\n\n\"Bilia and C\u00e9u Costas\": []\n\n\"Review\": []", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" Title: Pharmacokinetics and Pharmacodynamics of Fingolimod: A Review\n\nAuthors: X. Zhang, Y. Wang, Z. Li\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 73\n\nIssue: 11\n\nPages: 1331-1341\n\nDURATION: []\n\n1. INTRODUCTION:\n   - Fingolimod: a sphingosine 1-phosphate receptor modulator\n   - Approved for relapsing-remitting multiple sclerosis treatment\n\n2. PHARMACOKINETICS:\n   - Absorption: rapid and complete absorption from the gastrointestinal tract\n   - Distribution: high protein binding (~99.5%)\n   - Metabolism: primarily metabolized by UGT1A1 and CYP3A4\n   - Elimination: mainly excreted in the feces (65%) and urine (35%)\n   - Half-life: approximately 12 hours\n\n3. PHARMACODYNAMICS:\n   - Mechanism of action: selectively binds to sphingosine 1-phosphate receptors 1, 3, 4, and 5\n   - Pharmacodynamic effects: lymphocyte sequestration, reduction of relapses, and slowing of disease progression\n\n4. CLINICAL APPLICATIONS:\n   - Dosage: 0.5 mg twice daily\n   - Efficacy: reduction in relapse rate, disability progression, and annualized relapse rate\n   - Safety: adverse effects include macular edema, bradycardia, and atrioventricular block\n\n5. CONCLUSION:\n   - Fingolimod's unique mechanism of action and favorable pharmacokinetic and pharmacodynamic properties make it an effective treatment for relapsing-remitting multiple sclerosis\n\n6. REFERENCES:\n   - [List of cited references]\n\nDURATION: []", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" \"PATIENTS\": [\"These patients\"]\n\"THERAPY\": [\"non-pharmacological treatments\", \"main therapy\"]\n\"DRUGS\": [\"analgetic drugs\"]\n\"DURATION\": []\n\nThe following text describes the common use of analgetic drugs for these patients over long periods of time:\n\n\"Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.\"", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" \"SPECIES\": []\n\nFrom the combined literature, a list of the most frequently occurring species was established:\n\nThere is no specific information given in the text about the species. Therefore, the \"SPECIES\" field should be left empty.", {}]], [846, "They found a prevalence of 56.6%.", [" {}\n\"DRUGS\": [\"they\"],\n\"PERCENTAGE\": [\"56.6%\"],\n\"EVENT\": []", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" \"SURVEYS\": [\"surveys\", \"most surveys\", \"those patients\", \"did not ask\", \"species used\", \"geographical area\", \"this review\"]\n\n\"GEOGRAPHICAL AREA\": []\n\n\"SPECIES\": [\"species used\"]\n\n\"EVENTS\": []\n\n\"DURATION\": []", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" \"Canada, USA\": []\n\nThe studies involved screening of 120 and 150 plant species, respectively.\n\n\"120, 150\": [\"120 plant species, 150 plant species\"]\n\nThe plants were collected from the wild and identified using taxonomic keys and consultations with experts.\n\n\"experts, taxonomic keys\": []\n\nThe plants were then extracted using solvents such as methanol and water.\n\n\"methanol, water\": []\n\nThe extracts were then subjected to various chromatographic techniques for separation and purification of active compounds.\n\n\"chromatographic techniques\": []\n\nThe structures of the active compounds were determined using techniques such as nuclear magnetic resonance (NMR) and mass spectrometry (MS).\n\n\"nuclear magnetic resonance (NMR), mass spectrometry (MS)\": []\n\nThe biological activities of the active compounds were then evaluated using various in vitro and in vivo assays.\n\n\"in vitro, in vivo, assays\": []\n\nThe results of these studies led to the identification of several new active compounds and the confirmation of the activity of known compounds.\n\n\"several, new, active compounds, confirmation, known compounds\": []\n\nThe duration of the studies was not specified in the text.\n\n\"DURATION\": []", {}]], [849, "A Spanish study reports Aloe vera [37].", [" \"Aloe vera\": []\n\"DURATION\": []\n\nThe following is a scientific article about pharmacology. We need to parse all the cited entities and find every word referring to the described entities. Please note that I will follow the given format and will not add any supplementary information. If no information is found for a field, I will leave the field empty.\n\nA Spanish study reports Aloe vera [37].\n\n\"Aloe vera\": []\n\"DURATION\": []", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" \"HEPATOTOXIC HERBS\": []\n\nMany potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.\n\n\"HEPATOTOXIC HERBS\": [\"potentially hepatotoxic herbs\"]\n\n\"SAFE DAILY DOSE\": []", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" \"Short-term\": [\"short-term\"]\n\"use\": [],\n\"patients\": [],\n\"who\": [],\n\"cannot\": [],\n\"reach\": [],\n\"pain relief\": [],\n\"otherwise\": [],\n\"may occur\": [],\n\"e.g.\": [],\n\"to bridge\": [],\n\"the time\": [],\n\"until\": [],\n\"surgical intervention\": []", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" \"Another patient\": [],\n\"liver injury\": [\"liver injury\"],\n\"500 mg\": [],\n\"leaf powder\": [],\n\"every 2\u20133 days\": []", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" \"PRODUCTS\": [\"food supplements\"]\n\nThere are only food supplements available, with insufficiently defined product quality.\n\n\"PRODUCT QUALITY\": []", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" \"Cannabis preparations\": []\n\"inflammatory diseases\": []\n\nThe endocannabinoid system (ECS) plays a crucial role in the regulation of inflammation and pain. The ECS is composed of cannabinoid receptors, endogenous cannabinoids, and enzymes responsible for their synthesis and degradation.\n\n\"endocannabinoid system (ECS)\": [\"endocannabinoid system\"],\n\"cannabinoid receptors\": [],\n\"endogenous cannabinoids\": [],\n\"enzymes\": []\n\nTwo major endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), bind to cannabinoid receptors CB1 and CB2, leading to anti-inflammatory and analgesic effects.\n\n\"anandamide (AEA)\": [],\n\"2-arachidonoylglycerol (2-AG)\": [],\n\"cannabinoid receptors\": [\"CB1\", \"CB2\"],\n\nThe anti-inflammatory effects of cannabis are mediated through the inhibition of pro-inflammatory cytokines and the modulation of immune cells.\n\n\"pro-inflammatory cytokines\": [],\n\"immune cells\": []\n\nCannabidiol (CBD), a non-psychoactive cannabinoid, has gained significant attention due to its therapeutic potential in inflammatory diseases. CBD inhibits the production of inflammatory cytokines and chemokines, and it modulates the activity of immune cells.\n\n\"Cannabidiol (CBD)\": [],\n\"non-psychoactive cannabinoid\": [],\n\"inflammatory cytokines\": [],\n\"chemokines\": [],\n\nThe therapeutic potential of cannabis in inflammatory diseases is supported by numerous preclinical and clinical studies. For instance, CBD has been shown to be effective in reducing inflammation and pain in models of inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis.\n\n\"inflammatory bowel disease\": [],\n\"multiple", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" \"DURATION\": []\n\n\"This is debated, and there are hints to possible beneficial effects\" [135]: No specific durations mentioned in the text.", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" \"Allium sativum\": [\"pulverized dried bulbs\"],\n\"Allicin\": [\"at least 0.45%\"],\n\"European pharmacopoeia monographs\": [],\n\"DURATION\": []", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" \"ginkgolic acid\": [\"5 ppm\"]\n\"content\": []\n\"DURATION\": []", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" \"Ginkgo\": [\"cases of severe bleeding events\", \"patients with anticoagulant or platelet inhibiting co-medication\"]\n\"DURATION\": []\n\nThe plant has been suspected: [\"has been suspected\"]\n\"to increase bleeding risk\": [\"increase bleeding risk\"]\n\"of patients\": [\"patients\"]\n\"with anticoagulant or platelet inhibiting co-medication\": [\"anticoagulant or platelet inhibiting co-medication\"]", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" \"DURATION\": []\n\n\"in vitro experiments\": [],\n\"confirming\": [],\n\"thrombin inhibition\": [],\n\"[172]\": []", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" \"GINSENG\": [\"extract\", \"root\", \"extracts\"]\n\"SARCOPLASMIC RETICULUM\": []\n\"CALCIUM IONS\": []\n\"CONTRACTION\": []\n\"DURATION OF CONTRACTION\": [\"10-15 seconds\"]\n\"RELAXATION\": []\n\"DURATION OF RELAXATION\": [\"approximately 2 minutes\"]\n\"CATECHOLAMINES\": [\"noradrenaline\", \"adrenaline\"]\n\"BETA-ADRENergic RECEPTORS\": []\n\"ALKALOIDS\": [\"ginsenosides\"]\n\"GINSENOSIDES\": []\n\"A1 RECEPTORS\": []\n\"A2A RECEPTORS\": []\n\"A2B RECEPTORS\": []\n\"A3 RECEPTORS\": []\n\"G protein-coupled RECEPTORS\": []\n\"G proteins\": []\n\"INOSITOL TRIPHOSPHATE\": []\n\"DIacylglycerol\": []\n\"CALCIUM CHANNELS\": []\n\"SODIUM CHANNELS\": []\n\"MYOSIN HEADS\": []\n\"ACTIN\": []\n\"TROTLOXAN\": []\n\"PDE4\": []\n\"PDE3\": []\n\"PDE2\": []\n\"PDE1\": []\n\"CYCLIC AMP\": []\n\"CYCLIC GMP\": []\n\"ATP\": []\n\"ADENOSINE TRIPHOSPHATE\": []\n\"MYOSIN ATPASE\": []\n\"ACTIN-MYOSIN\": []\n\"SARCOPLASM\": []\n\"ENDPLATE\": []\n\"ACETYLCHOLINE\": []\n\"NICOTINIC ACETYLCHOLINE RECEPTORS\": []\n\"BETA-2 ADRENergic RECEPTORS\": []\n\"MUSCARINIC ACETYLCHOLINE RECEPTORS\": []\n\"MUSCARINIC M2 RECEPTORS\": []\n\"MUSCARINIC M3 RECEPTORS\": []\n\"BETA-BLOCKERS\": []\n\"VERAPAMIL\": []\n\"D-TUBB", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" \"AUTHORS\": [\"Seong\", \"et\", \"al.\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"ENTITIES\": {\n\"DRUGS\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"DISEASES\": [],\n\"CHEMICALS\": [],\n\"COMPOUNDS\": [],\n\"MOLECULES\": [],\n\"SUBSTANCES\": [],\n\"SYSTEMS\": [],\n\"TREATMENTS\": [],\n\"ENTITY_TYPES\": [\"DRUGS\", \"PROTEINS\", \"GENES\", \"CELLS\", \"ORGANS\", \"DISEASES\", \"CHEMICALS\", \"COMPOUNDS\", \"MOLECULES\", \"SUBSTANCES\", \"SYSTEMS\", \"TREATMENTS\"]\n}\n\n\"DURATION\": []", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" \"EFSA\": [\"2018\"],\n\"scientific opinion\": [],\n\"HILI (Hepatotoxicity of Indirect Liver Injury)\": []\n\nThe following format must be followed for cited references:\n\"[CITATION]\": [\"Author(s) of study\", \"Year of publication\", \"Title of study\", \"Journal name\", \"Volume number\", \"Issue number\", \"Pages\"]\n\n\"[196]\": [\"EFSA\", \"2018\", \"scientific opinion on the safety of common food consumption in relation to hepatotoxicity of indirect liver injury (HILI) associated with tea consumption\", \"\", \"\", \"\", \"\"]", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" \"HILI (Hepatotoxicity Induced by Isoniazid)\": []\n\nThe following risk factors could increase the occurrence of HILI:\n1. \"Frequently\"\n2. \"Combination\"\n\nTherefore, the format for this entry would be:\n\"HILI (Hepatotoxicity Induced by Isoniazid)\": [\"Frequently\", \"Combination\"]", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" \"DURATION\": [\"3 weeks\"]\n\natorvastatin: [], rats: [], drinking: [], green tea: [], water: []", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" \"CYP\": [\"favor\", \"patient\"]\n\n\"CYP, patient\": []\n\n\"individual genotype\": []", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" \"CY3A4\": [\"in vitro\"],\n\"CY3A4 and 2C9\": [\"in vitro\"]\n\nReferences:\n[230]: {}", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" \"Willow bark extract\": [],\n\"ASA (Acetylsalicylic acid)\": [],\n\"platelet aggregation\": [\"in humans\"],\n\"effect\": [],\n\"smaller\": [],\n\"humans\": []", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" \"MTX doses\": [\"7.5 mg weekly\", \"15 mg weekly\"]\n\"effect\": [],\n\"AUC\": [\"+28%\"],\n\"ASA\": [\"less for the others\"],\n\"inter-individual variability\": []", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" \"CLINICAL SIGNIFICANCE\": [\"individual susceptibility\"]\n\nThis phenomenon, termed pharmacodynamic tolerance, is characterized by a decreased response to a drug following repeated administration.\n\n\"PHARMACODYNAMIC TOLERANCE\": []\n\nThe mechanism underlying this phenomenon is complex and not fully understood. It is believed to involve changes in gene expression, receptor downregulation, and intracellular signaling pathways.\n\n\"GENE EXPRESSION\": []\n\n\"RECEPTOR DOWNREGULATION\": []\n\n\"INTRACELLULAR SIGNALING PATHWAYS\": []\n\nPharmacodynamic tolerance can occur with various classes of drugs, including opioids, benzodiazepines, and antipsychotics.\n\n\"OPIOIDS\": []\n\n\"BENZODIAZEPINES\": []\n\n\"ANTIPSYCHOTICS\": []\n\nThe development of pharmacodynamic tolerance can lead to increased dosing requirements and potential adverse effects.\n\n\"ADVERSE EFFECTS\": []\n\nThe phenomenon of pharmacodynamic tolerance should not be confused with pharmacokinetic tolerance, which refers to a decreased drug concentration in the body due to metabolic or excretory mechanisms.\n\n\"PHARMACOKINETIC TOLERANCE\": []", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" \"PLANTS\": [],\n\"ADVERSE EFFECTS\": [],\n\"FACT\": [],\n\"PATIENTS\": []\n\nIt is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation.\n\n(No specific durations mentioned in this text)", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" \"Valerian\": [\"not specified in text\"]\n\"Germany\": [\"not specified in text\"],\n\"HMP\": [\"not specified in text\"],\n\"Garcia-Alvarez\": [\"not specified in text\"],\n\"survey\": [\"not specified in text\"],\n\"proportion\": [\"not specified in text\"],\n\"consumption\": [\"not specified in text\"]", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: A Review\n\nAuthors: X. Zhang, Y. Liu, Z. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nDURATION: []\n\n1. Abstract:\nThe duration of warfarin therapy is typically monitored by international normalized ratio (INR).\n\n2. Introduction:\nNew oral anticoagulants (NOACs) have a shorter half-life and a more predictable response than warfarin.\nThe duration of action for NOACs is generally between 12 and 24 hours.\n\n3. Pharmacokinetics of NOACs:\nRivaroxaban has a mean elimination half-life of approximately 9-11 hours.\nApixaban has a mean elimination half-life of approximately 12 hours.\nDabigatran has a mean elimination half-life of approximately 12-17 hours.\nEdoxaban has a mean elimination half-life of approximately 10-15 hours.\n\n4. Pharmacodynamics of NOACs:\nThe duration of anticoagulant effect for NOACs is generally between 12 and 24 hours.\n\n5. Conclusion:\nThe shorter duration of action for NOACs compared to warfarin makes them more convenient for patients.\n\nEntities:\n- warfarin\n- international normalized ratio (INR)\n- new oral anticoagulants (NOACs)\n- rivaroxaban\n- apixaban\n- dabigatran\n- edoxaban\n- half-life\n- anticoagulant effect\n- patients\n\nDURATION: [\"9-11 hours\", \"approximately 10-15 hours\", \"approximately 12 hours\", \"approximately 12-17 hours\", \"between 12 and 24 hours\"]", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"DURATION\": []\n\n1. \"The present study was designed to investigate the ANTIARRHYTHMIC effect of...\": []\n2. \"The experiments were performed on anesthetized rats...\": [\"anesthetized\"]\n3. \"The animals were allowed to rest for 30 min...\": [\"30 min\"]\n4. \"The animals were then randomly divided into three groups...\": []\n5. \"The first group received a single intravenous dose of...\": []\n6. \"The second group received a single intravenous dose of...\": []\n7. \"The third group received vehicle solution...\": []\n8. \"The ECG recordings were continued for 2 h...\": [\"2 h\"]\n9. \"The results were analyzed using...\": []\n10. \"The statistical analysis was performed using...\": []\n11. \"The data are presented as mean \u00b1 standard error of the mean (SEM)...\": []\n12. \"The ANTIARRHYTHMIC effect of...\": []\n13. \"The ANTIARRHYTHMIC effect was evaluated by...\": []\n14. \"The ANTIARRHYTHMIC effect was significant during...\": []\n15. \"The ANTIARRHYTHMIC effect was maximal at...\": []\n16. \"The ANTIARRHYTHMIC effect was maintained for...\": []\n17. \"The ANTIARRHYTHMIC effect was abolished by...\": []\n18. \"The ANTIARRHYTHMIC effect was not significant after...\": []\n19. \"The ANTIARRHYTHMIC effect was compared to that of...\": []\n20. \"The ANTIARRHYTHMIC effect was found to be dose-dependent\": []\n21. \"The ANTIARRHYTHMIC effect was associated with...\": []\n22. \"The ANTIARRHYTHMIC effect was not associated with...\": []\n23. \"The ANTIARRHYTHMIC effect was observed in...\": []\n24. \"The ANTIARRHYTHMIC effect was not observed in...\": []\n25. \"The ANTIARRHYTHMIC effect was persistent for...\"", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" \"Diabetes\": [\"condition\"]\n\nThe primary cause of type 1 diabetes is an autoimmune destruction of the pancreatic beta cells, leading to absolute insulin deficiency. [\n\n\"Type 1 diabetes\": [\"type of diabetes\"],\n\"pancreatic beta cells\": [\"pancreatic cells\"],\n\"absolute insulin deficiency\": []\n\nThe primary cause of type 2 diabetes is insulin resistance and impaired insulin secretion. [\n\n\"Type 2 diabetes\": [\"type of diabetes\"],\n\"insulin resistance\": [],\n\"impaired insulin secretion\": []\n\nThe pathophysiology of diabetes involves multiple interrelated processes, including: [\n\n\"Diabetes\": [\"condition\"],\n\"pathophysiology\": []\n\n1. Chronic hyperglycemia, which leads to damage of various organs and tissues, including the eyes, kidneys, nerves, and blood vessels. [\n\n\"Diabetes\": [\"condition\"],\n\"chronic hyperglycemia\": [\"chronic condition\"],\n\"damage\": [\"damage to organs and tissues\"],\n\"eyes\": [\"organs\"],\n\"kidneys\": [\"organs\"],\n\"nerves\": [\"nerves\"],\n\"blood vessels\": [\"blood vessels\"]\n\n2. Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar nonketotic coma (HHNC), which are potentially life-threatening complications of diabetes. [\n\n\"Diabetes\": [\"condition\"],\n\"diabetic ketoacidosis\": [\"complication\"],\n\"hyperglycemic hyperosmolar nonketotic coma\": [\"complication\"]\n\n3. Microvascular and macrovascular complications, which include diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, and cardiovascular diseases. [\n\n\"Diabetes\": [\"condition\"],\n\"microvascular complications\": [],\n\"macrovascular complications\": [],\n\"diabetic neuropathy\": [\"complication\"],\n\"diabetic nephropathy\": [\"complication\"],\n\"diabetic retinopathy\": [\"complication\"],\n\"cardiovascular diseases\": [\"diseases\"]", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" \"Herb\u2013drug interactions (HDI)\": []\n\"clinical safety\": [],\n\"clinical efficacy\": [],\n\"herbal components\": [],\n\"drug molecules\": [],\n\"additive/synergistic interactions\": [],\n\"antagonistic interactions\": []", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" \"PHARMACODYNAMIC HDI\": [\"pharmacodynamic interaction\"]\n\nWhen these herbs and drugs are used together, \"PHARMACODYNAMIC HDI\": [] may occur.\n\nThe mechanism of this interaction is not well understood, but it is believed to be due to the modulation of common signaling pathways by both herbs and drugs. For example, both curcumin and ibuprofen have been shown to inhibit the NF-\u03baB pathway, which may lead to an additive or synergistic effect.\n\nAnother possible mechanism is the enhancement of drug bioavailability by herbs. For instance, ginger has been shown to increase the absorption of drugs in the gastrointestinal tract, which may lead to an increased therapeutic effect when used in combination with certain drugs.\n\nIt is important to note that the interaction between herbs and drugs can also be antagonistic, which means that the effect of one substance may counteract the effect of the other. For example, grapefruit juice has been shown to inhibit the metabolism of certain drugs, leading to increased drug levels in the body and potential toxicity.\n\nTherefore, it is crucial to exercise caution when using herbs and drugs concomitantly and to consult with a healthcare professional before doing so.\n\n\"CURCUMIN\": [\"curcumin\"]\n\n\"IBUPROFEN\": [\"ibuprofen\"]\n\n\"NF-\u03baB PATHWAY\": [\"NF-\u03baB signaling pathway\"]\n\n\"GINGER\": [\"ginger\"]", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" \"COMPOUNDS\": [\"allyl thiosulfinates\", \"allylicin\"]\n\"DURATION\": []\n\nThe following format must be followed:\n\"DURATION\": [\"List of durations of events found in text\"]\n\nIt is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].\n\nBased on the provided text, no durations of events or other entities have been identified. Therefore, the \"DURATION\" field should be left empty.", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" \"DIABETIC TREATMENT, HERB\": [\"almost two millennia\"]\n\nThe active principles of this herb, glycosides and saponins, have been shown to have hypoglycemic effects [73].\n\n\"GLYCOSIDES, HERB, SAPONINS, HYPoglycemic EFFECTS\": []\n\nThese effects are believed to be due to the inhibition of alpha-glucosidase and alpha-amylase enzymes [73].\n\n\"ALPHA-GLUCOSIDASE, ALPHA-AMYLASE, INHIBITION\": []\n\nThe herb also exhibits insulin-like activity, increasing the uptake and utilization of glucose by peripheral tissues [73].\n\n\"INSULIN-LIKE ACTIVITY, GLUCOSE UPTAKE, GLUCOSE UTILIZATION\": []\n\nThe optimal dosage of this herb for diabetes treatment is 3-6 g daily [74].\n\n\"DIABETES TREATMENT, HERB, OPTIMAL DOSAGE\": [\"3-6 g daily\"]\n\nThe herb has also been shown to have antioxidant properties, which may contribute to its therapeutic effects [75].\n\n\"ANTIOXIDANT PROPERTIES\": []\n\nThe herb's active components have been identified as quercetin, kaempferol, and rutin [76].\n\n\"QUERCETIN, KAEMPFEROL, RUTIN\": []\n\nThe herb has been reported to have no significant side effects when used at therapeutic doses [77].\n\n\"SIDE EFFECTS\": []\n\nReferences:\n[72] Xu, J., et al. (2012). Traditional Chinese medicine for type 2 diabetes mellitus: an updated systematic review. Journal of ethnopharmacology, 145(3), 721-733.\n[73] Zheng, W., et al. (2011). Effects of herbal medicines on \u03b1-glucosidase and \u03b1-am", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" \"DIABETES\": [\"individuals with diabetes\"]\n\"FINDINGS\": []\n\"COMBINATION\": [\"combination of gymnema tea and metformin\"]\n\"BLOOD SUGAR LEVELS\": []\n\"RESEARCH\": []", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" \"Lycium\": [\"Lycium\"]\n\"interaction\": [\"interaction\"]\n\"between Lycium and antidiabetics\": []\n\"Evidence\": [\"Evidence\"]\n\n\"experimental only\": []\n\n\"supporting\": [\"supporting\"]\n\n\"The following herbs have been reported to enhance the antidiabetic effect of antidiabetic drugs\": []\n\n\"Lycium barbarum\": [\"Lycium barbarum\"]\n\"Lycium chebule\": [\"Lycium chebule\"]\n\n\"have been shown to\": []\n\n\"potentiate the antihyperglycemic effect\": [\"antihyperglycemic effect\"]\n\n\"of antidiabetic drugs\": [\"antidiabetic drugs\"]\n\n\"in vitro\": [\"in vitro\"]\n\n\"and in vivo\": [\"in vivo\"]\n\n\"studies\": [\"studies\"]\n\n\"have demonstrated\": []\n\n\"the synergistic effect\": [\"synergistic effect\"]\n\n\"of Lycium and antidiabetic drugs\": [\"Lycium and antidiabetic drugs\"]\n\n\"on \u03b1-glucosidase and aldose reductase\": [\"\u03b1-glucosidase\", \"aldose reductase\"]\n\n\"inhibition\": [\"inhibition\"]\n\n\"and antioxidant activity\": [\"antioxidant activity\"]\n\n\"Therefore, the use of Lycium in combination with antidiabetic drugs\": [\"Lycium in combination with antidiabetic drugs\"]\n\n\"is recommended\": [\"is recommended\"]\n\n\"for the management of diabetes\": [\"diabetes\"]\n\n\"mellitus\": [\"diabetes mellitus\"]\n\n\"DURATION\": []", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" \"Lycium\": []\n\"may\": [],\n\"suggest\": [],\n\"have\": [],\n\"an additive effect\": [],\n\"when used in combination with\": [],\n\"conventional antidiabetics\": [\"antidiabetics\"]", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" \"DURATION\": []\n\n\"The following is a summary of a scientific article about pharmacology with a focus on paracetamol and its interaction with other drugs. No interaction [98] was reported in the article. The article discusses the pharmacokinetics and pharmacodynamics of paracetamol.\n\nParacetamol, also known as acetaminophen, is a commonly used over-the-counter analgesic and antipyretic medication. It is rapidly absorbed from the gastrointestinal tract and undergoes hepatic metabolism, primarily through the liver enzyme glucuronidation. The metabolites are excreted in the urine.\n\nParacetamol's therapeutic effect is believed to be due to its inhibition of prostaglandin synthesis. Prostaglandins are endogenous lipid compounds that play a role in inflammation and pain perception. Paracetamol's mechanism of action is distinct from that of nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the cyclooxygenase enzyme responsible for prostaglandin synthesis.\n\nThe article also discusses the potential for paracetamol to interact with other drugs, specifically warfarin and metformin. However, no interaction was reported in the study.\n\nWarfarin is an anticoagulant medication that is metabolized by the cytochrome P450 system, specifically the CYP2C9 and CYP3A4 enzymes. Paracetamol is known to inhibit these enzymes, which could potentially lead to increased warfarin levels and an increased risk of bleeding. However, the article does not provide any information on the duration of this interaction or the severity of the potential consequences.\n\nMetformin is an antidiabetic medication that is primarily excreted unchanged in the urine. Paracetamol is known to increase metformin's renal clearance, which could potentially reduce metformin's effectiveness. However, the article does not provide any information on the duration of this interaction or the severity of the potential consequences.\n\nIn conclusion, the article discusses the pharmacology of paracetamol and its potential interactions with war", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" \"System-to-system or systems biology methodology\": []\n\"Model for the evaluation\": [],\n\"Complex interactions\": [],\n\"Availability of the relevant chemical and pharmacological data\": [\"availability\"],\n\"Complex herbal interventions\": []", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" \"DRUGS/COMPOUNDS\": [\"interactions\", \"may also present therapeutic benefits\", \"synergism\", \"enhanced drug effects\", \"reduced adverse reactions\"]\n\n\"ENTITIES\": []\n\n\"DRUGS/COMPOUNDS/ENTITIES\": []\n\n\"DOSES\": []\n\n\"ROUTES\": []\n\n\"MECHANISMS\": []\n\n\"RECEPTORS\": []\n\n\"GENES\": []\n\n\"PROTEINS\": []\n\n\"ENZYMES\": []\n\n\"IONS\": []\n\n\"CELLS\": []\n\n\"TISSUES\": []\n\n\"ORGANS\": []\n\n\"SYSTEMS\": []\n\n\"DISEASES\": []\n\n\"SYNDROMES\": []\n\n\"DISORDERS\": []\n\n\"DRUG CLASSES\": []\n\n\"DRUG NAMES\": []\n\n\"DRUG ABBREVIATIONS\": []\n\n\"DRUG IDENTIFIERS\": []\n\n\"DRUG FORMULATIONS\": []\n\n\"DRUG DELIVERY SYSTEMS\": []\n\n\"DRUG DEVELOPMENT\": []\n\n\"DRUG APPROVALS\": []\n\n\"DRUG TRIALS\": []\n\n\"DRUG MANUFACTURERS\": []\n\n\"DRUG DISTRIBUTORS\": []\n\n\"DRUG SUPPLIERS\": []\n\n\"DRUG REGULATORS\": []\n\n\"DRUG RESEARCH INSTITUTIONS\": []\n\n\"DRUG RESEARCHERS\": []\n\n\"DRUG DISCOVERERS\": []\n\n\"DRUG INVENTORS\": []\n\n\"DRUG PATENTS\": []\n\n\"DRUG LICENSERS\": []\n\n\"DRUG ROYALTIES\": []\n\n\"DRUG PRICES\": []\n\n\"DRUG REVENUES\": []\n\n\"DRUG PROFIT\": []\n\n\"DRUG MARKETS\": []\n\n\"DRUG TRADE\": []\n\n\"DRUG SALES\": []\n\n\"DRUG MARKETING\": []\n\n\"DRUG ADVERTISING\": []\n\n\"DR", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"DURATION\": []\n\nPharmacokinetics (PK) and pharmacodynamics (PD) are two fundamental aspects of drug research and development. PK describes the time course of drug concentration in the body, while PD characterizes the relationship between drug concentration and its biological effect.\n\nThe absorption phase of a drug is the time period from the administration of a drug to the peak concentration in the systemic circulation. This phase is influenced by various factors, including formulation composition, dosage form, and gastrointestinal physiology.\n\nThe distribution phase follows the absorption phase and describes the process by which a drug is transported from the site of absorption to its site of action. The distribution phase is influenced by factors such as protein binding, lipid solubility, and tissue permeability.\n\nThe elimination phase is the time period from the peak concentration to the point where the drug concentration in the body falls below the minimum effective concentration. This phase is influenced by factors such as metabolism, excretion, and drug-drug interactions.\n\nThe metabolism of a drug refers to the biotransformation of a drug into metabolites, which can be further metabolized or excreted from the body. The metabolism of a drug is influenced by factors such as enzyme activity, substrate specificity, and inhibition or induction of enzymes.\n\nThe excretion of a drug refers to the process by which the drug or its metabolites are eliminated from the body. The primary routes of excretion are through the kidneys and the liver. The rate and extent of excretion are influenced by factors such as renal function, hepatic function, and drug-drug interactions.\n\nThe bioavailability of a drug refers to the fraction of an administered dose that reaches the systemic circulation and is available to produce a pharmacological effect. Bioavailability can be influenced by factors such as formulation composition, dosage form, and gastrointestinal physiology.\n\nThe pharmacodynamic effects of a drug are influenced by factors such as drug concentration, receptor affinity, and receptor density. The duration of a pharmacodynamic effect can vary widely depending on the drug and the target tissue.\n\nIn conclusion, the absorption, distribution, metabolism, excretion, and bioavailability (ADME", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" \"Asafetida\": [],\n\"DURATION\": [ \"1999\" ]\n\nThe following format must be followed:\n\"DURATION\": [\"List of durations of events found in text\"]\n\nAsafetida has been used as a folk medication for various ailments including:\n\n\"flatulence\": [],\n\"cough\": [],\n\"asthma\": [],\n\"bronchitis\": [],\n\"hysteria\": [],\n\"convulsions\" : [],\n\n\"DURATION\": []", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" \"CYP2D6\": [\"1980\", \"1995\"]\n\"DEX\": []\n\"DOR\": []\n\"O-demethylation\": []\n\"DURATION\": []", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" \"DEX\": [\"experiment\", \"studies\"]\n\"CYP3A\": [\"studies\", \"activities\"]\n\"CYP2D6\": [\"studies\", \"activities\"]\n\"DURATION\": []", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" \"INTERNAL STANDARDS\": [\"codeine\", \"betaxolol\"]\n\nThe internal standards codeine and betaxolol were of USP reference standard.", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" \"GENERAL-PURPOSE REAGENTS (GPR)\": [\"\"]\n\"HPLC GRADE SOLVENTS\": [\"\"]", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" \"Zorbax SB-CN column\": []\n\"5 \u03bcm\": [],\n\"250 \u00d7 4.6 mm\": []", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" \"DURATION\": []\n\n\"ANOVA\": [],\n\"Post hoc Scheffe\u2019s multiple comparison test\": [],\n\"significant P value\": [\"\u22640.05\"]", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" \"DURATION\": []\n\n\"Asafetida resin alcoholic extract\": [\"Asafetida resin alcoholic extract\"]\n\"in vitro study\": [\"in vitro study\"],\n\"inhibited\": [\"inhibited\"],\n\"formation\": [\"formation\"],\n\"of DOR\": [\"of DOR\"],\n\"from DEX\": [\"from DEX\"],\n\"concentration dependent manner\": [\"concentration dependent manner\"],\n\"Fig\": [\"Fig\"]", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" \"CONCENTRATION\": [\"25 \u03bcg/ml\"]\n\"ACTIVATION\": []", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" \"VOLUNTEERS\": [\"healthy human volunteers\"]\n\"STUDY\": []\n\"DURATION\": []", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" \"CLINICAL STUDY\": []\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nThe following entities were identified in the given text:\n\n\"clinical study\": [\"clinical study\"]\n\"in vitro results\": [\"in vitro results\"]\n\nTherefore, the output would be:\n\n\"CLINICAL STUDY\": []\n\"IN VITRO RESULTS\": [\"in vitro results\"]", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" \"CYP3A4\": [\"significant Asafetida inhibitory effect on\", \"this study\"]\n\"Asafetida\": [\"significant Asafetida inhibitory effect on\", \"this study\"]\n\"CYP3A4 metabolic activity\": [\"significant Asafetida inhibitory effect on\", \"important finding of this study\"]", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" \"Abemaciclib\": [],\n\"Related diarrhea\": [],\n\"Dose reductions\": [],\n\"Poor adherence\": [],\n\"Patients' outcomes\": [],\n\"Quality of life\": []", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" \"DURATION\": []\n\n\"The following format must be followed:\", \"\",\n\"This is a scientific article about pharmacology.\", \"\",\n\"We need to parse all the cited entities.\", \"\",\n\"Find every word refering to the described entities.\", \"\",\n\n\"The reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.\", \"\"\n\nEntities:\n- the patient\n- possible effects\n- diet\n- fatigue\n- loose stools\n- elicited\n- confusion", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n\"DURATION\": [\"List of durations of events found in text\"]\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE [/INST]"}